carmustine has been researched along with Glioma in 539 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
Glioma: Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Temozolomide (TMZ) and BCNU have demonstrated anti-glioma synergism in preclinical models." | 9.20 | BCNU wafer placement with temozolomide (TMZ) in the immediate postoperative period after tumor resection followed by radiation therapy with TMZ in patients with newly diagnosed high grade glioma: final results of a prospective, multi-institutional, phase ( Ashby, L; Asher, AL; Blaker, BD; Boltes, P; Brick, W; Burri, SH; Heideman, BE; Judy, K; Kelly, R; Norton, HJ; Prabhu, RS; Sumrall, AL; Symanowski, JT; Wiggins, WF, 2015) |
| "Patients with high-grade glioma can be treated with carmustine wafers or following the Stupp protocol." | 9.16 | Prognostic factors and survival in a prospective cohort of patients with high-grade glioma treated with carmustine wafers or temozolomide on an intention-to-treat basis. ( Aurrecoechea-Obieta, J; Bilbao-Barandica, G; Canales-Llantada, M; Carbayo-Lozano, G; Catalán-Uribarrena, G; Galbarriatu-Gutiérrez, L; Igartua-Azkune, A; Pomposo-Gaztelu, I; Ruiz de Gopegui-Ruiz, E; Undabeitia-Huertas, J, 2012) |
| "From February 2006 to January 2008, 32 patients were treated at our institution for cerebral supratentorial high grade glioma with surgery and intraoperative placement of carmustine wafers." | 9.15 | Safety and feasibility of the adjunct of local chemotherapy with biodegradable carmustine (BCNU) wafers to the standard multimodal approach to high grade gliomas at first diagnosis. ( Brogna, C; D'elia, A; Delfini, R; Frati, A; Salvati, M; Santoro, A, 2011) |
| "Temozolomide (TMZ) and 1, 3-bis (2-chloroethyl)-1-nitrosourea (BCNU) are reported to be active agents in anaplastic glioma (AG)." | 9.11 | Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial. ( Chang, SM; Fine, H; Fink, KL; Greenberg, H; Hess, K; Jaeckle, KA; Junck, L; Kuhn, J; Mehta, M; Prados, MD; Robins, HI; Schold, C; Yung, WK, 2004) |
| "In preclinical studies, BCNU, or 1,3-bis(2-chloroethyl)-1-nitrosourea, plus CPT-11 (irinotecan) exhibits schedule-dependent, synergistic activity against malignant glioma (MG)." | 9.11 | Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma. ( Affronti, ML; Allen, D; Badruddoja, M; Bigner, DD; Bohlin, C; Dowell, JM; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jackson, S; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Silverman, S; Tourt-Uhlig, S; Vredenburgh, J; Walker, A; Ziegler, K, 2004) |
| "Irinotecan is a topoisomerase I inhibitor previously shown to be active in the treatment of malignant glioma." | 9.11 | Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma. ( Affronti, ML; Allen, D; Bigner, DD; Bohlin, C; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jackson, S; Lentz, C; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Schweitzer, H; Tourt-Uhlig, S; Vredenburgh, J; Walker, A; Ziegler, K, 2004) |
| "This New Approaches to Brain Tumor Therapy CNS Consortium study sought to determine the maximum-tolerated dose (MTD) of carmustine (BCNU) that can be implanted in biodegradable polymers following resection of recurrent high-grade gliomas and the systemic BCNU exposure with increasing doses of interstitial BCNU." | 9.10 | Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a New Approaches to Brain Tumor Therapy CNS Consortium trial. ( Barker, F; Bruce, J; Fisher, J; Grossman, SA; Hilt, D; Judy, K; Olivi, A; Olsen, J; Piantadosi, S; Tatter, S, 2003) |
| "The use of thalidomide as an antiangiogenic agent has met with only limited success in the treatment of malignant gliomas." | 9.10 | Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. ( Batchelor, T; Borkowf, CB; Figg, WD; Fine, HA; Lakhani, N; Maher, EA; Purow, BW; Viscosi, E; Wen, PY, 2003) |
| "We conducted a phase II trial of carmustine (BCNU) plus the O(6)-alkylguanine-DNA alkyltransferase inhibitor O(6)-benzylguanine (O(6)-BG) to define the activity and toxicity of this regimen in the treatment of adults with progressive or recurrent malignant glioma resistant to nitrosoureas." | 9.10 | Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. ( Bigner, DD; Colvin, OM; Delaney, S; Dolan, ME; Friedman, AH; Friedman, HS; Gururangan, S; Haglund, MM; Herndon, JE; Kaplan, R; McLendon, RE; Moschel, RC; Pegg, AE; Pluda, J; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Tourt-Uhlig, S, 2002) |
| "A Phase I study was conducted to determine the safety, toxicity, and maximum tolerated dose of preirradiation chemotherapy using carmustine (BCNU) and cisplatin in the treatment of high-grade gliomas." | 9.09 | Phase I evaluation of preirradiation chemotherapy with carmustine and cisplatin and accelerated radiation therapy in patients with high-grade gliomas. ( Buckner, JC; Cascino, TL; Ingle, JN; Pitot, HC; Rajkumar, SV; Schomberg, PJ, 1999) |
| "The current study was conducted to determine whether the addition of interferon-alpha (IFN-alpha) to treatment with radiation therapy and carmustine (BCNU) improves time to disease progression or overall survival in patients with high-grade glioma." | 9.09 | A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade glioma. ( Bernath, AM; Buckner, JC; Cascino, TL; Cole, JT; Hatfield, AK; Kuross, SA; Mailliard, JA; McGinnis, WL; Morton, RF; O'Fallon, JR; Scheithauer, BW; Schomberg, PJ; Steen, PD, 2001) |
| "To quantify the quality of life of malignant glioma patients treated on a randomized Phase I/II trial of twice-daily radiation therapy (RT) and carmustine, using a modified quality adjusted survival (QAS) model, and to compare the QAS among assigned treatment arms." | 9.08 | Quality-adjusted survival analysis of malignant glioma. Patients treated with twice-daily radiation (RT) and carmustine: a report of Radiation Therapy Oncology Group (RTOG) 83-02. ( Curran, WJ; Farnan, N; Fischbach, AJ; Murray, KJ; Nelson, DF; Porter, A; Scott, C, 1995) |
| "Twenty-two patients, aged 16 to 67, who had malignant gliomas after surgical resection were treated with carmustine and cisplatin intravenous infusion before, during, and after radiotherapy." | 9.08 | Combination chemotherapy with carmustine and cisplatin before, during, and after radiotherapy for adult malignant gliomas. ( Chang, CN; Chen, LH; Cheng, WC; Ho, YS; Kiu, MC; Leung, WM; Lin, TK; Ng, KT; Tang, SG; Wong, CW, 1995) |
| "To find out the effect of carmustine (bischloroethyl-nitrosourea) combined with a biodegradable polymer in the treatment of malignant (Grades III and IV) gliomas, applied locally, at the time of the primary operation." | 9.08 | Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. ( Heiskanen, O; Kalimo, H; Kivipelto, L; Kuurne, T; Timonen, U; Toivanen, P; Unsgaard, G; Valtonen, S, 1997) |
| "We conducted a Phase I study of bischloroethylnitrosourea (BCNU), cisplatin, and oral etoposide administered prior to and during accelerated hyperfractionated radiation therapy in newly diagnosed high-grade glioma." | 9.08 | Phase I and pharmacokinetic study of preirradiation chemotherapy with BCNU, cisplatin, etoposide, and accelerated radiation therapy in patients with high-grade glioma. ( Ames, MM; Bagniewski, PJ; Buckner, JC; Cascino, TL; Marks, RS; Rajkumar, SV; Reid, JM; Schomberg, PJ, 1998) |
| "We performed a randomized trial to compare survival distributions and toxicity of radiation therapy (RT) and PCNU with those of RT and carmustine (BCNU) in patients with malignant glioma." | 9.07 | Phase III comparative evaluation of PCNU and carmustine combined with radiation therapy for high-grade glioma. ( Arusell, RM; Brown, LD; Buckner, JC; Dinapoli, RP; Earle, JD; Krook, JE; Maier, JA; O'Fallon, JR; Scheithauer, BW; Tschetter, LK, 1993) |
| "We conducted a phase III trial comparing intravenous (IV) diaziquone (AZQ) and carmustine (BCNU) as single agents in patients with cerebral anaplastic gliomas who had received surgery and radiotherapy." | 9.07 | Randomized comparison of diaziquone and carmustine in the treatment of adults with anaplastic glioma. ( Bigner, DD; Burger, PC; Cairncross, JG; Dropcho, EJ; Halperin, EC; Herndon, JE; Macdonald, DR; Morawetz, R; Schold, SC; Vick, NA, 1993) |
| "The purpose is twofold: (1) to identify the malignant glioma patients treated in a trial of hyperfractionated radiotherapy (RT) and carmustine (BCNU) who may have been eligible for a stereotactic radiosurgery (SRS) boost; and (2) to compare survival of such patients with that of those considered SRS-ineligible." | 9.07 | Survival comparison of radiosurgery-eligible and -ineligible malignant glioma patients treated with hyperfractionated radiation therapy and carmustine: a report of Radiation Therapy Oncology Group 83-02. ( Curran, WJ; Fischbach, AJ; Martin, LA; Murray, K; Nelson, JS; Phillips, TL; Schwade, JG; Scott, CB; Weinstein, AS; Yakar, D, 1993) |
| "This Phase III trial tested the efficacy and safety of intra-arterial 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) for the treatment of newly resected malignant glioma, comparing intra-arterial BCNU and intravenous BCNU (200 mg/sq m every 8 weeks), each regimen without or with intravenous 5-fluorouracil (1 gm/sq m three times daily given 2 weeks after BCNU)." | 9.07 | A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma. ( Burger, PC; Green, SB; Mahaley, MS; Mealey, J; Ransohff, J; Robertson, JT; Selker, RG; Shapiro, WR; VanGilder, JC, 1992) |
| " The protocol called for a randomized trial that compared the effects of following 60 Gy radiation/oral hydroxyurea treatment with either carmustine (BCNU) or the combination of procarbazine, lomustine (CCNU), and vincristine (PCV) for two histologic strata: glioblastoma multiforme and other anaplastic gliomas." | 9.06 | Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. ( Davis, RL; Gutin, PH; Hannigan, J; Levin, VA; Silver, P; Wara, WM; Wilson, CB, 1990) |
| "In Brain Tumor Cooperative Group Study 77-02, eleven institutions randomized 603 adult patients with supratentorial malignant glioma to one of four treatment groups following surgery: conventional radiotherapy (6000 cGy in 30-35 fractions) + BCNU, conventional radiotherapy + streptozotocin, hyperfractionated (twice daily) radiotherapy (6600 cGy in 60 fractions) + BCNU, and conventional radiotherapy with misonidazole followed by BCNU." | 9.06 | Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma. ( Burger, PC; Deutsch, M; Green, SB; Mealey, J; Paoletti, P; Ransohoff, J; Robertson, JT; Selker, RG; Shapiro, WR; Strike, TA, 1989) |
| "Carmustine (BCNU) was employed as the only chemotherapeutic agent in a Radiation Therapy Oncology Group multimodality study comparing misonidazole-radiosensitized radiation therapy to conventional radiation therapy in 318 patients with malignant glioma." | 9.06 | Pulmonary toxicity of carmustine in patients treated for malignant glioma. ( Diener-West, M; Nelson, DF; Pakuris, E; Weinstein, AS, 1986) |
| "This randomized RTOG study evaluated misonidazole radiosensitized radiation therapy in the treatment of malignant glioma." | 9.06 | A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery: final report of an RTOG study. ( Carabell, S; Chang, CH; Diener-West, M; Goodman, R; Nelson, DF; Nelson, JS; Sause, WT; Schoenfeld, D; Weinstein, AS, 1986) |
| "Diaziquone (AZQ) (NSC 182986), a lipid-soluble benzoquinone derivative, is presently being tested in a Phase III clinical trial to determine its efficacy in patients with anaplastic gliomas compared to the more standard 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) treatment following whole-brain irradiation." | 9.06 | Sister chromatid exchange induction in patients with anaplastic gliomas undergoing treatment with radiation plus diaziquone or 1,3-bis(2-chloroethyl)-1-nitrosourea. ( Erexson, GL; Kligerman, AD; Schold, SC; Wilmer, JL, 1987) |
| "Levamisole was evaluated as an immune stimulant in a randomized controlled study of patients with anaplastic gliomas, who had undergone surgical resection and who were also treated with radiotherapy and BCNU chemotherapy." | 9.05 | Immunobiology of primary intracranial tumors. Part 4: levamisole as an immune stimulant in patients and in the ASV glioma model. ( Aronin, P; Dudka, L; Mahaley, MS; Steinbok, P; Zinn, D, 1981) |
| "Within 3 weeks of definitive surgery, 609 patients with histologically demonstrated, supratentorial malignant glioma were randomized to receive, in addition to 6000 rads of radiotherapy, one of four treatment regimens: carmustine (BCNU), high-dose methylprednisolone, procarbazine, or BCNU plus high-dose methylprednisolone." | 9.05 | Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. ( Alexander, E; Batzdorf, U; Brooks, WH; Byar, DP; Green, SB; Hunt, WE; Mealey, J; Odom, GL; Paoletti, P; Pistenmaa, DA; Ransohoff, J; Robertson, JT; Selker, RG; Shapiro, WR; Smith, KR; Strike, TA; Walker, MD; Wilson, CB, 1983) |
| "A randomized prospective study was performed to evaluate misonidazole radiosensitized radiation therapy in the treatment of malignant glioma." | 9.05 | A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery; preliminary results of an RTOG study. ( Carabell, S; Goodman, RL; Nelson, DF; Nelson, JS; Schoenfeld, D; Wasserman, T; Weinstein, AS, 1983) |
| "The authors report the results of a randomized study conducted to evaluate the relative benefit of treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) or the combination of procarbazine, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, and vincristine (PCV) administered after radiation therapy with hydroxyurea to 76 evaluable patients with glioblastoma multiforme and 72 patients with other anaplastic gliomas." | 9.05 | Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas. ( Davis, RL; Gutin, PH; Levin, VA; Nutik, S; Resser, KJ; Vestnys, P; Wara, WM; Wilson, CB; Yatsko, K, 1985) |
| "There is a growing body of evidence that carmustine wafer implantation during surgery is an effective therapeutic adjunct to the standard combined radio-chemotherapy regimen using temozolomide in newly diagnosed and recurrent high-grade glioma patient management with a statistically significant survival benefit demonstrated across several randomized clinical trials, as well as prospective and retrospective studies (grade A recommendation)." | 8.95 | Carmustine wafer implantation for high-grade gliomas: Evidence-based safety efficacy and practical recommendations from the Neuro-oncology Club of the French Society of Neurosurgery. ( Caire, F; Guyotat, J; Menei, P; Metellus, P; Pallud, J; Roux, A, 2017) |
| "Carmustine wafers (CW; Gliadel(®) wafers) are approved to treat newly-diagnosed high-grade glioma (HGG) and recurrent glioblastoma." | 8.91 | Survival outcomes and safety of carmustine wafers in the treatment of high-grade gliomas: a meta-analysis. ( Chowdhary, SA; Newton, HB; Ryken, T, 2015) |
| "Significant advances in the encapsulation and release of drugs from degradable polymers have led to the Food and Drug Administration approval of Gliadel wafers for controlled local delivery of the chemotherapeutic drug carmustine to high-grade gliomas following surgical resection." | 8.90 | Modeling mass transfer from carmustine-loaded polymeric implants for malignant gliomas. ( Kamei, DT; Lee, BS; Pereira, DY; Yip, AT, 2014) |
| "Carmustine (1,3-bis [2-chloroethyl]-1-nitrosourea, or BCNU) wafers are approved for recurrent glioblastoma and newly diagnosed malignant glioma (MG)." | 8.84 | Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of clinical experience. ( Giese, A; Sabel, M, 2008) |
| "Widespread use of carmustine wafers (CWs) to treat high-grade gliomas (HGG) has been limited by uncertainties about their efficacy." | 8.31 | Newly Diagnosed High-Grade Glioma Surgery with Carmustine Wafers Implantation. A Long-Term Nationwide Retrospective Study. ( Champeaux-Depond, C; Constantinou, P; Jecko, V; Metellus, P; Tuppin, P; Weller, J, 2023) |
| "Widespread use of carmustine wafers (CW) to treat high-grade gliomas (HGG) has been limited by uncertainties about its efficacy." | 8.31 | Recurrent high grade glioma surgery with carmustine wafers implantation: a long-term nationwide retrospective study. ( Champeaux-Depond, C; Constantinou, P; Jecko, V; Metellus, P; Tuppin, P; Weller, J, 2023) |
| "Implantation of biodegradable Carmustine wafers in patients with malignant glioma is not generally recommended when the ventricular system is opened during tumor resection." | 8.02 | Implantation of Carmustine wafers after resection of malignant glioma with and without opening of the ventricular system. ( Abboud, T; Bettag, C; Bock, HC; Hussein, A; Mielke, D; Rohde, V; Sachkova, A, 2021) |
| "Given that FK506 binding protein 51 (FKBP51) is upregulated in multiple cancers, we designed the present study to characterize its role as well as underlying regulatory mechanisms in glioma in the presence and absence of the chemotherapeutic carmustine (BCNU)." | 7.96 | FKBP51 acts as a biomarker of early metastasis and is related to carmustine sensitivity in human glioma cells. ( Cui, B; Jiao, YL; Li, H; Liu, S; Liu, XW; Wang, LC; Zhao, YR; Zhou, RF, 2020) |
| "Carmustine wafers are approved for localized treatment of malignant glioma." | 7.83 | Evaluation of serial changes on computed tomography and magnetic resonance imaging after implantation of carmustine wafers in patients with malignant gliomas for differential diagnosis of tumor recurrence. ( Inoue, A; Kikuchi, K; Kohno, S; Kumon, Y; Ohnishi, T; Ohue, S; Seno, T; Suehiro, S; Yamashita, D, 2016) |
| "Carmustine (BCNU) wafer (Gliadel(®) Wafer) implantation after tumor resection is an approved treatment for high-grade glioma (HGG)." | 7.83 | Early Postoperative Expansion of Parenchymal High-intensity Areas on T2-weighted Imaging Predicts Delayed Cerebral Edema Caused by Carmustine Wafer Implantation in Patients with High-grade Glioma. ( Akutsu, H; Ishikawa, E; Kohzuki, H; Masuda, Y; Masumoto, T; Matsuda, M; Matsumura, A; Nakai, K; Okamoto, E; Takano, S; Yamamoto, T, 2016) |
| "The development of perifocal edema and tumor bed cyst has been reported after implantation of biodegradable carmustine wafers for the treatment of malignant gliomas." | 7.83 | The influence of carmustine wafer implantation on tumor bed cysts and peritumoral brain edema. ( Hasegawa, Y; Iuchi, T; Kawasaki, K; Sakaida, T; Yokoi, S, 2016) |
| "Taken together, these data strongly implicate an unexplored role of Nrf2 in glioma resistance to Carmustine and raise the possible use of Nrf2 inhibitors as adjunct to Carmustine for the treatment of malignant glioma." | 7.81 | Overexpression of Nrf2 attenuates Carmustine-induced cytotoxicity in U87MG human glioma cells. ( Alleyne, CH; Dhandapani, KM; Prasad, N; Sukumari-Ramesh, S; Vender, JR, 2015) |
| "Study the feasibility and effectiveness of a treatment associated surgery, intraoperative chemotherapy (carmustine wafers), and concomitant radiochemotherapy (temozolomide) for the management of newly diagnosed, high-grade gliomas." | 7.79 | Implanted carmustine wafers followed by concomitant radiochemotherapy to treat newly diagnosed malignant gliomas: prospective, observational, multicenter study on 92 cases. ( Colin, P; Debreuve, A; Duntze, J; Eap, C; Emery, E; Guillamo, JS; Jovenin, N; Lechapt-Zalcman, E; Litré, CF; Menei, P; Metellus, P; Peruzzi, P; Rousseaux, P; Théret, E, 2013) |
| " In this study, we have assessed the role of MDT in implementing the TA121 appraisal of the use of carmustine wafers in high grade gliomas." | 7.78 | NICE guidance on the use of carmustine wafers in high grade gliomas: a national study on variation in practice. ( Ashkan, K; Cruickshank, G; Grundy, P; Price, SJ; Whittle, IR, 2012) |
| "We hypothesized that the observed clinical synergy of orally administered TMZ and carmustine (BCNU) wafers would translate into even greater effectiveness with the local delivery of BCNU and TMZ and the addition of radiotherapy in animal models of malignant glioma." | 7.76 | Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model. ( Bekelis, K; Brem, H; Li, KW; Recinos, VR; Sunshine, SB; Tyler, BM; Vellimana, A, 2010) |
| "Temozolomide (TMZ) and carmustine (BCNU), cancer-drugs usually used in the treatment of gliomas, are DNA-methylating agents producing O6-methylguanine." | 7.75 | Temozolomide and carmustine cause large-scale heterochromatin reorganization in glioma cells. ( Cattaneo, E; Magrassi, L; Papait, R; Rigamonti, D, 2009) |
| "Transferrin (Tf), an iron-transporting serum glycoprotein, which binds to receptors expressed at the surface of most proliferating cells with particularly high expression on erythroblasts and cancer cells, was chosen as the ligand to develop BCNU-loaded biodegradable poly(D,L-lactic acid) nanoparticles (NPs) containing a ligand, which specifically binds to glioma cells, and their anti-tumor ability was evaluated using a C6 glioma model." | 7.75 | Growth inhibition against intracranial C6 glioma cells by stereotactic delivery of BCNU by controlled release from poly(D,L-lactic acid) nanoparticles. ( Albadany, A; Chang, J; Guo, Y; Kang, C; Li, Y; Pu, P; Sheng, J; Yu, S; Yuan, X; Zhang, Z; Zhong, Y, 2009) |
| " This was of interest because E6 silencing of p53 sensitizes U87MG astrocytic glioma cells to BCNU and temozolomide (TMZ), cytotoxic drugs that are modestly helpful in the treatment of aggressive astrocytic gliomas." | 7.73 | Pharmaceutical-mediated inactivation of p53 sensitizes U87MG glioma cells to BCNU and temozolomide. ( Cairncross, JG; Mymryk, JS; Xu, GW, 2005) |
| "To test in vitro and in vivo the safety and efficacy of a novel chemotherapeutic agent, KM-233, for the treatment of glioma." | 7.73 | Safety and efficacy of a novel cannabinoid chemotherapeutic, KM-233, for the treatment of high-grade glioma. ( Boehm, P; Divi, MK; Duntsch, C; Jones, T; Krishnamurthy, M; Moore, BM; Sills, A; Wood, G; Zhou, Q, 2006) |
| "The authors compared and characterized several new classes of camptothecin (CPT) analogs (a total of 22 drugs) directed against human and murine glioma cell lines in vitro, trying to identify CPT analogs that can be used for local therapy in future clinical trials." | 7.72 | Camptothecin analogs in malignant gliomas: comparative analysis and characterization. ( Alderson, LM; Amundson, E; Brem, H; Colvin, M; Sampath, P; Tyler, BM; Wall, ME; Wani, MC; Weingart, JD, 2003) |
| "Using a methylation-specific PCR approach, we assessed the methylation status of the CpG island of MGMT in 92 glioma patients who received temozolomide as first-line chemotherapy or as treatment for relapses." | 7.72 | CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. ( Aguirre-Cruz, L; Arribas, L; Balaña, C; Esteller, M; García-Lopez, JL; García-Villanueva, M; Paz, MF; Piquer, J; Pollan, M; Reynes, G; Rojas-Marcos, I; Safont, MJ; Sanchez-Cespedes, M; Yaya-Tur, R, 2004) |
| " To determine whether forced cell-cycle progression selectively sensitizes tumor cells to alkylating agents, we examined the effects of overexpressing the E2F-1 protein (a positive regulator of cell-cycle progression) on the sensitivity of two malignant human glioma cell lines, U-251 MG and D-54 MG, to BCNU and temozolomide." | 7.71 | Adenovirally-mediated transfer of E2F-1 potentiates chemosensitivity of human glioma cells to temozolomide and BCNU. ( Fueyo, J; Gomez-Manzano, C; Groves, MD; He, J; Hu, M; Lemoine, MG; Liu, TJ; Mitlianga, P; Yung, AW, 2001) |
| " We investigated whether quinacrine could improve carmustine therapy in C6 cell cultures and in C6 malignant gliomas implanted subcutaneously into Wistar rats." | 7.71 | Quinacrine enhances carmustine therapy of experimental rat glioma. ( Herrera, LA; Ostrosky, P; Reyes, S; Sotelo, J, 2001) |
| " Here, we examined the effects of 3-aminobenzamide, a poly(ADP-ribose) polymerase inhibitor, on the chemosensitivity of human malignant glioma cells." | 7.70 | Poly(ADP-ribose) polymerase-independent potentiation of nitrosourea cytotoxicity by 3-aminobenzamide in human malignant glioma cells. ( Weller, M; Winter, S, 2000) |
| "The authors previously demonstrated the presence of cells in primary human malignant gliomas that intrinsically are resistant to carmustine (BCNU)." | 7.70 | Identification of transforming growth factor-beta1-binding protein overexpression in carmustine-resistant glioma cells by MRNA differential display. ( Hoelzinger, DB; Norman, SA; Rankin Shapiro, J; Rhodes, SN; Scheck, AC; Treasurywala, S, 2000) |
| "We compared sequential single-agent BCNU and procarbazine (PCB) chemotherapy in 31 patients with gliomas [grade IV (10), grade III (15), grade II (6)]." | 7.68 | Comparison between BCNU and procarbazine chemotherapy for treatment of gliomas. ( Bromberg, J; Greenberg, HS; Junck, L; Newton, HB; Page, MA, 1993) |
| "Forty-five patients with malignant gliomas were treated after aggressive surgical resection with alternating intravenous carmustine and cisplatin both during and after radiation therapy." | 7.68 | Adjuvant chemotherapy with carmustine and cisplatin for patients with malignant gliomas. ( Feun, LG; Janus, TJ; Maor, M; Yung, WK, 1992) |
| "The effect of simvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on human glioma cell growth was investigated." | 7.68 | Simvastatin, an inhibitor of cholesterol biosynthesis, shows a synergistic effect with N,N'-bis(2-chloroethyl)-N-nitrosourea and beta-interferon on human glioma cells. ( Butti, G; Fumagalli, R; Pagliarini, P; Paoletti, P; Paoletti, R; Soma, MR, 1992) |
| "Biopsy samples and cultured cells derived from them were obtained from 39 patients with malignant glioma and were analyzed for 1) glutathione (GSH) content; 2) sensitivity to 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and/or nitrogen mustard (HN2) treatment and 3) the effect of buthionine sulfoximine (BSO) treatment on BCNU and/or HN2 cytotoxicity." | 7.68 | Glutathione levels and chemosensitizing effects of buthionine sulfoximine in human malignant glioma cells. ( Allalunis-Turner, MJ; Allen, PB; Aronyk, KE; Day, RS; Fulton, DS; Huyser-Wierenga, D; McKean, JD; Petruk, KC; Urtasun, RC; Weir, BK, 1991) |
| "The authors have used phosphorus magnetic resonance spectroscopy to monitor pH changes in malignant gliomas following treatment with intravenous and intra-arterial 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU)." | 7.67 | Early metabolic changes following chemotherapy of human gliomas in vivo demonstrated by phosphorus magnetic resonance spectroscopy. ( Arnold, DL; Emrich, J; Feindel, W; Shoubridge, EA; Villemure, JG, 1989) |
| "The Neuro-oncology Service of the University of California Brain Tumor Research Center conducted a nonrandomized phase II study to evaluate, in patients with recurrent malignant glioma, the benefit of a four-drug combination (BFHM) consisting of carmustine (1,3-bis (2-chloroethyl)-1-nitrosourea), 5-fluorouracil, hydroxyurea, and 6-mercaptopurine." | 7.67 | Phase II study of combined carmustine, 5-fluorouracil, hydroxyurea, and 6-mercaptopurine (BFHM) for the treatment of malignant gliomas. ( Berger, M; Chamberlain, M; Choucair, A; Da Silva, V; Davis, RL; Levin, VA; Liu, HC; Murovic, J; Phuphanich, S; Seager, M, 1986) |
| "A therapeutic regimen is described for sedative, analgesic, and anti-emetic effect in patients receiving intra-arterial carmustine (BCNU) for malignant gliomas." | 7.67 | Nalbuphine and droperidol in combination for sedation and prevention of nausea and vomiting during intra-carotid BCNU infusion. ( Klein, DS; Klein, PW; Mahaley, MS, 1986) |
| "Using the avian sarcoma virus (ASV) rat glioma model, we have evaluated the in vivo effectiveness of two lipid-soluble folate antagonists, metoprine (DDMP) and its 6-ethyl analog etoprine." | 7.66 | Evaluation of the lipid-soluble diaminopyrimidines, metoprine and etoprine, in the avian sarcoma virus rat glioma model. ( Bigner, DD; Nichol, CA; Serano, RD; Sigel, CW, 1982) |
| "We conducted a study to determine the dose-limiting toxicity of an extended dosing schedule of temozolomide (TMZ) when used with a fixed dose of BCNU, or 1,3-bis(2-chloroethyl)-1-nitrosourea (carmustine), taking advantage of TMZ's ability to deplete O6-alkylguanine-DNA-alkyltransferase and the synergistic activity of these two agents." | 6.71 | Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy. ( Abrey, LE; Kleber, M; Malkin, MG; Raizer, JJ, 2004) |
| "Carmustine (BCNU) has proved to be of value against a variety of primary brain tumors." | 6.68 | High-dose carmustine for high-grade gliomas in childhood. ( Biron, P; Bouffet, E; Brunat-Mentigny, M; Khelfaoui, F; Philip, I; Philip, T, 1997) |
| "Irinotecan is a water-soluble derivative of camptothecin, an alkylator originally extracted from the Chinese tree Camptotheca acuminata." | 6.42 | The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors. ( Friedman, HS; Houghton, PJ; Keir, ST, 2003) |
| "Gliomas are the most common brain tumors in humans." | 5.51 | A novel strategy to the formulation of carmustine and bioactive nanoparticles co-loaded PLGA biocomposite spheres for targeting drug delivery to glioma treatment and nursing care. ( Jie, C; Yang, F; Yi, S; Zhang, G, 2019) |
| "Gliomas are accompanied with high mortality owning to their invasive peculiarity and vulnerability to drug resistance." | 5.46 | MiR-21 enhanced glioma cells resistance to carmustine via decreasing Spry2 expression. ( Hu, J; Liu, JH; Wang, GB; Xue, K, 2017) |
| "High-grade gliomas are aggressive brain tumours that are extremely challenging to treat effectively." | 5.35 | Carmustine implants for the treatment of newly diagnosed high-grade gliomas: a cost-utility analysis. ( Anderson, R; Dyer, M; Garside, R; Mealing, S; Pitt, M; Rogers, G; Somerville, M; Stein, K, 2008) |
| "Thalidomide is a racemate with known pharmacologic and pharmacokinetic enantioselectivity." | 5.34 | Enantioselectivity of thalidomide serum and tissue concentrations in a rat glioma model and effects of combination treatment with cisplatin and BCNU. ( Boyle, FM; Davey, RA; Gu, XQ; Mather, LE; Murphy, S, 2007) |
| "Temozolomide (TMZ) is a methylating agent which prolongs survival when administered during and after radiotherapy in the first-line treatment of glioblastoma and which also has significant activity in recurrent disease." | 5.33 | O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. ( Hermisson, M; Kaina, B; Klumpp, A; Nagel, G; Roos, W; Weller, M; Wick, W; Wischhusen, J, 2006) |
| " Dose-response studies with SH-6 administered to glioma cell lines were performed using a luminescent cell-viability assay (0." | 5.33 | Cotreatment with a novel phosphoinositide analogue inhibitor and carmustine enhances chemotherapeutic efficacy by attenuating AKT activity in gliomas. ( Broaddus, WC; Cash, D; Fillmore, H; Van Meter, TE, 2006) |
| "Fotemustine is a chloroethylnitrosourea with antitumor activity in disseminated melanoma and adult primary brain tumors." | 5.30 | Activity of fotemustine in medulloblastoma and malignant glioma xenografts in relation to O6-alkylguanine-DNA alkyltransferase and alkylpurine-DNA N-glycosylase activity. ( Boland, I; Gouyette, A; Lacroix, C; Lellouch-Tubiana, A; Margison, GP; Morizet, J; Parker, F; Pierre-Kahn, A; Poullain, MG; Terrier-Lacombe, MJ; Vassal, G; Vénuat, AM; Watson, AJ, 1998) |
| " Additionally, we compared the antitumoral effect of protamine with that of another inhibitor of angiogenesis, suramin, and investigated a potential synergistic antitumoral action of low doses of protamine combined with the antineoplastic carmustine." | 5.30 | Protamine inhibits angiogenesis and growth of C6 rat glioma; a synergistic effect when combined with carmustine. ( Arrieta, O; Guevara, P; Ortiz, A; Rembao, D; Reyes, S; Sotelo, J, 1998) |
| "Temozolomide (TMZ) and BCNU have demonstrated anti-glioma synergism in preclinical models." | 5.20 | BCNU wafer placement with temozolomide (TMZ) in the immediate postoperative period after tumor resection followed by radiation therapy with TMZ in patients with newly diagnosed high grade glioma: final results of a prospective, multi-institutional, phase ( Ashby, L; Asher, AL; Blaker, BD; Boltes, P; Brick, W; Burri, SH; Heideman, BE; Judy, K; Kelly, R; Norton, HJ; Prabhu, RS; Sumrall, AL; Symanowski, JT; Wiggins, WF, 2015) |
| "Patients with high-grade glioma can be treated with carmustine wafers or following the Stupp protocol." | 5.16 | Prognostic factors and survival in a prospective cohort of patients with high-grade glioma treated with carmustine wafers or temozolomide on an intention-to-treat basis. ( Aurrecoechea-Obieta, J; Bilbao-Barandica, G; Canales-Llantada, M; Carbayo-Lozano, G; Catalán-Uribarrena, G; Galbarriatu-Gutiérrez, L; Igartua-Azkune, A; Pomposo-Gaztelu, I; Ruiz de Gopegui-Ruiz, E; Undabeitia-Huertas, J, 2012) |
| "From February 2006 to January 2008, 32 patients were treated at our institution for cerebral supratentorial high grade glioma with surgery and intraoperative placement of carmustine wafers." | 5.15 | Safety and feasibility of the adjunct of local chemotherapy with biodegradable carmustine (BCNU) wafers to the standard multimodal approach to high grade gliomas at first diagnosis. ( Brogna, C; D'elia, A; Delfini, R; Frati, A; Salvati, M; Santoro, A, 2011) |
| "Anticonvulsant therapy is usually recommended before surgery in all patients affected by high grade glioma who are planned to be treated with Carmustine 1,3-bis [2 chloroetyl]-1-nitrosurea, or BCNU) wafers." | 5.15 | Postoperative seizure in high grade glioma patients treated with BCNU wafers. A mono-institutional experience. ( Ciccarino, P; d'Avella, D; Del Moro, G; Della Puppa, A; Denaro, L; Lombardi, G; Manara, R; Rossetto, M; Rotilio, A; Scienza, R, 2011) |
| "Carmustine (1,3-bis[2-chloroetyl]-1-nitrosurea (BCNU)) wafers are approved for the local treatment of newly diagnosed and recurrent malignant glioma." | 5.14 | The first 3 months after BCNU wafers implantation in high-grade glioma patients: clinical and radiological considerations on a clinical series. ( Ciccarino, P; d'Avella, D; Del Moro, G; Della Puppa, A; Denaro, L; Manara, R; Paola Gardiman, M; Rossetto, M; Rotilio, A; Scienza, R, 2010) |
| "Temozolomide (TMZ) and 1, 3-bis (2-chloroethyl)-1-nitrosourea (BCNU) are reported to be active agents in anaplastic glioma (AG)." | 5.11 | Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial. ( Chang, SM; Fine, H; Fink, KL; Greenberg, H; Hess, K; Jaeckle, KA; Junck, L; Kuhn, J; Mehta, M; Prados, MD; Robins, HI; Schold, C; Yung, WK, 2004) |
| "In preclinical studies, BCNU, or 1,3-bis(2-chloroethyl)-1-nitrosourea, plus CPT-11 (irinotecan) exhibits schedule-dependent, synergistic activity against malignant glioma (MG)." | 5.11 | Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma. ( Affronti, ML; Allen, D; Badruddoja, M; Bigner, DD; Bohlin, C; Dowell, JM; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jackson, S; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Silverman, S; Tourt-Uhlig, S; Vredenburgh, J; Walker, A; Ziegler, K, 2004) |
| "Irinotecan is a topoisomerase I inhibitor previously shown to be active in the treatment of malignant glioma." | 5.11 | Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma. ( Affronti, ML; Allen, D; Bigner, DD; Bohlin, C; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jackson, S; Lentz, C; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Schweitzer, H; Tourt-Uhlig, S; Vredenburgh, J; Walker, A; Ziegler, K, 2004) |
| "The study involved a randomized comparison of surgery, external beam radiotherapy, and carmustine (BCNU) versus surgery, external beam therapy, interstitial radiotherapy boost, and BCNU in newly diagnosed malignant gliomas." | 5.10 | The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. ( Albright, R; Arena, VC; Barnett, GH; Blackwood, MS; Bloomfield, S; Burger, P; Gilder, JC; Green, S; Hiesiger, E; Hochberg, FH; Malkin, MG; Mealey, JJ; Neal, JH; Olson, J; Robertson, JT; Selker, RG; Shapiro, WR, 2002) |
| "This New Approaches to Brain Tumor Therapy CNS Consortium study sought to determine the maximum-tolerated dose (MTD) of carmustine (BCNU) that can be implanted in biodegradable polymers following resection of recurrent high-grade gliomas and the systemic BCNU exposure with increasing doses of interstitial BCNU." | 5.10 | Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a New Approaches to Brain Tumor Therapy CNS Consortium trial. ( Barker, F; Bruce, J; Fisher, J; Grossman, SA; Hilt, D; Judy, K; Olivi, A; Olsen, J; Piantadosi, S; Tatter, S, 2003) |
| "The use of thalidomide as an antiangiogenic agent has met with only limited success in the treatment of malignant gliomas." | 5.10 | Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. ( Batchelor, T; Borkowf, CB; Figg, WD; Fine, HA; Lakhani, N; Maher, EA; Purow, BW; Viscosi, E; Wen, PY, 2003) |
| "We conducted a phase II trial of carmustine (BCNU) plus the O(6)-alkylguanine-DNA alkyltransferase inhibitor O(6)-benzylguanine (O(6)-BG) to define the activity and toxicity of this regimen in the treatment of adults with progressive or recurrent malignant glioma resistant to nitrosoureas." | 5.10 | Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. ( Bigner, DD; Colvin, OM; Delaney, S; Dolan, ME; Friedman, AH; Friedman, HS; Gururangan, S; Haglund, MM; Herndon, JE; Kaplan, R; McLendon, RE; Moschel, RC; Pegg, AE; Pluda, J; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Tourt-Uhlig, S, 2002) |
| "To investigate the safety of thrice-daily hyperfractionated radiotherapy (RT) given in conjunction with BCNU (carmustine) in high-grade gliomas." | 5.10 | Safety of thrice-daily hyperfractionated radiation and BCNU for high-grade gliomas. ( Buckner, JC; Dinapoli, RP; Earle, JD; O'Fallon, J; Rao, RD; Thomé, SD, 2002) |
| "A Phase I study was conducted to determine the safety, toxicity, and maximum tolerated dose of preirradiation chemotherapy using carmustine (BCNU) and cisplatin in the treatment of high-grade gliomas." | 5.09 | Phase I evaluation of preirradiation chemotherapy with carmustine and cisplatin and accelerated radiation therapy in patients with high-grade gliomas. ( Buckner, JC; Cascino, TL; Ingle, JN; Pitot, HC; Rajkumar, SV; Schomberg, PJ, 1999) |
| "The current study was conducted to determine whether the addition of interferon-alpha (IFN-alpha) to treatment with radiation therapy and carmustine (BCNU) improves time to disease progression or overall survival in patients with high-grade glioma." | 5.09 | A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade glioma. ( Bernath, AM; Buckner, JC; Cascino, TL; Cole, JT; Hatfield, AK; Kuross, SA; Mailliard, JA; McGinnis, WL; Morton, RF; O'Fallon, JR; Scheithauer, BW; Schomberg, PJ; Steen, PD, 2001) |
| "Intra-arterial chemotherapy with carmustine (BCNU) and interstitial radiation therapy with the use of stereotactically placed 125I sources are aggressive local therapies for malignant glioma." | 5.08 | Evaluating glioma therapies: modeling treatments and predicting outcomes. ( Brothers, M; Cairncross, G; Florell, R; Irish, W; Kirby, S; Macdonald, D; Schold, C, 1995) |
| " We conducted a randomised, placebo-controlled, prospective study to evaluate the effectiveness of biodegradable polymers impregnated with carmustine to treat recurrent malignant gliomas." | 5.08 | Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. ( Black, K; Brem, H; Brem, S; Burger, PC; Mohr, G; Piantadosi, S; Selker, R; Sisti, M; Vick, NA; Walker, M, 1995) |
| "To quantify the quality of life of malignant glioma patients treated on a randomized Phase I/II trial of twice-daily radiation therapy (RT) and carmustine, using a modified quality adjusted survival (QAS) model, and to compare the QAS among assigned treatment arms." | 5.08 | Quality-adjusted survival analysis of malignant glioma. Patients treated with twice-daily radiation (RT) and carmustine: a report of Radiation Therapy Oncology Group (RTOG) 83-02. ( Curran, WJ; Farnan, N; Fischbach, AJ; Murray, KJ; Nelson, DF; Porter, A; Scott, C, 1995) |
| "Twenty-two patients, aged 16 to 67, who had malignant gliomas after surgical resection were treated with carmustine and cisplatin intravenous infusion before, during, and after radiotherapy." | 5.08 | Combination chemotherapy with carmustine and cisplatin before, during, and after radiotherapy for adult malignant gliomas. ( Chang, CN; Chen, LH; Cheng, WC; Ho, YS; Kiu, MC; Leung, WM; Lin, TK; Ng, KT; Tang, SG; Wong, CW, 1995) |
| " Conventional phase II clinical trials conducted in patients with recurrent or progressive brainstem gliomas using single chemotherapy agents such as cyclophosphamide, carboplatin, cisplatin, etoposide and thiotepa or combinations of chemotherapy agents have produced low response rates in the range of 15-20%." | 5.08 | Contemporary chemotherapy issues for children with brainstem gliomas. ( Allen, JC; Siffert, J, 1996) |
| "To find out the effect of carmustine (bischloroethyl-nitrosourea) combined with a biodegradable polymer in the treatment of malignant (Grades III and IV) gliomas, applied locally, at the time of the primary operation." | 5.08 | Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. ( Heiskanen, O; Kalimo, H; Kivipelto, L; Kuurne, T; Timonen, U; Toivanen, P; Unsgaard, G; Valtonen, S, 1997) |
| "A Phase I study to determine the safety, toxicity, and maximum tolerated dose (MTD) of carmustine (BCNU) and interferon alpha-2a (IFN-a) when combined with radiation as initial therapy in high-grade glioma." | 5.08 | Phase I evaluation of radiation combined with recombinant interferon alpha-2a and BCNU for patients with high-grade glioma. ( Buckner, JC; Burch, PA; Cascino, TL; Dinapoli, RP; Rajkumar, SV; Schomberg, PJ, 1998) |
| "We conducted a Phase I study of bischloroethylnitrosourea (BCNU), cisplatin, and oral etoposide administered prior to and during accelerated hyperfractionated radiation therapy in newly diagnosed high-grade glioma." | 5.08 | Phase I and pharmacokinetic study of preirradiation chemotherapy with BCNU, cisplatin, etoposide, and accelerated radiation therapy in patients with high-grade glioma. ( Ames, MM; Bagniewski, PJ; Buckner, JC; Cascino, TL; Marks, RS; Rajkumar, SV; Reid, JM; Schomberg, PJ, 1998) |
| "We performed a randomized trial to compare survival distributions and toxicity of radiation therapy (RT) and PCNU with those of RT and carmustine (BCNU) in patients with malignant glioma." | 5.07 | Phase III comparative evaluation of PCNU and carmustine combined with radiation therapy for high-grade glioma. ( Arusell, RM; Brown, LD; Buckner, JC; Dinapoli, RP; Earle, JD; Krook, JE; Maier, JA; O'Fallon, JR; Scheithauer, BW; Tschetter, LK, 1993) |
| "We conducted a phase III trial comparing intravenous (IV) diaziquone (AZQ) and carmustine (BCNU) as single agents in patients with cerebral anaplastic gliomas who had received surgery and radiotherapy." | 5.07 | Randomized comparison of diaziquone and carmustine in the treatment of adults with anaplastic glioma. ( Bigner, DD; Burger, PC; Cairncross, JG; Dropcho, EJ; Halperin, EC; Herndon, JE; Macdonald, DR; Morawetz, R; Schold, SC; Vick, NA, 1993) |
| "The purpose is twofold: (1) to identify the malignant glioma patients treated in a trial of hyperfractionated radiotherapy (RT) and carmustine (BCNU) who may have been eligible for a stereotactic radiosurgery (SRS) boost; and (2) to compare survival of such patients with that of those considered SRS-ineligible." | 5.07 | Survival comparison of radiosurgery-eligible and -ineligible malignant glioma patients treated with hyperfractionated radiation therapy and carmustine: a report of Radiation Therapy Oncology Group 83-02. ( Curran, WJ; Fischbach, AJ; Martin, LA; Murray, K; Nelson, JS; Phillips, TL; Schwade, JG; Scott, CB; Weinstein, AS; Yakar, D, 1993) |
| "This Phase III trial tested the efficacy and safety of intra-arterial 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) for the treatment of newly resected malignant glioma, comparing intra-arterial BCNU and intravenous BCNU (200 mg/sq m every 8 weeks), each regimen without or with intravenous 5-fluorouracil (1 gm/sq m three times daily given 2 weeks after BCNU)." | 5.07 | A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma. ( Burger, PC; Green, SB; Mahaley, MS; Mealey, J; Ransohff, J; Robertson, JT; Selker, RG; Shapiro, WR; VanGilder, JC, 1992) |
| "Seventy-nine patients with malignant gliomas (19 anaplastic astrocytomas and 60 glioblastoma multiforme) received 4 cycles of infra-ophthalmic carotid injection of 160 mg carmustine, 2 mg vincristine IV and procarbazine orally 50 mg 3 times daily for 1 week, followed by whole-brain irradiation, with a midpoint dose of 54 Gy/6 weeks." | 5.07 | Combined intra-arterial chemotherapy and irradiation of malignant gliomas. ( Hager, B; Hirschberg, H; Nome, O; Watne, K, 1991) |
| " The protocol called for a randomized trial that compared the effects of following 60 Gy radiation/oral hydroxyurea treatment with either carmustine (BCNU) or the combination of procarbazine, lomustine (CCNU), and vincristine (PCV) for two histologic strata: glioblastoma multiforme and other anaplastic gliomas." | 5.06 | Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. ( Davis, RL; Gutin, PH; Hannigan, J; Levin, VA; Silver, P; Wara, WM; Wilson, CB, 1990) |
| "In Brain Tumor Cooperative Group Study 77-02, eleven institutions randomized 603 adult patients with supratentorial malignant glioma to one of four treatment groups following surgery: conventional radiotherapy (6000 cGy in 30-35 fractions) + BCNU, conventional radiotherapy + streptozotocin, hyperfractionated (twice daily) radiotherapy (6600 cGy in 60 fractions) + BCNU, and conventional radiotherapy with misonidazole followed by BCNU." | 5.06 | Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma. ( Burger, PC; Deutsch, M; Green, SB; Mealey, J; Paoletti, P; Ransohoff, J; Robertson, JT; Selker, RG; Shapiro, WR; Strike, TA, 1989) |
| "Within 3 weeks of definitive surgery, 571 adult patients with histologically confirmed, supratentorial malignant gliomas were randomly assigned to receive one of three chemotherapy regimens: BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea) alone, alternating courses (every 8 weeks) of BCNU and procarbazine, or BCNU plus hydroxyurea alternating with procarbazine plus VM-26 (epipodophyllotoxin)." | 5.06 | Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001. ( Burger, PC; Green, SB; Mahaley, MS; Mealey, J; Ransohoff, J; Robertson, JT; Selker, RG; Shapiro, WR; Strike, TA; VanGilder, JC, 1989) |
| "The Radiation Therapy Oncology Group (RTOG) and the Eastern Cooperative Oncology Group (ECOG) conducted a phase III trial in patients with malignant gliomas to evaluate 4 treatment arms: 1) 60 Gy to the whole brain; 2) 60 Gy plus 10-Gy boost; 3) 60 Gy plus carmustine (BCNU); and 4) 60 Gy plus semustine plus dacarbazine." | 5.06 | Combined modality approach to treatment of malignant gliomas--re-evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and the Eastern Cooperative Oncology Group. ( Chang, CH; Diener-West, M; Horton, J; Nelson, DF; Nelson, JS; Schoenfeld, D, 1988) |
| "Carmustine (BCNU) was employed as the only chemotherapeutic agent in a Radiation Therapy Oncology Group multimodality study comparing misonidazole-radiosensitized radiation therapy to conventional radiation therapy in 318 patients with malignant glioma." | 5.06 | Pulmonary toxicity of carmustine in patients treated for malignant glioma. ( Diener-West, M; Nelson, DF; Pakuris, E; Weinstein, AS, 1986) |
| "This randomized RTOG study evaluated misonidazole radiosensitized radiation therapy in the treatment of malignant glioma." | 5.06 | A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery: final report of an RTOG study. ( Carabell, S; Chang, CH; Diener-West, M; Goodman, R; Nelson, DF; Nelson, JS; Sause, WT; Schoenfeld, D; Weinstein, AS, 1986) |
| "Diaziquone (AZQ) (NSC 182986), a lipid-soluble benzoquinone derivative, is presently being tested in a Phase III clinical trial to determine its efficacy in patients with anaplastic gliomas compared to the more standard 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) treatment following whole-brain irradiation." | 5.06 | Sister chromatid exchange induction in patients with anaplastic gliomas undergoing treatment with radiation plus diaziquone or 1,3-bis(2-chloroethyl)-1-nitrosourea. ( Erexson, GL; Kligerman, AD; Schold, SC; Wilmer, JL, 1987) |
| "Levamisole was evaluated as an immune stimulant in a randomized controlled study of patients with anaplastic gliomas, who had undergone surgical resection and who were also treated with radiotherapy and BCNU chemotherapy." | 5.05 | Immunobiology of primary intracranial tumors. Part 4: levamisole as an immune stimulant in patients and in the ASV glioma model. ( Aronin, P; Dudka, L; Mahaley, MS; Steinbok, P; Zinn, D, 1981) |
| "Within 3 weeks of definitive surgery, 609 patients with histologically demonstrated, supratentorial malignant glioma were randomized to receive, in addition to 6000 rads of radiotherapy, one of four treatment regimens: carmustine (BCNU), high-dose methylprednisolone, procarbazine, or BCNU plus high-dose methylprednisolone." | 5.05 | Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. ( Alexander, E; Batzdorf, U; Brooks, WH; Byar, DP; Green, SB; Hunt, WE; Mealey, J; Odom, GL; Paoletti, P; Pistenmaa, DA; Ransohoff, J; Robertson, JT; Selker, RG; Shapiro, WR; Smith, KR; Strike, TA; Walker, MD; Wilson, CB, 1983) |
| "A randomized prospective study was performed to evaluate misonidazole radiosensitized radiation therapy in the treatment of malignant glioma." | 5.05 | A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery; preliminary results of an RTOG study. ( Carabell, S; Goodman, RL; Nelson, DF; Nelson, JS; Schoenfeld, D; Wasserman, T; Weinstein, AS, 1983) |
| "Within three weeks of definitive surgical intervention, 467 patients with histologically proved malignant glioma were randomized to receive one of four treatment regimens: semustine (MeCCNU), radiotherapy, carmustine (BCNU) plus radiotherapy, or semustine plus radiotherapy." | 5.05 | Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. ( Alexander, E; Batzdorf, U; Brooks, WH; Byar, DP; Green, SB; Hunt, WE; MacCarty, CS; Mahaley, MS; Mealey, J; Owens, G; Ransohoff, J; Robertson, JT; Shapiro, WR; Smith, KR; Strike, TA; Walker, MD; Wilson, CB, 1980) |
| "The authors report the results of a randomized study conducted to evaluate the relative benefit of treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) or the combination of procarbazine, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, and vincristine (PCV) administered after radiation therapy with hydroxyurea to 76 evaluable patients with glioblastoma multiforme and 72 patients with other anaplastic gliomas." | 5.05 | Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas. ( Davis, RL; Gutin, PH; Levin, VA; Nutik, S; Resser, KJ; Vestnys, P; Wara, WM; Wilson, CB; Yatsko, K, 1985) |
| "There is a growing body of evidence that carmustine wafer implantation during surgery is an effective therapeutic adjunct to the standard combined radio-chemotherapy regimen using temozolomide in newly diagnosed and recurrent high-grade glioma patient management with a statistically significant survival benefit demonstrated across several randomized clinical trials, as well as prospective and retrospective studies (grade A recommendation)." | 4.95 | Carmustine wafer implantation for high-grade gliomas: Evidence-based safety efficacy and practical recommendations from the Neuro-oncology Club of the French Society of Neurosurgery. ( Caire, F; Guyotat, J; Menei, P; Metellus, P; Pallud, J; Roux, A, 2017) |
| " Area covered: The development of interstitial biodegradable carmustine wafers (Gliadel) for treating selected patients with malignant gliomas has resulted in marginal survival benefits in such patients (only approximately 2 months longer than that of those who did not receive the treatment)." | 4.93 | Advanced interstitial chemotherapy for treating malignant glioma. ( Kau, YC; Liu, SJ; Tseng, YY, 2016) |
| "Carmustine wafers (CW; Gliadel(®) wafers) are approved to treat newly-diagnosed high-grade glioma (HGG) and recurrent glioblastoma." | 4.91 | Survival outcomes and safety of carmustine wafers in the treatment of high-grade gliomas: a meta-analysis. ( Chowdhary, SA; Newton, HB; Ryken, T, 2015) |
| "Significant advances in the encapsulation and release of drugs from degradable polymers have led to the Food and Drug Administration approval of Gliadel wafers for controlled local delivery of the chemotherapeutic drug carmustine to high-grade gliomas following surgical resection." | 4.90 | Modeling mass transfer from carmustine-loaded polymeric implants for malignant gliomas. ( Kamei, DT; Lee, BS; Pereira, DY; Yip, AT, 2014) |
| "The 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; carmustine) polymer wafer (Gliadel) was developed for use in malignant glioma to deliver higher doses of chemotherapy directly to tumor tissue while bypassing systemic side effects." | 4.88 | The role of BCNU polymer wafers (Gliadel) in the treatment of malignant glioma. ( Nagpal, S, 2012) |
| "Carmustine (1,3-bis [2-chloroethyl]-1-nitrosourea, or BCNU) wafers are approved for recurrent glioblastoma and newly diagnosed malignant glioma (MG)." | 4.84 | Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of clinical experience. ( Giese, A; Sabel, M, 2008) |
| " Preclinical and phase I trials have shown the additive or synergistic activity of temozolomide combined with carmustine against solid tumors, including malignant glioma, and the sequence-dependent effects of the combination." | 4.81 | Temozolomide in combination with other cytotoxic agents. ( Prados, M, 2001) |
| "The median survival time of adults with supratentorial malignant glioma treated in clinical studies with surgery, 6 weeks of external-beam radiotherapy, and carmustine (BiCNU) is approximately 1 year." | 4.79 | Malignant gliomas in older adults with poor prognostic signs. Getting nowhere, and taking a long time to do it. ( Halperin, EC, 1995) |
| "Widespread use of carmustine wafers (CWs) to treat high-grade gliomas (HGG) has been limited by uncertainties about their efficacy." | 4.31 | Newly Diagnosed High-Grade Glioma Surgery with Carmustine Wafers Implantation. A Long-Term Nationwide Retrospective Study. ( Champeaux-Depond, C; Constantinou, P; Jecko, V; Metellus, P; Tuppin, P; Weller, J, 2023) |
| "Widespread use of carmustine wafers (CW) to treat high-grade gliomas (HGG) has been limited by uncertainties about its efficacy." | 4.31 | Recurrent high grade glioma surgery with carmustine wafers implantation: a long-term nationwide retrospective study. ( Champeaux-Depond, C; Constantinou, P; Jecko, V; Metellus, P; Tuppin, P; Weller, J, 2023) |
| " Model hydrophobic drugs carmustine and curcumin entrapment propelled glioma cells into apoptosis-based death evaluated by in vitro cytotoxicity assays and Western blot." | 4.12 | Supramolecular Hydrogel Based Post-Surgical Implant System for Hydrophobic Drug Delivery Against Glioma Recurrence. ( Ann Paul, R; James, J; Kumar, GSV; Sivakumar, KC; Sunil Jaikumar, V; Wanjale, MV, 2022) |
| "Factors predicting adverse events following implantation with wafers containing 1,3-bis(2-chloroethyl)-1-nitrosourea (carmustine, BCNU), which is used in local chemotherapy for malignant gliomas (MGs), are unknown." | 4.12 | Cerebral Edema Due to Chemotherapeutic Wafer Implantation for Malignant Glioma: Registry Study of Correlation with Perioperative Epileptic Seizures. ( Fujii, Y; Goto, T; Hanaoka, Y; Hardian, RF; Hongo, K; Horiuchi, T; Kato, H; Ogiwara, T, 2022) |
| "Clinical trial data of Carmustine implant (Gliadel Wafer) in Japanese patients with malignant glioma are limited; thus, we conducted a postmarketing surveillance study to evaluate the safety of Gliadel in real-world clinical practice in Japan." | 4.02 | Safety of Gliadel Implant for Malignant Glioma: Report of Postmarketing Surveillance in Japan. ( Iwata, H; Matsuoka, T; Muramoto, K; Nishikawa, R; Sakata, Y, 2021) |
| "Implantation of biodegradable Carmustine wafers in patients with malignant glioma is not generally recommended when the ventricular system is opened during tumor resection." | 4.02 | Implantation of Carmustine wafers after resection of malignant glioma with and without opening of the ventricular system. ( Abboud, T; Bettag, C; Bock, HC; Hussein, A; Mielke, D; Rohde, V; Sachkova, A, 2021) |
| "Carmustine wafers (CW) are approved to treat newly or recurrent high-grade gliomas (HGG)." | 3.96 | Implantation of carmustine wafers (Gliadel ( Champeaux, C; Weller, J, 2020) |
| "Given that FK506 binding protein 51 (FKBP51) is upregulated in multiple cancers, we designed the present study to characterize its role as well as underlying regulatory mechanisms in glioma in the presence and absence of the chemotherapeutic carmustine (BCNU)." | 3.96 | FKBP51 acts as a biomarker of early metastasis and is related to carmustine sensitivity in human glioma cells. ( Cui, B; Jiao, YL; Li, H; Liu, S; Liu, XW; Wang, LC; Zhao, YR; Zhou, RF, 2020) |
| "Although carmustine (Gliadel) wafers improve local tumor control and extend the overall survival in patients with malignant glioma, adverse effects have been documented." | 3.85 | Eosinophilic meningitis triggered by implanted Gliadel wafers: case report. ( Ivanova, A; Saito, K; Sato, Y; Takeishi, G; Takeshima, H; Yamasaki, K; Yokogami, K, 2017) |
| "Carmustine wafers are approved for localized treatment of malignant glioma." | 3.83 | Evaluation of serial changes on computed tomography and magnetic resonance imaging after implantation of carmustine wafers in patients with malignant gliomas for differential diagnosis of tumor recurrence. ( Inoue, A; Kikuchi, K; Kohno, S; Kumon, Y; Ohnishi, T; Ohue, S; Seno, T; Suehiro, S; Yamashita, D, 2016) |
| "Carmustine (BCNU) wafer (Gliadel(®) Wafer) implantation after tumor resection is an approved treatment for high-grade glioma (HGG)." | 3.83 | Early Postoperative Expansion of Parenchymal High-intensity Areas on T2-weighted Imaging Predicts Delayed Cerebral Edema Caused by Carmustine Wafer Implantation in Patients with High-grade Glioma. ( Akutsu, H; Ishikawa, E; Kohzuki, H; Masuda, Y; Masumoto, T; Matsuda, M; Matsumura, A; Nakai, K; Okamoto, E; Takano, S; Yamamoto, T, 2016) |
| "Carmustine (BCNU) wafer implantation has been used in Japanese patients after resection of high-grade glioma (HGG) since 2013." | 3.83 | [Intraoperative BCNU Wafer Implantation for High-Grade Glioma--A Questionnaire Targeting Japanese Neurosurgeons]. ( Ishikawa, E; Yamamoto, T, 2016) |
| "The development of perifocal edema and tumor bed cyst has been reported after implantation of biodegradable carmustine wafers for the treatment of malignant gliomas." | 3.83 | The influence of carmustine wafer implantation on tumor bed cysts and peritumoral brain edema. ( Hasegawa, Y; Iuchi, T; Kawasaki, K; Sakaida, T; Yokoi, S, 2016) |
| "Taken together, these data strongly implicate an unexplored role of Nrf2 in glioma resistance to Carmustine and raise the possible use of Nrf2 inhibitors as adjunct to Carmustine for the treatment of malignant glioma." | 3.81 | Overexpression of Nrf2 attenuates Carmustine-induced cytotoxicity in U87MG human glioma cells. ( Alleyne, CH; Dhandapani, KM; Prasad, N; Sukumari-Ramesh, S; Vender, JR, 2015) |
| " The proposed approach fares considerably better than previous approaches in simulations; data on the effectiveness of biodegradable carmustine polymers on recurrent brain malignant gliomas is investigated." | 3.80 | Accelerated hazards model based on parametric families generalized with Bernstein polynomials. ( Chen, Y; Hanson, T; Zhang, J, 2014) |
| "Study the feasibility and effectiveness of a treatment associated surgery, intraoperative chemotherapy (carmustine wafers), and concomitant radiochemotherapy (temozolomide) for the management of newly diagnosed, high-grade gliomas." | 3.79 | Implanted carmustine wafers followed by concomitant radiochemotherapy to treat newly diagnosed malignant gliomas: prospective, observational, multicenter study on 92 cases. ( Colin, P; Debreuve, A; Duntze, J; Eap, C; Emery, E; Guillamo, JS; Jovenin, N; Lechapt-Zalcman, E; Litré, CF; Menei, P; Metellus, P; Peruzzi, P; Rousseaux, P; Théret, E, 2013) |
| " In this study, we have assessed the role of MDT in implementing the TA121 appraisal of the use of carmustine wafers in high grade gliomas." | 3.78 | NICE guidance on the use of carmustine wafers in high grade gliomas: a national study on variation in practice. ( Ashkan, K; Cruickshank, G; Grundy, P; Price, SJ; Whittle, IR, 2012) |
| " The purpose of this study was to investigate the efficacy of concurrent therapy with 1,3 bis[2-chloroethyl]-1-nitrosourea (BCNU; carmustine) and Gamma Knife radiosurgery (GKRS; Gamma Knife® Model C, Elekta AB, Stockholm, Sweden) in the C6 rat glioma model." | 3.78 | Concurrent treatment with BCNU and Gamma Knife radiosurgery in the rat malignant glioma model. ( Cho, KT; Chung, HT; Jung, HW; Kim, DG; Paek, SH; Park, HW, 2012) |
| " Here we examine the extent of β-GUS release in small C6 glioma tumors after a single treatment of doxorubicin (DOX), carmustine (BCNU) and tumor necrosis factor α (TNF-α) with positron emission tomography (PET) and the tracer 1-O-(4-(2-fluoroethyl-carbamoyloxymethyl)-2-nitrophenyl)-O-β-d-glucopyronuronate, [(18)F]FEAnGA, which has been proven to be selective for extracellular β-GUS." | 3.78 | Induction of β-glucuronidase release by cytostatic agents in small tumors. ( Antunes, IF; de Vries, EF; Di Gialleonardo, V; Dierckx, RA; Elsinga, PH; Haisma, HJ; van Waarde, A; Willemsen, AT, 2012) |
| " Sixty nude rats were implanted with human glioma cells (U-87 MG) and randomized into three groups: one group received an anti-angiogenic treatment (Sorafenib), a second a cytotoxic drug [1,3-bis(2-chloroethyl)-1-nitrosourea, BCNU (Carmustine)] and a third no treatment." | 3.77 | Assessment of multiparametric MRI in a human glioma model to monitor cytotoxic and anti-angiogenic drug effects. ( Barbier, EL; Christen, T; Duchamp, O; Farion, R; Fondraz, N; Genne, P; Lemasson, B; Provent, P; Remy, C; Segebarth, C; Tizon, X, 2011) |
| "The introduction of temozolomide (TMZ) has advanced chemotherapy for malignant gliomas." | 3.76 | Inhibition of 90-kD heat shock protein potentiates the cytotoxicity of chemotherapeutic agents in human glioma cells. ( Hirose, Y; Kawase, T; Ohba, S; Yazaki, T; Yoshida, K, 2010) |
| "Carmustine (BCNU: N,N'-bis[2-chloroethyl]-N-nitrosourea) wafers are a local chemotherapeutic agent for the treatment of malignant glioma." | 3.76 | Incorporating BCNU wafers into malignant glioma treatment: European case studies. ( Balossier, A; Dörner, L; Emery, E; Heese, O; Mehdorn, HM; Menei, P; Singh, J, 2010) |
| "We hypothesized that the observed clinical synergy of orally administered TMZ and carmustine (BCNU) wafers would translate into even greater effectiveness with the local delivery of BCNU and TMZ and the addition of radiotherapy in animal models of malignant glioma." | 3.76 | Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model. ( Bekelis, K; Brem, H; Li, KW; Recinos, VR; Sunshine, SB; Tyler, BM; Vellimana, A, 2010) |
| "A retrospective multicenter study was conducted in 26 French Departments of Neurosurgery to analyze practices of French neurosurgeons using Gliadel, compare the adverse effects and survival with those of previous phase III trials, and assess survival in patients with newly diagnosed malignant gliomas (MG) receiving Gliadel plus radiochemotherapy with temozolomide (TMZ)." | 3.76 | Biodegradable carmustine wafers (Gliadel) alone or in combination with chemoradiotherapy: the French experience. ( Capelle, L; Guyotat, J; Jacquet, G; Loiseau, H; Menei, P; Metellus, P; Parot-Schinkel, E, 2010) |
| "Temozolomide (TMZ) and carmustine (BCNU), cancer-drugs usually used in the treatment of gliomas, are DNA-methylating agents producing O6-methylguanine." | 3.75 | Temozolomide and carmustine cause large-scale heterochromatin reorganization in glioma cells. ( Cattaneo, E; Magrassi, L; Papait, R; Rigamonti, D, 2009) |
| "Transferrin (Tf), an iron-transporting serum glycoprotein, which binds to receptors expressed at the surface of most proliferating cells with particularly high expression on erythroblasts and cancer cells, was chosen as the ligand to develop BCNU-loaded biodegradable poly(D,L-lactic acid) nanoparticles (NPs) containing a ligand, which specifically binds to glioma cells, and their anti-tumor ability was evaluated using a C6 glioma model." | 3.75 | Growth inhibition against intracranial C6 glioma cells by stereotactic delivery of BCNU by controlled release from poly(D,L-lactic acid) nanoparticles. ( Albadany, A; Chang, J; Guo, Y; Kang, C; Li, Y; Pu, P; Sheng, J; Yu, S; Yuan, X; Zhang, Z; Zhong, Y, 2009) |
| "DNA alkylating agents including temozolomide (TMZ) and 1,3-bis[2-chloroethyl]-1-nitroso-urea (BCNU) are the most common form of chemotherapy in the treatment of gliomas." | 3.74 | The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents. ( Chen, CC; D'Andrea, A; Taniguchi, T, 2007) |
| "While the introduction of carmustine wafers (Gliadel wafers) into the tumor resection cavity has been shown to be a beneficial therapy for malignant glioma, it is recognized that clinically significant cerebral edema is a potential adverse effect." | 3.73 | Cerebral edema associated with Gliadel wafers: two case studies. ( Goebel, EA; Weber, EL, 2005) |
| " This was of interest because E6 silencing of p53 sensitizes U87MG astrocytic glioma cells to BCNU and temozolomide (TMZ), cytotoxic drugs that are modestly helpful in the treatment of aggressive astrocytic gliomas." | 3.73 | Pharmaceutical-mediated inactivation of p53 sensitizes U87MG glioma cells to BCNU and temozolomide. ( Cairncross, JG; Mymryk, JS; Xu, GW, 2005) |
| "To test in vitro and in vivo the safety and efficacy of a novel chemotherapeutic agent, KM-233, for the treatment of glioma." | 3.73 | Safety and efficacy of a novel cannabinoid chemotherapeutic, KM-233, for the treatment of high-grade glioma. ( Boehm, P; Divi, MK; Duntsch, C; Jones, T; Krishnamurthy, M; Moore, BM; Sills, A; Wood, G; Zhou, Q, 2006) |
| " The best dose (product of 4x10(6) cells) of TF was also combined with carmustine for experimental therapy in rats with C6 malignant glioma." | 3.73 | Interstitial transfer factor as adjuvant immunotherapy for experimental glioma. ( Arrieta, O; Estrada-Parra, S; Pedraza-Medina, B; Pérez, R; Pineda, B; Rodriguez-Ropon, A, 2005) |
| "The authors compared and characterized several new classes of camptothecin (CPT) analogs (a total of 22 drugs) directed against human and murine glioma cell lines in vitro, trying to identify CPT analogs that can be used for local therapy in future clinical trials." | 3.72 | Camptothecin analogs in malignant gliomas: comparative analysis and characterization. ( Alderson, LM; Amundson, E; Brem, H; Colvin, M; Sampath, P; Tyler, BM; Wall, ME; Wani, MC; Weingart, JD, 2003) |
| " Using the human malignant glioma cell lines U87, A172, LN18, and LN229, we examined effects of the PI3K inhibitor LY294002 on both apoptosis and cytotoxicity induced by chemotherapeutic agents, including antimicrotubule agents vincristine and paclitaxel, an alkylating agent 1,3-bis(2-chloroethyl)-1-nitrosourea, a topoisomerase II inhibitor etoposide, and a DNA cross-linking agent cisplatin (cis-diamminedichloroplatinum), and we compared the LY294002-induced enhancement of effects of those agents." | 3.72 | Synergistic augmentation of antimicrotubule agent-induced cytotoxicity by a phosphoinositide 3-kinase inhibitor in human malignant glioma cells. ( Hara, N; Moritake, K; Osago, H; Shingu, T; Terashima, M; Tsuchiya, M; Uemura, T; Yamada, K; Yamasaki, T, 2003) |
| "Using a methylation-specific PCR approach, we assessed the methylation status of the CpG island of MGMT in 92 glioma patients who received temozolomide as first-line chemotherapy or as treatment for relapses." | 3.72 | CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. ( Aguirre-Cruz, L; Arribas, L; Balaña, C; Esteller, M; García-Lopez, JL; García-Villanueva, M; Paz, MF; Piquer, J; Pollan, M; Reynes, G; Rojas-Marcos, I; Safont, MJ; Sanchez-Cespedes, M; Yaya-Tur, R, 2004) |
| " BCNU, fotemustin, and temozolomide dramatically increased the time of survival of the Hs683 oligodendroglioma-bearing mice, whereas temozolomide only induced a weak but nevertheless statistically significant increase in the U373 glioma-bearing mice." | 3.71 | Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy. ( Branle, F; Camby, I; Geurts-Moespot, A; Jeuken, J; Kiss, R; Lefranc, F; Salmon, I; Sprenger, S; Sweep, F, 2002) |
| "Poorly-differentiated human brain glioma xenografted nude mice were treated with carmustine(1, 3-bis-(2-chloroethyl)-1-nitrosourea, BCNU) and sodium phenylbutyrate (SPB)." | 3.71 | [Experimental study of combination therapy against human glioma xenograft by differentiation-inducing agent and cytotoxic chemotherapeutic drug]. ( Dong, J; Huang, Q; Lan, Q; Shi, MG; Sun, ZF, 2002) |
| " To determine whether forced cell-cycle progression selectively sensitizes tumor cells to alkylating agents, we examined the effects of overexpressing the E2F-1 protein (a positive regulator of cell-cycle progression) on the sensitivity of two malignant human glioma cell lines, U-251 MG and D-54 MG, to BCNU and temozolomide." | 3.71 | Adenovirally-mediated transfer of E2F-1 potentiates chemosensitivity of human glioma cells to temozolomide and BCNU. ( Fueyo, J; Gomez-Manzano, C; Groves, MD; He, J; Hu, M; Lemoine, MG; Liu, TJ; Mitlianga, P; Yung, AW, 2001) |
| " We investigated whether quinacrine could improve carmustine therapy in C6 cell cultures and in C6 malignant gliomas implanted subcutaneously into Wistar rats." | 3.71 | Quinacrine enhances carmustine therapy of experimental rat glioma. ( Herrera, LA; Ostrosky, P; Reyes, S; Sotelo, J, 2001) |
| "Eighteen patients had carmustine (BCNU) wafers implanted during reoperation for malignant glioma; three patients had empty, placebo wafers placed." | 3.70 | Serial CT and MR imaging of carmustine wafers. ( Chiowanich, P; Cozzens, JW; Gorey, MT; Grenier, Y; Meyer, JR; Prager, JM, 2000) |
| " Here, we examined the effects of 3-aminobenzamide, a poly(ADP-ribose) polymerase inhibitor, on the chemosensitivity of human malignant glioma cells." | 3.70 | Poly(ADP-ribose) polymerase-independent potentiation of nitrosourea cytotoxicity by 3-aminobenzamide in human malignant glioma cells. ( Weller, M; Winter, S, 2000) |
| " Survival data from an actual randomized placebo-controlled trial, which evaluates the effectiveness of biodegradable polymers with carmustine to treat malignant gliomas, is used for illustration." | 3.70 | Estimating a treatment effect with the accelerated hazards models. ( Chen, YQ; Wang, M, 2000) |
| "Carmustine and lomustine are nitrosourea antitumor chemotherapeutic agents which were used to determine whether or not they could affect arylamine N-acetyltransferase (NAT) activity and DNA-2-aminofluorene adducts in rat glial tumor cell line (C6 glioma)." | 3.70 | Effects of carmustine and lomustine on arylamine N-acetyltransferase activity and 2-aminofluorene-DNA adducts in rat glial tumor cells. ( Hung, CF, 2000) |
| "The authors previously demonstrated the presence of cells in primary human malignant gliomas that intrinsically are resistant to carmustine (BCNU)." | 3.70 | Identification of transforming growth factor-beta1-binding protein overexpression in carmustine-resistant glioma cells by MRNA differential display. ( Hoelzinger, DB; Norman, SA; Rankin Shapiro, J; Rhodes, SN; Scheck, AC; Treasurywala, S, 2000) |
| " The present studies examined the ability of injectable polymeric microspheres, formulated to release carboplatin or BCNU for 2-3 weeks, to enhance survival in a rodent model of surgically-resected glioma." | 3.70 | Injectable chemotherapeutic microspheres and glioma I: enhanced survival following implantation into the cavity wall of debulked tumors. ( Bartus, RT; Emerich, DF; Hasler, BP; Hu, Y; LaFreniere, D; Marsh, J; Snodgrass, P; Wiens, T; Winn, SR, 2000) |
| " The present studies examined the ability of injectable microspheres, formulated to release carboplatin or BCNU for 2-3 weeks, to enhance survival in a rodent model of deep, inoperable glioma." | 3.70 | Injectable chemotherapeutic microspheres and glioma II: enhanced survival following implantation into deep inoperable tumors. ( Agostino, M; Bartus, RT; Emerich, DF; LaFreniere, D; Snodgrass, P; Wiens, T; Winn, SR; Xiong, H, 2000) |
| " The gliomas were obtained from patients who had been treated with carmustine (1,3-bis(2-chloroethyl)-1-nitrosourea, or BCNU)." | 3.70 | Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. ( Andion, E; Baylin, SB; Esteller, M; Garcia-Foncillas, J; Goodman, SN; Herman, JG; Hidalgo, OF; Vanaclocha, V, 2000) |
| "Diffusion MRI could detect water diffusion changes in orthotopic 9L gliomas after doses of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU or carmustine) that resulted in as little as 0." | 3.70 | Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. ( Chenevert, TL; Greenberg, HS; Rehemtulla, A; Robertson, PL; Ross, BD; Stegman, LD; Taylor, JM, 2000) |
| "To evaluate the potential differential effect of pretreatment with pharmacologic doses of the trace element zinc on the chemosensitivity of glioma cells and bone marrow cells for carmustine (BCNU), we performed in vitro and in vivo studies of zinc toxicity as well as of the combined treatment with zinc and the anticancer drug." | 3.69 | Effect of pharmacologic doses of zinc on the therapeutic index of brain tumor chemotherapy with carmustine. ( Dougherty, DV; Doz, F; Roosen, N; Rosenblum, ML; Yeomans, KL, 1994) |
| "The effects of a combination of simvastatin, a cholesterol-lowering agent, and carmustine (BCNU; N,N'-bis(2-chloroethyl)-N-nitrosourea) on experimental C6 glioma were studied in vitro and in vivo." | 3.69 | In vivo enhanced antitumor activity of carmustine [N,N'-bis(2-chloroethyl)-N-nitrosourea] by simvastatin. ( Baetta, R; Butti, G; Davegna, C; De Renzis, MR; Fumagalli, R; Magrassi, L; Mazzini, G; Paoletti, R; Pezzotta, S; Soma, MR, 1995) |
| " It has been shown previously that implantation of controlled-release polymers impregnated with the nitrosourea carmustine (BCNU) extended the period of survival in rats bearing the 9L glioma compared with similar rats treated with systemically administered BCNU." | 3.69 | Biodegradable polymers for controlled delivery of chemotherapy with and without radiation therapy in the monkey brain. ( Brem, H; Epstein, JI; Olivi, A; Pinn, M; Tamargo, RJ; Weingart, JD; Wharam, M, 1994) |
| " This was done using antibromodeoxyuridine immunohistochemical stain and multiple tracer quantitative autoradiography in a C6 rat brain with an implanted glioma." | 3.69 | The sequential changes in DNA synthesis, glucose utilization, protein synthesis, and peripheral benzodiazepine receptor density in C6 brain tumors after chemotherapy to predict the response of tumors to chemotherapy. ( Diksic, M; Takeda, N; Yamamoto, YL, 1996) |
| "Fifteen human glioma cell lines were examined for their sensitivity to 1,3-bis(chloroethyl)-nitrosourea (BCNU, carmustine) and cis-dichlorodiamminoplatinum (cisplatin), the induction of DNA interstrand cross-linking (DNA-ISC) induced by the two agents and cellular O6-alkylguanine alkyltransferase (ATase) activity." | 3.69 | DNA interstrand cross-linking and cytotoxicity induced by chloroethylnitrosoureas and cisplatin in human glioma cell lines which vary in cellular concentration of O6-alkylguanine-DNA alkyltransferase. ( Beith, J; Darling, J; Hartley, J; Souhami, R, 1997) |
| "A total of 379 patients with histologic intracranial low-grade glioma received post-operative radiotherapy (n = 361) and intraarterial carmustine (BCNU) chemotherapy (n = 153)." | 3.69 | Survival, prognostic factors, and therapeutic efficacy in low-grade glioma: a retrospective study in 379 patients. ( Berg-Johnsen, J; Egeland, T; Hager, B; Hirschberg, H; Lote, K; Skullerud, K; Stenwig, B; Storm-Mathisen, I, 1997) |
| "We compared sequential single-agent BCNU and procarbazine (PCB) chemotherapy in 31 patients with gliomas [grade IV (10), grade III (15), grade II (6)]." | 3.68 | Comparison between BCNU and procarbazine chemotherapy for treatment of gliomas. ( Bromberg, J; Greenberg, HS; Junck, L; Newton, HB; Page, MA, 1993) |
| "Eight patients with malignant gliomas were monitored with clinical examinations to study the effects of the combination of intravenous administration of carmustine and infraophthalmic intra-arterial administration of cisplatin on retinal and optic nerve function." | 3.68 | Maculopathy caused by intra-arterially administered cisplatin and intravenously administered carmustine. ( Hiesiger, E; Holopigian, K; Kupersmith, MJ; Noble, K; Seiple, WH; Warren, F, 1992) |
| "Forty-five patients with malignant gliomas were treated after aggressive surgical resection with alternating intravenous carmustine and cisplatin both during and after radiation therapy." | 3.68 | Adjuvant chemotherapy with carmustine and cisplatin for patients with malignant gliomas. ( Feun, LG; Janus, TJ; Maor, M; Yung, WK, 1992) |
| "The effect of simvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on human glioma cell growth was investigated." | 3.68 | Simvastatin, an inhibitor of cholesterol biosynthesis, shows a synergistic effect with N,N'-bis(2-chloroethyl)-N-nitrosourea and beta-interferon on human glioma cells. ( Butti, G; Fumagalli, R; Pagliarini, P; Paoletti, P; Paoletti, R; Soma, MR, 1992) |
| "Biopsy samples and cultured cells derived from them were obtained from 39 patients with malignant glioma and were analyzed for 1) glutathione (GSH) content; 2) sensitivity to 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and/or nitrogen mustard (HN2) treatment and 3) the effect of buthionine sulfoximine (BSO) treatment on BCNU and/or HN2 cytotoxicity." | 3.68 | Glutathione levels and chemosensitizing effects of buthionine sulfoximine in human malignant glioma cells. ( Allalunis-Turner, MJ; Allen, PB; Aronyk, KE; Day, RS; Fulton, DS; Huyser-Wierenga, D; McKean, JD; Petruk, KC; Urtasun, RC; Weir, BK, 1991) |
| " The water-soluble ACNU (nimustine) is an alternative to other nitrosoureas in the treatment of gliomas." | 3.68 | Thermal enhancement of ACNU and potentiation of thermochemotherapy with ACNU by hypertonic glucose in the BT4An rat glioma. ( Dahl, O; Schem, BC, 1991) |
| "We used human anaplastic glioma xenografts to evaluate the therapeutic efficacy of combinations of alkylating drugs, either 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), 1-(2-chloroethyl)-3-(2,5-dioxo-3-piperidyl)-1-nitrosourea (PCNU), or procarbazine, and thiopurines, either 6-mercaptopurine (6MP) or 6-thioguanine (6TG)." | 3.68 | Positive therapeutic interaction between thiopurines and alkylating drugs in human glioma xenografts. ( Bigner, DD; Bodell, WJ; Elion, GB; Friedman, HS; Schold, SC; Wang, AM, 1991) |
| "Twenty-six patients with intracerebral tumors (predominantly gliomas) were treated with intraarterial BCNU, VM-26, and cisplatin combined with the systemic administration of VM-26, methotrexate, vincristine, bleomycin, and procarbazine." | 3.67 | Combined intraarterial and systemic chemotherapy for intracerebral tumors. ( Benoit, B; Grahovac, Z; Hugenholtz, H; Richard, M; Russell, N; Stewart, DJ, 1987) |
| "The authors have used phosphorus magnetic resonance spectroscopy to monitor pH changes in malignant gliomas following treatment with intravenous and intra-arterial 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU)." | 3.67 | Early metabolic changes following chemotherapy of human gliomas in vivo demonstrated by phosphorus magnetic resonance spectroscopy. ( Arnold, DL; Emrich, J; Feindel, W; Shoubridge, EA; Villemure, JG, 1989) |
| "Intensive monochemotherapy with carmustine (BCNU) (either 1,050, 1,200, or 1,350 mg/m2) and cryopreserved autologous marrow transplantation was administered to 36 patients with malignant glioma: 27 with progressive disease and nine without progression (adjuvant therapy group)." | 3.67 | Intensive 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) monochemotherapy and autologous marrow transplantation for malignant glioma. ( Fay, JW; Herzig, GP; Herzig, RH; Lazarus, HM; Phillips, GL; Schold, C; Wolff, SN, 1986) |
| "The Neuro-oncology Service of the University of California Brain Tumor Research Center conducted a nonrandomized phase II study to evaluate, in patients with recurrent malignant glioma, the benefit of a four-drug combination (BFHM) consisting of carmustine (1,3-bis (2-chloroethyl)-1-nitrosourea), 5-fluorouracil, hydroxyurea, and 6-mercaptopurine." | 3.67 | Phase II study of combined carmustine, 5-fluorouracil, hydroxyurea, and 6-mercaptopurine (BFHM) for the treatment of malignant gliomas. ( Berger, M; Chamberlain, M; Choucair, A; Da Silva, V; Davis, RL; Levin, VA; Liu, HC; Murovic, J; Phuphanich, S; Seager, M, 1986) |
| " We treated 25 consecutive patients (13 pilot patients and 12 protocol patients) with histologically confirmed unresectable grade 3 or 4 malignant gliomas with high-dose BCNU (carmustine) followed by autologous bone marrow transplantation and whole brain irradiation." | 3.67 | Prolongation of survival for high-grade malignant gliomas with adjuvant high-dose BCNU and autologous bone marrow transplantation. ( Corwin, JA; Daly, MB; de los Reyes, RA; Johnson, DB; Lamaster, D; Mosley, KR; Petty, AM; Pierson, WP; Smith, MT; Thompson, JM, 1987) |
| "A therapeutic regimen is described for sedative, analgesic, and anti-emetic effect in patients receiving intra-arterial carmustine (BCNU) for malignant gliomas." | 3.67 | Nalbuphine and droperidol in combination for sedation and prevention of nausea and vomiting during intra-carotid BCNU infusion. ( Klein, DS; Klein, PW; Mahaley, MS, 1986) |
| "Using the avian sarcoma virus (ASV) rat glioma model, we have evaluated the in vivo effectiveness of two lipid-soluble folate antagonists, metoprine (DDMP) and its 6-ethyl analog etoprine." | 3.66 | Evaluation of the lipid-soluble diaminopyrimidines, metoprine and etoprine, in the avian sarcoma virus rat glioma model. ( Bigner, DD; Nichol, CA; Serano, RD; Sigel, CW, 1982) |
| "A human medulloblastoma (BN-2) and a glioblastoma (BN-3) which were previously established in nude mice were used to determine the effect of combined modality therapy with gamma-radiation, and three chemotherapeutic agents, procarbazine, 1,4-cyclohexadiene-1,4-dicarbamic acid, 2,5-bis(1-aziridinyl)-3,6-dioxo diethylester (AZQ), and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)." | 3.66 | Combined modality treatment using radiation and/or chemotherapy in an athymic nude mouse-human medulloblastoma and glioblastoma xenograft model. ( Feola, J; Houchens, DP; Ovejera, AA; Slagel, DE, 1982) |
| "Symptomatic pulmonary disease occurred in 20 per cent of 93 patients with anaplastic gliomas being treated with carmustine (BCNU)." | 3.66 | Prediction of BCNU pulmonary toxicity in patients with malignant gliomas: an assessment of risk factors. ( Aronin, PA; Donohue, JF; Dudka, L; Mahaley, MS; Moore, P; Rudnick, SA; Selker, RG, 1980) |
| "Intracerebral murine glioma 26 was used as a model system for evaluating two-drug combinations of antitumor agents, BCNU was combined with either procarbazine, dianhydrogalactitol, or ellipticine." | 3.66 | Correlations between experimental chemotherapy in the murine glioma and effectiveness of clinical therapy regimens. ( Levin, VA; Wilson, CB, 1978) |
| "High grade gliomas are associated with poor prognosis and high mortality." | 2.94 | A phase I trial of surgical resection with Gliadel Wafer placement followed by vaccination with dendritic cells pulsed with tumor lysate for patients with malignant glioma. ( Black, KL; Chu, RM; Hu, JL; Mazer, MJ; Nuno, M; Phuphanich, S; Rudnick, JD; Sarmiento, JM; Uy, B; Wang, H; Wheeler, CJ; Yu, JS, 2020) |
| " Subgaleal effusion was the most common adverse event, presenting in 7 patients (46." | 2.79 | Safety evaluation of high-dose BCNU-loaded biodegradable implants in Chinese patients with recurrent malignant gliomas. ( Chen, YS; Chen, ZH; Chen, ZP; Gao, WC; Guo, CC; Ke, C; Li, X; Lin, FH; Lv, YC; Mou, YG; Sai, K; Wang, J; Yang, QY; Zeng, J; Zhang, XH; Zhong, MG, 2014) |
| "We conducted a study to determine the dose-limiting toxicity of an extended dosing schedule of temozolomide (TMZ) when used with a fixed dose of BCNU, or 1,3-bis(2-chloroethyl)-1-nitrosourea (carmustine), taking advantage of TMZ's ability to deplete O6-alkylguanine-DNA-alkyltransferase and the synergistic activity of these two agents." | 2.71 | Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy. ( Abrey, LE; Kleber, M; Malkin, MG; Raizer, JJ, 2004) |
| "To investigate the therapeutic effect of photodynamic therapy (PDT) combined with interstitial chemo- therapy on gliomas after microsurgery." | 2.71 | [Effect of photodynamic therapy combined with interstitial chemotherapy for gliomas]. ( Chen, LF; Ke, YQ; Wang, SQ; Xu, RX; Yang, ZL, 2005) |
| "Histology included anaplastic astrocytoma (AA) in 15 patients and glioblastoma multiforme (GBM) in 49 patients." | 2.68 | Accelerated hyperfractionated radiation therapy for malignant glioma. A phase II study. ( Antunovic, V; Djuric, L; Grujicic, D; Jeremic, B; Shibamoto, Y, 1995) |
| " Interstitial chemotherapy with BCNU-polymer with subsequent radiation therapy appears to be safe as an initial therapy." | 2.68 | The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: phase I trial. ( Brem, H; Burger, PC; Ewend, MG; Greenhoot, J; Piantadosi, S; Sisti, M, 1995) |
| "Carmustine (BCNU) has proved to be of value against a variety of primary brain tumors." | 2.68 | High-dose carmustine for high-grade gliomas in childhood. ( Biron, P; Bouffet, E; Brunat-Mentigny, M; Khelfaoui, F; Philip, I; Philip, T, 1997) |
| "Sixteen patients with intracerebral tumors received intraarterial cisplatin, teniposide, and BCNU combined with intravenous cisplatin, teniposide, and cytosine arabinoside." | 2.67 | Feasibility study of intraarterial vs intravenous cisplatin, BCNU, and teniposide combined with systemic cisplatin, teniposide, cytosine arabinoside, glycerol and mannitol in the treatment of primary and metastatic brain tumors. ( Belanger, G; Benoit, B; DaSilva, V; Grahovac, Z; Hugenholtz, H; Richard, MT; Russell, N; Stewart, DJ, 1993) |
| "Malignant gliomas have been difficult to treat with chemotherapy." | 2.67 | Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. ( Black, KL; Brem, H; Burger, PC; Ciric, IS; Cozzens, JW; Eller, TW; Friedman, AH; Mahaley, MS; Schold, SC; Vick, NA, 1991) |
| "Pulmonary fibrosis is the end point of progressive functional disorder of respiratory mechanism and alveolo-capillary gas exchanges." | 2.66 | Nitrosourea derivatives-induced pulmonary toxicity in patients treated for malignant brain tumors. Early subclinical detection and its prevention. ( Butti, G; Gaetani, P; Knerich, R; Rossi, A; Silvani, V; Spanu, G, 1987) |
| "Patients with anaplastic astrocytoma had a median survival of 27 months as compared to 8 months for patients with glioblastoma." | 2.65 | Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. ( Chang, CH; Horton, J; Kramer, S; Nelson, JS; Perez-Tamayo, R; Salazer, O; Schoenfeld, D; Tsukada, Y; Weinstein, A, 1983) |
| "Thirteen of 19 (68%) evaluable primary brain tumors and 9 of 16 (56%) evaluable brain metastases responded." | 2.65 | Intracarotid chemotherapy with a combination of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), cis-diaminedichloroplatinum (cisplatin), and 4'-O-demethyl-1-O-(4,6-O-2-thenylidene-beta-D-glucopyranosyl) epipodophyllotoxin (VM-26) in the treatment of primary ( Addison, D; Benoit, B; Dennery, J; Grahovac, Z; Hugenholtz, H; Maroun, JA; Peterson, E; Richard, MT; Russell, N; Stewart, DJ, 1984) |
| "Sixty-five patients with malignant brain tumors were treated with a combination of BCNU (100 mg/m2 qd X 1) and procarbazine (100 mg/m2 qd X 14); the cycle was repeated in 1 month and then on a 6-week schedule with procarbazine being given for 21 days." | 2.64 | BCNU (NSC-409962) and procarbazine (NSC-77213) treatment for malignant brain tumors. ( Boldrey, EB; Crafts, DC; Elashoff, RM; Enot, KJ; Levin, VA; Pischer, TL; Schultz, MJ; Seager, M; Wilson, CB, 1976) |
| "Malignant glioma is one of the most challenging central nervous system (CNS) diseases, which is typically associated with high rates of recurrence and mortality." | 2.50 | Combining microbubbles and ultrasound for drug delivery to brain tumors: current progress and overview. ( Fan, CH; Liu, HL; Ting, CY; Yeh, CK, 2014) |
| "Malignant gliomas are the most frequently occurring, devastating primary brain tumors, and are coupled with a poor survival rate." | 2.49 | Current status of local therapy in malignant gliomas--a clinical review of three selected approaches. ( Juratli, TA; Krex, D; Schackert, G, 2013) |
| "Malignant gliomas are very difficult neoplasms for clinicians to treat." | 2.44 | Interstitial chemotherapy for malignant gliomas: the Johns Hopkins experience. ( Bohan, E; Brem, H; Hussain, N; Kleinberg, L; Lawson, HC; Olivi, A; Park, MC; Sampath, P; Weingart, J, 2007) |
| "High-grade glioma is a devastating disease that leaves the majority of its victims dead within 2 years." | 2.44 | Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies. ( Kleinberg, LR; Lin, SH, 2008) |
| "Malignant gliomas are among the most devastating human cancers." | 2.43 | Local treatment of malignant brain tumors using implantable chemotherapeutic polymers. ( Brem, H; Brem, S; Gallia, GL, 2005) |
| "Radiation therapy for five primary brain tumors is discussed based on the results of prospective trials." | 2.42 | [Evidence-based radiation therapy for primary brain tumors]. ( Kono, T; Nankoh, S; Shibamoto, Y; Taniguchi, H; Tomita, N; Tsuji, H, 2003) |
| "Irinotecan is a water-soluble derivative of camptothecin, an alkylator originally extracted from the Chinese tree Camptotheca acuminata." | 2.42 | The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors. ( Friedman, HS; Houghton, PJ; Keir, ST, 2003) |
| "New approaches to malignant glioma are being actively investigated." | 2.42 | Recent advances in brain tumor therapy: local intracerebral drug delivery by polymers. ( Brem, H; Guerin, C; Lawson, HC; Olivi, A; Weingart, JD, 2004) |
| "Use of interstitial BCNU wafers in the treatment of malignant glioma is currently a controversial topic among neurosurgeons." | 2.41 | The role of interstitial BCNU chemotherapy in the treatment of malignant glioma. ( Engelhard, HH, 2000) |
| "High-grade malignant gliomas are inevitably fatal, despite every effort to improve this prognosis, including various radiotherapeutic modalities, radio- and chemotherapeutic associations, and combinations of several drugs." | 2.41 | High-dose chemotherapy with bone marrow rescue for high-grade gliomas in adults. ( Basso, U; Brandes, AA; Monfardini, S; Palmisano, V; Pasetto, LM, 2001) |
| "Carmustine (BCNU) has been shown to have limited activity at conventional dosage but is still the standard chemotherapy." | 2.41 | [Role of high-dose chemotherapy with hemopoietic stem-cell support in the treatment of adult patients with high-grade glioma]. ( Alcaraz, L; Benboubker, L; Bergemer-Fouquet, AM; Calais, G; Colombat, P; Destrieux, C; Jan, M; Linassier, C, 2001) |
| "Contemporary treatment of malignant brain tumors has been hampered by problems with drug delivery to the tumor bed." | 2.41 | Drug delivery to tumors of the central nervous system. ( Brem, H; Langer, R; Lesniak, MS, 2001) |
| " Given the localised nature of the drug in the brain tissue, no direct pharmacokinetic measurements have been made in humans after implantation of a carmustine wafer." | 2.41 | Pharmacokinetics of the carmustine implant. ( Fleming, AB; Saltzman, WM, 2002) |
| "Human malignant gliomas are karyotypically heterogeneous, composed of many cellular populations and isolated cell types identifiable by cytogenetic techniques." | 2.37 | The subpopulations and isolated cell types of freshly resected high grade human gliomas: their influence on the tumor's evolution in vivo and behavior and therapy in vitro. ( Shapiro, JR; Shapiro, WR, 1985) |
| "In small cell lung cancer initial high dose therapy followed by non-cross-resistant regimens may prove effective." | 2.37 | High dose chemotherapy in solid tumours in adults. ( Peters, W; Souhami, R, 1986) |
| "Gliomas are the most common brain tumors in humans." | 1.51 | A novel strategy to the formulation of carmustine and bioactive nanoparticles co-loaded PLGA biocomposite spheres for targeting drug delivery to glioma treatment and nursing care. ( Jie, C; Yang, F; Yi, S; Zhang, G, 2019) |
| "Here, we report a case of external hydrocephalus caused by Gliadel-induced eosinophilic meningitis that has been previously reported in only 1 case and can be diagnosed by time-spatial labeling inversion pulse magnetic resonance imaging (time-SLIP MRI)." | 1.48 | Novel Application of Time-Spatial Labeling Inversion Pulse Magnetic Resonance Imaging for Diagnosis of External Hydrocephalus. ( Abe, M; Adachi, K; Hirose, Y; Kumai, T; Murayama, K; Nakae, S, 2018) |
| "Gliomas are accompanied with high mortality owning to their invasive peculiarity and vulnerability to drug resistance." | 1.46 | MiR-21 enhanced glioma cells resistance to carmustine via decreasing Spry2 expression. ( Hu, J; Liu, JH; Wang, GB; Xue, K, 2017) |
| " Additionally, medical records of 163 patients treated with BCNU for recurrent glioma WHO grade II to IV were retrospectively evaluated for BCNU-related side effects classified according to the National Cancer Institute Common Toxicity Criteria for Adverse Events (CTCAE) version 2." | 1.43 | Chemotherapy with BCNU in recurrent glioma: Analysis of clinical outcome and side effects in chemotherapy-naïve patients. ( Ahmadi, R; Bermejo, JL; Capper, D; Chatziaslanidou, D; Exner, J; Herold-Mende, C; Jungk, C; Unterberg, A; von Deimling, A, 2016) |
| " Several adverse events(AEs)associated with implantation of BCNU wafers, including cerebral edema or cyst formation, are recognized." | 1.42 | [Risk Factors for Adverse Events after Implantation of BCNU Wafers in High-grade Gliomas]. ( Asaoka, K; Endo, S; Houkin, K; Ishi, Y; Kamoshima, Y; Kobayashi, H; Motegi, H; Terasaka, S; Yamaguchi, S; Yoshida, M, 2015) |
| "According to different treatments, glioma U251 cells were randomly divided into blank group, Lipofectamine group, siRNA-Gli1 group, BCNU group and combination group." | 1.42 | Knockdown of Gli1 by small-interfering RNA enhances the effects of BCNU on the proliferation and apoptosis of glioma U251 cells. ( Bai, J; Dong, X; Guo, W; Tian, H; Yang, X, 2015) |
| " The in vitro anticancer efficacy of PAA-GO-BCNU was demonstrated by a 30% increase in DNA interstrand cross-linking and a 77% decrease in the IC(50) value toward GL261 compared with the same dosage of free drug." | 1.38 | Improving thermal stability and efficacy of BCNU in treating glioma cells using PAA-functionalized graphene oxide. ( Chen, JP; Chen, PY; Huang, CY; Hung, SC; Li, SM; Lu, YJ; Ma, CC; Tsai, HC; Wei, KC; Yang, HW, 2012) |
| "Malignant gliomas are the most destructive type of brain cancer." | 1.37 | Pro-apoptotic role of integrin β3 in glioma cells. ( Kim, JH; Lee, WH; Suk, K; Zheng, LT, 2011) |
| "Malignant glioma is a common and severe primary brain tumor with a high recurrence rate and an extremely high mortality rate within 2 years of diagnosis, even when surgical, radiological, and chemotherapeutic interventions are applied." | 1.36 | Novel magnetic/ultrasound focusing system enhances nanoparticle drug delivery for glioma treatment. ( Chen, JP; Chen, PY; Chen, SM; Chu, PC; Chuang, JI; Feng, LY; Hsueh, C; Hua, MY; Huang, CY; Liu, HL; Lu, YJ; Lyu, LA; Ma, YH; Shin, JW; Tsai, HC; Tseng, IC; Wang, JJ; Wei, KC; Wu, T; Yang, HW; Yen, TC, 2010) |
| "Malignant gliomas are the most common primary brain tumors." | 1.35 | Possible novel therapy for malignant gliomas with secretable trimeric TRAIL. ( Billiar, TR; Jeong, M; Jeun, SS; Kim, BM; Kim, CY; Ko, Y; Kwon, YS; Park, SH; Robbins, PD; Seol, DW; Song, KW, 2009) |
| "High-grade gliomas are aggressive brain tumours that are extremely challenging to treat effectively." | 1.35 | Carmustine implants for the treatment of newly diagnosed high-grade gliomas: a cost-utility analysis. ( Anderson, R; Dyer, M; Garside, R; Mealing, S; Pitt, M; Rogers, G; Somerville, M; Stein, K, 2008) |
| "Thalidomide is a racemate with known pharmacologic and pharmacokinetic enantioselectivity." | 1.34 | Enantioselectivity of thalidomide serum and tissue concentrations in a rat glioma model and effects of combination treatment with cisplatin and BCNU. ( Boyle, FM; Davey, RA; Gu, XQ; Mather, LE; Murphy, S, 2007) |
| "Histology included anaplastic astrocytoma (60) (AA), and glioblastoma multiforme (312) (GBM)." | 1.34 | Imaging response in malignant glioma, RTOG 90-06. ( Berkey, B; Curran, WJ; Fishbach, J; Jones, CU; Lustig, RA; Movsas, B; Scarantino, C; Seiferheld, W; Simpson, JR; Yung, AW, 2007) |
| "While cells from untreated gliomas often have over-representation of chromosome 7, chromosome 22 is typically under-represented." | 1.33 | Over-representation of specific regions of chromosome 22 in cells from human glioma correlate with resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea. ( Hank, NC; Scheck, AC; Shapiro, JR, 2006) |
| "Temozolomide (TMZ) is a methylating agent which prolongs survival when administered during and after radiotherapy in the first-line treatment of glioblastoma and which also has significant activity in recurrent disease." | 1.33 | O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. ( Hermisson, M; Kaina, B; Klumpp, A; Nagel, G; Roos, W; Weller, M; Wick, W; Wischhusen, J, 2006) |
| "A substantial percentage of brain tumors overexpressed biomarkers associated with drug resistance, including MGMT (67%), GSTP1 (49%), and mutant p53 (41%)." | 1.33 | In vitro drug response and molecular markers associated with drug resistance in malignant gliomas. ( Barger, G; Brem, H; Brem, S; Fruehauf, JP; Huang, W; Parker, R; Sloan, A, 2006) |
| "Cell lines derived from primary and recurrent brain tumors from the same patient and cells selected for resistance to the chemotherapeutic agent 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) were used to identify antiproliferative effects of this extract when used alone and in conjunction with BCNU." | 1.33 | Anticancer activity of extracts derived from the mature roots of Scutellaria baicalensis on human malignant brain tumor cells. ( Clark, WD; Hank, NC; Perry, K; Scheck, AC, 2006) |
| " Dose-response studies with SH-6 administered to glioma cell lines were performed using a luminescent cell-viability assay (0." | 1.33 | Cotreatment with a novel phosphoinositide analogue inhibitor and carmustine enhances chemotherapeutic efficacy by attenuating AKT activity in gliomas. ( Broaddus, WC; Cash, D; Fillmore, H; Van Meter, TE, 2006) |
| "In all cell lines tested, treatment of glioblastoma multiforme cells with BCNU followed by AMD3100 results in synergistic antitumor efficacy in vitro." | 1.33 | CXCR4 inhibition synergizes with cytotoxic chemotherapy in gliomas. ( Chan, JA; Kung, AL; Redjal, N; Segal, RA, 2006) |
| " The LD50 values for MX2, M2 and BCNU were 10." | 1.31 | An investigation of the cytotoxicity of the morpholino anthracycline MX2 against glioma cells in vitro. ( Hill, JS; Kaye, AH; Park, SJ, 2000) |
| "Treatment of malignant brain tumors with chloroethylnitrosoureas (CENUs) in addition to surgical resection and radiotherapy remains the foundation of glioma therapy." | 1.31 | Antitumor efficacy of SarCNU in a human glioma xenograft model expressing both MGMT and extraneuronal monoamine transporter. ( Chen, ZP; Huang, Q; Pan, J; Sun, ZF; Wang, AD; Zhou, LY, 2001) |
| " With a similar dosing schedule, BCNU produced no tumor-free animals, six regressions, and one drug-related death at its optimum of 30 mg/kg/dose." | 1.30 | 2-Chloroethyl-3-sarcosinamide-1-nitrosourea, a novel chloroethylnitrosourea analogue with enhanced antitumor activity against human glioma xenografts. ( Alley, MC; Camalier, RF; Carter, CA; Dykes, DJ; Hollingshead, MG; Malspeis, L; Marcantonio, D; Panasci, LC; Sausville, EA, 1997) |
| "Fotemustine is a chloroethylnitrosourea with antitumor activity in disseminated melanoma and adult primary brain tumors." | 1.30 | Activity of fotemustine in medulloblastoma and malignant glioma xenografts in relation to O6-alkylguanine-DNA alkyltransferase and alkylpurine-DNA N-glycosylase activity. ( Boland, I; Gouyette, A; Lacroix, C; Lellouch-Tubiana, A; Margison, GP; Morizet, J; Parker, F; Pierre-Kahn, A; Poullain, MG; Terrier-Lacombe, MJ; Vassal, G; Vénuat, AM; Watson, AJ, 1998) |
| " Additionally, we compared the antitumoral effect of protamine with that of another inhibitor of angiogenesis, suramin, and investigated a potential synergistic antitumoral action of low doses of protamine combined with the antineoplastic carmustine." | 1.30 | Protamine inhibits angiogenesis and growth of C6 rat glioma; a synergistic effect when combined with carmustine. ( Arrieta, O; Guevara, P; Ortiz, A; Rembao, D; Reyes, S; Sotelo, J, 1998) |
| "Animals with brain tumors treated with 4HC had a median survival span of 77 days compared to the median survival of 21 days in BCNU-treated animals and median survival of 14 days in untreated animals." | 1.29 | Effectiveness of controlled release of a cyclophosphamide derivative with polymers against rat gliomas. ( Brem, H; Buahin, KG; Colvin, OM; Domb, A; Epstein, JI; Judy, KD; Olivi, A, 1995) |
| "Carmustine is a chemotherapeutic agent frequently employed in the treatment of malignant brain tumors." | 1.29 | Carmustine toxicity presenting as a lobar infiltrate. ( Byron, WA; Lee, TH; Patterson, DL; Wiemann, MC, 1993) |
| "BCNU treatment of both glioma cell lines led to reduced nicotinamide adenine dinucleotide levels, indicating activation of PARP." | 1.29 | Identification of a 116 kDa protein able to bind 1,3-bis(2-chloroethyl)-1-nitrosourea-damaged DNA as poly(ADP-ribose) polymerase. ( Berger, NA; Desnoyers, S; Malapetsa, A; Noë, AJ; Panasci, LC; Poirier, GG, 1996) |
| "Recurrent gliomas are most often treated by chemotherapy." | 1.29 | Effects of hypoxia on drug resistance phenotype and genotype in human glioma cell lines. ( Liang, BC, 1996) |
| "Forty-three patients with brain tumors were entered into the study." | 1.29 | Human brain tumor O(6)-methylguanine-DNA methyltransferase mRNA and its significance as an indicator of selective chloroethylnitrosourea chemotherapy. ( Kowada, M; Mineura, K; Watanabe, K; Yanagisawa, T; Yasui, N, 1996) |
| " A method to individualize IA drug dosage is needed to provide each patient with the safest, most effective dose." | 1.28 | Effect of intra-arterial cisplatin and 1,3-bis(2chloroethyl)-1-nitrosourea (BCNU) dosage on radiographic response and regional toxicity in malignant glioma patients: proposal of a new method of intra-arterial dosage calculation. ( Bobo, H; Kapp, JP; Vance, R, 1992) |
| "Berberine was evaluated for antitumor activity against malignant brain tumors." | 1.28 | Laboratory studies of berberine used alone and in combination with 1,3-bis(2-chloroethyl)-1-nitrosourea to treat malignant brain tumors. ( Dougherty, DV; Rosenblum, ML; Zhang, RX, 1990) |
| " The single dosage was 100 mg/m2 and repeated every 4-6 weeks." | 1.28 | [Internal carotid arterial BCNU perfusion in the treatment of cerebral glioma]. ( Wu, ZL, 1989) |
| "Human gliomas were grown as permanent tissue cultures and xenografts in nude mice." | 1.28 | Establishment and characterization of human glioblastoma cell lines in vitro and their xenografts in nude mice. ( Fischer, H; Hutter, KJ; Kunze, S; Schwechheimer, K; Sturm, V; Wowra, B; Zeller, WJ, 1989) |
| "Four who had nonirradiated anaplastic astrocytomas all responded and survived for 38+ to 48." | 1.27 | Intraarterial 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and systemic chemotherapy for malignant gliomas: a follow-up study. ( Avellanosa, AM; Barua, NR; Hong, CI; Patel, A; West, CR, 1983) |
| "Metronidazole, 1." | 1.27 | Feasibility study of combining metronidazole with chemotherapy. ( Bélanger, R; Crook, AF; Heringer, R; Hopkins, HS; Hugenholtz, H; Maroun, JA; Richard, MT; Stewart, DJ; Yan, RC; Young, V, 1983) |
| " BCNU in combination with Vincristine and Procarbazine every 6 weeks." | 1.27 | Complications associated with intra-arterial BCNU administered in combination with vincristine and procarbazine for the treatment of malignant brain tumors. ( Balsys, R; Bremer, AM; Duarte, P; Gonzalez, N; Kleriga, E; Miller, RI; Nguyen, TQ; Northup, HM, 1984) |
| "Two human brain tumors which were previously established in nude mice were used to determine antitumor efficacy of various therapeutic agents." | 1.27 | Human brain tumor xenografts in nude mice as a chemotherapy model. ( Houchens, DP; Ovejera, AA; Riblet, SM; Slagel, DE, 1983) |
| "A combination chemotherapy regimen for brain tumors was developed, based on investigations of the survival of animals harboring the intracerebral 9L rat brain-tumor model and on analyses of their clonogenic tumor cells." | 1.27 | Improved treatment of a brain-tumor model. Part 2: Sequential therapy with BCNU and 5-fluorouracil. ( Dougherty, DV; Gerosa, MA; Rosenblum, ML; Wilson, CB, 1983) |
| " In the case of 2,5-diaziridinyl-3,6-bis(carboethoxyamine)-1,4-benzoquinone, we observed about an 80-fold difference between its in vitro half-life of 40." | 1.27 | Application of in vivo and in vitro pharmacokinetics for physiologically relevant drug exposure in a human tumor clonogenic cell assay. ( Ali-Osman, F; Dougherty, D; Giblin, J; Rosenblum, ML, 1987) |
| "Positive results were obtained in the treatment of oligodendrogliomas and astrocytomas grade III and IV." | 1.27 | Intracarotid infusion of ACNU and BCNU as adjuvant therapy of malignant gliomas. Clinical aspects and critical considerations. ( Jaksche, H; Loew, F; Papavero, L, 1987) |
| " Comparison of the slope of the regression line for the dose-response curve and the interpolated ID90 for each drug showed that U251-MG was equally sensitive to aziridinylbenzoquinone and dianhydrogalactitol in all three assays." | 1.27 | Comparison of in vitro cloning assays for drug sensitivity testing of human brain tumours. ( Berens, ME; Dougherty, DV; Giblin, JR; Hoifodt, HK; Rosenblum, ML; Tveit, K, 1988) |
| " A recently described statistical model, which employs the LD50 dose of new agents in mice, was used to estimate the achievable peak plasma concentration (PPC) of SarCNU." | 1.27 | The cytotoxicity of sarcosinamide chloroethylnitrosourea (SarCNU) and BCNU in primary gliomas and glioma cell lines: analysis of data in reference to theoretical peak plasma concentrations in man. ( Feindel, W; McQuillan, A; Panasci, L; Rivas, J; Skalski, V, 1988) |
| "Multimodal treatment of malignant gliomas is routinely used at New York University Medical Center." | 1.26 | Malignant glioma. Results of combined modality therapy. ( Borok, TL; Carella, RJ; Cooper, JS; Ransohoff, J, 1982) |
| " Dose-response curves from some clones differed statistically (log-probit analysis) from those of others, and when the curves were parallel, their 50% effective doses often differed." | 1.26 | Heterogeneous chemosensitivities of subpopulations of human glioma cells in culture. ( Shapiro, JR; Shapiro, WR; Yung, WK, 1982) |
| "It is concluded that BCNU causes pulmonary fibrosis that is primarily but not necessarily dose-related and may not be reversible." | 1.26 | 1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU)-induced pulmonary fibrosis. ( Bellot, P; Cohen, M; Fisher, ER; Jacobs, SA; Moore, PB; Selker, RG; Wald, M, 1980) |
| " Dose-response curves showed that the inhibitory responses after 1 day in these pretreated cultures exposed to 0." | 1.26 | Combined growth-inhibitory responses and ultrastructural alterations produced by 1,3-bis(2-chloroethyl)-1-nitrosourea and dexamethasone in rat glioma cell cultures. ( Boler, RK; Grasso, RJ; Johnson, CE; Moore, NA, 1977) |
| " A comparison of the in vitro colony-forming capacity of treated and untreated tumor cells permits calculation of the fraction of clonogenic tumor cells surviving in vivo therapy; The plateau that we previously observed o the BCNU dose-response curve is not the result of repair of potentially lethal damage, since no change in the 0." | 1.26 | Brain-tumor therapy. Quantitative analysis using a model system. ( Knebel, KD; Rosenblum, MK; Vasquez, DA; Wilson, CB, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 189 (35.06) | 18.7374 |
| 1990's | 128 (23.75) | 18.2507 |
| 2000's | 125 (23.19) | 29.6817 |
| 2010's | 81 (15.03) | 24.3611 |
| 2020's | 16 (2.97) | 2.80 |
| Authors | Studies |
|---|---|
| Kokoshka, JM | 1 |
| Ireland, CM | 1 |
| Barrows, LR | 1 |
| Mohler, ML | 2 |
| Kang, GS | 2 |
| Hong, SS | 1 |
| Patil, R | 2 |
| Kirichenko, OV | 2 |
| Li, W | 2 |
| Rakov, IM | 1 |
| Geisert, EE | 2 |
| Miller, DD | 2 |
| Wanjale, MV | 1 |
| Sunil Jaikumar, V | 1 |
| Sivakumar, KC | 1 |
| Ann Paul, R | 1 |
| James, J | 1 |
| Kumar, GSV | 1 |
| Fujii, Y | 1 |
| Ogiwara, T | 1 |
| Kato, H | 1 |
| Hanaoka, Y | 1 |
| Hardian, RF | 1 |
| Goto, T | 1 |
| Hongo, K | 1 |
| Horiuchi, T | 1 |
| Chen, S | 1 |
| Qiu, Q | 1 |
| Wang, D | 1 |
| She, D | 1 |
| Yin, B | 1 |
| Gu, G | 1 |
| Chai, M | 1 |
| Heo, DN | 1 |
| He, H | 1 |
| Wang, J | 2 |
| Park, J | 1 |
| Sim, J | 1 |
| Ahn, J | 1 |
| Kim, YJ | 1 |
| Hwang, S | 1 |
| Cho, K | 1 |
| Chang, DY | 1 |
| Jung, JH | 1 |
| Moon, JH | 1 |
| Sung, K | 1 |
| Lim, J | 1 |
| Matsuda, R | 1 |
| Maeoka, R | 1 |
| Tokuda, N | 1 |
| Nakazawa, T | 1 |
| Morimoto, T | 1 |
| Kotsugi, M | 1 |
| Takeshima, Y | 1 |
| Tamura, K | 1 |
| Yamada, S | 3 |
| Nishimura, F | 1 |
| Nakagawa, I | 1 |
| Park, YS | 1 |
| Nakase, H | 1 |
| Das, D | 1 |
| Narayanan, D | 1 |
| Ramachandran, R | 1 |
| Gowd, GS | 1 |
| Manohar, M | 1 |
| Arumugam, T | 1 |
| Panikar, D | 1 |
| Nair, SV | 1 |
| Koyakutty, M | 1 |
| Champeaux-Depond, C | 2 |
| Jecko, V | 2 |
| Weller, J | 3 |
| Constantinou, P | 2 |
| Tuppin, P | 2 |
| Metellus, P | 5 |
| Serduc, R | 1 |
| Bouchet, A | 1 |
| Ninomiya, Y | 1 |
| Imaoka, T | 1 |
| Daino, K | 1 |
| Kakinuma, S | 1 |
| Nakajima, T | 1 |
| Yi, S | 1 |
| Yang, F | 1 |
| Jie, C | 1 |
| Zhang, G | 1 |
| Champeaux, C | 1 |
| Sun, X | 1 |
| Sun, G | 1 |
| Huang, Y | 2 |
| Zhang, S | 1 |
| Tang, X | 1 |
| Zhang, N | 1 |
| Zhao, L | 1 |
| Zhong, R | 1 |
| Peng, Y | 1 |
| Rudnick, JD | 1 |
| Sarmiento, JM | 1 |
| Uy, B | 1 |
| Nuno, M | 1 |
| Wheeler, CJ | 1 |
| Mazer, MJ | 1 |
| Wang, H | 3 |
| Hu, JL | 1 |
| Chu, RM | 1 |
| Phuphanich, S | 2 |
| Black, KL | 2 |
| Yu, JS | 1 |
| Li, H | 2 |
| Jiao, YL | 1 |
| Zhou, RF | 1 |
| Liu, S | 1 |
| Cui, B | 1 |
| Wang, LC | 1 |
| Liu, XW | 1 |
| Zhao, YR | 1 |
| Nishikawa, R | 2 |
| Iwata, H | 1 |
| Sakata, Y | 1 |
| Muramoto, K | 1 |
| Matsuoka, T | 1 |
| Bettag, C | 1 |
| Hussein, A | 1 |
| Sachkova, A | 1 |
| Bock, HC | 2 |
| Mielke, D | 1 |
| Rohde, V | 2 |
| Abboud, T | 1 |
| Azzalin, A | 1 |
| Nato, G | 1 |
| Parmigiani, E | 1 |
| Garello, F | 1 |
| Buffo, A | 1 |
| Magrassi, L | 3 |
| Ham, SW | 1 |
| Jeon, HY | 1 |
| Kim, H | 1 |
| Beez, T | 1 |
| Burgula, S | 1 |
| Kamp, M | 1 |
| Rapp, M | 1 |
| Steiger, HJ | 1 |
| Sabel, M | 3 |
| Nakae, S | 1 |
| Murayama, K | 1 |
| Adachi, K | 1 |
| Kumai, T | 1 |
| Abe, M | 1 |
| Hirose, Y | 2 |
| Roux, A | 1 |
| Caire, F | 1 |
| Guyotat, J | 2 |
| Menei, P | 4 |
| Pallud, J | 1 |
| Wang, GB | 1 |
| Liu, JH | 1 |
| Hu, J | 1 |
| Xue, K | 1 |
| Ali, AN | 1 |
| Zhang, P | 1 |
| Yung, WKA | 1 |
| Chen, Y | 2 |
| Movsas, B | 2 |
| Urtasun, RC | 3 |
| Jones, CU | 2 |
| Choi, KN | 1 |
| Michalski, JM | 1 |
| Fischbach, AJ | 4 |
| Markoe, AM | 1 |
| Schultz, CJ | 1 |
| Penas-Prado, M | 1 |
| Garg, MK | 1 |
| Hartford, AC | 1 |
| Kim, HE | 1 |
| Won, M | 1 |
| Curran, WJ | 7 |
| Matsumura, H | 1 |
| Ishikawa, E | 5 |
| Matsuda, M | 3 |
| Sakamoto, N | 2 |
| Akutsu, H | 3 |
| Takano, S | 3 |
| Matsumura, A | 3 |
| Asano, K | 1 |
| Kurose, A | 1 |
| Kamataki, A | 1 |
| Kato, N | 1 |
| Ogawa, K | 1 |
| Katayama, K | 1 |
| Kakuta, K | 1 |
| Fumoto, T | 1 |
| Ohkuma, H | 1 |
| López-Valero, I | 1 |
| Torres, S | 1 |
| Salazar-Roa, M | 1 |
| García-Taboada, E | 1 |
| Hernández-Tiedra, S | 1 |
| Guzmán, M | 1 |
| Sepúlveda, JM | 1 |
| Velasco, G | 1 |
| Lorente, M | 1 |
| Guo, X | 1 |
| Wu, G | 1 |
| Chen, L | 1 |
| Autran, D | 1 |
| Barrie, M | 1 |
| Matta, M | 1 |
| Monserrat, C | 1 |
| Campello, C | 1 |
| Petrirena, G | 1 |
| Boucard, C | 1 |
| Padovani, L | 1 |
| Loundou, A | 1 |
| Appay, R | 1 |
| Graillon, T | 1 |
| Dufour, H | 1 |
| Figarella-Branger, D | 1 |
| Chinot, O | 1 |
| Tabouret, E | 1 |
| Gutenberg, A | 1 |
| Lumenta, CB | 1 |
| Braunsdorf, WE | 1 |
| Mehdorn, HM | 5 |
| Westphal, M | 3 |
| Giese, A | 3 |
| Juratli, TA | 1 |
| Schackert, G | 1 |
| Krex, D | 1 |
| Aoki, T | 2 |
| Pereira, DY | 1 |
| Yip, AT | 1 |
| Lee, BS | 1 |
| Kamei, DT | 1 |
| Yan, YR | 1 |
| Xie, Q | 1 |
| Li, F | 1 |
| Zhang, Y | 1 |
| Ma, JW | 1 |
| Xie, SM | 3 |
| Li, HY | 1 |
| Zhong, XY | 3 |
| Bregy, A | 1 |
| Shah, AH | 1 |
| Diaz, MV | 1 |
| Pierce, HE | 1 |
| Ames, PL | 1 |
| Diaz, D | 1 |
| Komotar, RJ | 1 |
| Hanson, T | 1 |
| Zhang, J | 1 |
| Zhu, HL | 1 |
| Fang, M | 2 |
| Zhang, JJ | 1 |
| Weng, ZP | 1 |
| Yamamoto, T | 5 |
| Satomi, K | 1 |
| Shibuya, M | 1 |
| Nakai, K | 2 |
| Liu, HL | 5 |
| Fan, CH | 2 |
| Ting, CY | 2 |
| Yeh, CK | 2 |
| Sugiyama, K | 1 |
| Nonoguchi, N | 1 |
| Kawabata, N | 1 |
| Mishima, K | 1 |
| Adachi, J | 1 |
| Kurisu, K | 1 |
| Yamasaki, F | 1 |
| Tominaga, T | 1 |
| Kumabe, T | 1 |
| Ueki, K | 1 |
| Higuchi, F | 1 |
| Takeshima, H | 2 |
| Yamashita, S | 1 |
| Arita, K | 1 |
| Hirano, H | 1 |
| Matsutani, M | 1 |
| Sai, K | 1 |
| Zhong, MG | 1 |
| Chen, YS | 1 |
| Mou, YG | 1 |
| Ke, C | 1 |
| Zhang, XH | 1 |
| Yang, QY | 1 |
| Lin, FH | 1 |
| Guo, CC | 1 |
| Chen, ZH | 1 |
| Zeng, J | 1 |
| Lv, YC | 1 |
| Li, X | 2 |
| Gao, WC | 1 |
| Chen, ZP | 4 |
| Mack, F | 1 |
| Schäfer, N | 1 |
| Kebir, S | 1 |
| Stuplich, M | 1 |
| Schaub, C | 1 |
| Niessen, M | 1 |
| Scheffler, B | 1 |
| Herrlinger, U | 1 |
| Glas, M | 1 |
| Patil, AA | 1 |
| Sayal, P | 1 |
| Depondt, ML | 1 |
| Beveridge, RD | 1 |
| Roylance, A | 1 |
| Kriplani, DH | 1 |
| Myers, KN | 1 |
| Cox, A | 1 |
| Jellinek, D | 1 |
| Fernando, M | 1 |
| Carroll, TA | 1 |
| Collis, SJ | 1 |
| Sewing, AC | 1 |
| Caretti, V | 1 |
| Lagerweij, T | 1 |
| Schellen, P | 1 |
| Jansen, MH | 1 |
| van Vuurden, DG | 1 |
| Idema, S | 1 |
| Molthoff, CF | 1 |
| Vandertop, WP | 1 |
| Kaspers, GJ | 1 |
| Noske, DP | 1 |
| Hulleman, E | 1 |
| Poschmann, G | 1 |
| Grzendowski, M | 1 |
| Stefanski, A | 1 |
| Bruns, E | 1 |
| Meyer, HE | 1 |
| Stühler, K | 1 |
| Chowdhary, SA | 1 |
| Ryken, T | 1 |
| Newton, HB | 2 |
| Sukumari-Ramesh, S | 1 |
| Prasad, N | 1 |
| Alleyne, CH | 1 |
| Vender, JR | 1 |
| Dhandapani, KM | 1 |
| Burri, SH | 1 |
| Prabhu, RS | 1 |
| Sumrall, AL | 1 |
| Brick, W | 1 |
| Blaker, BD | 1 |
| Heideman, BE | 1 |
| Boltes, P | 1 |
| Kelly, R | 1 |
| Symanowski, JT | 1 |
| Wiggins, WF | 1 |
| Ashby, L | 1 |
| Norton, HJ | 1 |
| Judy, K | 3 |
| Asher, AL | 1 |
| Stojković, S | 1 |
| Podolski-Renić, A | 1 |
| Dinić, J | 1 |
| Stanković, T | 1 |
| Banković, J | 1 |
| Hadžić, S | 1 |
| Paunović, V | 1 |
| Isaković, A | 1 |
| Tanić, N | 1 |
| Pešić, M | 1 |
| Yoshida, M | 1 |
| Yamaguchi, S | 1 |
| Ishi, Y | 1 |
| Endo, S | 1 |
| Motegi, H | 1 |
| Kobayashi, H | 1 |
| Asaoka, K | 1 |
| Kamoshima, Y | 1 |
| Terasaka, S | 1 |
| Houkin, K | 1 |
| Guo, W | 1 |
| Tian, H | 1 |
| Dong, X | 1 |
| Bai, J | 1 |
| Yang, X | 1 |
| Ohue, S | 1 |
| Kohno, S | 1 |
| Inoue, A | 1 |
| Yamashita, D | 1 |
| Suehiro, S | 1 |
| Seno, T | 1 |
| Kumon, Y | 1 |
| Kikuchi, K | 1 |
| Ohnishi, T | 1 |
| Masuda, Y | 1 |
| Kohzuki, H | 1 |
| Okamoto, E | 1 |
| Masumoto, T | 1 |
| Jungk, C | 1 |
| Chatziaslanidou, D | 1 |
| Ahmadi, R | 1 |
| Capper, D | 1 |
| Bermejo, JL | 1 |
| Exner, J | 1 |
| von Deimling, A | 1 |
| Herold-Mende, C | 1 |
| Unterberg, A | 1 |
| Shimato, S | 1 |
| Nishizawa, T | 1 |
| Ohshima, T | 1 |
| Imai, T | 1 |
| Goto, S | 1 |
| Kato, K | 1 |
| Tseng, YY | 1 |
| Kau, YC | 1 |
| Liu, SJ | 1 |
| Saito, K | 1 |
| Yamasaki, K | 1 |
| Yokogami, K | 1 |
| Ivanova, A | 1 |
| Takeishi, G | 1 |
| Sato, Y | 1 |
| Hasegawa, Y | 1 |
| Iuchi, T | 1 |
| Sakaida, T | 1 |
| Yokoi, S | 1 |
| Kawasaki, K | 1 |
| Murai, S | 1 |
| Ichikawa, T | 1 |
| Kurozumi, K | 1 |
| Shimazu, Y | 1 |
| Oka, T | 1 |
| Otani, Y | 1 |
| Shimizu, T | 1 |
| Date, I | 1 |
| Arakawa, Y | 1 |
| Liu, C | 1 |
| Yao, S | 1 |
| Wang, F | 1 |
| Jiang, Y | 1 |
| Mathios, D | 1 |
| Kim, JE | 1 |
| Mangraviti, A | 1 |
| Phallen, J | 1 |
| Park, CK | 1 |
| Jackson, CM | 1 |
| Garzon-Muvdi, T | 1 |
| Kim, E | 1 |
| Theodros, D | 1 |
| Polanczyk, M | 1 |
| Martin, AM | 1 |
| Suk, I | 1 |
| Ye, X | 1 |
| Tyler, B | 1 |
| Bettegowda, C | 1 |
| Brem, H | 22 |
| Pardoll, DM | 1 |
| Lim, M | 1 |
| Blumenthal, DT | 1 |
| Rankin, C | 1 |
| Eyre, HJ | 1 |
| Livingston, RB | 1 |
| Spence, AM | 2 |
| Stelzer, KJ | 1 |
| Rushing, EJ | 1 |
| Berger, MS | 3 |
| Rivkin, SE | 1 |
| Cohn, AL | 1 |
| Petersdorf, SH | 1 |
| Monfared, P | 1 |
| Winkeler, A | 1 |
| Klein, M | 1 |
| Klose, A | 1 |
| Hoesel, M | 1 |
| Waerzeggers, Y | 1 |
| Korsching, S | 1 |
| Jacobs, AH | 1 |
| Hart, MG | 2 |
| Grant, R | 2 |
| Garside, R | 4 |
| Rogers, G | 4 |
| Somerville, M | 4 |
| Stein, K | 4 |
| Wang, XD | 1 |
| Orr, WE | 1 |
| Amarasingh, S | 1 |
| Macleod, MR | 1 |
| Whittle, IR | 4 |
| Bodell, WJ | 8 |
| Papait, R | 1 |
| Rigamonti, D | 1 |
| Cattaneo, E | 1 |
| Ng, WH | 1 |
| Wan, GQ | 1 |
| Peng, ZN | 1 |
| Too, HP | 1 |
| Kang, C | 2 |
| Yuan, X | 2 |
| Zhong, Y | 2 |
| Pu, P | 2 |
| Guo, Y | 1 |
| Albadany, A | 1 |
| Yu, S | 1 |
| Zhang, Z | 2 |
| Li, Y | 1 |
| Chang, J | 1 |
| Sheng, J | 1 |
| La Rocca, RV | 2 |
| Jeong, M | 1 |
| Kwon, YS | 1 |
| Park, SH | 1 |
| Kim, CY | 1 |
| Jeun, SS | 1 |
| Song, KW | 1 |
| Ko, Y | 1 |
| Robbins, PD | 1 |
| Billiar, TR | 1 |
| Kim, BM | 1 |
| Seol, DW | 1 |
| Asthagiri, AR | 1 |
| Baggenstos, M | 1 |
| Lonser, RR | 1 |
| Ohba, S | 1 |
| Yoshida, K | 1 |
| Yazaki, T | 1 |
| Kawase, T | 1 |
| Jenkinson, MD | 1 |
| Smith, TS | 1 |
| Haylock, B | 1 |
| Husband, D | 1 |
| Shenoy, A | 1 |
| Vinjamuri, S | 1 |
| Walker, C | 1 |
| Pietronigro, D | 4 |
| Warnke, PC | 2 |
| Kantelhardt, SR | 1 |
| Kosteljanetz, M | 1 |
| Poulsen, HS | 1 |
| Balossier, A | 1 |
| Dörner, L | 3 |
| Emery, E | 2 |
| Heese, O | 1 |
| Singh, J | 1 |
| Recinos, VR | 1 |
| Tyler, BM | 4 |
| Bekelis, K | 1 |
| Sunshine, SB | 1 |
| Vellimana, A | 1 |
| Li, KW | 1 |
| Parot-Schinkel, E | 1 |
| Loiseau, H | 1 |
| Capelle, L | 1 |
| Jacquet, G | 1 |
| Chen, PY | 4 |
| Hua, MY | 3 |
| Yang, HW | 4 |
| Huang, CY | 5 |
| Chu, PC | 1 |
| Lyu, LA | 2 |
| Tseng, IC | 2 |
| Feng, LY | 1 |
| Tsai, HC | 2 |
| Chen, SM | 1 |
| Lu, YJ | 3 |
| Wang, JJ | 1 |
| Yen, TC | 4 |
| Ma, YH | 1 |
| Wu, T | 1 |
| Chen, JP | 2 |
| Chuang, JI | 1 |
| Shin, JW | 1 |
| Hsueh, C | 1 |
| Wei, KC | 5 |
| Della Puppa, A | 2 |
| Rossetto, M | 2 |
| Ciccarino, P | 2 |
| Del Moro, G | 2 |
| Rotilio, A | 3 |
| Manara, R | 2 |
| Paola Gardiman, M | 1 |
| Denaro, L | 2 |
| d'Avella, D | 2 |
| Scienza, R | 2 |
| Zhou, Y | 1 |
| Xu, Q | 1 |
| Tsai, RY | 2 |
| Ma, CC | 2 |
| Tang, HJ | 2 |
| Colvin, DC | 1 |
| Loveless, ME | 1 |
| Does, MD | 1 |
| Yue, Z | 1 |
| Yankeelov, TE | 1 |
| Gore, JC | 1 |
| Ulmer, S | 1 |
| Rohr, A | 2 |
| Nabavi, A | 2 |
| Chansriwong, P | 1 |
| Sirisinha, T | 1 |
| Kim, JH | 1 |
| Zheng, LT | 1 |
| Lee, WH | 1 |
| Suk, K | 1 |
| Liu, X | 1 |
| Madhankumar, AB | 1 |
| Slagle-Webb, B | 1 |
| Sheehan, JM | 1 |
| Surguladze, N | 1 |
| Connor, JR | 1 |
| Salvati, M | 1 |
| D'elia, A | 1 |
| Frati, A | 1 |
| Brogna, C | 1 |
| Santoro, A | 1 |
| Delfini, R | 1 |
| Lombardi, G | 1 |
| Rezazadeh, A | 1 |
| Chen, JY | 1 |
| Hsien, HY | 1 |
| Chang, YS | 1 |
| Lemasson, B | 1 |
| Christen, T | 1 |
| Tizon, X | 1 |
| Farion, R | 1 |
| Fondraz, N | 1 |
| Provent, P | 1 |
| Segebarth, C | 1 |
| Barbier, EL | 1 |
| Genne, P | 1 |
| Duchamp, O | 1 |
| Remy, C | 1 |
| Kim, BS | 1 |
| Kang, KS | 1 |
| Choi, JI | 1 |
| Jung, JS | 1 |
| Im, YB | 1 |
| Kang, SK | 1 |
| Han, L | 1 |
| Ren, Y | 1 |
| Long, L | 1 |
| Shen, C | 1 |
| Catalán-Uribarrena, G | 1 |
| Bilbao-Barandica, G | 1 |
| Pomposo-Gaztelu, I | 1 |
| Undabeitia-Huertas, J | 1 |
| Ruiz de Gopegui-Ruiz, E | 1 |
| Galbarriatu-Gutiérrez, L | 1 |
| Canales-Llantada, M | 1 |
| Aurrecoechea-Obieta, J | 1 |
| Igartua-Azkune, A | 1 |
| Carbayo-Lozano, G | 1 |
| Guo, H | 1 |
| Nagpal, S | 1 |
| Price, SJ | 1 |
| Ashkan, K | 1 |
| Grundy, P | 1 |
| Cruickshank, G | 1 |
| Hung, SC | 1 |
| Li, SM | 1 |
| Cho, KT | 1 |
| Kim, DG | 1 |
| Paek, SH | 1 |
| Chung, HT | 1 |
| Jung, HW | 2 |
| Park, HW | 1 |
| Antunes, IF | 1 |
| Haisma, HJ | 1 |
| Elsinga, PH | 1 |
| Di Gialleonardo, V | 1 |
| van Waarde, A | 1 |
| Willemsen, AT | 1 |
| Dierckx, RA | 1 |
| de Vries, EF | 1 |
| Duntze, J | 1 |
| Litré, CF | 1 |
| Eap, C | 1 |
| Théret, E | 1 |
| Debreuve, A | 1 |
| Jovenin, N | 1 |
| Lechapt-Zalcman, E | 1 |
| Colin, P | 1 |
| Guillamo, JS | 1 |
| Rousseaux, P | 1 |
| Peruzzi, P | 1 |
| Hsieh, HY | 1 |
| Mustafa, A | 1 |
| Selker, RG | 9 |
| Shapiro, WR | 22 |
| Burger, P | 3 |
| Blackwood, MS | 1 |
| Arena, VC | 1 |
| Gilder, JC | 1 |
| Malkin, MG | 3 |
| Mealey, JJ | 1 |
| Neal, JH | 1 |
| Olson, J | 1 |
| Robertson, JT | 6 |
| Barnett, GH | 1 |
| Bloomfield, S | 1 |
| Albright, R | 1 |
| Hochberg, FH | 3 |
| Hiesiger, E | 2 |
| Green, S | 1 |
| Branle, F | 1 |
| Lefranc, F | 1 |
| Camby, I | 2 |
| Jeuken, J | 1 |
| Geurts-Moespot, A | 1 |
| Sprenger, S | 1 |
| Sweep, F | 1 |
| Kiss, R | 2 |
| Salmon, I | 2 |
| Shi, MG | 1 |
| Huang, Q | 3 |
| Dong, J | 1 |
| Sun, ZF | 3 |
| Lan, Q | 1 |
| Sampath, P | 4 |
| Amundson, E | 1 |
| Wall, ME | 1 |
| Wani, MC | 1 |
| Alderson, LM | 1 |
| Colvin, M | 1 |
| Weingart, JD | 3 |
| Shibamoto, Y | 3 |
| Tomita, N | 1 |
| Kono, T | 1 |
| Tsuji, H | 1 |
| Nankoh, S | 1 |
| Taniguchi, H | 1 |
| Hilt, DC | 2 |
| Bortey, E | 2 |
| Delavault, P | 1 |
| Olivares, R | 1 |
| Jääskeläinen, J | 1 |
| Ram, Z | 2 |
| Weaver, KD | 1 |
| Yeyeodu, S | 1 |
| Cusack, JC | 1 |
| Baldwin, AS | 1 |
| Ewend, MG | 2 |
| Hammoud, DA | 1 |
| Belden, CJ | 1 |
| Ho, AC | 1 |
| Dal Pan, GJ | 1 |
| Herskovits, EH | 1 |
| Pomper, MG | 1 |
| Friedman, HS | 8 |
| Keir, ST | 2 |
| Houghton, PJ | 3 |
| Olivi, A | 8 |
| Grossman, SA | 3 |
| Tatter, S | 1 |
| Barker, F | 1 |
| Olsen, J | 1 |
| Bruce, J | 1 |
| Hilt, D | 2 |
| Fisher, J | 1 |
| Piantadosi, S | 3 |
| Giannini, DD | 1 |
| Singh, S | 1 |
| Levin, VA | 15 |
| Fine, HA | 1 |
| Wen, PY | 1 |
| Maher, EA | 1 |
| Viscosi, E | 1 |
| Batchelor, T | 1 |
| Lakhani, N | 1 |
| Figg, WD | 1 |
| Purow, BW | 1 |
| Borkowf, CB | 1 |
| Shingu, T | 1 |
| Yamada, K | 1 |
| Hara, N | 1 |
| Moritake, K | 1 |
| Osago, H | 1 |
| Terashima, M | 1 |
| Uemura, T | 1 |
| Yamasaki, T | 1 |
| Tsuchiya, M | 1 |
| Lyles, S | 1 |
| Walker, M | 2 |
| Kreklau, EL | 2 |
| Pollok, KE | 1 |
| Bailey, BJ | 1 |
| Liu, N | 1 |
| Hartwell, JR | 1 |
| Williams, DA | 2 |
| Erickson, LC | 2 |
| Guerin, C | 1 |
| Lawson, HC | 2 |
| Pérez-Calvo, J | 1 |
| Fernàndez, O | 1 |
| Aristu, JJ | 1 |
| Aramendia, JM | 1 |
| Rifón, J | 1 |
| Prosper, F | 1 |
| Bendandi, M | 1 |
| Rocha, E | 1 |
| Martin-Algarra, S | 1 |
| Yang, DI | 5 |
| Chen, SD | 2 |
| Yang, YT | 1 |
| Ju, TC | 2 |
| Xu, JM | 1 |
| Hsu, CY | 6 |
| Kleinberg, LR | 2 |
| Weingart, J | 5 |
| Carson, K | 1 |
| Li, K | 1 |
| Wharam, MD | 1 |
| Abrey, LE | 2 |
| Chang, SM | 2 |
| Prados, MD | 2 |
| Yung, WK | 4 |
| Fine, H | 1 |
| Junck, L | 3 |
| Greenberg, H | 1 |
| Robins, HI | 1 |
| Mehta, M | 1 |
| Fink, KL | 1 |
| Jaeckle, KA | 1 |
| Kuhn, J | 1 |
| Hess, K | 1 |
| Schold, C | 3 |
| Rosenthal, MA | 1 |
| Ashley, DL | 1 |
| Cher, L | 1 |
| Yin, JH | 4 |
| Chen, LS | 1 |
| Reardon, DA | 3 |
| Quinn, JA | 3 |
| Rich, JN | 3 |
| Gururangan, S | 3 |
| Vredenburgh, J | 2 |
| Sampson, JH | 3 |
| Provenzale, JM | 3 |
| Walker, A | 2 |
| Badruddoja, M | 1 |
| Tourt-Uhlig, S | 3 |
| Herndon, JE | 4 |
| Dowell, JM | 1 |
| Affronti, ML | 2 |
| Jackson, S | 2 |
| Allen, D | 2 |
| Ziegler, K | 2 |
| Silverman, S | 1 |
| Bohlin, C | 2 |
| Friedman, AH | 5 |
| Bigner, DD | 14 |
| Schweitzer, H | 1 |
| Lentz, C | 1 |
| Takeuchi, H | 1 |
| Kanzawa, T | 1 |
| Kondo, Y | 1 |
| Komata, T | 1 |
| Hirohata, S | 1 |
| Kyo, S | 1 |
| Kondo, S | 1 |
| Raizer, JJ | 1 |
| Kleber, M | 1 |
| Paz, MF | 1 |
| Yaya-Tur, R | 1 |
| Rojas-Marcos, I | 1 |
| Reynes, G | 1 |
| Pollan, M | 1 |
| Aguirre-Cruz, L | 1 |
| García-Lopez, JL | 1 |
| Piquer, J | 1 |
| Safont, MJ | 1 |
| Balaña, C | 1 |
| Sanchez-Cespedes, M | 1 |
| García-Villanueva, M | 1 |
| Arribas, L | 1 |
| Esteller, M | 2 |
| Horvath, Z | 1 |
| Bauer, W | 1 |
| Hoechtl, T | 1 |
| Saiko, P | 1 |
| Fritzer-Szekeres, M | 1 |
| Tihan, T | 1 |
| Szekeres, T | 1 |
| Hall, DE | 3 |
| Moffat, BA | 3 |
| Stojanovska, J | 1 |
| Johnson, TD | 2 |
| Li, Z | 2 |
| Hamstra, DA | 2 |
| Rehemtulla, A | 4 |
| Chenevert, TL | 5 |
| Carter, J | 2 |
| Ross, BD | 6 |
| Post, DE | 1 |
| Devi, NS | 1 |
| Brat, DJ | 1 |
| Kaur, B | 1 |
| Nicholson, A | 1 |
| Olson, JJ | 1 |
| Van Meir, EG | 1 |
| Chen, LF | 1 |
| Ke, YQ | 1 |
| Yang, ZL | 1 |
| Wang, SQ | 1 |
| Xu, RX | 1 |
| Weber, EL | 1 |
| Goebel, EA | 1 |
| Xu, GW | 2 |
| Mymryk, JS | 1 |
| Cairncross, JG | 6 |
| Bandres, E | 1 |
| Andion, E | 2 |
| Escalada, A | 1 |
| Honorato, B | 1 |
| Catalan, V | 1 |
| Cubedo, E | 1 |
| Cordeu, L | 1 |
| Garcia, F | 1 |
| Zarate, R | 1 |
| Zabalegui, N | 1 |
| Garcia-Foncillas, J | 2 |
| Young, JM | 1 |
| Desmond, TJ | 1 |
| Frey, KA | 1 |
| Tsao, MN | 1 |
| Mehta, MP | 1 |
| Whelan, TJ | 1 |
| Morris, DE | 1 |
| Hayman, JA | 1 |
| Flickinger, JC | 1 |
| Mills, M | 1 |
| Rogers, CL | 1 |
| Souhami, L | 1 |
| Gallia, GL | 1 |
| Brem, S | 4 |
| Duntsch, C | 1 |
| Divi, MK | 1 |
| Jones, T | 1 |
| Zhou, Q | 1 |
| Krishnamurthy, M | 1 |
| Boehm, P | 1 |
| Wood, G | 1 |
| Sills, A | 1 |
| Moore, BM | 1 |
| Shibui, S | 1 |
| Hank, NC | 2 |
| Shapiro, JR | 9 |
| Scheck, AC | 4 |
| Hermisson, M | 1 |
| Klumpp, A | 1 |
| Wick, W | 1 |
| Wischhusen, J | 1 |
| Nagel, G | 1 |
| Roos, W | 1 |
| Kaina, B | 1 |
| Weller, M | 5 |
| Pineda, B | 1 |
| Estrada-Parra, S | 1 |
| Pedraza-Medina, B | 1 |
| Rodriguez-Ropon, A | 1 |
| Pérez, R | 1 |
| Arrieta, O | 2 |
| Riddle, V | 1 |
| Rhines, LD | 2 |
| DiMeco, F | 1 |
| Park, MC | 2 |
| Lee, KC | 1 |
| Hoff, BA | 1 |
| Sharma, S | 1 |
| Meyer, CR | 1 |
| Leopold, WR | 1 |
| Mazurchuk, RV | 1 |
| Babsky, AM | 1 |
| Hekmatyar, SK | 1 |
| Zhang, H | 1 |
| Solomon, JL | 1 |
| Bansal, N | 2 |
| Simon, M | 1 |
| Voss, D | 1 |
| Park-Simon, TW | 1 |
| Mahlberg, R | 1 |
| Köster, G | 1 |
| Xu, X | 2 |
| Chen, X | 1 |
| Lu, T | 1 |
| Wang, X | 1 |
| Yang, L | 1 |
| Jing, X | 1 |
| Fruehauf, JP | 1 |
| Sloan, A | 1 |
| Barger, G | 1 |
| Huang, W | 1 |
| Parker, R | 1 |
| Perry, K | 1 |
| Clark, WD | 1 |
| Van Meter, TE | 1 |
| Broaddus, WC | 1 |
| Cash, D | 1 |
| Fillmore, H | 1 |
| Chastagner, P | 1 |
| Kalifa, C | 1 |
| Doz, F | 2 |
| Bouffet, E | 2 |
| Gentet, JC | 1 |
| Ruchoux, MM | 1 |
| Bracard, S | 1 |
| Desandes, E | 1 |
| Frappaz, D | 1 |
| Redjal, N | 1 |
| Chan, JA | 1 |
| Segal, RA | 1 |
| Kung, AL | 1 |
| Bohan, E | 1 |
| Hussain, N | 1 |
| Kleinberg, L | 1 |
| Chen, CC | 1 |
| Taniguchi, T | 1 |
| D'Andrea, A | 1 |
| Murphy, S | 1 |
| Boyle, FM | 1 |
| Davey, RA | 1 |
| Gu, XQ | 1 |
| Mather, LE | 1 |
| Carson, KA | 1 |
| Fisher, JD | 1 |
| Delaney, SM | 1 |
| Rosenblum, ML | 14 |
| Tatter, SB | 1 |
| Dolan, ME | 3 |
| Lustig, RA | 1 |
| Seiferheld, W | 1 |
| Berkey, B | 1 |
| Yung, AW | 2 |
| Scarantino, C | 1 |
| Simpson, JR | 1 |
| Fishbach, J | 1 |
| Gomez, GG | 1 |
| Kruse, CA | 1 |
| Jordan, JT | 1 |
| Sun, W | 1 |
| Hussain, SF | 1 |
| DeAngulo, G | 1 |
| Prabhu, SS | 1 |
| Heimberger, AB | 1 |
| Pitt, M | 2 |
| Anderson, R | 2 |
| Dyer, M | 2 |
| Mealing, S | 2 |
| Price, A | 1 |
| Wolff, JE | 1 |
| Berrak, S | 1 |
| Koontz Webb, SE | 1 |
| Zhang, M | 1 |
| Lin, SH | 1 |
| Kobiakov, GL | 1 |
| Kessinger, A | 1 |
| Gerosa, M | 1 |
| Dougherty, DV | 7 |
| Reese, C | 1 |
| Barger, GR | 2 |
| Davis, RL | 5 |
| Wilson, CB | 24 |
| Nomura, K | 1 |
| Hoshino, T | 4 |
| Pentecost, SM | 1 |
| Kuwamura, K | 4 |
| Kokunai, T | 4 |
| Kanazawa, Y | 1 |
| Yamada, T | 1 |
| Morantz, RA | 1 |
| Kimler, BF | 1 |
| Vats, TS | 1 |
| Henderson, SD | 1 |
| Yoshida, T | 2 |
| Ushio, Y | 4 |
| Hayakawa, T | 2 |
| Shimizu, K | 2 |
| Mogami, H | 2 |
| Nakata, Y | 2 |
| Sakamoto, Y | 2 |
| Mahaley, MS | 16 |
| Urso, MB | 1 |
| Whaley, RA | 3 |
| Williams, TE | 1 |
| Guaspari, A | 1 |
| Schold, SC | 9 |
| Steinbok, P | 3 |
| Aronin, P | 1 |
| Dudka, L | 2 |
| Zinn, D | 1 |
| Serano, RD | 1 |
| Sigel, CW | 1 |
| Nichol, CA | 1 |
| Robustelli della Cuna, G | 1 |
| Paoletti, P | 9 |
| Bernardo, G | 1 |
| Knerich, R | 5 |
| Butti, G | 6 |
| Cuzzoni, Q | 1 |
| Pertuiset, BF | 2 |
| Poisson, M | 1 |
| Hauw, JJ | 1 |
| Deen, DF | 5 |
| Buge, A | 1 |
| West, CR | 1 |
| Avellanosa, AM | 1 |
| Barua, NR | 1 |
| Patel, A | 1 |
| Hong, CI | 1 |
| Green, SB | 7 |
| Byar, DP | 2 |
| Walker, MD | 10 |
| Pistenmaa, DA | 1 |
| Alexander, E | 3 |
| Batzdorf, U | 2 |
| Brooks, WH | 2 |
| Hunt, WE | 3 |
| Mealey, J | 6 |
| Odom, GL | 1 |
| Ransohoff, J | 11 |
| Smith, KR | 2 |
| Strike, TA | 5 |
| Nelson, DF | 8 |
| Schoenfeld, D | 4 |
| Weinstein, AS | 6 |
| Nelson, JS | 7 |
| Wasserman, T | 1 |
| Goodman, RL | 1 |
| Carabell, S | 2 |
| Chang, CH | 3 |
| Horton, J | 2 |
| Salazer, O | 1 |
| Perez-Tamayo, R | 1 |
| Kramer, S | 1 |
| Weinstein, A | 1 |
| Tsukada, Y | 1 |
| Fingert, HJ | 1 |
| Tanghetti, B | 1 |
| Adinolfi, D | 1 |
| Gaetani, P | 3 |
| Buoncristiani, P | 1 |
| Stewart, DJ | 5 |
| Grahovac, Z | 3 |
| Benoit, B | 4 |
| Addison, D | 1 |
| Richard, MT | 3 |
| Dennery, J | 1 |
| Hugenholtz, H | 5 |
| Russell, N | 4 |
| Peterson, E | 1 |
| Maroun, JA | 2 |
| Young, V | 1 |
| Crook, AF | 1 |
| Hopkins, HS | 1 |
| Yan, RC | 1 |
| Bélanger, R | 1 |
| Heringer, R | 1 |
| Silberman, AW | 1 |
| Morgan, DF | 1 |
| Storm, FK | 1 |
| Rand, RW | 1 |
| Benz, M | 1 |
| Drury, B | 1 |
| Morton, DL | 1 |
| Bremer, AM | 1 |
| Kleriga, E | 1 |
| Nguyen, TQ | 1 |
| Balsys, R | 1 |
| Northup, HM | 1 |
| Gonzalez, N | 1 |
| Duarte, P | 1 |
| Miller, RI | 1 |
| Gutin, PH | 5 |
| Bernstein, M | 1 |
| Sano, Y | 1 |
| Chadduck, WM | 1 |
| Gillespie, GY | 1 |
| Houchens, DP | 2 |
| Ovejera, AA | 2 |
| Riblet, SM | 1 |
| Slagel, DE | 2 |
| Rawlings, CE | 1 |
| Bigner, SH | 2 |
| Greenberg, HS | 4 |
| Ensminger, WD | 1 |
| Chandler, WF | 1 |
| Layton, PB | 1 |
| Knake, J | 1 |
| Vine, AK | 1 |
| Hung, DT | 1 |
| Seidenfeld, J | 1 |
| Marton, LJ | 2 |
| Gerosa, MA | 3 |
| de Tribolet, N | 2 |
| Ross, RL | 1 |
| Kapp, JP | 6 |
| Hochberg, F | 2 |
| Krull, IS | 1 |
| Ding, XD | 1 |
| Selavka, C | 1 |
| Weizsäcker, M | 1 |
| Nagamune, A | 1 |
| Winkelströter, R | 1 |
| Vieten, H | 1 |
| Wechsler, W | 2 |
| Dougherty, DA | 1 |
| MacCarty, CS | 2 |
| Owens, G | 2 |
| Vestnys, PS | 1 |
| Muir, W | 1 |
| Chin, HW | 1 |
| Young, AB | 1 |
| Maruyama, Y | 1 |
| Volkin, RL | 1 |
| Shadduck, RK | 1 |
| Winkelstein, A | 1 |
| Zeigler, ZR | 1 |
| Feola, J | 1 |
| Cooper, JS | 1 |
| Borok, TL | 1 |
| Carella, RJ | 1 |
| Eagan, RT | 1 |
| Dinapoli, RP | 5 |
| Hermann, RC | 1 |
| Groover, RV | 1 |
| Layton, DD | 1 |
| Scott, M | 1 |
| Kapp, J | 1 |
| Vance, R | 2 |
| Parker, JL | 1 |
| Smith, RR | 1 |
| Witman, G | 1 |
| Cadman, E | 1 |
| Kapp, D | 1 |
| Wagner, F | 1 |
| Geraci, JP | 1 |
| Jacobs, SA | 1 |
| Moore, PB | 1 |
| Wald, M | 1 |
| Fisher, ER | 1 |
| Cohen, M | 1 |
| Bellot, P | 1 |
| Bullard, DE | 1 |
| Yung, WA | 1 |
| Basler, GA | 1 |
| Aronin, PA | 1 |
| Rudnick, SA | 1 |
| Donohue, JF | 1 |
| Moore, P | 1 |
| U, R | 2 |
| Varia, MA | 1 |
| Lipper, S | 2 |
| Mahaley, J | 1 |
| Dalzell, JG | 1 |
| Kornblith, PL | 2 |
| Smith, BH | 1 |
| Leonard, LA | 1 |
| Kirby, S | 1 |
| Brothers, M | 1 |
| Irish, W | 1 |
| Florell, R | 1 |
| Macdonald, D | 1 |
| Cairncross, G | 1 |
| Roosen, N | 1 |
| Yeomans, KL | 1 |
| Jeremic, B | 2 |
| Grujicic, D | 2 |
| Antunovic, V | 2 |
| Djuric, L | 2 |
| Bobola, MS | 1 |
| Silber, JR | 1 |
| Nutt, CL | 2 |
| Costello, JF | 1 |
| Bambrick, LL | 1 |
| Yarosh, DB | 2 |
| Swinnen, LJ | 1 |
| Chambers, AF | 1 |
| Halperin, EC | 3 |
| Burger, PC | 8 |
| Selker, R | 1 |
| Vick, NA | 4 |
| Black, K | 1 |
| Sisti, M | 2 |
| Mohr, G | 2 |
| Ali-Osman, F | 4 |
| Rairkar, A | 1 |
| Young, P | 1 |
| Soma, MR | 2 |
| Baetta, R | 1 |
| De Renzis, MR | 1 |
| Mazzini, G | 1 |
| Davegna, C | 1 |
| Pezzotta, S | 3 |
| Paoletti, R | 2 |
| Fumagalli, R | 4 |
| Murray, KJ | 2 |
| Scott, C | 1 |
| Porter, A | 1 |
| Farnan, N | 1 |
| Buckner, JC | 9 |
| Brown, LD | 2 |
| Kugler, JW | 1 |
| Cascino, TL | 6 |
| Krook, JE | 2 |
| Mailliard, JA | 2 |
| Kardinal, CG | 1 |
| Tschetter, LK | 2 |
| O'Fallon, JR | 4 |
| Scheithauer, BW | 3 |
| Judy, KD | 1 |
| Buahin, KG | 1 |
| Domb, A | 1 |
| Epstein, JI | 3 |
| Colvin, OM | 3 |
| Corn, BW | 1 |
| Yousem, DM | 1 |
| Scott, CB | 4 |
| Rotman, M | 1 |
| Asbell, SO | 1 |
| Martin, L | 1 |
| Stojanovic, M | 1 |
| Kuratsu, J | 2 |
| Ebert, PS | 2 |
| Salcman, M | 2 |
| Hildebrand, J | 1 |
| Sahmoud, T | 1 |
| Mignolet, F | 1 |
| Brucher, JM | 1 |
| Afra, D | 1 |
| DaSilva, V | 2 |
| Belanger, G | 1 |
| Rampling, R | 1 |
| Steward, W | 1 |
| Paul, J | 1 |
| Macham, MA | 1 |
| Harvey, E | 1 |
| Eckley, D | 1 |
| Schmoor, C | 1 |
| Ulm, K | 1 |
| Schumacher, M | 1 |
| Noë, AJ | 4 |
| Malapetsa, A | 4 |
| Panasci, LC | 12 |
| Archibald, YM | 1 |
| Lunn, D | 1 |
| Ruttan, LA | 1 |
| Macdonald, DR | 2 |
| Del Maestro, RF | 1 |
| Barr, HW | 1 |
| Pexman, JH | 1 |
| Fisher, BJ | 2 |
| Gaspar, LE | 2 |
| Tamargo, RJ | 4 |
| Pinn, M | 1 |
| Wharam, M | 1 |
| Arusell, RM | 1 |
| Earle, JD | 2 |
| Maier, JA | 1 |
| Watne, K | 3 |
| Hannisdal, E | 1 |
| Nome, O | 2 |
| Hager, B | 4 |
| Hirschberg, H | 3 |
| Patterson, DL | 1 |
| Wiemann, MC | 1 |
| Lee, TH | 1 |
| Byron, WA | 1 |
| Bromberg, J | 1 |
| Page, MA | 1 |
| Gaspar, L | 1 |
| Imperato, J | 1 |
| Salter, M | 1 |
| Herndon, J | 1 |
| Dowling, S | 1 |
| Myseros, JS | 1 |
| Yang, MB | 1 |
| Chasin, M | 1 |
| Dropcho, EJ | 1 |
| Morawetz, R | 1 |
| Martin, LA | 1 |
| Phillips, TL | 3 |
| Murray, K | 2 |
| Yakar, D | 3 |
| Schwade, JG | 2 |
| Buckman, TD | 1 |
| Sutphin, MS | 1 |
| Mitrovic, B | 1 |
| Poirier, GG | 1 |
| Desnoyers, S | 1 |
| Berger, NA | 1 |
| Kiu, MC | 1 |
| Chang, CN | 1 |
| Cheng, WC | 1 |
| Lin, TK | 1 |
| Wong, CW | 1 |
| Tang, SG | 1 |
| Leung, WM | 1 |
| Chen, LH | 1 |
| Ho, YS | 1 |
| Ng, KT | 1 |
| Werner-Wasik, M | 1 |
| Fischbach, JA | 1 |
| Takeda, N | 2 |
| Diksic, M | 4 |
| Yamamoto, YL | 3 |
| Antoun, G | 1 |
| Rajagopal, S | 1 |
| Gagucas, E | 1 |
| Marcantonio, D | 2 |
| Barton, J | 1 |
| Kaaijk, P | 1 |
| Troost, D | 1 |
| de Boer, OJ | 1 |
| Van Amstel, P | 1 |
| Bakker, PJ | 1 |
| Leenstra, S | 1 |
| Bosch, DA | 1 |
| Danguy, A | 1 |
| Pasteels, JL | 1 |
| Kitamura, I | 1 |
| Kochi, M | 1 |
| Matsumoto, Y | 1 |
| Ueoka, R | 1 |
| Greenhoot, J | 1 |
| Allen, JC | 1 |
| Siffert, J | 1 |
| Pollack, IF | 1 |
| Kawecki, S | 1 |
| Lazo, JS | 1 |
| Schlegel, J | 1 |
| Stumm, G | 1 |
| Ruschoff, J | 1 |
| Mennel, HD | 1 |
| Liang, BC | 1 |
| Zhong, W | 2 |
| Oberley, LW | 2 |
| Oberley, TD | 1 |
| Yan, T | 2 |
| Domann, FE | 1 |
| St Clair, DK | 1 |
| Mineura, K | 1 |
| Yanagisawa, T | 1 |
| Watanabe, K | 1 |
| Kowada, M | 1 |
| Yasui, N | 1 |
| Khelfaoui, F | 1 |
| Philip, I | 1 |
| Biron, P | 1 |
| Brunat-Mentigny, M | 1 |
| Philip, T | 1 |
| Prados, M | 2 |
| Russell, C | 1 |
| Weissman, D | 1 |
| Evans, R | 1 |
| Cook, P | 1 |
| Burton, G | 1 |
| Eisenberg, PD | 1 |
| Valenzuela, R | 1 |
| Verkh, L | 1 |
| Beith, J | 1 |
| Hartley, J | 1 |
| Darling, J | 1 |
| Souhami, R | 2 |
| Shuper, A | 1 |
| Horev, G | 1 |
| Kornreich, L | 1 |
| Michowiz, S | 1 |
| Weitz, R | 1 |
| Zaizov, R | 1 |
| Cohen, IJ | 1 |
| Boiardi, A | 3 |
| Silvani, A | 3 |
| Pozzi, A | 1 |
| Farinotti, M | 1 |
| Fariselli, L | 1 |
| Broggi, G | 2 |
| Salmaggi, A | 1 |
| Valtonen, S | 1 |
| Timonen, U | 1 |
| Toivanen, P | 1 |
| Kalimo, H | 1 |
| Kivipelto, L | 1 |
| Heiskanen, O | 1 |
| Unsgaard, G | 2 |
| Kuurne, T | 1 |
| Brandes, AA | 2 |
| Scelzi, E | 1 |
| Zampieri, P | 1 |
| Rigon, A | 1 |
| Amista, P | 1 |
| Berti, F | 1 |
| Fiorentino, MV | 1 |
| Lote, K | 1 |
| Egeland, T | 1 |
| Stenwig, B | 1 |
| Skullerud, K | 1 |
| Berg-Johnsen, J | 1 |
| Storm-Mathisen, I | 1 |
| Hollingshead, MG | 1 |
| Alley, MC | 1 |
| Camalier, RF | 1 |
| Sausville, EA | 2 |
| Dykes, DJ | 1 |
| Carter, CA | 1 |
| Malspeis, L | 1 |
| Larson, DA | 1 |
| Lamborn, K | 1 |
| McDermott, MW | 1 |
| Sneed, PK | 1 |
| Wara, WM | 5 |
| Mack, EE | 1 |
| Krouwer, HG | 2 |
| Chandler, KL | 1 |
| Warnick, RE | 1 |
| Rabbitt, JE | 1 |
| Malec, M | 1 |
| Rajkumar, SV | 3 |
| Schomberg, PJ | 4 |
| Burch, PA | 1 |
| Arguello, F | 1 |
| Alexander, MA | 1 |
| Greene, JF | 1 |
| Stinson, SF | 1 |
| Jorden, JL | 1 |
| Smith, EM | 1 |
| Kalavar, NT | 1 |
| Alvord, WG | 1 |
| Klabansky, RL | 1 |
| Vassal, G | 1 |
| Boland, I | 1 |
| Terrier-Lacombe, MJ | 1 |
| Watson, AJ | 1 |
| Margison, GP | 1 |
| Vénuat, AM | 1 |
| Morizet, J | 1 |
| Parker, F | 1 |
| Lacroix, C | 1 |
| Lellouch-Tubiana, A | 1 |
| Pierre-Kahn, A | 1 |
| Poullain, MG | 1 |
| Gouyette, A | 1 |
| Coggins, CA | 1 |
| Elion, GB | 3 |
| Hare, CB | 1 |
| Keir, S | 1 |
| McQuillan, A | 3 |
| Taylor, BV | 1 |
| Schaefer, PL | 1 |
| Schomberg, P | 1 |
| Roth, W | 1 |
| Wagenknecht, B | 1 |
| Dichgans, J | 2 |
| Trepel, M | 1 |
| Groscurth, P | 1 |
| Malipiero, U | 1 |
| Gulbins, E | 1 |
| DeAngelis, LM | 1 |
| McKeever, PE | 1 |
| Kim, B | 1 |
| Reid, JM | 1 |
| Bagniewski, PJ | 1 |
| Ames, MM | 1 |
| Marks, RS | 1 |
| Ma, J | 1 |
| Fei, ZL | 1 |
| Klein-Szanto, A | 1 |
| Gallo, JM | 1 |
| Pitot, HC | 1 |
| Ingle, JN | 1 |
| Guevara, P | 1 |
| Reyes, S | 2 |
| Ortiz, A | 1 |
| Rembao, D | 1 |
| Sotelo, J | 2 |
| Williams, D | 1 |
| Mancini, WR | 1 |
| Glaze, ER | 1 |
| Stetson, PL | 1 |
| Rolhion, C | 1 |
| Penault-Llorca, F | 1 |
| Kemeny, JL | 1 |
| Kwiatkowski, F | 1 |
| Lemaire, JJ | 1 |
| Chollet, P | 1 |
| Finat-Duclos, F | 1 |
| Verrelle, P | 1 |
| Kurpad, C | 1 |
| Wang, G | 1 |
| Zhou, LY | 2 |
| Wang, AD | 2 |
| Bartussek, C | 1 |
| Naumann, U | 1 |
| Lim, R | 1 |
| Prager, JM | 1 |
| Grenier, Y | 1 |
| Cozzens, JW | 2 |
| Chiowanich, P | 1 |
| Gorey, MT | 1 |
| Meyer, JR | 1 |
| Bruce, JN | 1 |
| Falavigna, A | 1 |
| Johnson, JP | 1 |
| Hall, JS | 1 |
| Birch, BD | 1 |
| Yoon, JT | 1 |
| Wu, EX | 1 |
| Fine, RL | 1 |
| Parsa, AT | 1 |
| Bauman, GS | 1 |
| MacDonald, W | 1 |
| Moore, E | 1 |
| Ramsey, DA | 1 |
| Amberger, VR | 1 |
| Del Maestro, RM | 1 |
| Chao, KS | 1 |
| Hsu, JS | 1 |
| Xu, J | 2 |
| Ezekiel, UR | 1 |
| Eves, E | 1 |
| Rosner, M | 1 |
| Castellino, RC | 1 |
| Johnson, SP | 1 |
| Park, SJ | 1 |
| Kaye, AH | 1 |
| Hill, JS | 1 |
| Winter, S | 1 |
| Engelhard, HH | 1 |
| Chen, YQ | 2 |
| Wang, M | 1 |
| Hung, CF | 1 |
| Norman, SA | 1 |
| Rhodes, SN | 1 |
| Treasurywala, S | 1 |
| Hoelzinger, DB | 1 |
| Rankin Shapiro, J | 1 |
| Lee, A | 1 |
| DeJong, G | 1 |
| Guo, J | 1 |
| Bu, X | 1 |
| Jia, WW | 1 |
| Emerich, DF | 3 |
| Winn, SR | 3 |
| Hu, Y | 1 |
| Marsh, J | 1 |
| Snodgrass, P | 2 |
| LaFreniere, D | 2 |
| Wiens, T | 2 |
| Hasler, BP | 1 |
| Bartus, RT | 3 |
| Agostino, M | 1 |
| Xiong, H | 1 |
| Goodman, SN | 1 |
| Hidalgo, OF | 1 |
| Vanaclocha, V | 1 |
| Baylin, SB | 1 |
| Herman, JG | 1 |
| Weinstein, JN | 1 |
| Stegman, LD | 1 |
| Taylor, JM | 1 |
| Robertson, PL | 1 |
| Potthoff, RF | 1 |
| Peterson, BL | 1 |
| George, SL | 1 |
| Joy, A | 1 |
| Panicker, S | 1 |
| Schlegel, U | 1 |
| Moynihan, TJ | 1 |
| Quinn, DI | 1 |
| Srivenugopal, K | 1 |
| Sawaya, R | 1 |
| Kokkinakis, DM | 1 |
| Bocangel, DB | 1 |
| Moschel, RC | 2 |
| Pegg, AE | 2 |
| Chou, H | 1 |
| Thompson, EM | 1 |
| Gildenberg, PL | 2 |
| Winter, PM | 1 |
| Poptani, H | 1 |
| Palmisano, V | 1 |
| Pasetto, LM | 1 |
| Basso, U | 1 |
| Monfardini, S | 1 |
| Pan, J | 1 |
| Zlatescu, MC | 1 |
| Keeney, M | 1 |
| Chin-Yee, I | 1 |
| Gomez-Manzano, C | 1 |
| Lemoine, MG | 1 |
| Hu, M | 1 |
| He, J | 1 |
| Mitlianga, P | 1 |
| Liu, TJ | 2 |
| Fueyo, J | 1 |
| Groves, MD | 1 |
| McGinnis, WL | 1 |
| Morton, RF | 1 |
| Kuross, SA | 1 |
| Hatfield, AK | 1 |
| Cole, JT | 1 |
| Steen, PD | 1 |
| Bernath, AM | 1 |
| Herrera, LA | 1 |
| Ostrosky, P | 1 |
| Linassier, C | 1 |
| Destrieux, C | 1 |
| Benboubker, L | 1 |
| Alcaraz, L | 1 |
| Bergemer-Fouquet, AM | 1 |
| Jan, M | 1 |
| Calais, G | 1 |
| Colombat, P | 1 |
| Woo, SY | 1 |
| Shono, T | 1 |
| Tofilon, PJ | 2 |
| Schaefer, TS | 1 |
| Parikh, D | 1 |
| Lang, FF | 1 |
| Lesniak, MS | 1 |
| Langer, R | 1 |
| Pluda, J | 1 |
| Delaney, S | 1 |
| Kaplan, R | 1 |
| Haglund, MM | 1 |
| McLendon, RE | 1 |
| Rao, RD | 1 |
| Thomé, SD | 1 |
| O'Fallon, J | 1 |
| Fleming, AB | 1 |
| Saltzman, WM | 1 |
| Mishra, S | 1 |
| Mishra, R | 1 |
| Bloom, HJ | 1 |
| Crafts, DC | 2 |
| Schultz, MJ | 1 |
| Boldrey, EB | 5 |
| Enot, KJ | 4 |
| Pischer, TL | 4 |
| Seager, M | 2 |
| Elashoff, RM | 1 |
| Gutin, P | 1 |
| Drafts, D | 1 |
| Hoffman, WF | 1 |
| Seager, ML | 1 |
| Davis, R | 2 |
| Irwin, L | 2 |
| Paillas, JE | 1 |
| Prince, MA | 1 |
| Hassoun, J | 1 |
| Pellet, W | 1 |
| Peragut, JC | 1 |
| Zinn, DC | 1 |
| Mahaley, JL | 1 |
| Wara, W | 1 |
| Norrell, HA | 1 |
| Gehan, EA | 1 |
| Vogel, FS | 1 |
| Ghatak, NR | 1 |
| Baldini, M | 1 |
| Princi, L | 1 |
| Spence, JD | 1 |
| Weiss, JF | 1 |
| Szypko, PE | 1 |
| Zander, E | 1 |
| Wagenknecht, L | 1 |
| Sheline, GE | 2 |
| Lieberman, A | 1 |
| Grasso, RJ | 2 |
| Johnson, CE | 2 |
| Boler, RK | 2 |
| Moore, NA | 2 |
| Rosenblum, MK | 2 |
| Knebel, KD | 1 |
| Vasquez, DA | 1 |
| Garfield, JS | 1 |
| Hilton, J | 1 |
| Brisman, R | 1 |
| Housepian, EM | 1 |
| Chang, C | 1 |
| Duffy, P | 1 |
| Balis, E | 1 |
| Racca, AR | 1 |
| Calogero, J | 1 |
| Rosenberg, A | 1 |
| Posner, JB | 2 |
| Tokuda, K | 2 |
| Powlis, WD | 1 |
| Milanesi, I | 2 |
| Botturi, M | 2 |
| Caballero Navarro, A | 1 |
| Conde Guerri, B | 1 |
| Sinues Porta, E | 1 |
| Boada Apilluelo, E | 1 |
| Alcalá Arellano, A | 1 |
| Bobo, H | 2 |
| Salford, LG | 1 |
| Pero, RW | 1 |
| Aas, AT | 1 |
| Brun, A | 1 |
| Kupersmith, MJ | 2 |
| Seiple, WH | 1 |
| Holopigian, K | 1 |
| Noble, K | 1 |
| Warren, F | 1 |
| Janus, TJ | 1 |
| Maor, M | 1 |
| Feun, LG | 2 |
| VanGilder, JC | 2 |
| Ransohff, J | 1 |
| Nikkhah, G | 1 |
| Tonn, JC | 3 |
| Hoffmann, O | 1 |
| Kraemer, HP | 2 |
| Darling, JL | 2 |
| Schachenmayr, W | 2 |
| Schönmayr, R | 2 |
| Pagliarini, P | 1 |
| Smith, DC | 1 |
| Trump, DL | 1 |
| Purvis, J | 1 |
| Gauspari, A | 1 |
| Skalski, V | 5 |
| Feindel, W | 9 |
| Allalunis-Turner, MJ | 1 |
| Day, RS | 1 |
| McKean, JD | 1 |
| Petruk, KC | 1 |
| Allen, PB | 1 |
| Aronyk, KE | 1 |
| Weir, BK | 1 |
| Huyser-Wierenga, D | 1 |
| Fulton, DS | 1 |
| Commodari, F | 1 |
| Sanctuary, BC | 1 |
| Shoubridge, EA | 2 |
| Mehta, BM | 1 |
| Ebrahim, SA | 1 |
| Moots, PL | 1 |
| Fiola, MR | 1 |
| Roosen, K | 1 |
| Munari, L | 1 |
| Solero, CL | 1 |
| Schem, BC | 1 |
| Dahl, O | 2 |
| Mitsuki, S | 1 |
| Conway, T | 1 |
| Villemure, JG | 5 |
| Steen, RG | 4 |
| Graham, MM | 1 |
| Da Silva, VF | 2 |
| Feeley, M | 2 |
| Raaphorst, GP | 2 |
| Berens, ME | 2 |
| Obbens, EA | 1 |
| Ogilvy-Stuart, AL | 1 |
| Shalet, SM | 1 |
| Gattamaneni, HR | 1 |
| Ciric, IS | 1 |
| Eller, TW | 1 |
| Wang, AM | 1 |
| Rogers, LR | 2 |
| Purvis, JB | 1 |
| Lederman, RJ | 2 |
| Rosenbloom, SA | 1 |
| Tomsak, RL | 2 |
| Estes, ML | 1 |
| Magdinec, M | 1 |
| Medendorp, SV | 1 |
| Boyett, JM | 1 |
| Zhang, RX | 1 |
| Silver, P | 1 |
| Hannigan, J | 1 |
| Schipper, HM | 1 |
| Wang, E | 1 |
| Bradford, R | 1 |
| Sier, N | 1 |
| Thomas, DG | 1 |
| Heuser, K | 1 |
| Bowles, AP | 2 |
| Pantazis, CG | 2 |
| Wansley, W | 2 |
| Allen, MB | 1 |
| Assietti, R | 1 |
| Batist, G | 1 |
| Gros, P | 1 |
| Kopriva, D | 1 |
| Hamada, H | 1 |
| Asakura, T | 1 |
| Matsuda, K | 1 |
| Rathmer, K | 1 |
| Richard, M | 2 |
| Helseth, E | 1 |
| Vik, R | 1 |
| Dalen, A | 1 |
| Deutsch, M | 1 |
| Stuschke, M | 1 |
| Bamberg, M | 1 |
| Strehl, K | 1 |
| Budach, W | 1 |
| Sprengel, M | 1 |
| Elsås, T | 1 |
| Fostad, K | 1 |
| Zamorano, L | 1 |
| Katanick, D | 1 |
| Dujovny, M | 1 |
| Malik, G | 1 |
| Ausman, JI | 1 |
| Wu, ZL | 1 |
| Arnold, DL | 1 |
| Emrich, J | 2 |
| Fischer, H | 1 |
| Zeller, WJ | 1 |
| Schwechheimer, K | 1 |
| Hutter, KJ | 1 |
| Wowra, B | 1 |
| Kunze, S | 1 |
| Sturm, V | 1 |
| Glickson, JD | 3 |
| Wehrle, JP | 3 |
| Harris, MI | 1 |
| Bruner, JM | 1 |
| Delattre, JY | 1 |
| Walker, RW | 1 |
| Abernathey, CD | 1 |
| Kooistra, KL | 1 |
| Wilcox, GL | 1 |
| Laws, ER | 1 |
| Evans, CG | 1 |
| Doane-Setzer, P | 1 |
| Smith, MT | 2 |
| Giblin, J | 1 |
| Dougherty, D | 1 |
| Pickrell, L | 1 |
| Purvin, V | 1 |
| Fontaine, S | 1 |
| Théron, J | 3 |
| Melanson, D | 1 |
| Raymond, J | 1 |
| Ethier, R | 1 |
| Miller, DF | 1 |
| Bay, JW | 1 |
| Purvis, JD | 1 |
| Comella, G | 1 |
| Scoppa, G | 1 |
| De Marco, M | 1 |
| Ianniello, GP | 1 |
| Melillo, G | 1 |
| Coucourde, F | 1 |
| Zarrilli, D | 1 |
| Vance, RB | 3 |
| Vestnys, P | 1 |
| Resser, KJ | 1 |
| Yatsko, K | 1 |
| Nutik, S | 1 |
| Peters, W | 1 |
| Phillips, GL | 1 |
| Wolff, SN | 1 |
| Fay, JW | 1 |
| Herzig, RH | 1 |
| Lazarus, HM | 1 |
| Herzig, GP | 1 |
| Liu, HC | 1 |
| Da Silva, V | 1 |
| Murovic, J | 1 |
| Choucair, A | 1 |
| Chamberlain, M | 1 |
| Berger, M | 1 |
| Papavero, L | 1 |
| Loew, F | 1 |
| Jaksche, H | 1 |
| Saunders, WM | 1 |
| Cohen, AR | 1 |
| Pietronigro, DD | 1 |
| Cravioto, H | 1 |
| Flamm, ES | 1 |
| Colombatti, M | 1 |
| Bisconti, M | 1 |
| Dell'Arciprete, L | 1 |
| Tridente, G | 1 |
| Teicher, BA | 1 |
| Herman, TS | 1 |
| Rose, CM | 1 |
| Aida, T | 5 |
| Zupi, G | 1 |
| Candiloro, A | 1 |
| Laudonio, N | 1 |
| Carapella, C | 1 |
| Benassi, M | 1 |
| Riccio, A | 1 |
| Bellocci, M | 1 |
| Greco, C | 1 |
| Giblin, JR | 1 |
| Hoifodt, HK | 1 |
| Tveit, K | 1 |
| Diener-West, M | 3 |
| Silvani, V | 1 |
| Spanu, G | 1 |
| Rossi, A | 1 |
| McGovern, KA | 1 |
| Rajan, SS | 2 |
| Wolpert, SM | 3 |
| Kwan, ES | 2 |
| Heros, D | 1 |
| Kasdon, DL | 3 |
| Hedges, TR | 1 |
| Frohman, LP | 1 |
| Choi, IS | 2 |
| Foo, SH | 3 |
| Hiesinger, E | 1 |
| Berenstein, A | 3 |
| Wise, A | 2 |
| Carr, RE | 1 |
| Heros, DO | 1 |
| Renkens, K | 1 |
| Adelman, LS | 1 |
| Mella, O | 1 |
| Mehus, A | 1 |
| Rivas, J | 1 |
| Panasci, L | 1 |
| Sijens, PE | 1 |
| Bovee, WM | 1 |
| Li, SJ | 1 |
| Tyler, JL | 2 |
| Worthington, C | 2 |
| Evans, AC | 1 |
| Pakuris, E | 1 |
| Sause, WT | 1 |
| Goodman, R | 1 |
| Kimmel, DW | 1 |
| Krigman, MR | 1 |
| Bouldin, TW | 1 |
| Bertsch, L | 2 |
| Cush, S | 1 |
| Johnson, DB | 1 |
| Thompson, JM | 1 |
| Corwin, JA | 1 |
| Mosley, KR | 1 |
| de los Reyes, RA | 1 |
| Daly, MB | 1 |
| Petty, AM | 1 |
| Lamaster, D | 1 |
| Pierson, WP | 1 |
| Johnson, DW | 1 |
| Parkinson, D | 1 |
| Laucella, M | 1 |
| Anderson, ML | 1 |
| Maroun, J | 1 |
| Verma, S | 1 |
| Cheitlin, RA | 1 |
| Constine, LS | 1 |
| Rubin, P | 1 |
| Woolf, PD | 1 |
| Doane, K | 1 |
| Lush, CM | 1 |
| Goyal, R | 1 |
| Koslow, M | 1 |
| George, A | 1 |
| Lin, J | 1 |
| Feigin, I | 1 |
| Budzilovich, G | 1 |
| Pittisapu, J | 1 |
| Sanford, RA | 1 |
| Kligerman, AD | 1 |
| Erexson, GL | 1 |
| Wilmer, JL | 1 |
| Kendall, LE | 1 |
| Blue, M | 1 |
| Klein, DS | 1 |
| Klein, PW | 1 |
| Dufour, M | 1 |
| Chevalier, L | 1 |
| Isabel, G | 1 |
| Lazarus, P | 1 |
| Arbit, E | 1 |
| Choy, IS | 1 |
| Persson, L | 1 |
| Boethius, J | 1 |
| Gronowitz, JS | 1 |
| Källander, C | 1 |
| Lindgren, L | 1 |
| Safdari, H | 1 |
| Mompeon, B | 1 |
| Dubois, JB | 1 |
| Gros, C | 1 |
| Calvo, FA | 1 |
| Pastor, MA | 1 |
| Dy, C | 1 |
| Alegría, E | 1 |
| Antón Aparicio, LM | 1 |
| Gil, A | 1 |
| Harguindey, S | 1 |
| Zubieta, JL | 1 |
| Martinez Lage, M | 1 |
| Oldfield, EH | 1 |
| Dedrick, RL | 1 |
| Yeager, RL | 1 |
| Clark, WC | 1 |
| DeVroom, HL | 1 |
| Chatterji, DC | 1 |
| Doppman, JL | 1 |
| Beck, DO | 1 |
| Nagata, K | 1 |
| Gross, CE | 1 |
| Kindt, GW | 1 |
| Geier, JM | 1 |
| Adey, GR | 1 |
| Kobayashi, S | 1 |
| Fewer, D | 1 |
| Powell, MR | 1 |
| Jacobi, H | 1 |
| Chernik, NL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluating the Expression Levels of microRNA-10b in Patients With Gliomas[NCT01849952] | 200 participants (Anticipated) | Observational | 2020-02-28 | Recruiting | |||
| PHASE I, OPEN LABEL, MULTICENTER DOSE ESCALATION STUDY OF GLIADEL IN PATIENTS WITH RECURRENT MALIGNANT GLIOMA[NCT00004028] | Phase 1 | 0 participants | Interventional | 1996-09-30 | Completed | ||
| A Phase II Trial of Temozolomide and BCNU for Anaplastic Gliomas[NCT00003176] | Phase 2 | 82 participants | Interventional | 1998-03-25 | Completed | ||
| A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma[NCT01235793] | Phase 2 | 11 participants (Actual) | Interventional | 2010-10-14 | Terminated (stopped due to The clinical trial was terminated due to poor enrollment) | ||
| A Pilot Study Investigating Neoadjuvant Temozolomide-based Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas[NCT00881595] | Phase 2 | 0 participants (Actual) | Interventional | 2009-02-28 | Withdrawn (stopped due to No patients accrued since study opened) | ||
| Chemo Sensitization Before Hematopoietic Stem Cell Transplantation With a CXCR4 Antagonist in Patients With Acute Leukemia in Complete Remission: Pilot Study[NCT02605460] | Phase 2 | 20 participants (Anticipated) | Interventional | 2014-02-28 | Recruiting | ||
| Phase I GLIADEL and Continuous Infusion of Intravenous O6-Benzylguanine Trial in Patients With Recurrent Malignant Glioma[NCT00004892] | Phase 1 | 0 participants | Interventional | 2000-04-30 | Completed | ||
| (Cost)Effectiveness of MR-guided LITT Therapy in Patients With Primary Irresectable Glioblastoma: a Prospective Multicenter Randomized Controlled Trial (EMITT)[NCT05318612] | Phase 3 | 238 participants (Anticipated) | Interventional | 2022-04-08 | Recruiting | ||
| A Family Study of Adults With Glioma[NCT00339352] | 1,871 participants (Actual) | Observational | 1999-03-11 | Completed | |||
| EUS-Guided Radiofrequency Ablation of Pancreatic Cysts - A Safety and Efficacy Trial[NCT05916846] | 28 participants (Anticipated) | Interventional | 2023-04-24 | Recruiting | |||
| EFFECT OF DIBROMODULCITOL PLUS BCNU ON FREE INTERVAL AND SURVIVAL OF PATIENTS WITH SUPRATENTORIAL MALIGNANT BRAIN GLIOMAS, A PHASE III TYPE STUDY[NCT00002620] | Phase 3 | 212 participants (Anticipated) | Interventional | 1994-11-30 | Completed | ||
| A Phase II Study of Peg-Interferon Alpha-2B (Peg-Intron(TM)) and Thalidomide in Adults With Recurrent High-Grade Gliomas[NCT00047879] | Phase 2 | 7 participants (Actual) | Interventional | 2002-10-31 | Completed | ||
| Phase II, Single Arm, Open Label Clinical Trial With Irinotecan in Combination With Cisplatin in Pediatric Patients With Unfavorable Prognosis Gliomas[NCT01574092] | Phase 2 | 39 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| Development of Quantitative Imaging Biomarkers for Evaluating Sarcoma Patients[NCT02579980] | 32 participants (Actual) | Interventional | 2015-10-31 | Completed | |||
| Phase I Trial of AZD8055, An Oral MTOR Kinase Inhibitor, for Adults With Recurrent Gliomas[NCT01316809] | Phase 1 | 22 participants (Actual) | Interventional | 2011-03-04 | Completed | ||
| (11C)N-Desmethyl-Loperamide as a Marker of P-Glycoprotein Function in Patients With Gliomas[NCT01281982] | 2 participants (Actual) | Observational | 2011-01-13 | Terminated | |||
| Phase I Trial of AZD7451, A Topomysin-Receptor Kinase (TRK) Inhibitor, For Adults With Recurrent Glioblastoma Multiforme (GBM)[NCT01468324] | Phase 1 | 14 participants (Actual) | Interventional | 2011-10-05 | Completed | ||
| A Phase I/II Study of the Safety and Feasibility of Administering T Cells Expressing Anti-EGFRvIII Chimeric Antigen Receptor to Patients With Malignant Gliomas Expressing EGFRvIII[NCT01454596] | Phase 1/Phase 2 | 18 participants (Actual) | Interventional | 2012-05-16 | Completed | ||
| Does Varenicline Influence Alcohol Consumption in Alcohol Dependent Individuals?[NCT00846859] | Phase 2 | 162 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Safety will be assessed using a dose escalation design for temozolomide's use to determine the target dose and also to evaluate any and all acute treatment related toxicities. During the course of patient follow up and therapy, toxicities will be evaluated, particularly as the investigators will be determining the target dose of temozolomide. One of the major criteria for dose limiting toxicity for the study will be any Grade 3 or 4 nonhematologic toxicity from a list of commonly expected toxicities associated with autologous transplantation and temozolomide. (NCT01235793)
Timeframe: One Year
| Intervention | dose in mg/m^2 (Number) |
|---|---|
| DRBEAT Regimen | 773.25 |
"Efficacy of the DRBEAT Regimen will be assessed by analysis of~one-year progression-free survival (PFS), defined as the time interval from maximal response from therapy to tumor regrowth, progression*, or death, (*Progression is defined as meeting the response criteria listed in Table 4: Response Criteria for Primary Central Nervous System Lymphoma according to Abrey LE, Batchelor TT, Ferreri AJM et al.)~and~Overall survival, defined as the time interval between the date of transplant and the date of death from any cause." (NCT01235793)
Timeframe: (1) One Year (2) Until date of death from any cause, assessed up to 2 years
| Intervention | Days (Median) | |
|---|---|---|
| Progression Free Survival | Overall Survival | |
| DRBEAT Regimen | 132 | 564 |
Here are the total number of participants with adverse events. For the detailed list of adverse events see the adverse event module. (NCT00047879)
Timeframe: 4 months
| Intervention | Participants (Number) |
|---|---|
| Glioblastoma Multiforme Stratum | 4 |
| Anaplastic Glioma Stratum | 2 |
CAR and vector presence were quantitated in peripheral blood mononuclear cell (PBMC) samples using established polymerase chain reaction (PCR) techniques (NCT01454596)
Timeframe: 1 month post transplant
| Intervention | K/µL (Median) |
|---|---|
| Group A (Steroids) - Cohort 1: 1x10(7) | 23 |
| Group A (Steroids) - Cohort 2: 3x10(7) | 70 |
| Group A (Steroids) - Cohort 3: 1x10(8) | 36 |
| Group B (No Steroids) - Cohort 1: 1x10(7) | 67 |
| Group B (No Steroids) - Cohort 2: 3x10(7) | 7 |
| Group B (No Steroids) - Cohort 3: 1x10(8) | 43 |
| Group B (No Steroids) - Cohort 4: 3x10(8) | 28 |
| Group B (No Steroids) - Cohort 5: 1x10(9) | 25 |
| Combined Steroids/no Steroids) - Cohort 6: 3x10(9) | 12 |
| Combined Steroids/no Steroids) - Cohort 7: 1x10(10) | 67.5 |
| Combined Steroids/no Steroids) - Cohort 8: 3-6x10(10) | NA |
| Combined Steroids/no Steroids) - Cohort 9: 3x10(10) | 8 |
Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01454596)
Timeframe: 51 dys Grp A, Cohort 1; Cohort 2:68 dys; Cohort 3:40 dys; Grp B, Cohort 1:67 dys; Cohort 2:48 dys; Cohort 3:55 dys; Cohort 4: 46 dys; Cohort 5:147 dys; C. Ster/No Ster Grp, Cohort 6:12 mos, 26 dys; Cohort 7:11 mos, 18 dys; Cohort 8:7 dys; Cohort 9:70 dys.
| Intervention | Participants (Count of Participants) |
|---|---|
| Group A (Steroids) - Cohort 1: 1x10(7) | 1 |
| Group A (Steroids) - Cohort 2: 3x10(7) | 1 |
| Group A (Steroids) - Cohort 3: 1x10(8) | 1 |
| Group B (No Steroids) - Cohort 1: 1x10(7) | 1 |
| Group B (No Steroids) - Cohort 2: 3x10(7) | 1 |
| Group B (No Steroids) - Cohort 3: 1x10(8) | 1 |
| Group B (No Steroids) - Cohort 4: 3x10(8) | 1 |
| Group B (No Steroids) - Cohort 5: 1x10(9) | 3 |
| Combined Steroids/no Steroids) - Cohort 6: 3x10(9) | 3 |
| Combined Steroids/no Steroids) - Cohort 7: 1x10(10) | 3 |
| Combined Steroids/no Steroids) - Cohort 8: 3-6x10(10) | 1 |
| Combined Steroids/no Steroids) - Cohort 9: 3x10(10) | 1 |
Objective response was assessed by comparison with baseline dynamic contrast enhanced magnetic resonance imaging with perfusion using Neuro-oncology Working Group proposed guidelines. Complete Response is disappearance of all measurable and non-measurable disease for at least 4 weeks. Partial Response is >/= 50% decrease in lesions for at least 4 weeks. Stable Disease does not meet the criteria for complete response, partial response or progression and requires stable lesions compared with baseline. Progression is >/= 25% increase in lesions. (NCT01454596)
Timeframe: 4 weeks after cell infusion and monthly as feasible up to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Group A (Steroids) - Cohort 1: 1x10(7) | 0 |
| Group A (Steroids) - Cohort 2: 3x10(7) | 0 |
| Group A (Steroids) - Cohort 3: 1x10(8) | 0 |
| Group B (No Steroids) - Cohort 1: 1x10(7) | 0 |
| Group B (No Steroids) - Cohort 2: 3x10(7) | 0 |
| Group B (No Steroids) - Cohort 3: 1x10(8) | 0 |
| Group B (No Steroids) - Cohort 4: 3x10(8) | 0 |
| Group B (No Steroids) - Cohort 5: 1x10(9) | 0 |
| Combined Steroids/no Steroids) - Cohort 6: 3x10(9) | 0 |
| Combined Steroids/no Steroids) - Cohort 7: 1x10(10) | 0 |
| Combined Steroids/no Steroids) - Cohort 8: 3-6x10(10) | 0 |
| Combined Steroids/no Steroids) - Cohort 9: 3x10(10) | 0 |
Aggregate of all adverse events ≥Grade 3 that are possibly, probably, and definitely related to treatment. Adverse events were assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). Per CTCAE, Grade 3 adverse events are severe, Grade 4 is life threatening, and Grade 5 is death. (NCT01454596)
Timeframe: From 4 weeks after cell infusion up to 77 days
| Intervention | adverse events (Number) |
|---|---|
| Group A (Steroids) - Cohort 1: 1x10(7) | 0 |
| Group A (Steroids) - Cohort 2: 3x10(7) | 0 |
| Group A (Steroids) - Cohort 3: 1x10(8) | 0 |
| Group B (No Steroids) - Cohort 1: 1x10(7) | 0 |
| Group B (No Steroids) - Cohort 2: 3x10(7) | 0 |
| Group B (No Steroids) - Cohort 3: 1x10(8) | 0 |
| Group B (No Steroids) - Cohort 4: 3x10(8) | 0 |
| Group B (No Steroids) - Cohort 5: 1x10(9) | 0 |
| Combined Steroids/no Steroids) - Cohort 6: 3x10(9) | 0 |
| Combined Steroids/no Steroids) - Cohort 7: 1x10(10) | 0 |
| Combined Steroids/no Steroids) - Cohort 8: 3-6x10(10) | 1 |
| Combined Steroids/no Steroids) - Cohort 9: 3x10(10) | 1 |
Progression was assessed by the Response Assessment in Neuro-Oncology (RANO) criteria and is defined as the circumstance when the magnetic resonance imaging (MRI) scan is ranked -2 (definitely worse) or -3 (development of a new lesion). (NCT01454596)
Timeframe: Time from the date of registration to the date of first observation of progressive disease up to 6 months after end of treatment
| Intervention | months (Median) |
|---|---|
| Group A (Steroids) - Cohort 1: 1x10(7) | 1.1 |
| Group A (Steroids) - Cohort 2: 3x10(7) | 1.1 |
| Group A (Steroids) - Cohort 3: 1x10(8) | 1.3 |
| Group B (No Steroids) - Cohort 1: 1x10(7) | 1.9 |
| Group B (No Steroids) - Cohort 2: 3x10(7) | 2.0 |
| Group B (No Steroids) - Cohort 3: 1x10(8) | 1.5 |
| Group B (No Steroids) - Cohort 4: 3x10(8) | 1.2 |
| Group B (No Steroids) - Cohort 5: 1x10(9) | 1.1 |
| Combined Steroids/no Steroids) - Cohort 6: 3x10(9) | 2.7 |
| Combined Steroids/no Steroids) - Cohort 7: 1x10(10) | 1.1 |
| Combined Steroids/no Steroids) - Cohort 8: 3-6x10(10) | 0 |
| Combined Steroids/no Steroids) - Cohort 9: 3x10(10) | 2.0 |
59 reviews available for carmustine and Glioma
| Article | Year |
|---|---|
Carmustine wafer implantation for high-grade gliomas: Evidence-based safety efficacy and practical recommendations from the Neuro-oncology Club of the French Society of Neurosurgery.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2017 |
Carmustine wafer implantation for high-grade gliomas: Evidence-based safety efficacy and practical recommendations from the Neuro-oncology Club of the French Society of Neurosurgery.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2017 |
Carmustine wafer implantation for high-grade gliomas: Evidence-based safety efficacy and practical recommendations from the Neuro-oncology Club of the French Society of Neurosurgery.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2017 |
The combination of carmustine wafers and temozolomide for the treatment of malignant gliomas. A comprehensive review of the rationale and clinical experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Clinical Trials as Topi | 2013 |
The combination of carmustine wafers and temozolomide for the treatment of malignant gliomas. A comprehensive review of the rationale and clinical experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Clinical Trials as Topi | 2013 |
The combination of carmustine wafers and temozolomide for the treatment of malignant gliomas. A comprehensive review of the rationale and clinical experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Clinical Trials as Topi | 2013 |
Current status of local therapy in malignant gliomas--a clinical review of three selected approaches.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Clinical Trials as | 2013 |
Current status of local therapy in malignant gliomas--a clinical review of three selected approaches.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Clinical Trials as | 2013 |
Current status of local therapy in malignant gliomas--a clinical review of three selected approaches.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Clinical Trials as | 2013 |
[II. Current status of BCNU stent in the brain for treatment of glioma].
Topics: Animals; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Decanoic Acids; Drug-Eluting Stents; | 2013 |
[II. Current status of BCNU stent in the brain for treatment of glioma].
Topics: Animals; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Decanoic Acids; Drug-Eluting Stents; | 2013 |
[II. Current status of BCNU stent in the brain for treatment of glioma].
Topics: Animals; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Decanoic Acids; Drug-Eluting Stents; | 2013 |
Modeling mass transfer from carmustine-loaded polymeric implants for malignant gliomas.
Topics: Animals; Carmustine; Glioma; Humans; Infusion Pumps, Implantable; Models, Theoretical | 2014 |
Modeling mass transfer from carmustine-loaded polymeric implants for malignant gliomas.
Topics: Animals; Carmustine; Glioma; Humans; Infusion Pumps, Implantable; Models, Theoretical | 2014 |
Modeling mass transfer from carmustine-loaded polymeric implants for malignant gliomas.
Topics: Animals; Carmustine; Glioma; Humans; Infusion Pumps, Implantable; Models, Theoretical | 2014 |
The role of Gliadel wafers in the treatment of high-grade gliomas.
Topics: Brain Neoplasms; Carmustine; Decanoic Acids; Glioblastoma; Glioma; Humans; Middle Aged; Polyesters | 2013 |
The role of Gliadel wafers in the treatment of high-grade gliomas.
Topics: Brain Neoplasms; Carmustine; Decanoic Acids; Glioblastoma; Glioma; Humans; Middle Aged; Polyesters | 2013 |
The role of Gliadel wafers in the treatment of high-grade gliomas.
Topics: Brain Neoplasms; Carmustine; Decanoic Acids; Glioblastoma; Glioma; Humans; Middle Aged; Polyesters | 2013 |
Combining microbubbles and ultrasound for drug delivery to brain tumors: current progress and overview.
Topics: Blood-Brain Barrier; Brain Neoplasms; Carmustine; Contrast Media; Drug Delivery Systems; Glioma; Hum | 2014 |
Combining microbubbles and ultrasound for drug delivery to brain tumors: current progress and overview.
Topics: Blood-Brain Barrier; Brain Neoplasms; Carmustine; Contrast Media; Drug Delivery Systems; Glioma; Hum | 2014 |
Combining microbubbles and ultrasound for drug delivery to brain tumors: current progress and overview.
Topics: Blood-Brain Barrier; Brain Neoplasms; Carmustine; Contrast Media; Drug Delivery Systems; Glioma; Hum | 2014 |
Survival outcomes and safety of carmustine wafers in the treatment of high-grade gliomas: a meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Decanoic Acids; Drug Implants; Gliom | 2015 |
Survival outcomes and safety of carmustine wafers in the treatment of high-grade gliomas: a meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Decanoic Acids; Drug Implants; Gliom | 2015 |
Survival outcomes and safety of carmustine wafers in the treatment of high-grade gliomas: a meta-analysis.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Decanoic Acids; Drug Implants; Gliom | 2015 |
Advanced interstitial chemotherapy for treating malignant glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Therapy; Decanoic | 2016 |
Advanced interstitial chemotherapy for treating malignant glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Therapy; Decanoic | 2016 |
Advanced interstitial chemotherapy for treating malignant glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Therapy; Decanoic | 2016 |
Chemotherapeutic wafers for High Grade Glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Therapy; Glioma; H | 2008 |
Chemotherapeutic wafers for High Grade Glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Therapy; Glioma; H | 2008 |
Chemotherapeutic wafers for High Grade Glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Therapy; Glioma; H | 2008 |
What is the translational efficacy of chemotherapeutic drug research in neuro-oncology? A systematic review and meta-analysis of the efficacy of BCNU and CCNU in animal models of glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Carmustine; Disease Models, Animal; Drug Evaluation; Gli | 2009 |
What is the translational efficacy of chemotherapeutic drug research in neuro-oncology? A systematic review and meta-analysis of the efficacy of BCNU and CCNU in animal models of glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Carmustine; Disease Models, Animal; Drug Evaluation; Gli | 2009 |
What is the translational efficacy of chemotherapeutic drug research in neuro-oncology? A systematic review and meta-analysis of the efficacy of BCNU and CCNU in animal models of glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Carmustine; Disease Models, Animal; Drug Evaluation; Gli | 2009 |
Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of clinical experience.
Topics: Absorbable Implants; Administration, Topical; Algorithms; Antineoplastic Agents, Alkylating; Brain N | 2008 |
Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of clinical experience.
Topics: Absorbable Implants; Administration, Topical; Algorithms; Antineoplastic Agents, Alkylating; Brain N | 2008 |
Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of clinical experience.
Topics: Absorbable Implants; Administration, Topical; Algorithms; Antineoplastic Agents, Alkylating; Brain N | 2008 |
Localized BCNU chemotherapy and the multimodal management of malignant glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Glioma; Humans; Prognosis | 2009 |
Localized BCNU chemotherapy and the multimodal management of malignant glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Glioma; Humans; Prognosis | 2009 |
Localized BCNU chemotherapy and the multimodal management of malignant glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Glioma; Humans; Prognosis | 2009 |
Crossing borders: surgically mediated drug delivery techniques.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bacterial Toxins; Biological Availability; Brain Neop | 2008 |
Crossing borders: surgically mediated drug delivery techniques.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bacterial Toxins; Biological Availability; Brain Neop | 2008 |
Crossing borders: surgically mediated drug delivery techniques.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bacterial Toxins; Biological Availability; Brain Neop | 2008 |
Risk management in the treatment of malignant gliomas with BCNU wafer implants.
Topics: Absorbable Implants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modali | 2010 |
Risk management in the treatment of malignant gliomas with BCNU wafer implants.
Topics: Absorbable Implants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modali | 2010 |
Risk management in the treatment of malignant gliomas with BCNU wafer implants.
Topics: Absorbable Implants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modali | 2010 |
[Chemotherapeutic wafers in treatment of malignant cerebral glioma. Assessment of a Cochrane review].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Drug Implants; Evidence-Based Medici | 2010 |
[Chemotherapeutic wafers in treatment of malignant cerebral glioma. Assessment of a Cochrane review].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Drug Implants; Evidence-Based Medici | 2010 |
[Chemotherapeutic wafers in treatment of malignant cerebral glioma. Assessment of a Cochrane review].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Drug Implants; Evidence-Based Medici | 2010 |
Chemotherapy wafers for high grade glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Therapy; Decanoic | 2011 |
Chemotherapy wafers for high grade glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Therapy; Decanoic | 2011 |
Chemotherapy wafers for high grade glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Therapy; Decanoic | 2011 |
The role of BCNU polymer wafers (Gliadel) in the treatment of malignant glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Decanoic Acids; Delayed-Action Prepa | 2012 |
The role of BCNU polymer wafers (Gliadel) in the treatment of malignant glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Decanoic Acids; Delayed-Action Prepa | 2012 |
The role of BCNU polymer wafers (Gliadel) in the treatment of malignant glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Decanoic Acids; Delayed-Action Prepa | 2012 |
[Evidence-based radiation therapy for primary brain tumors].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Evidence-Based Medicine; Glioma; Hum | 2003 |
[Evidence-based radiation therapy for primary brain tumors].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Evidence-Based Medicine; Glioma; Hum | 2003 |
[Evidence-based radiation therapy for primary brain tumors].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Evidence-Based Medicine; Glioma; Hum | 2003 |
The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic | 2003 |
The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic | 2003 |
The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic | 2003 |
Recent advances in brain tumor therapy: local intracerebral drug delivery by polymers.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Clinical Trials as Topic; D | 2004 |
Recent advances in brain tumor therapy: local intracerebral drug delivery by polymers.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Clinical Trials as Topic; D | 2004 |
Recent advances in brain tumor therapy: local intracerebral drug delivery by polymers.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Clinical Trials as Topic; D | 2004 |
The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for malignant glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Therapy; Cr | 2005 |
The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for malignant glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Therapy; Cr | 2005 |
The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for malignant glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Therapy; Cr | 2005 |
Local treatment of malignant brain tumors using implantable chemotherapeutic polymers.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Biocompatible Materials; Biodegradation, E | 2005 |
Local treatment of malignant brain tumors using implantable chemotherapeutic polymers.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Biocompatible Materials; Biodegradation, E | 2005 |
Local treatment of malignant brain tumors using implantable chemotherapeutic polymers.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Biocompatible Materials; Biodegradation, E | 2005 |
[Treatment for malignant glioma].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2005 |
[Treatment for malignant glioma].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2005 |
[Treatment for malignant glioma].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2005 |
Interstitial chemotherapy for malignant gliomas: the Johns Hopkins experience.
Topics: Animals; Antineoplastic Agents, Alkylating; Carmustine; Central Nervous System Neoplasms; Decanoic A | 2007 |
Interstitial chemotherapy for malignant gliomas: the Johns Hopkins experience.
Topics: Animals; Antineoplastic Agents, Alkylating; Carmustine; Central Nervous System Neoplasms; Decanoic A | 2007 |
Interstitial chemotherapy for malignant gliomas: the Johns Hopkins experience.
Topics: Animals; Antineoplastic Agents, Alkylating; Carmustine; Central Nervous System Neoplasms; Decanoic A | 2007 |
The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 2007 |
The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 2007 |
The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 2007 |
Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Dac | 2008 |
Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Dac | 2008 |
Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Dac | 2008 |
[Clinical significance of mustoforan in management of malignant glioma].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Astrocytoma; Blood-Brain Barr | 2007 |
[Clinical significance of mustoforan in management of malignant glioma].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Astrocytoma; Blood-Brain Barr | 2007 |
[Clinical significance of mustoforan in management of malignant glioma].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Astrocytoma; Blood-Brain Barr | 2007 |
High dose chemotherapy with autologous bone marrow rescue for high grade gliomas of the brain: a potential for improvement in therapeutic results.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Brain Neoplasms; Carmus | 1984 |
High dose chemotherapy with autologous bone marrow rescue for high grade gliomas of the brain: a potential for improvement in therapeutic results.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Brain Neoplasms; Carmus | 1984 |
High dose chemotherapy with autologous bone marrow rescue for high grade gliomas of the brain: a potential for improvement in therapeutic results.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Brain Neoplasms; Carmus | 1984 |
Clonal tumor cell heterogeneity.
Topics: Brain Neoplasms; Carmustine; Chromosome Aberrations; Cisplatin; Culture Techniques; Drug Resistance; | 1984 |
Clonal tumor cell heterogeneity.
Topics: Brain Neoplasms; Carmustine; Chromosome Aberrations; Cisplatin; Culture Techniques; Drug Resistance; | 1984 |
Clonal tumor cell heterogeneity.
Topics: Brain Neoplasms; Carmustine; Chromosome Aberrations; Cisplatin; Culture Techniques; Drug Resistance; | 1984 |
Treatment of neuroectodermal brain tumors.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Astrocytoma; Blood-Brain Barrier; Brain Neoplasms; | 1982 |
Treatment of neuroectodermal brain tumors.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Astrocytoma; Blood-Brain Barrier; Brain Neoplasms; | 1982 |
Treatment of neuroectodermal brain tumors.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Astrocytoma; Blood-Brain Barrier; Brain Neoplasms; | 1982 |
[Colony forming efficiency assay and human tumor (author's transl)].
Topics: Animals; Brain Neoplasms; Carmustine; Cell Division; Cells, Cultured; Colony-Forming Units Assay; Gl | 1981 |
[Colony forming efficiency assay and human tumor (author's transl)].
Topics: Animals; Brain Neoplasms; Carmustine; Cell Division; Cells, Cultured; Colony-Forming Units Assay; Gl | 1981 |
[Colony forming efficiency assay and human tumor (author's transl)].
Topics: Animals; Brain Neoplasms; Carmustine; Cell Division; Cells, Cultured; Colony-Forming Units Assay; Gl | 1981 |
Malignant gliomas in older adults with poor prognostic signs. Getting nowhere, and taking a long time to do it.
Topics: Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine | 1995 |
Malignant gliomas in older adults with poor prognostic signs. Getting nowhere, and taking a long time to do it.
Topics: Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine | 1995 |
Malignant gliomas in older adults with poor prognostic signs. Getting nowhere, and taking a long time to do it.
Topics: Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine | 1995 |
[Chemotherapy of brain tumors].
Topics: Blood-Brain Barrier; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Combined Modality Therapy; | 1994 |
[Chemotherapy of brain tumors].
Topics: Blood-Brain Barrier; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Combined Modality Therapy; | 1994 |
[Chemotherapy of brain tumors].
Topics: Blood-Brain Barrier; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Combined Modality Therapy; | 1994 |
Interstitial chemotherapy with sustained-release polymer systems for the treatment of malignant gliomas.
Topics: Animals; Antineoplastic Agents; Biocompatible Materials; Brain Neoplasms; Carmustine; Chemotherapy, | 1994 |
Interstitial chemotherapy with sustained-release polymer systems for the treatment of malignant gliomas.
Topics: Animals; Antineoplastic Agents; Biocompatible Materials; Brain Neoplasms; Carmustine; Chemotherapy, | 1994 |
Interstitial chemotherapy with sustained-release polymer systems for the treatment of malignant gliomas.
Topics: Animals; Antineoplastic Agents; Biocompatible Materials; Brain Neoplasms; Carmustine; Chemotherapy, | 1994 |
The role of interstitial BCNU chemotherapy in the treatment of malignant glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Biocompatible Materials; Brain Neoplasms; Carmustine; Cl | 2000 |
The role of interstitial BCNU chemotherapy in the treatment of malignant glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Biocompatible Materials; Brain Neoplasms; Carmustine; Cl | 2000 |
The role of interstitial BCNU chemotherapy in the treatment of malignant glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Biocompatible Materials; Brain Neoplasms; Carmustine; Cl | 2000 |
High-dose chemotherapy with bone marrow rescue for high-grade gliomas in adults.
Topics: Adult; Antineoplastic Agents; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Chemotherapy | 2001 |
High-dose chemotherapy with bone marrow rescue for high-grade gliomas in adults.
Topics: Adult; Antineoplastic Agents; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Chemotherapy | 2001 |
High-dose chemotherapy with bone marrow rescue for high-grade gliomas in adults.
Topics: Adult; Antineoplastic Agents; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Chemotherapy | 2001 |
Temozolomide in combination with other cytotoxic agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carmustine; Central Nervous System Neo | 2001 |
Temozolomide in combination with other cytotoxic agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carmustine; Central Nervous System Neo | 2001 |
Temozolomide in combination with other cytotoxic agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carmustine; Central Nervous System Neo | 2001 |
[Role of high-dose chemotherapy with hemopoietic stem-cell support in the treatment of adult patients with high-grade glioma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Blood-Brain Barrier; Brain Neoplasms; C | 2001 |
[Role of high-dose chemotherapy with hemopoietic stem-cell support in the treatment of adult patients with high-grade glioma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Blood-Brain Barrier; Brain Neoplasms; C | 2001 |
[Role of high-dose chemotherapy with hemopoietic stem-cell support in the treatment of adult patients with high-grade glioma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Blood-Brain Barrier; Brain Neoplasms; C | 2001 |
Multimodality program involving stereotactic surgery in brain tumor management.
Topics: Adult; Antineoplastic Agents; Biopsy; Brachytherapy; Brain Neoplasms; Carmustine; Combined Modality | 2000 |
Multimodality program involving stereotactic surgery in brain tumor management.
Topics: Adult; Antineoplastic Agents; Biopsy; Brachytherapy; Brain Neoplasms; Carmustine; Combined Modality | 2000 |
Multimodality program involving stereotactic surgery in brain tumor management.
Topics: Adult; Antineoplastic Agents; Biopsy; Brachytherapy; Brain Neoplasms; Carmustine; Combined Modality | 2000 |
Drug delivery to tumors of the central nervous system.
Topics: Antineoplastic Agents; Biodegradation, Environmental; Blood-Brain Barrier; Brain Neoplasms; Carmusti | 2001 |
Drug delivery to tumors of the central nervous system.
Topics: Antineoplastic Agents; Biodegradation, Environmental; Blood-Brain Barrier; Brain Neoplasms; Carmusti | 2001 |
Drug delivery to tumors of the central nervous system.
Topics: Antineoplastic Agents; Biodegradation, Environmental; Blood-Brain Barrier; Brain Neoplasms; Carmusti | 2001 |
Pharmacokinetics of the carmustine implant.
Topics: Animals; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Comput | 2002 |
Pharmacokinetics of the carmustine implant.
Topics: Animals; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Comput | 2002 |
Pharmacokinetics of the carmustine implant.
Topics: Animals; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Comput | 2002 |
NO-mediated chemoresistance in C6 glioma cells.
Topics: Animals; Carmustine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Glioblastoma; Glioma; Humans; | 2002 |
NO-mediated chemoresistance in C6 glioma cells.
Topics: Animals; Carmustine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Glioblastoma; Glioma; Humans; | 2002 |
NO-mediated chemoresistance in C6 glioma cells.
Topics: Animals; Carmustine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Glioblastoma; Glioma; Humans; | 2002 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Treatment of brain tumors.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Cell Divis | 1977 |
Treatment of brain tumors.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Cell Divis | 1977 |
Treatment of brain tumors.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Cell Divis | 1977 |
Chemotherapy: the agents in current use.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Dacarbazine; Drug Therapy, Combination; Glioma; | 1975 |
Chemotherapy: the agents in current use.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Dacarbazine; Drug Therapy, Combination; Glioma; | 1975 |
Chemotherapy: the agents in current use.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Dacarbazine; Drug Therapy, Combination; Glioma; | 1975 |
Chemotherapy of malignant gliomas: studies of the BTCG.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cisplatin; Combined Mod | 1992 |
Chemotherapy of malignant gliomas: studies of the BTCG.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cisplatin; Combined Mod | 1992 |
Chemotherapy of malignant gliomas: studies of the BTCG.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cisplatin; Combined Mod | 1992 |
Biology and therapy of glial tumors.
Topics: Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Cell Division; Cell Surviva | 1992 |
Biology and therapy of glial tumors.
Topics: Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Cell Division; Cell Surviva | 1992 |
Biology and therapy of glial tumors.
Topics: Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Cell Division; Cell Surviva | 1992 |
Tumor heterogeneity and intrinsically chemoresistant subpopulations in freshly resected human malignant gliomas.
Topics: Aneuploidy; Antineoplastic Agents; Brain Neoplasms; Carmustine; Clone Cells; Drug Resistance; Geneti | 1991 |
Tumor heterogeneity and intrinsically chemoresistant subpopulations in freshly resected human malignant gliomas.
Topics: Aneuploidy; Antineoplastic Agents; Brain Neoplasms; Carmustine; Clone Cells; Drug Resistance; Geneti | 1991 |
Tumor heterogeneity and intrinsically chemoresistant subpopulations in freshly resected human malignant gliomas.
Topics: Aneuploidy; Antineoplastic Agents; Brain Neoplasms; Carmustine; Clone Cells; Drug Resistance; Geneti | 1991 |
Brain tumors.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Carmustine; Child; Combined Modality Therapy; Glioma; | 1991 |
Brain tumors.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Carmustine; Child; Combined Modality Therapy; Glioma; | 1991 |
Brain tumors.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Carmustine; Child; Combined Modality Therapy; Glioma; | 1991 |
The subpopulations and isolated cell types of freshly resected high grade human gliomas: their influence on the tumor's evolution in vivo and behavior and therapy in vitro.
Topics: Carmustine; Cell Line; Cells, Cultured; Chromosome Banding; Clone Cells; Genetic Variation; Glioblas | 1985 |
The subpopulations and isolated cell types of freshly resected high grade human gliomas: their influence on the tumor's evolution in vivo and behavior and therapy in vitro.
Topics: Carmustine; Cell Line; Cells, Cultured; Chromosome Banding; Clone Cells; Genetic Variation; Glioblas | 1985 |
The subpopulations and isolated cell types of freshly resected high grade human gliomas: their influence on the tumor's evolution in vivo and behavior and therapy in vitro.
Topics: Carmustine; Cell Line; Cells, Cultured; Chromosome Banding; Clone Cells; Genetic Variation; Glioblas | 1985 |
High dose chemotherapy in solid tumours in adults.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marr | 1986 |
High dose chemotherapy in solid tumours in adults.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marr | 1986 |
High dose chemotherapy in solid tumours in adults.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marr | 1986 |
Brain tumors.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Child; Glioma; Humans; Infusions, Intra-Arterial | 1987 |
Brain tumors.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Child; Glioma; Humans; Infusions, Intra-Arterial | 1987 |
Brain tumors.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Child; Glioma; Humans; Infusions, Intra-Arterial | 1987 |
Principles of brain tumor chemotherapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; | 1986 |
Principles of brain tumor chemotherapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; | 1986 |
Principles of brain tumor chemotherapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; | 1986 |
Recent and current investigations of radiation therapy of malignant gliomas.
Topics: Brachytherapy; Brain; Brain Neoplasms; Bromodeoxyuridine; Carmustine; Glioma; Helium; Humans; Hyperb | 1986 |
Recent and current investigations of radiation therapy of malignant gliomas.
Topics: Brachytherapy; Brain; Brain Neoplasms; Bromodeoxyuridine; Carmustine; Glioma; Helium; Humans; Hyperb | 1986 |
Recent and current investigations of radiation therapy of malignant gliomas.
Topics: Brachytherapy; Brain; Brain Neoplasms; Bromodeoxyuridine; Carmustine; Glioma; Helium; Humans; Hyperb | 1986 |
In vitro drug sensitivity testing in human gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Cells, Cultured; Drug Evaluation, Preclinical; G | 1987 |
In vitro drug sensitivity testing in human gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Cells, Cultured; Drug Evaluation, Preclinical; G | 1987 |
In vitro drug sensitivity testing in human gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Cells, Cultured; Drug Evaluation, Preclinical; G | 1987 |
Proceedings: Chemotherapy of malignant glioma.
Topics: Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Evaluation Studies as Topic | 1972 |
Proceedings: Chemotherapy of malignant glioma.
Topics: Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Evaluation Studies as Topic | 1972 |
Proceedings: Chemotherapy of malignant glioma.
Topics: Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Evaluation Studies as Topic | 1972 |
[Chemotherapy of brain neoplasms in children].
Topics: Age Factors; Astrocytoma; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Child; Cyclophosphamide; | 1974 |
[Chemotherapy of brain neoplasms in children].
Topics: Age Factors; Astrocytoma; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Child; Cyclophosphamide; | 1974 |
[Chemotherapy of brain neoplasms in children].
Topics: Age Factors; Astrocytoma; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Child; Cyclophosphamide; | 1974 |
Nitrosoureas in central nervous system tumors.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Cyclohexanes; Glioma; Humans; Injections, Intrav | 1973 |
Nitrosoureas in central nervous system tumors.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Cyclohexanes; Glioma; Humans; Injections, Intrav | 1973 |
Nitrosoureas in central nervous system tumors.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Cyclohexanes; Glioma; Humans; Injections, Intrav | 1973 |
96 trials available for carmustine and Glioma
| Article | Year |
|---|---|
A phase I trial of surgical resection with Gliadel Wafer placement followed by vaccination with dendritic cells pulsed with tumor lysate for patients with malignant glioma.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Agents; Brain Neoplasms; Cancer Vaccines; Carmustine | 2020 |
A phase I trial of surgical resection with Gliadel Wafer placement followed by vaccination with dendritic cells pulsed with tumor lysate for patients with malignant glioma.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Agents; Brain Neoplasms; Cancer Vaccines; Carmustine | 2020 |
A phase I trial of surgical resection with Gliadel Wafer placement followed by vaccination with dendritic cells pulsed with tumor lysate for patients with malignant glioma.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Agents; Brain Neoplasms; Cancer Vaccines; Carmustine | 2020 |
NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carm | 2018 |
NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carm | 2018 |
NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carm | 2018 |
A multicenter phase I/II study of the BCNU implant (Gliadel(®) Wafer) for Japanese patients with malignant gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Thera | 2014 |
A multicenter phase I/II study of the BCNU implant (Gliadel(®) Wafer) for Japanese patients with malignant gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Thera | 2014 |
A multicenter phase I/II study of the BCNU implant (Gliadel(®) Wafer) for Japanese patients with malignant gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Thera | 2014 |
Safety evaluation of high-dose BCNU-loaded biodegradable implants in Chinese patients with recurrent malignant gliomas.
Topics: Absorbable Implants; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Asian People; Brain | 2014 |
Safety evaluation of high-dose BCNU-loaded biodegradable implants in Chinese patients with recurrent malignant gliomas.
Topics: Absorbable Implants; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Asian People; Brain | 2014 |
Safety evaluation of high-dose BCNU-loaded biodegradable implants in Chinese patients with recurrent malignant gliomas.
Topics: Absorbable Implants; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Asian People; Brain | 2014 |
BCNU wafer placement with temozolomide (TMZ) in the immediate postoperative period after tumor resection followed by radiation therapy with TMZ in patients with newly diagnosed high grade glioma: final results of a prospective, multi-institutional, phase
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined M | 2015 |
BCNU wafer placement with temozolomide (TMZ) in the immediate postoperative period after tumor resection followed by radiation therapy with TMZ in patients with newly diagnosed high grade glioma: final results of a prospective, multi-institutional, phase
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined M | 2015 |
BCNU wafer placement with temozolomide (TMZ) in the immediate postoperative period after tumor resection followed by radiation therapy with TMZ in patients with newly diagnosed high grade glioma: final results of a prospective, multi-institutional, phase
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined M | 2015 |
External beam irradiation and the combination of cisplatin and carmustine followed by carmustine alone for the treatment of high-grade glioma: a phase 2 Southwest Oncology Group trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 2008 |
External beam irradiation and the combination of cisplatin and carmustine followed by carmustine alone for the treatment of high-grade glioma: a phase 2 Southwest Oncology Group trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 2008 |
External beam irradiation and the combination of cisplatin and carmustine followed by carmustine alone for the treatment of high-grade glioma: a phase 2 Southwest Oncology Group trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 2008 |
Phase II trial of intratumoral BCNU injection and radiotherapy on untreated adult malignant glioma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Mapping; Brain Neoplasms; Carmustine; Cerebrovascular | 2010 |
Phase II trial of intratumoral BCNU injection and radiotherapy on untreated adult malignant glioma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Mapping; Brain Neoplasms; Carmustine; Cerebrovascular | 2010 |
Phase II trial of intratumoral BCNU injection and radiotherapy on untreated adult malignant glioma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Mapping; Brain Neoplasms; Carmustine; Cerebrovascular | 2010 |
The first 3 months after BCNU wafers implantation in high-grade glioma patients: clinical and radiological considerations on a clinical series.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Female; Glioma; Humans; | 2010 |
The first 3 months after BCNU wafers implantation in high-grade glioma patients: clinical and radiological considerations on a clinical series.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Female; Glioma; Humans; | 2010 |
The first 3 months after BCNU wafers implantation in high-grade glioma patients: clinical and radiological considerations on a clinical series.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Female; Glioma; Humans; | 2010 |
Safety and feasibility of the adjunct of local chemotherapy with biodegradable carmustine (BCNU) wafers to the standard multimodal approach to high grade gliomas at first diagnosis.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biocompatible Materials; Carmustine; Combined Modali | 2011 |
Safety and feasibility of the adjunct of local chemotherapy with biodegradable carmustine (BCNU) wafers to the standard multimodal approach to high grade gliomas at first diagnosis.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biocompatible Materials; Carmustine; Combined Modali | 2011 |
Safety and feasibility of the adjunct of local chemotherapy with biodegradable carmustine (BCNU) wafers to the standard multimodal approach to high grade gliomas at first diagnosis.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biocompatible Materials; Carmustine; Combined Modali | 2011 |
Postoperative seizure in high grade glioma patients treated with BCNU wafers. A mono-institutional experience.
Topics: Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Clinical Trials, Ph | 2011 |
Postoperative seizure in high grade glioma patients treated with BCNU wafers. A mono-institutional experience.
Topics: Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Clinical Trials, Ph | 2011 |
Postoperative seizure in high grade glioma patients treated with BCNU wafers. A mono-institutional experience.
Topics: Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Clinical Trials, Ph | 2011 |
Prognostic factors and survival in a prospective cohort of patients with high-grade glioma treated with carmustine wafers or temozolomide on an intention-to-treat basis.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2012 |
Prognostic factors and survival in a prospective cohort of patients with high-grade glioma treated with carmustine wafers or temozolomide on an intention-to-treat basis.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2012 |
Prognostic factors and survival in a prospective cohort of patients with high-grade glioma treated with carmustine wafers or temozolomide on an intention-to-treat basis.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2012 |
The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine.
Topics: Antineoplastic Agents, Alkylating; Brachytherapy; Brain Neoplasms; Carmustine; Combined Modality The | 2002 |
The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine.
Topics: Antineoplastic Agents, Alkylating; Brachytherapy; Brain Neoplasms; Carmustine; Combined Modality The | 2002 |
The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine.
Topics: Antineoplastic Agents, Alkylating; Brachytherapy; Brain Neoplasms; Carmustine; Combined Modality The | 2002 |
A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma.
Topics: Adult; Aged; Biocompatible Materials; Brain Neoplasms; Carmustine; Delayed-Action Preparations; Doub | 2003 |
A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma.
Topics: Adult; Aged; Biocompatible Materials; Brain Neoplasms; Carmustine; Delayed-Action Preparations; Doub | 2003 |
A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma.
Topics: Adult; Aged; Biocompatible Materials; Brain Neoplasms; Carmustine; Delayed-Action Preparations; Doub | 2003 |
The surgical bed after BCNU polymer wafer placement for recurrent glioma: serial assessment on CT and MR imaging.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Drug Administration Rou | 2003 |
The surgical bed after BCNU polymer wafer placement for recurrent glioma: serial assessment on CT and MR imaging.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Drug Administration Rou | 2003 |
The surgical bed after BCNU polymer wafer placement for recurrent glioma: serial assessment on CT and MR imaging.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Drug Administration Rou | 2003 |
Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a New Approaches to Brain Tumor Therapy CNS Consortium trial.
Topics: Absorbable Implants; Adult; Aged; Antineoplastic Agents, Alkylating; Biocompatible Materials; Brain | 2003 |
Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a New Approaches to Brain Tumor Therapy CNS Consortium trial.
Topics: Absorbable Implants; Adult; Aged; Antineoplastic Agents, Alkylating; Biocompatible Materials; Brain | 2003 |
Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a New Approaches to Brain Tumor Therapy CNS Consortium trial.
Topics: Absorbable Implants; Adult; Aged; Antineoplastic Agents, Alkylating; Biocompatible Materials; Brain | 2003 |
Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasm | 2003 |
Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasm | 2003 |
Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasm | 2003 |
A single prior course of BCNU-cisplatin chemotherapy has a significant deleterious effect on mobilization kinetics of otherwise untreated patients.
Topics: Adult; Antigens, CD34; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Ca | 2004 |
A single prior course of BCNU-cisplatin chemotherapy has a significant deleterious effect on mobilization kinetics of otherwise untreated patients.
Topics: Adult; Antigens, CD34; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Ca | 2004 |
A single prior course of BCNU-cisplatin chemotherapy has a significant deleterious effect on mobilization kinetics of otherwise untreated patients.
Topics: Adult; Antigens, CD34; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Ca | 2004 |
Clinical course and pathologic findings after Gliadel and radiotherapy for newly diagnosed malignant glioma: implications for patient management.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Thera | 2004 |
Clinical course and pathologic findings after Gliadel and radiotherapy for newly diagnosed malignant glioma: implications for patient management.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Thera | 2004 |
Clinical course and pathologic findings after Gliadel and radiotherapy for newly diagnosed malignant glioma: implications for patient management.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Thera | 2004 |
Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pro | 2004 |
Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pro | 2004 |
Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pro | 2004 |
BCNU as second line therapy for recurrent high-grade glioma previously treated with Temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Dacarbazine; Disease Pr | 2004 |
BCNU as second line therapy for recurrent high-grade glioma previously treated with Temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Dacarbazine; Disease Pr | 2004 |
BCNU as second line therapy for recurrent high-grade glioma previously treated with Temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Dacarbazine; Disease Pr | 2004 |
Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Camptothecin; Carmustine; | 2004 |
Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Camptothecin; Carmustine; | 2004 |
Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Camptothecin; Carmustine; | 2004 |
Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Camptothecin; Carmustine; | 2004 |
Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Camptothecin; Carmustine; | 2004 |
Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Camptothecin; Carmustine; | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 2004 |
[Effect of photodynamic therapy combined with interstitial chemotherapy for gliomas].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Mo | 2005 |
[Effect of photodynamic therapy combined with interstitial chemotherapy for gliomas].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Mo | 2005 |
[Effect of photodynamic therapy combined with interstitial chemotherapy for gliomas].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Mo | 2005 |
Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Carmustine; Decanoic Acids; | 2006 |
Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Carmustine; Decanoic Acids; | 2006 |
Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Carmustine; Decanoic Acids; | 2006 |
Outcome of children treated with preradiation chemotherapy for a high-grade glioma: results of a French Society of Pediatric Oncology (SFOP) Pilot Study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvan | 2007 |
Outcome of children treated with preradiation chemotherapy for a high-grade glioma: results of a French Society of Pediatric Oncology (SFOP) Pilot Study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvan | 2007 |
Outcome of children treated with preradiation chemotherapy for a high-grade glioma: results of a French Society of Pediatric Oncology (SFOP) Pilot Study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvan | 2007 |
Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2007 |
Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2007 |
Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2007 |
Bleomycin and brain tumors. A review.
Topics: Adult; Aged; Animals; Bleomycin; Brain; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Combi | 1983 |
Bleomycin and brain tumors. A review.
Topics: Adult; Aged; Animals; Bleomycin; Brain; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Combi | 1983 |
Bleomycin and brain tumors. A review.
Topics: Adult; Aged; Animals; Bleomycin; Brain; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Combi | 1983 |
Immunobiology of primary intracranial tumors. Part 4: levamisole as an immune stimulant in patients and in the ASV glioma model.
Topics: Adjuvants, Immunologic; Alpharetrovirus; Animals; Brain Neoplasms; Carmustine; Clinical Trials as To | 1981 |
Immunobiology of primary intracranial tumors. Part 4: levamisole as an immune stimulant in patients and in the ASV glioma model.
Topics: Adjuvants, Immunologic; Alpharetrovirus; Animals; Brain Neoplasms; Carmustine; Clinical Trials as To | 1981 |
Immunobiology of primary intracranial tumors. Part 4: levamisole as an immune stimulant in patients and in the ASV glioma model.
Topics: Adjuvants, Immunologic; Alpharetrovirus; Animals; Brain Neoplasms; Carmustine; Clinical Trials as To | 1981 |
Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Drug Administration | 1983 |
Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Drug Administration | 1983 |
Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Drug Administration | 1983 |
A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery; preliminary results of an RTOG study.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Drug Administration | 1983 |
A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery; preliminary results of an RTOG study.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Drug Administration | 1983 |
A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery; preliminary results of an RTOG study.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Drug Administration | 1983 |
Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study.
Topics: Adult; Age Factors; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Clinical Trials | 1983 |
Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study.
Topics: Adult; Age Factors; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Clinical Trials | 1983 |
Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study.
Topics: Adult; Age Factors; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Clinical Trials | 1983 |
Perioperative carmustine chemotherapy for malignant brain tumors.
Topics: Adolescent; Adult; Aged; Astrocytoma; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Combine | 1984 |
Perioperative carmustine chemotherapy for malignant brain tumors.
Topics: Adolescent; Adult; Aged; Astrocytoma; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Combine | 1984 |
Perioperative carmustine chemotherapy for malignant brain tumors.
Topics: Adolescent; Adult; Aged; Astrocytoma; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Combine | 1984 |
Intracarotid chemotherapy with a combination of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), cis-diaminedichloroplatinum (cisplatin), and 4'-O-demethyl-1-O-(4,6-O-2-thenylidene-beta-D-glucopyranosyl) epipodophyllotoxin (VM-26) in the treatment of primary
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 1984 |
Intracarotid chemotherapy with a combination of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), cis-diaminedichloroplatinum (cisplatin), and 4'-O-demethyl-1-O-(4,6-O-2-thenylidene-beta-D-glucopyranosyl) epipodophyllotoxin (VM-26) in the treatment of primary
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 1984 |
Intracarotid chemotherapy with a combination of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), cis-diaminedichloroplatinum (cisplatin), and 4'-O-demethyl-1-O-(4,6-O-2-thenylidene-beta-D-glucopyranosyl) epipodophyllotoxin (VM-26) in the treatment of primary
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 1984 |
Treatment of neuroectodermal brain tumors.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Astrocytoma; Blood-Brain Barrier; Brain Neoplasms; | 1982 |
Treatment of neuroectodermal brain tumors.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Astrocytoma; Blood-Brain Barrier; Brain Neoplasms; | 1982 |
Treatment of neuroectodermal brain tumors.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Astrocytoma; Blood-Brain Barrier; Brain Neoplasms; | 1982 |
Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery.
Topics: Aged; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Drug Administration Schedule; Glioma; H | 1980 |
Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery.
Topics: Aged; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Drug Administration Schedule; Glioma; H | 1980 |
Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery.
Topics: Aged; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Drug Administration Schedule; Glioma; H | 1980 |
Primary intracranial gliomas: clinical studies and treatment regimens of the Brain Tumor Research Center, University of California, San Francisco, 1977-1979.
Topics: Antineoplastic Agents; Brain Neoplasms; California; Carmustine; Clinical Trials as Topic; Drug Thera | 1981 |
Primary intracranial gliomas: clinical studies and treatment regimens of the Brain Tumor Research Center, University of California, San Francisco, 1977-1979.
Topics: Antineoplastic Agents; Brain Neoplasms; California; Carmustine; Clinical Trials as Topic; Drug Thera | 1981 |
Primary intracranial gliomas: clinical studies and treatment regimens of the Brain Tumor Research Center, University of California, San Francisco, 1977-1979.
Topics: Antineoplastic Agents; Brain Neoplasms; California; Carmustine; Clinical Trials as Topic; Drug Thera | 1981 |
Evaluating glioma therapies: modeling treatments and predicting outcomes.
Topics: Adolescent; Adult; Aged; Brachytherapy; Brain Neoplasms; Carmustine; Child; Combined Modality Therap | 1995 |
Evaluating glioma therapies: modeling treatments and predicting outcomes.
Topics: Adolescent; Adult; Aged; Brachytherapy; Brain Neoplasms; Carmustine; Child; Combined Modality Therap | 1995 |
Evaluating glioma therapies: modeling treatments and predicting outcomes.
Topics: Adolescent; Adult; Aged; Brachytherapy; Brain Neoplasms; Carmustine; Child; Combined Modality Therap | 1995 |
Accelerated hyperfractionated radiation therapy for malignant glioma. A phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Combined M | 1995 |
Accelerated hyperfractionated radiation therapy for malignant glioma. A phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Combined M | 1995 |
Accelerated hyperfractionated radiation therapy for malignant glioma. A phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Combined M | 1995 |
Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group.
Topics: Biodegradation, Environmental; Brain Neoplasms; Carmustine; Drug Implants; Female; Glioma; Humans; M | 1995 |
Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group.
Topics: Biodegradation, Environmental; Brain Neoplasms; Carmustine; Drug Implants; Female; Glioma; Humans; M | 1995 |
Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group.
Topics: Biodegradation, Environmental; Brain Neoplasms; Carmustine; Drug Implants; Female; Glioma; Humans; M | 1995 |
Quality-adjusted survival analysis of malignant glioma. Patients treated with twice-daily radiation (RT) and carmustine: a report of Radiation Therapy Oncology Group (RTOG) 83-02.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Combined Modality Therapy; Female; Glioma; Humans; Male; M | 1995 |
Quality-adjusted survival analysis of malignant glioma. Patients treated with twice-daily radiation (RT) and carmustine: a report of Radiation Therapy Oncology Group (RTOG) 83-02.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Combined Modality Therapy; Female; Glioma; Humans; Male; M | 1995 |
Quality-adjusted survival analysis of malignant glioma. Patients treated with twice-daily radiation (RT) and carmustine: a report of Radiation Therapy Oncology Group (RTOG) 83-02.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Combined Modality Therapy; Female; Glioma; Humans; Male; M | 1995 |
Phase II evaluation of recombinant interferon alpha and BCNU in recurrent glioma.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Combined Modality Therapy; Female; Glioma; Humans; Interfe | 1995 |
Phase II evaluation of recombinant interferon alpha and BCNU in recurrent glioma.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Combined Modality Therapy; Female; Glioma; Humans; Interfe | 1995 |
Phase II evaluation of recombinant interferon alpha and BCNU in recurrent glioma.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Combined Modality Therapy; Female; Glioma; Humans; Interfe | 1995 |
White matter changes are correlated significantly with radiation dose. Observations from a randomized dose-escalation trial for malignant glioma (Radiation Therapy Oncology Group 83-02).
Topics: Brain; Brain Neoplasms; Carmustine; Dose-Response Relationship, Radiation; Female; Glioma; Humans; M | 1994 |
White matter changes are correlated significantly with radiation dose. Observations from a randomized dose-escalation trial for malignant glioma (Radiation Therapy Oncology Group 83-02).
Topics: Brain; Brain Neoplasms; Carmustine; Dose-Response Relationship, Radiation; Female; Glioma; Humans; M | 1994 |
White matter changes are correlated significantly with radiation dose. Observations from a randomized dose-escalation trial for malignant glioma (Radiation Therapy Oncology Group 83-02).
Topics: Brain; Brain Neoplasms; Carmustine; Dose-Response Relationship, Radiation; Female; Glioma; Humans; M | 1994 |
Hyperfractionated radiation therapy (HFX RT) followed by multiagent chemotherapy (CHT) in patients with malignant glioma: a phase II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cisplatin; Combi | 1994 |
Hyperfractionated radiation therapy (HFX RT) followed by multiagent chemotherapy (CHT) in patients with malignant glioma: a phase II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cisplatin; Combi | 1994 |
Hyperfractionated radiation therapy (HFX RT) followed by multiagent chemotherapy (CHT) in patients with malignant glioma: a phase II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cisplatin; Combi | 1994 |
Adjuvant therapy with dibromodulcitol and BCNU increases survival of adults with malignant gliomas. EORTC Brain Tumor Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemothera | 1994 |
Adjuvant therapy with dibromodulcitol and BCNU increases survival of adults with malignant gliomas. EORTC Brain Tumor Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemothera | 1994 |
Adjuvant therapy with dibromodulcitol and BCNU increases survival of adults with malignant gliomas. EORTC Brain Tumor Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemothera | 1994 |
Feasibility study of intraarterial vs intravenous cisplatin, BCNU, and teniposide combined with systemic cisplatin, teniposide, cytosine arabinoside, glycerol and mannitol in the treatment of primary and metastatic brain tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cisplatin; | 1993 |
Feasibility study of intraarterial vs intravenous cisplatin, BCNU, and teniposide combined with systemic cisplatin, teniposide, cytosine arabinoside, glycerol and mannitol in the treatment of primary and metastatic brain tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cisplatin; | 1993 |
Feasibility study of intraarterial vs intravenous cisplatin, BCNU, and teniposide combined with systemic cisplatin, teniposide, cytosine arabinoside, glycerol and mannitol in the treatment of primary and metastatic brain tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cisplatin; | 1993 |
rhGM-CSF ameliorates neutropenia in patients with malignant glioma treated with BCNU.
Topics: Adult; Brain Neoplasms; Carmustine; Female; Glioblastoma; Glioma; Granulocyte-Macrophage Colony-Stim | 1994 |
rhGM-CSF ameliorates neutropenia in patients with malignant glioma treated with BCNU.
Topics: Adult; Brain Neoplasms; Carmustine; Female; Glioblastoma; Glioma; Granulocyte-Macrophage Colony-Stim | 1994 |
rhGM-CSF ameliorates neutropenia in patients with malignant glioma treated with BCNU.
Topics: Adult; Brain Neoplasms; Carmustine; Female; Glioblastoma; Glioma; Granulocyte-Macrophage Colony-Stim | 1994 |
Comparison of the Cox model and the regression tree procedure in analysing a randomized clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bias; Brain Neoplasms; Carmustine; Clin | 1993 |
Comparison of the Cox model and the regression tree procedure in analysing a randomized clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bias; Brain Neoplasms; Carmustine; Clin | 1993 |
Comparison of the Cox model and the regression tree procedure in analysing a randomized clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bias; Brain Neoplasms; Carmustine; Clin | 1993 |
Phase III comparative evaluation of PCNU and carmustine combined with radiation therapy for high-grade glioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Car | 1993 |
Phase III comparative evaluation of PCNU and carmustine combined with radiation therapy for high-grade glioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Car | 1993 |
Phase III comparative evaluation of PCNU and carmustine combined with radiation therapy for high-grade glioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Car | 1993 |
An analysis of radiotherapy data from the CNS cancer consortium's randomized prospective trial comparing AZQ to BCNU in the treatment of patients with primary malignant brain tumors. The CNS cancer consortium.
Topics: Adult; Aged; Aged, 80 and over; Astrocytoma; Aziridines; Benzoquinones; Brain Neoplasms; Carmustine; | 1993 |
An analysis of radiotherapy data from the CNS cancer consortium's randomized prospective trial comparing AZQ to BCNU in the treatment of patients with primary malignant brain tumors. The CNS cancer consortium.
Topics: Adult; Aged; Aged, 80 and over; Astrocytoma; Aziridines; Benzoquinones; Brain Neoplasms; Carmustine; | 1993 |
An analysis of radiotherapy data from the CNS cancer consortium's randomized prospective trial comparing AZQ to BCNU in the treatment of patients with primary malignant brain tumors. The CNS cancer consortium.
Topics: Adult; Aged; Aged, 80 and over; Astrocytoma; Aziridines; Benzoquinones; Brain Neoplasms; Carmustine; | 1993 |
Randomized comparison of diaziquone and carmustine in the treatment of adults with anaplastic glioma.
Topics: Adult; Analysis of Variance; Antineoplastic Agents; Aziridines; Benzoquinones; Brain Neoplasms; Carm | 1993 |
Randomized comparison of diaziquone and carmustine in the treatment of adults with anaplastic glioma.
Topics: Adult; Analysis of Variance; Antineoplastic Agents; Aziridines; Benzoquinones; Brain Neoplasms; Carm | 1993 |
Randomized comparison of diaziquone and carmustine in the treatment of adults with anaplastic glioma.
Topics: Adult; Analysis of Variance; Antineoplastic Agents; Aziridines; Benzoquinones; Brain Neoplasms; Carm | 1993 |
Survival comparison of radiosurgery-eligible and -ineligible malignant glioma patients treated with hyperfractionated radiation therapy and carmustine: a report of Radiation Therapy Oncology Group 83-02.
Topics: Carmustine; Combined Modality Therapy; Contraindications; Female; Glioma; Humans; Male; Middle Aged; | 1993 |
Survival comparison of radiosurgery-eligible and -ineligible malignant glioma patients treated with hyperfractionated radiation therapy and carmustine: a report of Radiation Therapy Oncology Group 83-02.
Topics: Carmustine; Combined Modality Therapy; Contraindications; Female; Glioma; Humans; Male; Middle Aged; | 1993 |
Survival comparison of radiosurgery-eligible and -ineligible malignant glioma patients treated with hyperfractionated radiation therapy and carmustine: a report of Radiation Therapy Oncology Group 83-02.
Topics: Carmustine; Combined Modality Therapy; Contraindications; Female; Glioma; Humans; Male; Middle Aged; | 1993 |
Combination chemotherapy with carmustine and cisplatin before, during, and after radiotherapy for adult malignant gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 1995 |
Combination chemotherapy with carmustine and cisplatin before, during, and after radiotherapy for adult malignant gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 1995 |
Combination chemotherapy with carmustine and cisplatin before, during, and after radiotherapy for adult malignant gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 1995 |
Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas. Radiation Therapy Oncology Group Study 83-02.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Carmustine; Combined Modality Therapy; F | 1996 |
Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas. Radiation Therapy Oncology Group Study 83-02.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Carmustine; Combined Modality Therapy; F | 1996 |
Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas. Radiation Therapy Oncology Group Study 83-02.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Carmustine; Combined Modality Therapy; F | 1996 |
The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: phase I trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Brain N | 1995 |
The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: phase I trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Brain N | 1995 |
The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: phase I trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Brain N | 1995 |
Contemporary chemotherapy issues for children with brainstem gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Brain Stem; Carboplatin; Carmustine; Dose-Response Relations | 1996 |
Contemporary chemotherapy issues for children with brainstem gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Brain Stem; Carboplatin; Carmustine; Dose-Response Relations | 1996 |
Contemporary chemotherapy issues for children with brainstem gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Brain Stem; Carboplatin; Carmustine; Dose-Response Relations | 1996 |
High-dose carmustine for high-grade gliomas in childhood.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Bone Marrow Transplantation; Brain Neoplasms; Carmust | 1997 |
High-dose carmustine for high-grade gliomas in childhood.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Bone Marrow Transplantation; Brain Neoplasms; Carmust | 1997 |
High-dose carmustine for high-grade gliomas in childhood.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Bone Marrow Transplantation; Brain Neoplasms; Carmust | 1997 |
Treatment of recurrent malignant glioma with BCNU-fluosol and oxygen inhalation. A phase I-II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine | 1997 |
Treatment of recurrent malignant glioma with BCNU-fluosol and oxygen inhalation. A phase I-II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine | 1997 |
Treatment of recurrent malignant glioma with BCNU-fluosol and oxygen inhalation. A phase I-II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine | 1997 |
Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; | 1997 |
Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; | 1997 |
Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; | 1997 |
Phase II trial with BCNU plus alpha-interferon in patients with recurrent high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemo | 1997 |
Phase II trial with BCNU plus alpha-interferon in patients with recurrent high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemo | 1997 |
Phase II trial with BCNU plus alpha-interferon in patients with recurrent high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemo | 1997 |
Phase I evaluation of radiation combined with recombinant interferon alpha-2a and BCNU for patients with high-grade glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined M | 1998 |
Phase I evaluation of radiation combined with recombinant interferon alpha-2a and BCNU for patients with high-grade glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined M | 1998 |
Phase I evaluation of radiation combined with recombinant interferon alpha-2a and BCNU for patients with high-grade glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined M | 1998 |
Effects of radiation and chemotherapy on cognitive function in patients with high-grade glioma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carm | 1998 |
Effects of radiation and chemotherapy on cognitive function in patients with high-grade glioma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carm | 1998 |
Effects of radiation and chemotherapy on cognitive function in patients with high-grade glioma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carm | 1998 |
Phase I and pharmacokinetic study of preirradiation chemotherapy with BCNU, cisplatin, etoposide, and accelerated radiation therapy in patients with high-grade glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Brain Neoplasms; Carmustin | 1998 |
Phase I and pharmacokinetic study of preirradiation chemotherapy with BCNU, cisplatin, etoposide, and accelerated radiation therapy in patients with high-grade glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Brain Neoplasms; Carmustin | 1998 |
Phase I and pharmacokinetic study of preirradiation chemotherapy with BCNU, cisplatin, etoposide, and accelerated radiation therapy in patients with high-grade glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Brain Neoplasms; Carmustin | 1998 |
Phase I evaluation of preirradiation chemotherapy with carmustine and cisplatin and accelerated radiation therapy in patients with high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cisplatin; | 1999 |
Phase I evaluation of preirradiation chemotherapy with carmustine and cisplatin and accelerated radiation therapy in patients with high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cisplatin; | 1999 |
Phase I evaluation of preirradiation chemotherapy with carmustine and cisplatin and accelerated radiation therapy in patients with high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cisplatin; | 1999 |
A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade glioma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemo | 2001 |
A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade glioma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemo | 2001 |
A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade glioma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemo | 2001 |
Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Brain Neoplasms; Carm | 2002 |
Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Brain Neoplasms; Carm | 2002 |
Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Brain Neoplasms; Carm | 2002 |
Safety of thrice-daily hyperfractionated radiation and BCNU for high-grade gliomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Diseases; Carm | 2002 |
Safety of thrice-daily hyperfractionated radiation and BCNU for high-grade gliomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Diseases; Carm | 2002 |
Safety of thrice-daily hyperfractionated radiation and BCNU for high-grade gliomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Diseases; Carm | 2002 |
Chemotherapy: adjuvant to surgery and radiation therapy.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Fluorouracil; Glioma; | 1975 |
Chemotherapy: adjuvant to surgery and radiation therapy.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Fluorouracil; Glioma; | 1975 |
Chemotherapy: adjuvant to surgery and radiation therapy.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Fluorouracil; Glioma; | 1975 |
Brain Tumor Study Group: a survey of current activities.
Topics: Brain Neoplasms; Carmustine; Clinical Trials as Topic; Drug Evaluation; Glioma; Humans; National Ins | 1977 |
Brain Tumor Study Group: a survey of current activities.
Topics: Brain Neoplasms; Carmustine; Clinical Trials as Topic; Drug Evaluation; Glioma; Humans; National Ins | 1977 |
Brain Tumor Study Group: a survey of current activities.
Topics: Brain Neoplasms; Carmustine; Clinical Trials as Topic; Drug Evaluation; Glioma; Humans; National Ins | 1977 |
BCNU (NSC-409962) and procarbazine (NSC-77213) treatment for malignant brain tumors.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, C | 1976 |
BCNU (NSC-409962) and procarbazine (NSC-77213) treatment for malignant brain tumors.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, C | 1976 |
BCNU (NSC-409962) and procarbazine (NSC-77213) treatment for malignant brain tumors.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, C | 1976 |
Treatment of brain tumors.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Cell Divis | 1977 |
Treatment of brain tumors.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Cell Divis | 1977 |
Treatment of brain tumors.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Cell Divis | 1977 |
A phase III comparison of BCNU, hydroxyurea, and radiation therapy to BCNU and radiation therapy for treatment of primary malignant gliomas.
Topics: Adult; Aged; Astrocytoma; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Cobalt Radioisotope | 1979 |
A phase III comparison of BCNU, hydroxyurea, and radiation therapy to BCNU and radiation therapy for treatment of primary malignant gliomas.
Topics: Adult; Aged; Astrocytoma; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Cobalt Radioisotope | 1979 |
A phase III comparison of BCNU, hydroxyurea, and radiation therapy to BCNU and radiation therapy for treatment of primary malignant gliomas.
Topics: Adult; Aged; Astrocytoma; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Cobalt Radioisotope | 1979 |
Preliminary results of a phase III comparison study of BCNU, hydroxyurea and radiation to BCNU and radiation.
Topics: Brain Neoplasms; Carmustine; Clinical Trials as Topic; Drug Therapy, Combination; Glioblastoma; Glio | 1979 |
Preliminary results of a phase III comparison study of BCNU, hydroxyurea and radiation to BCNU and radiation.
Topics: Brain Neoplasms; Carmustine; Clinical Trials as Topic; Drug Therapy, Combination; Glioblastoma; Glio | 1979 |
Preliminary results of a phase III comparison study of BCNU, hydroxyurea and radiation to BCNU and radiation.
Topics: Brain Neoplasms; Carmustine; Clinical Trials as Topic; Drug Therapy, Combination; Glioblastoma; Glio | 1979 |
Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Carmustine; Child; Clinical Trials as Topic; Evaluation St | 1978 |
Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Carmustine; Child; Clinical Trials as Topic; Evaluation St | 1978 |
Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Carmustine; Child; Clinical Trials as Topic; Evaluation St | 1978 |
Adjuvant nitrosourea therapy for glioblastoma.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Carmustine; Child; Child, Preschool; Drug Evaluation; Fema | 1976 |
Adjuvant nitrosourea therapy for glioblastoma.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Carmustine; Child; Child, Preschool; Drug Evaluation; Fema | 1976 |
Adjuvant nitrosourea therapy for glioblastoma.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Carmustine; Child; Child, Preschool; Drug Evaluation; Fema | 1976 |
Chemotherapy of malignant gliomas: studies of the BTCG.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cisplatin; Combined Mod | 1992 |
Chemotherapy of malignant gliomas: studies of the BTCG.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cisplatin; Combined Mod | 1992 |
Chemotherapy of malignant gliomas: studies of the BTCG.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cisplatin; Combined Mod | 1992 |
A randomized trial of accelerated hyperfractionated radiation therapy and bis-chloroethyl nitrosourea for malignant glioma. A preliminary report of Radiation Therapy Oncology Group 83-02.
Topics: Carmustine; Combined Modality Therapy; Dose-Response Relationship, Radiation; Female; Glioma; Humans | 1992 |
A randomized trial of accelerated hyperfractionated radiation therapy and bis-chloroethyl nitrosourea for malignant glioma. A preliminary report of Radiation Therapy Oncology Group 83-02.
Topics: Carmustine; Combined Modality Therapy; Dose-Response Relationship, Radiation; Female; Glioma; Humans | 1992 |
A randomized trial of accelerated hyperfractionated radiation therapy and bis-chloroethyl nitrosourea for malignant glioma. A preliminary report of Radiation Therapy Oncology Group 83-02.
Topics: Carmustine; Combined Modality Therapy; Dose-Response Relationship, Radiation; Female; Glioma; Humans | 1992 |
Carboplatin combined with carmustine and etoposide in the treatment of glioblastoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carmustine; Eto | 1992 |
Carboplatin combined with carmustine and etoposide in the treatment of glioblastoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carmustine; Eto | 1992 |
Carboplatin combined with carmustine and etoposide in the treatment of glioblastoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carmustine; Eto | 1992 |
A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modali | 1992 |
A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modali | 1992 |
A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modali | 1992 |
Phase I study of BCNU and intravenous 6-mercaptopurine in patients with anaplastic gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Brain Stem | 1992 |
Phase I study of BCNU and intravenous 6-mercaptopurine in patients with anaplastic gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Brain Stem | 1992 |
Phase I study of BCNU and intravenous 6-mercaptopurine in patients with anaplastic gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Brain Stem | 1992 |
Combined intra-arterial chemotherapy and irradiation of malignant gliomas.
Topics: Adolescent; Adult; Astrocytoma; Brain Neoplasms; Carmustine; Combined Modality Therapy; Eye Diseases | 1991 |
Combined intra-arterial chemotherapy and irradiation of malignant gliomas.
Topics: Adolescent; Adult; Astrocytoma; Brain Neoplasms; Carmustine; Combined Modality Therapy; Eye Diseases | 1991 |
Combined intra-arterial chemotherapy and irradiation of malignant gliomas.
Topics: Adolescent; Adult; Astrocytoma; Brain Neoplasms; Carmustine; Combined Modality Therapy; Eye Diseases | 1991 |
Cisplatin and etoposide combination therapy for primary glial tumors: preliminary results.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Cis | 1991 |
Cisplatin and etoposide combination therapy for primary glial tumors: preliminary results.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Cis | 1991 |
Cisplatin and etoposide combination therapy for primary glial tumors: preliminary results.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Cis | 1991 |
Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas.
Topics: Brain Neoplasms; Carmustine; Decanoic Acids; Dicarboxylic Acids; Drug Combinations; Drug Implants; F | 1991 |
Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas.
Topics: Brain Neoplasms; Carmustine; Decanoic Acids; Dicarboxylic Acids; Drug Combinations; Drug Implants; F | 1991 |
Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas.
Topics: Brain Neoplasms; Carmustine; Decanoic Acids; Dicarboxylic Acids; Drug Combinations; Drug Implants; F | 1991 |
Alternating sequential intracarotid BCNU and cisplatin in recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modalit | 1991 |
Alternating sequential intracarotid BCNU and cisplatin in recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modalit | 1991 |
Alternating sequential intracarotid BCNU and cisplatin in recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modalit | 1991 |
Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined M | 1990 |
Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined M | 1990 |
Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined M | 1990 |
Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma.
Topics: Adolescent; Adult; Aged; Astrocytoma; Carmustine; Combined Modality Therapy; Glioblastoma; Glioma; H | 1989 |
Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma.
Topics: Adolescent; Adult; Aged; Astrocytoma; Carmustine; Combined Modality Therapy; Glioblastoma; Glioma; H | 1989 |
Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma.
Topics: Adolescent; Adult; Aged; Astrocytoma; Carmustine; Combined Modality Therapy; Glioblastoma; Glioma; H | 1989 |
Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cerebellar Neoplasms; Clinical Trials as | 1989 |
Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cerebellar Neoplasms; Clinical Trials as | 1989 |
Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cerebellar Neoplasms; Clinical Trials as | 1989 |
Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; C | 1985 |
Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; C | 1985 |
Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; C | 1985 |
Combined modality approach to treatment of malignant gliomas--re-evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and the Eastern Cooperative Oncology Group.
Topics: Adult; Age Factors; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Combined Modality Therapy | 1988 |
Combined modality approach to treatment of malignant gliomas--re-evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and the Eastern Cooperative Oncology Group.
Topics: Adult; Age Factors; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Combined Modality Therapy | 1988 |
Combined modality approach to treatment of malignant gliomas--re-evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and the Eastern Cooperative Oncology Group.
Topics: Adult; Age Factors; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Combined Modality Therapy | 1988 |
Nitrosourea derivatives-induced pulmonary toxicity in patients treated for malignant brain tumors. Early subclinical detection and its prevention.
Topics: Adult; Aged; Ambroxol; Brain Neoplasms; Bromhexine; Carmustine; Clinical Trials as Topic; Double-Bli | 1987 |
Nitrosourea derivatives-induced pulmonary toxicity in patients treated for malignant brain tumors. Early subclinical detection and its prevention.
Topics: Adult; Aged; Ambroxol; Brain Neoplasms; Bromhexine; Carmustine; Clinical Trials as Topic; Double-Bli | 1987 |
Nitrosourea derivatives-induced pulmonary toxicity in patients treated for malignant brain tumors. Early subclinical detection and its prevention.
Topics: Adult; Aged; Ambroxol; Brain Neoplasms; Bromhexine; Carmustine; Clinical Trials as Topic; Double-Bli | 1987 |
Pulmonary toxicity of carmustine in patients treated for malignant glioma.
Topics: Adult; Aged; Carmustine; Clinical Trials as Topic; Combined Modality Therapy; Dose-Response Relation | 1986 |
Pulmonary toxicity of carmustine in patients treated for malignant glioma.
Topics: Adult; Aged; Carmustine; Clinical Trials as Topic; Combined Modality Therapy; Dose-Response Relation | 1986 |
Pulmonary toxicity of carmustine in patients treated for malignant glioma.
Topics: Adult; Aged; Carmustine; Clinical Trials as Topic; Combined Modality Therapy; Dose-Response Relation | 1986 |
A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery: final report of an RTOG study.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Combined Modality Therapy; Gliom | 1986 |
A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery: final report of an RTOG study.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Combined Modality Therapy; Gliom | 1986 |
A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery: final report of an RTOG study.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Combined Modality Therapy; Gliom | 1986 |
Reevaluating the efficacy of intra-arterial BCNU.
Topics: Brain Diseases; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Glioma; Humans; Infusions, In | 1987 |
Reevaluating the efficacy of intra-arterial BCNU.
Topics: Brain Diseases; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Glioma; Humans; Infusions, In | 1987 |
Reevaluating the efficacy of intra-arterial BCNU.
Topics: Brain Diseases; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Glioma; Humans; Infusions, In | 1987 |
Randomized phase III trial of single versus multiple chemotherapeutic treatment following surgery and during radiotherapy for patients with anaplastic gliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Clinical Trials as Topi | 1987 |
Randomized phase III trial of single versus multiple chemotherapeutic treatment following surgery and during radiotherapy for patients with anaplastic gliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Clinical Trials as Topi | 1987 |
Randomized phase III trial of single versus multiple chemotherapeutic treatment following surgery and during radiotherapy for patients with anaplastic gliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Clinical Trials as Topi | 1987 |
Sister chromatid exchange induction in patients with anaplastic gliomas undergoing treatment with radiation plus diaziquone or 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Aziridines; Azirines; Benzoquinones; Brain Neoplasms; Carmustine; Combined Modality Therapy; Female; | 1987 |
Sister chromatid exchange induction in patients with anaplastic gliomas undergoing treatment with radiation plus diaziquone or 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Aziridines; Azirines; Benzoquinones; Brain Neoplasms; Carmustine; Combined Modality Therapy; Female; | 1987 |
Sister chromatid exchange induction in patients with anaplastic gliomas undergoing treatment with radiation plus diaziquone or 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Aziridines; Azirines; Benzoquinones; Brain Neoplasms; Carmustine; Combined Modality Therapy; Female; | 1987 |
The chemotherapy of brain tumors. Clinical experience with carmustine (BCNU) and vincristine.
Topics: Astrocytoma; Brain Neoplasms; Carcinosarcoma; Carmustine; Cerebral Angiography; Ependymoma; Evaluati | 1972 |
The chemotherapy of brain tumors. Clinical experience with carmustine (BCNU) and vincristine.
Topics: Astrocytoma; Brain Neoplasms; Carcinosarcoma; Carmustine; Cerebral Angiography; Ependymoma; Evaluati | 1972 |
The chemotherapy of brain tumors. Clinical experience with carmustine (BCNU) and vincristine.
Topics: Astrocytoma; Brain Neoplasms; Carcinosarcoma; Carmustine; Cerebral Angiography; Ependymoma; Evaluati | 1972 |
387 other studies available for carmustine and Glioma
| Article | Year |
|---|---|
Cell-based screen for identification of inhibitors of tubulin polymerization.
Topics: Animals; Brain Neoplasms; Bucladesine; Cell Differentiation; Drug Screening Assays, Antitumor; Forma | 1996 |
Cell-based screen for identification of inhibitors of tubulin polymerization.
Topics: Animals; Brain Neoplasms; Bucladesine; Cell Differentiation; Drug Screening Assays, Antitumor; Forma | 1996 |
Cell-based screen for identification of inhibitors of tubulin polymerization.
Topics: Animals; Brain Neoplasms; Bucladesine; Cell Differentiation; Drug Screening Assays, Antitumor; Forma | 1996 |
Discovery of antiglioma activity of biaryl 1,2,3,4-tetrahydroisoquinoline derivatives and conformationally flexible analogues.
Topics: Animals; Antineoplastic Agents; Astrocytes; Biphenyl Compounds; Cell Line, Tumor; Cells, Cultured; D | 2006 |
Discovery of antiglioma activity of biaryl 1,2,3,4-tetrahydroisoquinoline derivatives and conformationally flexible analogues.
Topics: Animals; Antineoplastic Agents; Astrocytes; Biphenyl Compounds; Cell Line, Tumor; Cells, Cultured; D | 2006 |
Discovery of antiglioma activity of biaryl 1,2,3,4-tetrahydroisoquinoline derivatives and conformationally flexible analogues.
Topics: Animals; Antineoplastic Agents; Astrocytes; Biphenyl Compounds; Cell Line, Tumor; Cells, Cultured; D | 2006 |
Supramolecular Hydrogel Based Post-Surgical Implant System for Hydrophobic Drug Delivery Against Glioma Recurrence.
Topics: Animals; Biocompatible Materials; Carmustine; Curcumin; Drug Delivery Systems; Glioma; Humans; Hydro | 2022 |
Supramolecular Hydrogel Based Post-Surgical Implant System for Hydrophobic Drug Delivery Against Glioma Recurrence.
Topics: Animals; Biocompatible Materials; Carmustine; Curcumin; Drug Delivery Systems; Glioma; Humans; Hydro | 2022 |
Supramolecular Hydrogel Based Post-Surgical Implant System for Hydrophobic Drug Delivery Against Glioma Recurrence.
Topics: Animals; Biocompatible Materials; Carmustine; Curcumin; Drug Delivery Systems; Glioma; Humans; Hydro | 2022 |
Cerebral Edema Due to Chemotherapeutic Wafer Implantation for Malignant Glioma: Registry Study of Correlation with Perioperative Epileptic Seizures.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Edema; Brain Neoplasms; Carmustine; Combined Modalit | 2022 |
Cerebral Edema Due to Chemotherapeutic Wafer Implantation for Malignant Glioma: Registry Study of Correlation with Perioperative Epileptic Seizures.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Edema; Brain Neoplasms; Carmustine; Combined Modalit | 2022 |
Cerebral Edema Due to Chemotherapeutic Wafer Implantation for Malignant Glioma: Registry Study of Correlation with Perioperative Epileptic Seizures.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Edema; Brain Neoplasms; Carmustine; Combined Modalit | 2022 |
Dual-sensitive drug-loaded hydrogel system for local inhibition of post-surgical glioma recurrence.
Topics: Brain Neoplasms; Carmustine; Cell Line, Tumor; Glioma; Humans; Hydrogels; Neoplasm Recurrence, Local | 2022 |
Dual-sensitive drug-loaded hydrogel system for local inhibition of post-surgical glioma recurrence.
Topics: Brain Neoplasms; Carmustine; Cell Line, Tumor; Glioma; Humans; Hydrogels; Neoplasm Recurrence, Local | 2022 |
Dual-sensitive drug-loaded hydrogel system for local inhibition of post-surgical glioma recurrence.
Topics: Brain Neoplasms; Carmustine; Cell Line, Tumor; Glioma; Humans; Hydrogels; Neoplasm Recurrence, Local | 2022 |
Molecular characteristics of incidental lower-grade glioma for treatment decision-making.
Topics: Brain Neoplasms; Carmustine; Glioma; Humans; Isocitrate Dehydrogenase; Mutation; Prognosis; Retrospe | 2023 |
Molecular characteristics of incidental lower-grade glioma for treatment decision-making.
Topics: Brain Neoplasms; Carmustine; Glioma; Humans; Isocitrate Dehydrogenase; Mutation; Prognosis; Retrospe | 2023 |
Molecular characteristics of incidental lower-grade glioma for treatment decision-making.
Topics: Brain Neoplasms; Carmustine; Glioma; Humans; Isocitrate Dehydrogenase; Mutation; Prognosis; Retrospe | 2023 |
Intraoperative Ventricular Opening has No Effect on Complication Development Following BCNU Wafer Implantation for Malignant Glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Therapy; Glioma; H | 2023 |
Intraoperative Ventricular Opening has No Effect on Complication Development Following BCNU Wafer Implantation for Malignant Glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Therapy; Glioma; H | 2023 |
Intraoperative Ventricular Opening has No Effect on Complication Development Following BCNU Wafer Implantation for Malignant Glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Therapy; Glioma; H | 2023 |
Intracranial nanomedicine-gel with deep brain-penetration for glioblastoma therapy.
Topics: Animals; Brain; Brain Neoplasms; Carmustine; Delayed-Action Preparations; Glioblastoma; Glioma; Nano | 2023 |
Intracranial nanomedicine-gel with deep brain-penetration for glioblastoma therapy.
Topics: Animals; Brain; Brain Neoplasms; Carmustine; Delayed-Action Preparations; Glioblastoma; Glioma; Nano | 2023 |
Intracranial nanomedicine-gel with deep brain-penetration for glioblastoma therapy.
Topics: Animals; Brain; Brain Neoplasms; Carmustine; Delayed-Action Preparations; Glioblastoma; Glioma; Nano | 2023 |
Newly Diagnosed High-Grade Glioma Surgery with Carmustine Wafers Implantation. A Long-Term Nationwide Retrospective Study.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Male; | 2023 |
Newly Diagnosed High-Grade Glioma Surgery with Carmustine Wafers Implantation. A Long-Term Nationwide Retrospective Study.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Male; | 2023 |
Newly Diagnosed High-Grade Glioma Surgery with Carmustine Wafers Implantation. A Long-Term Nationwide Retrospective Study.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Male; | 2023 |
Recurrent high grade glioma surgery with carmustine wafers implantation: a long-term nationwide retrospective study.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Male; | 2023 |
Recurrent high grade glioma surgery with carmustine wafers implantation: a long-term nationwide retrospective study.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Male; | 2023 |
Recurrent high grade glioma surgery with carmustine wafers implantation: a long-term nationwide retrospective study.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Male; | 2023 |
MRT-boost as the last fraction may be the most efficient irradiation schedule for increased survival times in a rat glioma model.
Topics: Animals; Brain Neoplasms; Carmustine; Dose Fractionation, Radiation; Glioma; Radiotherapy; Rats; Syn | 2023 |
MRT-boost as the last fraction may be the most efficient irradiation schedule for increased survival times in a rat glioma model.
Topics: Animals; Brain Neoplasms; Carmustine; Dose Fractionation, Radiation; Glioma; Radiotherapy; Rats; Syn | 2023 |
MRT-boost as the last fraction may be the most efficient irradiation schedule for increased survival times in a rat glioma model.
Topics: Animals; Brain Neoplasms; Carmustine; Dose Fractionation, Radiation; Glioma; Radiotherapy; Rats; Syn | 2023 |
Arsenite-induced Radiosensitization of Glioma Cells Is Dependent on p53 Deficiency.
Topics: Arsenites; Carbon; Carmustine; Cell Line, Tumor; Cell Survival; Glioma; Humans; Tumor Suppressor Pro | 2023 |
Arsenite-induced Radiosensitization of Glioma Cells Is Dependent on p53 Deficiency.
Topics: Arsenites; Carbon; Carmustine; Cell Line, Tumor; Cell Survival; Glioma; Humans; Tumor Suppressor Pro | 2023 |
Arsenite-induced Radiosensitization of Glioma Cells Is Dependent on p53 Deficiency.
Topics: Arsenites; Carbon; Carmustine; Cell Line, Tumor; Cell Survival; Glioma; Humans; Tumor Suppressor Pro | 2023 |
A novel strategy to the formulation of carmustine and bioactive nanoparticles co-loaded PLGA biocomposite spheres for targeting drug delivery to glioma treatment and nursing care.
Topics: Brain Neoplasms; Carmustine; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Compounding; Gliom | 2019 |
A novel strategy to the formulation of carmustine and bioactive nanoparticles co-loaded PLGA biocomposite spheres for targeting drug delivery to glioma treatment and nursing care.
Topics: Brain Neoplasms; Carmustine; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Compounding; Gliom | 2019 |
A novel strategy to the formulation of carmustine and bioactive nanoparticles co-loaded PLGA biocomposite spheres for targeting drug delivery to glioma treatment and nursing care.
Topics: Brain Neoplasms; Carmustine; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Compounding; Gliom | 2019 |
Implantation of carmustine wafers (Gliadel
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Infusi | 2020 |
Implantation of carmustine wafers (Gliadel
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Infusi | 2020 |
Implantation of carmustine wafers (Gliadel
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Infusi | 2020 |
Glycolytic inhibition by 3-bromopyruvate increases the cytotoxic effects of chloroethylnitrosoureas to human glioma cells and the DNA interstrand cross-links formation.
Topics: Adenosine Triphosphate; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Prot | 2020 |
Glycolytic inhibition by 3-bromopyruvate increases the cytotoxic effects of chloroethylnitrosoureas to human glioma cells and the DNA interstrand cross-links formation.
Topics: Adenosine Triphosphate; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Prot | 2020 |
Glycolytic inhibition by 3-bromopyruvate increases the cytotoxic effects of chloroethylnitrosoureas to human glioma cells and the DNA interstrand cross-links formation.
Topics: Adenosine Triphosphate; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Prot | 2020 |
FKBP51 acts as a biomarker of early metastasis and is related to carmustine sensitivity in human glioma cells.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Carmustine; Cell Movement; Cell Proliferation; | 2020 |
FKBP51 acts as a biomarker of early metastasis and is related to carmustine sensitivity in human glioma cells.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Carmustine; Cell Movement; Cell Proliferation; | 2020 |
FKBP51 acts as a biomarker of early metastasis and is related to carmustine sensitivity in human glioma cells.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Carmustine; Cell Movement; Cell Proliferation; | 2020 |
Safety of Gliadel Implant for Malignant Glioma: Report of Postmarketing Surveillance in Japan.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Decanoic Acids; Glioma; Humans; Japa | 2021 |
Safety of Gliadel Implant for Malignant Glioma: Report of Postmarketing Surveillance in Japan.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Decanoic Acids; Glioma; Humans; Japa | 2021 |
Safety of Gliadel Implant for Malignant Glioma: Report of Postmarketing Surveillance in Japan.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Decanoic Acids; Glioma; Humans; Japa | 2021 |
Implantation of Carmustine wafers after resection of malignant glioma with and without opening of the ventricular system.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Drug Implants; Glioma; Humans; Neopl | 2021 |
Implantation of Carmustine wafers after resection of malignant glioma with and without opening of the ventricular system.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Drug Implants; Glioma; Humans; Neopl | 2021 |
Implantation of Carmustine wafers after resection of malignant glioma with and without opening of the ventricular system.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Drug Implants; Glioma; Humans; Neopl | 2021 |
Inhibitors of GLUT/SLC2A Enhance the Action of BCNU and Temozolomide against High-Grade Gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Biological Transport; Carmustine; Cell Line, Tumor; Cell | 2017 |
Inhibitors of GLUT/SLC2A Enhance the Action of BCNU and Temozolomide against High-Grade Gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Biological Transport; Carmustine; Cell Line, Tumor; Cell | 2017 |
Inhibitors of GLUT/SLC2A Enhance the Action of BCNU and Temozolomide against High-Grade Gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Biological Transport; Carmustine; Cell Line, Tumor; Cell | 2017 |
Verapamil augments carmustine- and irradiation-induced senescence in glioma cells by reducing intracellular reactive oxygen species and calcium ion levels.
Topics: Antineoplastic Combined Chemotherapy Protocols; Calcium; Calcium Channels, L-Type; Carmustine; Cell | 2017 |
Verapamil augments carmustine- and irradiation-induced senescence in glioma cells by reducing intracellular reactive oxygen species and calcium ion levels.
Topics: Antineoplastic Combined Chemotherapy Protocols; Calcium; Calcium Channels, L-Type; Carmustine; Cell | 2017 |
Verapamil augments carmustine- and irradiation-induced senescence in glioma cells by reducing intracellular reactive oxygen species and calcium ion levels.
Topics: Antineoplastic Combined Chemotherapy Protocols; Calcium; Calcium Channels, L-Type; Carmustine; Cell | 2017 |
Space-Occupying Tumor Bed Cysts as a Complication of Modern Treatment for High-Grade Glioma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Brain Edema; Carmustine; Central Nervous System Cysts; C | 2017 |
Space-Occupying Tumor Bed Cysts as a Complication of Modern Treatment for High-Grade Glioma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Brain Edema; Carmustine; Central Nervous System Cysts; C | 2017 |
Space-Occupying Tumor Bed Cysts as a Complication of Modern Treatment for High-Grade Glioma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Brain Edema; Carmustine; Central Nervous System Cysts; C | 2017 |
Novel Application of Time-Spatial Labeling Inversion Pulse Magnetic Resonance Imaging for Diagnosis of External Hydrocephalus.
Topics: Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carmustine; Decanoic Acids; Glioma; Human | 2018 |
Novel Application of Time-Spatial Labeling Inversion Pulse Magnetic Resonance Imaging for Diagnosis of External Hydrocephalus.
Topics: Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carmustine; Decanoic Acids; Glioma; Human | 2018 |
Novel Application of Time-Spatial Labeling Inversion Pulse Magnetic Resonance Imaging for Diagnosis of External Hydrocephalus.
Topics: Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carmustine; Decanoic Acids; Glioma; Human | 2018 |
MiR-21 enhanced glioma cells resistance to carmustine via decreasing Spry2 expression.
Topics: Antagomirs; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B, Member | 2017 |
MiR-21 enhanced glioma cells resistance to carmustine via decreasing Spry2 expression.
Topics: Antagomirs; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B, Member | 2017 |
MiR-21 enhanced glioma cells resistance to carmustine via decreasing Spry2 expression.
Topics: Antagomirs; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B, Member | 2017 |
Symptomatic Remote Cyst after BCNU Wafer Implantation for Malignant Glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Central Nervous System Cysts; | 2018 |
Symptomatic Remote Cyst after BCNU Wafer Implantation for Malignant Glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Central Nervous System Cysts; | 2018 |
Symptomatic Remote Cyst after BCNU Wafer Implantation for Malignant Glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Central Nervous System Cysts; | 2018 |
Importance and accuracy of intraoperative frozen section diagnosis of the resection margin for effective carmustine wafer implantation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carm | 2018 |
Importance and accuracy of intraoperative frozen section diagnosis of the resection margin for effective carmustine wafer implantation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carm | 2018 |
Importance and accuracy of intraoperative frozen section diagnosis of the resection margin for effective carmustine wafer implantation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carm | 2018 |
Optimization of a preclinical therapy of cannabinoids in combination with temozolomide against glioma.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cann | 2018 |
Optimization of a preclinical therapy of cannabinoids in combination with temozolomide against glioma.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cann | 2018 |
Optimization of a preclinical therapy of cannabinoids in combination with temozolomide against glioma.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cann | 2018 |
Pep-1&borneol-Bifunctionalized Carmustine-Loaded Micelles Enhance Anti-Glioma Efficacy Through Tumor-Targeting and BBB-Penetrating.
Topics: Animals; Apoptosis; Blood-Brain Barrier; Brain; Brain Neoplasms; Camphanes; Carmustine; Cell Line, T | 2019 |
Pep-1&borneol-Bifunctionalized Carmustine-Loaded Micelles Enhance Anti-Glioma Efficacy Through Tumor-Targeting and BBB-Penetrating.
Topics: Animals; Apoptosis; Blood-Brain Barrier; Brain; Brain Neoplasms; Camphanes; Carmustine; Cell Line, T | 2019 |
Pep-1&borneol-Bifunctionalized Carmustine-Loaded Micelles Enhance Anti-Glioma Efficacy Through Tumor-Targeting and BBB-Penetrating.
Topics: Animals; Apoptosis; Blood-Brain Barrier; Brain; Brain Neoplasms; Camphanes; Carmustine; Cell Line, T | 2019 |
Leptomeningeal Gliomatosis: A Single Institution Study of 31 Patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined M | 2019 |
Leptomeningeal Gliomatosis: A Single Institution Study of 31 Patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined M | 2019 |
Leptomeningeal Gliomatosis: A Single Institution Study of 31 Patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined M | 2019 |
Epithelial-to-mesenchymal transition is involved in BCNU resistance in human glioma cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cadherins; Carmustine; Cell Line, Tumor; Drug Re | 2014 |
Epithelial-to-mesenchymal transition is involved in BCNU resistance in human glioma cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cadherins; Carmustine; Cell Line, Tumor; Drug Re | 2014 |
Epithelial-to-mesenchymal transition is involved in BCNU resistance in human glioma cells.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cadherins; Carmustine; Cell Line, Tumor; Drug Re | 2014 |
Accelerated hazards model based on parametric families generalized with Bernstein polynomials.
Topics: Bayes Theorem; Brain Neoplasms; Carmustine; Computer Simulation; Data Interpretation, Statistical; G | 2014 |
Accelerated hazards model based on parametric families generalized with Bernstein polynomials.
Topics: Bayes Theorem; Brain Neoplasms; Carmustine; Computer Simulation; Data Interpretation, Statistical; G | 2014 |
Accelerated hazards model based on parametric families generalized with Bernstein polynomials.
Topics: Bayes Theorem; Brain Neoplasms; Carmustine; Computer Simulation; Data Interpretation, Statistical; G | 2014 |
4E-BP1 regulates the sensitivity of human glioma cells to chemotherapy through PI3K/Akt/mTOR-independent pathway.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents, Alkylating; Carmustine; Cell Cycle Prot | 2014 |
4E-BP1 regulates the sensitivity of human glioma cells to chemotherapy through PI3K/Akt/mTOR-independent pathway.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents, Alkylating; Carmustine; Cell Cycle Prot | 2014 |
4E-BP1 regulates the sensitivity of human glioma cells to chemotherapy through PI3K/Akt/mTOR-independent pathway.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents, Alkylating; Carmustine; Cell Cycle Prot | 2014 |
Intraoperative pathological diagnosis in 205 glioma patients in the pre-BCNU wafer era: retrospective analysis with intraoperative implantation of BCNU wafers in mind.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Female; Frozen Sections | 2014 |
Intraoperative pathological diagnosis in 205 glioma patients in the pre-BCNU wafer era: retrospective analysis with intraoperative implantation of BCNU wafers in mind.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Female; Frozen Sections | 2014 |
Intraoperative pathological diagnosis in 205 glioma patients in the pre-BCNU wafer era: retrospective analysis with intraoperative implantation of BCNU wafers in mind.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Female; Frozen Sections | 2014 |
Carmustine (BCNU) plus Teniposide (VM26) in recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Disease-Fr | 2014 |
Carmustine (BCNU) plus Teniposide (VM26) in recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Disease-Fr | 2014 |
Carmustine (BCNU) plus Teniposide (VM26) in recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Disease-Fr | 2014 |
FANCD2 re-expression is associated with glioma grade and chemical inhibition of the Fanconi Anaemia pathway sensitises gliomas to chemotherapeutic agents.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Line, Tumor; Curcumin; Dacarbaz | 2014 |
FANCD2 re-expression is associated with glioma grade and chemical inhibition of the Fanconi Anaemia pathway sensitises gliomas to chemotherapeutic agents.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Line, Tumor; Curcumin; Dacarbaz | 2014 |
FANCD2 re-expression is associated with glioma grade and chemical inhibition of the Fanconi Anaemia pathway sensitises gliomas to chemotherapeutic agents.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Line, Tumor; Curcumin; Dacarbaz | 2014 |
Convection enhanced delivery of carmustine to the murine brainstem: a feasibility study.
Topics: Animals; Antineoplastic Agents; Brain Stem; Brain Stem Neoplasms; Carmustine; Catheters; Convection; | 2014 |
Convection enhanced delivery of carmustine to the murine brainstem: a feasibility study.
Topics: Animals; Antineoplastic Agents; Brain Stem; Brain Stem Neoplasms; Carmustine; Catheters; Convection; | 2014 |
Convection enhanced delivery of carmustine to the murine brainstem: a feasibility study.
Topics: Animals; Antineoplastic Agents; Brain Stem; Brain Stem Neoplasms; Carmustine; Catheters; Convection; | 2014 |
Redox proteomics reveal stress responsive proteins linking peroxiredoxin-1 status in glioma to chemosensitivity and oxidative stress.
Topics: Antineoplastic Agents, Alkylating; Carmustine; Cell Line, Tumor; DNA Damage; Drug Resistance, Neopla | 2015 |
Redox proteomics reveal stress responsive proteins linking peroxiredoxin-1 status in glioma to chemosensitivity and oxidative stress.
Topics: Antineoplastic Agents, Alkylating; Carmustine; Cell Line, Tumor; DNA Damage; Drug Resistance, Neopla | 2015 |
Redox proteomics reveal stress responsive proteins linking peroxiredoxin-1 status in glioma to chemosensitivity and oxidative stress.
Topics: Antineoplastic Agents, Alkylating; Carmustine; Cell Line, Tumor; DNA Damage; Drug Resistance, Neopla | 2015 |
Overexpression of Nrf2 attenuates Carmustine-induced cytotoxicity in U87MG human glioma cells.
Topics: Antineoplastic Agents, Alkylating; Antioxidants; Carmustine; Cell Line, Tumor; Cell Proliferation; D | 2015 |
Overexpression of Nrf2 attenuates Carmustine-induced cytotoxicity in U87MG human glioma cells.
Topics: Antineoplastic Agents, Alkylating; Antioxidants; Carmustine; Cell Line, Tumor; Cell Proliferation; D | 2015 |
Overexpression of Nrf2 attenuates Carmustine-induced cytotoxicity in U87MG human glioma cells.
Topics: Antineoplastic Agents, Alkylating; Antioxidants; Carmustine; Cell Line, Tumor; Cell Proliferation; D | 2015 |
Development of resistance to antiglioma agents in rat C6 cells caused collateral sensitivity to doxorubicin.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regula | 2015 |
Development of resistance to antiglioma agents in rat C6 cells caused collateral sensitivity to doxorubicin.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regula | 2015 |
Development of resistance to antiglioma agents in rat C6 cells caused collateral sensitivity to doxorubicin.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regula | 2015 |
[Risk Factors for Adverse Events after Implantation of BCNU Wafers in High-grade Gliomas].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Comb | 2015 |
[Risk Factors for Adverse Events after Implantation of BCNU Wafers in High-grade Gliomas].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Comb | 2015 |
[Risk Factors for Adverse Events after Implantation of BCNU Wafers in High-grade Gliomas].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Comb | 2015 |
Knockdown of Gli1 by small-interfering RNA enhances the effects of BCNU on the proliferation and apoptosis of glioma U251 cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Carmustine; Cell Cycle; Cell Division; Cell Line, Tumo | 2015 |
Knockdown of Gli1 by small-interfering RNA enhances the effects of BCNU on the proliferation and apoptosis of glioma U251 cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Carmustine; Cell Cycle; Cell Division; Cell Line, Tumo | 2015 |
Knockdown of Gli1 by small-interfering RNA enhances the effects of BCNU on the proliferation and apoptosis of glioma U251 cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Carmustine; Cell Cycle; Cell Division; Cell Line, Tumo | 2015 |
Evaluation of serial changes on computed tomography and magnetic resonance imaging after implantation of carmustine wafers in patients with malignant gliomas for differential diagnosis of tumor recurrence.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carm | 2016 |
Evaluation of serial changes on computed tomography and magnetic resonance imaging after implantation of carmustine wafers in patients with malignant gliomas for differential diagnosis of tumor recurrence.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carm | 2016 |
Evaluation of serial changes on computed tomography and magnetic resonance imaging after implantation of carmustine wafers in patients with malignant gliomas for differential diagnosis of tumor recurrence.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carm | 2016 |
Early Postoperative Expansion of Parenchymal High-intensity Areas on T2-weighted Imaging Predicts Delayed Cerebral Edema Caused by Carmustine Wafer Implantation in Patients with High-grade Glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Edema; Brain Neoplasms; Carmustine; Female; Gl | 2016 |
Early Postoperative Expansion of Parenchymal High-intensity Areas on T2-weighted Imaging Predicts Delayed Cerebral Edema Caused by Carmustine Wafer Implantation in Patients with High-grade Glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Edema; Brain Neoplasms; Carmustine; Female; Gl | 2016 |
Early Postoperative Expansion of Parenchymal High-intensity Areas on T2-weighted Imaging Predicts Delayed Cerebral Edema Caused by Carmustine Wafer Implantation in Patients with High-grade Glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Edema; Brain Neoplasms; Carmustine; Female; Gl | 2016 |
Chemotherapy with BCNU in recurrent glioma: Analysis of clinical outcome and side effects in chemotherapy-naïve patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carmustine; Combined Modality Therapy; Disease-Free Surv | 2016 |
Chemotherapy with BCNU in recurrent glioma: Analysis of clinical outcome and side effects in chemotherapy-naïve patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carmustine; Combined Modality Therapy; Disease-Free Surv | 2016 |
Chemotherapy with BCNU in recurrent glioma: Analysis of clinical outcome and side effects in chemotherapy-naïve patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carmustine; Combined Modality Therapy; Disease-Free Surv | 2016 |
Patterns of Recurrence After Resection of Malignant Gliomas With BCNU Wafer Implants: Retrospective Review in a Single Institution.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Carmustine; Chemotherapy, Ad | 2016 |
Patterns of Recurrence After Resection of Malignant Gliomas With BCNU Wafer Implants: Retrospective Review in a Single Institution.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Carmustine; Chemotherapy, Ad | 2016 |
Patterns of Recurrence After Resection of Malignant Gliomas With BCNU Wafer Implants: Retrospective Review in a Single Institution.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Carmustine; Chemotherapy, Ad | 2016 |
[Intraoperative BCNU Wafer Implantation for High-Grade Glioma--A Questionnaire Targeting Japanese Neurosurgeons].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Glioma; Humans; Surveys and Question | 2016 |
[Intraoperative BCNU Wafer Implantation for High-Grade Glioma--A Questionnaire Targeting Japanese Neurosurgeons].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Glioma; Humans; Surveys and Question | 2016 |
[Intraoperative BCNU Wafer Implantation for High-Grade Glioma--A Questionnaire Targeting Japanese Neurosurgeons].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Glioma; Humans; Surveys and Question | 2016 |
Eosinophilic meningitis triggered by implanted Gliadel wafers: case report.
Topics: Antineoplastic Agents; Brain; Brain Neoplasms; Carmustine; Decanoic Acids; Drug Delivery Systems; Dr | 2017 |
Eosinophilic meningitis triggered by implanted Gliadel wafers: case report.
Topics: Antineoplastic Agents; Brain; Brain Neoplasms; Carmustine; Decanoic Acids; Drug Delivery Systems; Dr | 2017 |
Eosinophilic meningitis triggered by implanted Gliadel wafers: case report.
Topics: Antineoplastic Agents; Brain; Brain Neoplasms; Carmustine; Decanoic Acids; Drug Delivery Systems; Dr | 2017 |
The influence of carmustine wafer implantation on tumor bed cysts and peritumoral brain edema.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Edema; Brain Neoplasms; Carmustine; Cysts; Female; Gl | 2016 |
The influence of carmustine wafer implantation on tumor bed cysts and peritumoral brain edema.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Edema; Brain Neoplasms; Carmustine; Cysts; Female; Gl | 2016 |
The influence of carmustine wafer implantation on tumor bed cysts and peritumoral brain edema.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Edema; Brain Neoplasms; Carmustine; Cysts; Female; Gl | 2016 |
Quantitative analysis of brain edema in patients with malignant glioma treated with BCNU wafers.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Edema; Brain Neoplasms; Carmustine | 2016 |
Quantitative analysis of brain edema in patients with malignant glioma treated with BCNU wafers.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Edema; Brain Neoplasms; Carmustine | 2016 |
Quantitative analysis of brain edema in patients with malignant glioma treated with BCNU wafers.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Edema; Brain Neoplasms; Carmustine | 2016 |
[Long-Term Efficacy of BCNU Wafers for Malignant Gliomas].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2016 |
[Long-Term Efficacy of BCNU Wafers for Malignant Gliomas].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2016 |
[Long-Term Efficacy of BCNU Wafers for Malignant Gliomas].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2016 |
iRGD-mediated core-shell nanoparticles loading carmustine and O
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cell Line, Tum | 2017 |
iRGD-mediated core-shell nanoparticles loading carmustine and O
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cell Line, Tum | 2017 |
iRGD-mediated core-shell nanoparticles loading carmustine and O
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cell Line, Tum | 2017 |
Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Neoplasm; Antineoplastic Agents; Brain Neoplasms; Carmu | 2016 |
Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Neoplasm; Antineoplastic Agents; Brain Neoplasms; Carmu | 2016 |
Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Neoplasm; Antineoplastic Agents; Brain Neoplasms; Carmu | 2016 |
Noninvasive assessment of E2F-1-mediated transcriptional regulation in vivo.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Line, Tumor; Disease Progression; DNA Damage; E2F1 Transc | 2008 |
Noninvasive assessment of E2F-1-mediated transcriptional regulation in vivo.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Line, Tumor; Disease Progression; DNA Damage; E2F1 Transc | 2008 |
Noninvasive assessment of E2F-1-mediated transcriptional regulation in vivo.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Line, Tumor; Disease Progression; DNA Damage; E2F1 Transc | 2008 |
Effects, in an in-vivo model system, of 1,2,3,4-tetrahydroisoquinoline on glioma.
Topics: Animals; Antineoplastic Agents; Astrocytes; Brain Neoplasms; Carmustine; Cell Line, Tumor; Dacarbazi | 2008 |
Effects, in an in-vivo model system, of 1,2,3,4-tetrahydroisoquinoline on glioma.
Topics: Animals; Antineoplastic Agents; Astrocytes; Brain Neoplasms; Carmustine; Cell Line, Tumor; Dacarbazi | 2008 |
Effects, in an in-vivo model system, of 1,2,3,4-tetrahydroisoquinoline on glioma.
Topics: Animals; Antineoplastic Agents; Astrocytes; Brain Neoplasms; Carmustine; Cell Line, Tumor; Dacarbazi | 2008 |
DNA alkylation products formed by 1-(2-chloroethyl)-1-nitrosourea as molecular dosimeters of therapeutic response.
Topics: Alkylation; Antineoplastic Agents, Alkylating; Carmustine; Cell Line, Tumor; Cell Survival; Chromato | 2009 |
DNA alkylation products formed by 1-(2-chloroethyl)-1-nitrosourea as molecular dosimeters of therapeutic response.
Topics: Alkylation; Antineoplastic Agents, Alkylating; Carmustine; Cell Line, Tumor; Cell Survival; Chromato | 2009 |
DNA alkylation products formed by 1-(2-chloroethyl)-1-nitrosourea as molecular dosimeters of therapeutic response.
Topics: Alkylation; Antineoplastic Agents, Alkylating; Carmustine; Cell Line, Tumor; Cell Survival; Chromato | 2009 |
Temozolomide and carmustine cause large-scale heterochromatin reorganization in glioma cells.
Topics: Acetylation; Antineoplastic Agents, Alkylating; Apoptosis; Carmustine; Cell Line, Tumor; Cellular Se | 2009 |
Temozolomide and carmustine cause large-scale heterochromatin reorganization in glioma cells.
Topics: Acetylation; Antineoplastic Agents, Alkylating; Apoptosis; Carmustine; Cell Line, Tumor; Cellular Se | 2009 |
Temozolomide and carmustine cause large-scale heterochromatin reorganization in glioma cells.
Topics: Acetylation; Antineoplastic Agents, Alkylating; Apoptosis; Carmustine; Cell Line, Tumor; Cellular Se | 2009 |
Glial cell-line derived neurotrophic factor (GDNF) family of ligands confer chemoresistance in a ligand-specific fashion in malignant gliomas.
Topics: Antineoplastic Agents, Alkylating; Carmustine; Cell Line, Tumor; Cell Survival; Dose-Response Relati | 2009 |
Glial cell-line derived neurotrophic factor (GDNF) family of ligands confer chemoresistance in a ligand-specific fashion in malignant gliomas.
Topics: Antineoplastic Agents, Alkylating; Carmustine; Cell Line, Tumor; Cell Survival; Dose-Response Relati | 2009 |
Glial cell-line derived neurotrophic factor (GDNF) family of ligands confer chemoresistance in a ligand-specific fashion in malignant gliomas.
Topics: Antineoplastic Agents, Alkylating; Carmustine; Cell Line, Tumor; Cell Survival; Dose-Response Relati | 2009 |
Growth inhibition against intracranial C6 glioma cells by stereotactic delivery of BCNU by controlled release from poly(D,L-lactic acid) nanoparticles.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Line, Tumor; Glioma; Lactic Acid; Male; Nanoparticles; Po | 2009 |
Growth inhibition against intracranial C6 glioma cells by stereotactic delivery of BCNU by controlled release from poly(D,L-lactic acid) nanoparticles.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Line, Tumor; Glioma; Lactic Acid; Male; Nanoparticles; Po | 2009 |
Growth inhibition against intracranial C6 glioma cells by stereotactic delivery of BCNU by controlled release from poly(D,L-lactic acid) nanoparticles.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Line, Tumor; Glioma; Lactic Acid; Male; Nanoparticles; Po | 2009 |
Possible novel therapy for malignant gliomas with secretable trimeric TRAIL.
Topics: Adenoviridae; Animals; Carmustine; Drug Therapy, Combination; Genetic Therapy; Genetic Vectors; Glio | 2009 |
Possible novel therapy for malignant gliomas with secretable trimeric TRAIL.
Topics: Adenoviridae; Animals; Carmustine; Drug Therapy, Combination; Genetic Therapy; Genetic Vectors; Glio | 2009 |
Possible novel therapy for malignant gliomas with secretable trimeric TRAIL.
Topics: Adenoviridae; Animals; Carmustine; Drug Therapy, Combination; Genetic Therapy; Genetic Vectors; Glio | 2009 |
Inhibition of 90-kD heat shock protein potentiates the cytotoxicity of chemotherapeutic agents in human glioma cells.
Topics: Animals; Annexin A5; Antineoplastic Agents; Apoptosis; Benzoquinones; Carmustine; Cell Cycle; Cell L | 2010 |
Inhibition of 90-kD heat shock protein potentiates the cytotoxicity of chemotherapeutic agents in human glioma cells.
Topics: Animals; Annexin A5; Antineoplastic Agents; Apoptosis; Benzoquinones; Carmustine; Cell Cycle; Cell L | 2010 |
Inhibition of 90-kD heat shock protein potentiates the cytotoxicity of chemotherapeutic agents in human glioma cells.
Topics: Animals; Annexin A5; Antineoplastic Agents; Apoptosis; Benzoquinones; Carmustine; Cell Cycle; Cell L | 2010 |
Incorporating BCNU wafers into malignant glioma treatment: European case studies.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2010 |
Incorporating BCNU wafers into malignant glioma treatment: European case studies.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2010 |
Incorporating BCNU wafers into malignant glioma treatment: European case studies.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2010 |
Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Dacarbazine; Disease Models | 2010 |
Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Dacarbazine; Disease Models | 2010 |
Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Dacarbazine; Disease Models | 2010 |
Biodegradable carmustine wafers (Gliadel) alone or in combination with chemoradiotherapy: the French experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biocompa | 2010 |
Biodegradable carmustine wafers (Gliadel) alone or in combination with chemoradiotherapy: the French experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biocompa | 2010 |
Biodegradable carmustine wafers (Gliadel) alone or in combination with chemoradiotherapy: the French experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biocompa | 2010 |
Novel magnetic/ultrasound focusing system enhances nanoparticle drug delivery for glioma treatment.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Drug Delivery Syst | 2010 |
Novel magnetic/ultrasound focusing system enhances nanoparticle drug delivery for glioma treatment.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Drug Delivery Syst | 2010 |
Novel magnetic/ultrasound focusing system enhances nanoparticle drug delivery for glioma treatment.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Drug Delivery Syst | 2010 |
Elevated expression of Dickkopf-1 increases the sensitivity of human glioma cell line SHG44 to BCNU.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Brain N | 2010 |
Elevated expression of Dickkopf-1 increases the sensitivity of human glioma cell line SHG44 to BCNU.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Brain N | 2010 |
Elevated expression of Dickkopf-1 increases the sensitivity of human glioma cell line SHG44 to BCNU.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Brain N | 2010 |
The effectiveness of a magnetic nanoparticle-based delivery system for BCNU in the treatment of gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Carmustine; Cell Line; Cell Line, Tumor; Drug Delivery S | 2011 |
The effectiveness of a magnetic nanoparticle-based delivery system for BCNU in the treatment of gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Carmustine; Cell Line; Cell Line, Tumor; Drug Delivery S | 2011 |
The effectiveness of a magnetic nanoparticle-based delivery system for BCNU in the treatment of gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Carmustine; Cell Line; Cell Line, Tumor; Drug Delivery S | 2011 |
Earlier detection of tumor treatment response using magnetic resonance diffusion imaging with oscillating gradients.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Line, Tumor; Diffusion | 2011 |
Earlier detection of tumor treatment response using magnetic resonance diffusion imaging with oscillating gradients.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Line, Tumor; Diffusion | 2011 |
Earlier detection of tumor treatment response using magnetic resonance diffusion imaging with oscillating gradients.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Line, Tumor; Diffusion | 2011 |
Space-occupying cyst development in the resection cavity of malignant gliomas following Gliadel® implantation--incidence, therapeutic strategies, and outcome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biocompatible Materials; Brain Ne | 2011 |
Space-occupying cyst development in the resection cavity of malignant gliomas following Gliadel® implantation--incidence, therapeutic strategies, and outcome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biocompatible Materials; Brain Ne | 2011 |
Space-occupying cyst development in the resection cavity of malignant gliomas following Gliadel® implantation--incidence, therapeutic strategies, and outcome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biocompatible Materials; Brain Ne | 2011 |
Clinical features, management and outcomes of high-grade glioma patients in Ramathibodi Hospital.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Mo | 2010 |
Clinical features, management and outcomes of high-grade glioma patients in Ramathibodi Hospital.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Mo | 2010 |
Clinical features, management and outcomes of high-grade glioma patients in Ramathibodi Hospital.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Mo | 2010 |
Pro-apoptotic role of integrin β3 in glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Carmustine; Cell Line, Tumor; Drug Interactio | 2011 |
Pro-apoptotic role of integrin β3 in glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Carmustine; Cell Line, Tumor; Drug Interactio | 2011 |
Pro-apoptotic role of integrin β3 in glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Carmustine; Cell Line, Tumor; Drug Interactio | 2011 |
Heavy chain ferritin siRNA delivered by cationic liposomes increases sensitivity of cancer cells to chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoferritins; Apoptosis; Blotting, Western; Carmustine; | 2011 |
Heavy chain ferritin siRNA delivered by cationic liposomes increases sensitivity of cancer cells to chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoferritins; Apoptosis; Blotting, Western; Carmustine; | 2011 |
Heavy chain ferritin siRNA delivered by cationic liposomes increases sensitivity of cancer cells to chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoferritins; Apoptosis; Blotting, Western; Carmustine; | 2011 |
Carmustine-impregnated wafers and their impact in the management of high-grade glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Drug Carri | 2011 |
Carmustine-impregnated wafers and their impact in the management of high-grade glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Drug Carri | 2011 |
Carmustine-impregnated wafers and their impact in the management of high-grade glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Drug Carri | 2011 |
Self-protecting core-shell magnetic nanoparticles for targeted, traceable, long half-life delivery of BCNU to gliomas.
Topics: Animals; Antineoplastic Agents; Carmustine; Cell Death; Cell Line, Tumor; Computer Simulation; Cross | 2011 |
Self-protecting core-shell magnetic nanoparticles for targeted, traceable, long half-life delivery of BCNU to gliomas.
Topics: Animals; Antineoplastic Agents; Carmustine; Cell Death; Cell Line, Tumor; Computer Simulation; Cross | 2011 |
Self-protecting core-shell magnetic nanoparticles for targeted, traceable, long half-life delivery of BCNU to gliomas.
Topics: Animals; Antineoplastic Agents; Carmustine; Cell Death; Cell Line, Tumor; Computer Simulation; Cross | 2011 |
Assessment of multiparametric MRI in a human glioma model to monitor cytotoxic and anti-angiogenic drug effects.
Topics: Angiogenesis Inhibitors; Animals; Benzenesulfonates; Blood Volume; Carmustine; Cell Death; Cell Line | 2011 |
Assessment of multiparametric MRI in a human glioma model to monitor cytotoxic and anti-angiogenic drug effects.
Topics: Angiogenesis Inhibitors; Animals; Benzenesulfonates; Blood Volume; Carmustine; Cell Death; Cell Line | 2011 |
Assessment of multiparametric MRI in a human glioma model to monitor cytotoxic and anti-angiogenic drug effects.
Topics: Angiogenesis Inhibitors; Animals; Benzenesulfonates; Blood Volume; Carmustine; Cell Death; Cell Line | 2011 |
Knockdown of the potential cancer stem-like cell marker Rex-1 improves chemotherapeutic effects in gliomas.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Brain Neoplasms; Carmustine; Cell Move | 2011 |
Knockdown of the potential cancer stem-like cell marker Rex-1 improves chemotherapeutic effects in gliomas.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Brain Neoplasms; Carmustine; Cell Move | 2011 |
Knockdown of the potential cancer stem-like cell marker Rex-1 improves chemotherapeutic effects in gliomas.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Brain Neoplasms; Carmustine; Cell Move | 2011 |
Inhibition of C6 glioma in vivo by combination chemotherapy of implantation of polymer wafer and intracarotid perfusion of transferrin-decorated nanoparticles.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Car | 2012 |
Inhibition of C6 glioma in vivo by combination chemotherapy of implantation of polymer wafer and intracarotid perfusion of transferrin-decorated nanoparticles.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Car | 2012 |
Inhibition of C6 glioma in vivo by combination chemotherapy of implantation of polymer wafer and intracarotid perfusion of transferrin-decorated nanoparticles.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Car | 2012 |
Silencing of MGMT with small interference RNA reversed resistance in human BCUN-resistant glioma cell lines.
Topics: Blotting, Western; Carmustine; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Glio | 2011 |
Silencing of MGMT with small interference RNA reversed resistance in human BCUN-resistant glioma cell lines.
Topics: Blotting, Western; Carmustine; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Glio | 2011 |
Silencing of MGMT with small interference RNA reversed resistance in human BCUN-resistant glioma cell lines.
Topics: Blotting, Western; Carmustine; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Glio | 2011 |
NICE guidance on the use of carmustine wafers in high grade gliomas: a national study on variation in practice.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Therapy; Fem | 2012 |
NICE guidance on the use of carmustine wafers in high grade gliomas: a national study on variation in practice.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Therapy; Fem | 2012 |
NICE guidance on the use of carmustine wafers in high grade gliomas: a national study on variation in practice.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Combined Modality Therapy; Fem | 2012 |
Improving thermal stability and efficacy of BCNU in treating glioma cells using PAA-functionalized graphene oxide.
Topics: Acrylic Resins; Animals; Antineoplastic Agents, Alkylating; Carmustine; Cell Line, Tumor; Drug Carri | 2012 |
Improving thermal stability and efficacy of BCNU in treating glioma cells using PAA-functionalized graphene oxide.
Topics: Acrylic Resins; Animals; Antineoplastic Agents, Alkylating; Carmustine; Cell Line, Tumor; Drug Carri | 2012 |
Improving thermal stability and efficacy of BCNU in treating glioma cells using PAA-functionalized graphene oxide.
Topics: Acrylic Resins; Animals; Antineoplastic Agents, Alkylating; Carmustine; Cell Line, Tumor; Drug Carri | 2012 |
Concurrent treatment with BCNU and Gamma Knife radiosurgery in the rat malignant glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Line, Tumor; Combined | 2012 |
Concurrent treatment with BCNU and Gamma Knife radiosurgery in the rat malignant glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Line, Tumor; Combined | 2012 |
Concurrent treatment with BCNU and Gamma Knife radiosurgery in the rat malignant glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Line, Tumor; Combined | 2012 |
Induction of β-glucuronidase release by cytostatic agents in small tumors.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine | 2012 |
Induction of β-glucuronidase release by cytostatic agents in small tumors.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine | 2012 |
Induction of β-glucuronidase release by cytostatic agents in small tumors.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine | 2012 |
Implanted carmustine wafers followed by concomitant radiochemotherapy to treat newly diagnosed malignant gliomas: prospective, observational, multicenter study on 92 cases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemoradiotherapy, Adjuvant; Dacarbazine | 2013 |
Implanted carmustine wafers followed by concomitant radiochemotherapy to treat newly diagnosed malignant gliomas: prospective, observational, multicenter study on 92 cases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemoradiotherapy, Adjuvant; Dacarbazine | 2013 |
Implanted carmustine wafers followed by concomitant radiochemotherapy to treat newly diagnosed malignant gliomas: prospective, observational, multicenter study on 92 cases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemoradiotherapy, Adjuvant; Dacarbazine | 2013 |
Antiangiogenic-targeting drug-loaded microbubbles combined with focused ultrasound for glioma treatment.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain; Brain Neoplasms | 2013 |
Antiangiogenic-targeting drug-loaded microbubbles combined with focused ultrasound for glioma treatment.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain; Brain Neoplasms | 2013 |
Antiangiogenic-targeting drug-loaded microbubbles combined with focused ultrasound for glioma treatment.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain; Brain Neoplasms | 2013 |
Growth pattern of tumor recurrence following bis-chloroethylnitrosourea (BCNU) wafer implantation in malignant glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Kaplan-Meier | 2013 |
Growth pattern of tumor recurrence following bis-chloroethylnitrosourea (BCNU) wafer implantation in malignant glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Kaplan-Meier | 2013 |
Growth pattern of tumor recurrence following bis-chloroethylnitrosourea (BCNU) wafer implantation in malignant glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Kaplan-Meier | 2013 |
Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chromosome Deletion; Chromosome | 2002 |
Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chromosome Deletion; Chromosome | 2002 |
Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chromosome Deletion; Chromosome | 2002 |
[Experimental study of combination therapy against human glioma xenograft by differentiation-inducing agent and cytotoxic chemotherapeutic drug].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Body Weight; Carmustine; Cell Cy | 2002 |
[Experimental study of combination therapy against human glioma xenograft by differentiation-inducing agent and cytotoxic chemotherapeutic drug].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Body Weight; Carmustine; Cell Cy | 2002 |
[Experimental study of combination therapy against human glioma xenograft by differentiation-inducing agent and cytotoxic chemotherapeutic drug].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Body Weight; Carmustine; Cell Cy | 2002 |
Camptothecin analogs in malignant gliomas: comparative analysis and characterization.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Camptothecin; Carmust | 2003 |
Camptothecin analogs in malignant gliomas: comparative analysis and characterization.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Camptothecin; Carmust | 2003 |
Camptothecin analogs in malignant gliomas: comparative analysis and characterization.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Camptothecin; Carmust | 2003 |
Potentiation of chemotherapeutic agents following antagonism of nuclear factor kappa B in human gliomas.
Topics: Adenoviridae; Antineoplastic Agents; Apoptosis; Camptothecin; Carboplatin; Carmustine; Drug Synergis | 2003 |
Potentiation of chemotherapeutic agents following antagonism of nuclear factor kappa B in human gliomas.
Topics: Adenoviridae; Antineoplastic Agents; Apoptosis; Camptothecin; Carboplatin; Carmustine; Drug Synergis | 2003 |
Potentiation of chemotherapeutic agents following antagonism of nuclear factor kappa B in human gliomas.
Topics: Adenoviridae; Antineoplastic Agents; Apoptosis; Camptothecin; Carboplatin; Carmustine; Drug Synergis | 2003 |
Formation of DNA adducts and tumor growth delay following intratumoral administration of DTI-015.
Topics: Animals; Antineoplastic Agents, Alkylating; Carmustine; Chromatography, High Pressure Liquid; DNA Ad | 2003 |
Formation of DNA adducts and tumor growth delay following intratumoral administration of DTI-015.
Topics: Animals; Antineoplastic Agents, Alkylating; Carmustine; Chromatography, High Pressure Liquid; DNA Ad | 2003 |
Formation of DNA adducts and tumor growth delay following intratumoral administration of DTI-015.
Topics: Animals; Antineoplastic Agents, Alkylating; Carmustine; Chromatography, High Pressure Liquid; DNA Ad | 2003 |
Synergistic augmentation of antimicrotubule agent-induced cytotoxicity by a phosphoinositide 3-kinase inhibitor in human malignant glioma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chromones; Cisplatin; Drug Synergism; En | 2003 |
Synergistic augmentation of antimicrotubule agent-induced cytotoxicity by a phosphoinositide 3-kinase inhibitor in human malignant glioma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chromones; Cisplatin; Drug Synergism; En | 2003 |
Synergistic augmentation of antimicrotubule agent-induced cytotoxicity by a phosphoinositide 3-kinase inhibitor in human malignant glioma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chromones; Cisplatin; Drug Synergism; En | 2003 |
Gliadel therapy given for first resection of malignant glioma: a single centre study of the potential use of Gliadel.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biocompa | 2003 |
Gliadel therapy given for first resection of malignant glioma: a single centre study of the potential use of Gliadel.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biocompa | 2003 |
Gliadel therapy given for first resection of malignant glioma: a single centre study of the potential use of Gliadel.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biocompa | 2003 |
Hematopoietic expression of O(6)-methylguanine DNA methyltransferase-P140K allows intensive treatment of human glioma xenografts with combination O(6)-benzylguanine and 1,3-bis-(2-chloroethyl)-1-nitrosourea.
Topics: Animals; Antineoplastic Agents, Alkylating; Bone Marrow; Brain Neoplasms; Carmustine; Glioma; Guanin | 2003 |
Hematopoietic expression of O(6)-methylguanine DNA methyltransferase-P140K allows intensive treatment of human glioma xenografts with combination O(6)-benzylguanine and 1,3-bis-(2-chloroethyl)-1-nitrosourea.
Topics: Animals; Antineoplastic Agents, Alkylating; Bone Marrow; Brain Neoplasms; Carmustine; Glioma; Guanin | 2003 |
Hematopoietic expression of O(6)-methylguanine DNA methyltransferase-P140K allows intensive treatment of human glioma xenografts with combination O(6)-benzylguanine and 1,3-bis-(2-chloroethyl)-1-nitrosourea.
Topics: Animals; Antineoplastic Agents, Alkylating; Bone Marrow; Brain Neoplasms; Carmustine; Glioma; Guanin | 2003 |
Carbamoylating chemoresistance induced by cobalt pretreatment in C6 glioma cells: putative roles of hypoxia-inducible factor-1.
Topics: Animals; Antineoplastic Agents, Alkylating; Carmustine; Cell Line, Tumor; Cell Survival; Cobalt; Def | 2004 |
Carbamoylating chemoresistance induced by cobalt pretreatment in C6 glioma cells: putative roles of hypoxia-inducible factor-1.
Topics: Animals; Antineoplastic Agents, Alkylating; Carmustine; Cell Line, Tumor; Cell Survival; Cobalt; Def | 2004 |
Carbamoylating chemoresistance induced by cobalt pretreatment in C6 glioma cells: putative roles of hypoxia-inducible factor-1.
Topics: Animals; Antineoplastic Agents, Alkylating; Carmustine; Cell Line, Tumor; Cell Survival; Cobalt; Def | 2004 |
Advancing the treatment of malignant glioma: act local, think global.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Glioma; Hu | 2004 |
Advancing the treatment of malignant glioma: act local, think global.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Glioma; Hu | 2004 |
Advancing the treatment of malignant glioma: act local, think global.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Glioma; Hu | 2004 |
Nitric oxide and BCNU chemoresistance in C6 glioma cells: role of S-nitrosoglutathione.
Topics: Alkylation; Animals; Antineoplastic Agents, Alkylating; Antioxidants; Carbamates; Carmustine; Chelat | 2004 |
Nitric oxide and BCNU chemoresistance in C6 glioma cells: role of S-nitrosoglutathione.
Topics: Alkylation; Animals; Antineoplastic Agents, Alkylating; Antioxidants; Carbamates; Carmustine; Chelat | 2004 |
Nitric oxide and BCNU chemoresistance in C6 glioma cells: role of S-nitrosoglutathione.
Topics: Alkylation; Animals; Antineoplastic Agents, Alkylating; Antioxidants; Carbamates; Carmustine; Chelat | 2004 |
Combination of caspase transfer using the human telomerase reverse transcriptase promoter and conventional therapies for malignant glioma cells.
Topics: Antineoplastic Agents; Carmustine; Caspases; Cell Line, Tumor; Cell Survival; Cisplatin; DNA-Binding | 2004 |
Combination of caspase transfer using the human telomerase reverse transcriptase promoter and conventional therapies for malignant glioma cells.
Topics: Antineoplastic Agents; Carmustine; Caspases; Cell Line, Tumor; Cell Survival; Cisplatin; DNA-Binding | 2004 |
Combination of caspase transfer using the human telomerase reverse transcriptase promoter and conventional therapies for malignant glioma cells.
Topics: Antineoplastic Agents; Carmustine; Caspases; Cell Line, Tumor; Cell Survival; Cisplatin; DNA-Binding | 2004 |
CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas.
Topics: Adult; Aged; Alkylating Agents; Brain Neoplasms; Carmustine; CpG Islands; Dacarbazine; DNA; DNA Meth | 2004 |
CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas.
Topics: Adult; Aged; Alkylating Agents; Brain Neoplasms; Carmustine; CpG Islands; Dacarbazine; DNA; DNA Meth | 2004 |
CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas.
Topics: Adult; Aged; Alkylating Agents; Brain Neoplasms; Carmustine; CpG Islands; Dacarbazine; DNA; DNA Meth | 2004 |
Combination chemotherapy of BCNU and Didox acts synergystically in 9L glioma cells.
Topics: Animals; Anti-Infective Agents, Local; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Ant | 2004 |
Combination chemotherapy of BCNU and Didox acts synergystically in 9L glioma cells.
Topics: Animals; Anti-Infective Agents, Local; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Ant | 2004 |
Combination chemotherapy of BCNU and Didox acts synergystically in 9L glioma cells.
Topics: Animals; Anti-Infective Agents, Local; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Ant | 2004 |
Therapeutic efficacy of DTI-015 using diffusion magnetic resonance imaging as an early surrogate marker.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Carmustine; Diffusio | 2004 |
Therapeutic efficacy of DTI-015 using diffusion magnetic resonance imaging as an early surrogate marker.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Carmustine; Diffusio | 2004 |
Therapeutic efficacy of DTI-015 using diffusion magnetic resonance imaging as an early surrogate marker.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Carmustine; Diffusio | 2004 |
Cancer therapy with a replicating oncolytic adenovirus targeting the hypoxic microenvironment of tumors.
Topics: Adenoviridae; Adenovirus E1A Proteins; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; | 2004 |
Cancer therapy with a replicating oncolytic adenovirus targeting the hypoxic microenvironment of tumors.
Topics: Adenoviridae; Adenovirus E1A Proteins; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; | 2004 |
Cancer therapy with a replicating oncolytic adenovirus targeting the hypoxic microenvironment of tumors.
Topics: Adenoviridae; Adenovirus E1A Proteins; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; | 2004 |
Cerebral edema associated with Gliadel wafers: two case studies.
Topics: Antineoplastic Agents, Alkylating; Biocompatible Materials; Brain Edema; Brain Neoplasms; Carmustine | 2005 |
Cerebral edema associated with Gliadel wafers: two case studies.
Topics: Antineoplastic Agents, Alkylating; Biocompatible Materials; Brain Edema; Brain Neoplasms; Carmustine | 2005 |
Cerebral edema associated with Gliadel wafers: two case studies.
Topics: Antineoplastic Agents, Alkylating; Biocompatible Materials; Brain Edema; Brain Neoplasms; Carmustine | 2005 |
Pharmaceutical-mediated inactivation of p53 sensitizes U87MG glioma cells to BCNU and temozolomide.
Topics: Antineoplastic Agents, Alkylating; Benzothiazoles; Brain Neoplasms; Carmustine; Dacarbazine; DNA Dam | 2005 |
Pharmaceutical-mediated inactivation of p53 sensitizes U87MG glioma cells to BCNU and temozolomide.
Topics: Antineoplastic Agents, Alkylating; Benzothiazoles; Brain Neoplasms; Carmustine; Dacarbazine; DNA Dam | 2005 |
Pharmaceutical-mediated inactivation of p53 sensitizes U87MG glioma cells to BCNU and temozolomide.
Topics: Antineoplastic Agents, Alkylating; Benzothiazoles; Brain Neoplasms; Carmustine; Dacarbazine; DNA Dam | 2005 |
S-nitrosoglutathione and hypoxia-inducible factor-1 confer chemoresistance against carbamoylating cytotoxicity of BCNU in rat C6 glioma cells.
Topics: Animals; Carmustine; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioma; Hypoxia-Inducible Factor 1 | 2005 |
S-nitrosoglutathione and hypoxia-inducible factor-1 confer chemoresistance against carbamoylating cytotoxicity of BCNU in rat C6 glioma cells.
Topics: Animals; Carmustine; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioma; Hypoxia-Inducible Factor 1 | 2005 |
S-nitrosoglutathione and hypoxia-inducible factor-1 confer chemoresistance against carbamoylating cytotoxicity of BCNU in rat C6 glioma cells.
Topics: Animals; Carmustine; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioma; Hypoxia-Inducible Factor 1 | 2005 |
Gene expression profile induced by BCNU in human glioma cell lines with differential MGMT expression.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Line, Tumor; Cell Proliferation | 2005 |
Gene expression profile induced by BCNU in human glioma cell lines with differential MGMT expression.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Line, Tumor; Cell Proliferation | 2005 |
Gene expression profile induced by BCNU in human glioma cell lines with differential MGMT expression.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Line, Tumor; Cell Proliferation | 2005 |
Intratumoral injection of BCNU in ethanol (DTI-015) results in enhanced delivery to tumor--a pharmacokinetic study.
Topics: Animals; Antineoplastic Agents, Alkylating; Area Under Curve; Brain Neoplasms; Carmustine; Ethanol; | 2005 |
Intratumoral injection of BCNU in ethanol (DTI-015) results in enhanced delivery to tumor--a pharmacokinetic study.
Topics: Animals; Antineoplastic Agents, Alkylating; Area Under Curve; Brain Neoplasms; Carmustine; Ethanol; | 2005 |
Intratumoral injection of BCNU in ethanol (DTI-015) results in enhanced delivery to tumor--a pharmacokinetic study.
Topics: Animals; Antineoplastic Agents, Alkylating; Area Under Curve; Brain Neoplasms; Carmustine; Ethanol; | 2005 |
Safety and efficacy of a novel cannabinoid chemotherapeutic, KM-233, for the treatment of high-grade glioma.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cannabinoids; Carmustine; Cell Line, Tumor; Dronabi | 2006 |
Safety and efficacy of a novel cannabinoid chemotherapeutic, KM-233, for the treatment of high-grade glioma.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cannabinoids; Carmustine; Cell Line, Tumor; Dronabi | 2006 |
Safety and efficacy of a novel cannabinoid chemotherapeutic, KM-233, for the treatment of high-grade glioma.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cannabinoids; Carmustine; Cell Line, Tumor; Dronabi | 2006 |
Over-representation of specific regions of chromosome 22 in cells from human glioma correlate with resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Survival; Chromosomes, H | 2006 |
Over-representation of specific regions of chromosome 22 in cells from human glioma correlate with resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Survival; Chromosomes, H | 2006 |
Over-representation of specific regions of chromosome 22 in cells from human glioma correlate with resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Survival; Chromosomes, H | 2006 |
O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells.
Topics: Antineoplastic Agents, Alkylating; bcl-X Protein; Carmustine; Cell Death; Cell Line, Tumor; Cell Sur | 2006 |
O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells.
Topics: Antineoplastic Agents, Alkylating; bcl-X Protein; Carmustine; Cell Death; Cell Line, Tumor; Cell Sur | 2006 |
O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells.
Topics: Antineoplastic Agents, Alkylating; bcl-X Protein; Carmustine; Cell Death; Cell Line, Tumor; Cell Sur | 2006 |
Interstitial transfer factor as adjuvant immunotherapy for experimental glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Carmustine; Cell Line, Tumor | 2005 |
Interstitial transfer factor as adjuvant immunotherapy for experimental glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Carmustine; Cell Line, Tumor | 2005 |
Interstitial transfer factor as adjuvant immunotherapy for experimental glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Carmustine; Cell Line, Tumor | 2005 |
Interstitial docetaxel (taxotere), carmustine and combined interstitial therapy: a novel treatment for experimental malignant glioma.
Topics: Absorbable Implants; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmu | 2006 |
Interstitial docetaxel (taxotere), carmustine and combined interstitial therapy: a novel treatment for experimental malignant glioma.
Topics: Absorbable Implants; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmu | 2006 |
Interstitial docetaxel (taxotere), carmustine and combined interstitial therapy: a novel treatment for experimental malignant glioma.
Topics: Absorbable Implants; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmu | 2006 |
Dynamic imaging of emerging resistance during cancer therapy.
Topics: Animals; Brain Neoplasms; Carmustine; Diffusion Magnetic Resonance Imaging; Drug Administration Sche | 2006 |
Dynamic imaging of emerging resistance during cancer therapy.
Topics: Animals; Brain Neoplasms; Carmustine; Diffusion Magnetic Resonance Imaging; Drug Administration Sche | 2006 |
Dynamic imaging of emerging resistance during cancer therapy.
Topics: Animals; Brain Neoplasms; Carmustine; Diffusion Magnetic Resonance Imaging; Drug Administration Sche | 2006 |
Predicting and monitoring response to chemotherapy by 1,3-bis(2-chloroethyl)-1-nitrosourea in subcutaneously implanted 9L glioma using the apparent diffusion coefficient of water and 23Na MRI.
Topics: Animals; Antineoplastic Agents, Alkylating; Carmustine; Cell Line, Tumor; Glioma; Magnetic Resonance | 2006 |
Predicting and monitoring response to chemotherapy by 1,3-bis(2-chloroethyl)-1-nitrosourea in subcutaneously implanted 9L glioma using the apparent diffusion coefficient of water and 23Na MRI.
Topics: Animals; Antineoplastic Agents, Alkylating; Carmustine; Cell Line, Tumor; Glioma; Magnetic Resonance | 2006 |
Predicting and monitoring response to chemotherapy by 1,3-bis(2-chloroethyl)-1-nitrosourea in subcutaneously implanted 9L glioma using the apparent diffusion coefficient of water and 23Na MRI.
Topics: Animals; Antineoplastic Agents, Alkylating; Carmustine; Cell Line, Tumor; Glioma; Magnetic Resonance | 2006 |
Role of p16 and p14ARF in radio- and chemosensitivity of malignant gliomas.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Carmustine; C | 2006 |
Role of p16 and p14ARF in radio- and chemosensitivity of malignant gliomas.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Carmustine; C | 2006 |
Role of p16 and p14ARF in radio- and chemosensitivity of malignant gliomas.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Carmustine; C | 2006 |
BCNU-loaded PEG-PLLA ultrafine fibers and their in vitro antitumor activity against Glioma C6 cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Carmustine; Cell Line, Tumor; Cell Survival; Drug Carrie | 2006 |
BCNU-loaded PEG-PLLA ultrafine fibers and their in vitro antitumor activity against Glioma C6 cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Carmustine; Cell Line, Tumor; Cell Survival; Drug Carrie | 2006 |
BCNU-loaded PEG-PLLA ultrafine fibers and their in vitro antitumor activity against Glioma C6 cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Carmustine; Cell Line, Tumor; Cell Survival; Drug Carrie | 2006 |
In vitro drug response and molecular markers associated with drug resistance in malignant gliomas.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member | 2006 |
In vitro drug response and molecular markers associated with drug resistance in malignant gliomas.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member | 2006 |
In vitro drug response and molecular markers associated with drug resistance in malignant gliomas.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member | 2006 |
Anticancer activity of extracts derived from the mature roots of Scutellaria baicalensis on human malignant brain tumor cells.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Cell Proliferation; Cell Survival; Drug Therapy, | 2006 |
Anticancer activity of extracts derived from the mature roots of Scutellaria baicalensis on human malignant brain tumor cells.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Cell Proliferation; Cell Survival; Drug Therapy, | 2006 |
Anticancer activity of extracts derived from the mature roots of Scutellaria baicalensis on human malignant brain tumor cells.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Cell Proliferation; Cell Survival; Drug Therapy, | 2006 |
Cotreatment with a novel phosphoinositide analogue inhibitor and carmustine enhances chemotherapeutic efficacy by attenuating AKT activity in gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Caspases; Cell Survival; Chemotherap | 2006 |
Cotreatment with a novel phosphoinositide analogue inhibitor and carmustine enhances chemotherapeutic efficacy by attenuating AKT activity in gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Caspases; Cell Survival; Chemotherap | 2006 |
Cotreatment with a novel phosphoinositide analogue inhibitor and carmustine enhances chemotherapeutic efficacy by attenuating AKT activity in gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Caspases; Cell Survival; Chemotherap | 2006 |
CXCR4 inhibition synergizes with cytotoxic chemotherapy in gliomas.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzylamines; Brain Neoplasms; C | 2006 |
CXCR4 inhibition synergizes with cytotoxic chemotherapy in gliomas.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzylamines; Brain Neoplasms; C | 2006 |
CXCR4 inhibition synergizes with cytotoxic chemotherapy in gliomas.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzylamines; Brain Neoplasms; C | 2006 |
[Local chemotherapy for brain tumors].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Drug Implants; Glioma; Humans | 2006 |
[Local chemotherapy for brain tumors].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Drug Implants; Glioma; Humans | 2006 |
[Local chemotherapy for brain tumors].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Drug Implants; Glioma; Humans | 2006 |
The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Line, Tumor; Curcumin; Dacarbaz | 2007 |
The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Line, Tumor; Curcumin; Dacarbaz | 2007 |
The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cell Line, Tumor; Curcumin; Dacarbaz | 2007 |
Enantioselectivity of thalidomide serum and tissue concentrations in a rat glioma model and effects of combination treatment with cisplatin and BCNU.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplati | 2007 |
Enantioselectivity of thalidomide serum and tissue concentrations in a rat glioma model and effects of combination treatment with cisplatin and BCNU.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplati | 2007 |
Enantioselectivity of thalidomide serum and tissue concentrations in a rat glioma model and effects of combination treatment with cisplatin and BCNU.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplati | 2007 |
Imaging response in malignant glioma, RTOG 90-06.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Biopsy; Brain Neoplasms; Carmustine; Disease Progres | 2007 |
Imaging response in malignant glioma, RTOG 90-06.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Biopsy; Brain Neoplasms; Carmustine; Disease Progres | 2007 |
Imaging response in malignant glioma, RTOG 90-06.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Biopsy; Brain Neoplasms; Carmustine; Disease Progres | 2007 |
Cellular and functional characterization of immunoresistant human glioma cell clones selected with alloreactive cytotoxic T lymphocytes reveals their up-regulated synthesis of biologically active TGF-beta.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Calcium; Carmustine; Cell Adhesion; C | 2007 |
Cellular and functional characterization of immunoresistant human glioma cell clones selected with alloreactive cytotoxic T lymphocytes reveals their up-regulated synthesis of biologically active TGF-beta.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Calcium; Carmustine; Cell Adhesion; C | 2007 |
Cellular and functional characterization of immunoresistant human glioma cell clones selected with alloreactive cytotoxic T lymphocytes reveals their up-regulated synthesis of biologically active TGF-beta.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Calcium; Carmustine; Cell Adhesion; C | 2007 |
Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Cell Line, Tumor; Chemokine CCL2; Chemokine CCL2 | 2008 |
Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Cell Line, Tumor; Chemokine CCL2; Chemokine CCL2 | 2008 |
Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Cell Line, Tumor; Chemokine CCL2; Chemokine CCL2 | 2008 |
Carmustine implants for the treatment of newly diagnosed high-grade gliomas: a cost-utility analysis.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Cohort Studies; Cost-Ben | 2008 |
Carmustine implants for the treatment of newly diagnosed high-grade gliomas: a cost-utility analysis.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Cohort Studies; Cost-Ben | 2008 |
Carmustine implants for the treatment of newly diagnosed high-grade gliomas: a cost-utility analysis.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Cohort Studies; Cost-Ben | 2008 |
Nitrosourea efficacy in high-grade glioma: a survival gain analysis summarizing 504 cohorts with 24193 patients.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; | 2008 |
Nitrosourea efficacy in high-grade glioma: a survival gain analysis summarizing 504 cohorts with 24193 patients.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; | 2008 |
Nitrosourea efficacy in high-grade glioma: a survival gain analysis summarizing 504 cohorts with 24193 patients.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; | 2008 |
Age-related chemosensitivity of stem cells from human malignant brain tumours.
Topics: Age Factors; Aged; Astrocytoma; Brain Neoplasms; Carmustine; Cell Survival; DNA Repair; Glioblastoma | 1982 |
Age-related chemosensitivity of stem cells from human malignant brain tumours.
Topics: Age Factors; Aged; Astrocytoma; Brain Neoplasms; Carmustine; Cell Survival; DNA Repair; Glioblastoma | 1982 |
Age-related chemosensitivity of stem cells from human malignant brain tumours.
Topics: Age Factors; Aged; Astrocytoma; Brain Neoplasms; Carmustine; Cell Survival; DNA Repair; Glioblastoma | 1982 |
Post-treatment kinetics of BCNU in a 9L rat brain tumor model.
Topics: Animals; Brain Neoplasms; Carmustine; Glioma; Kinetics; Male; Neoplasms, Experimental; Rats | 1981 |
Post-treatment kinetics of BCNU in a 9L rat brain tumor model.
Topics: Animals; Brain Neoplasms; Carmustine; Glioma; Kinetics; Male; Neoplasms, Experimental; Rats | 1981 |
Post-treatment kinetics of BCNU in a 9L rat brain tumor model.
Topics: Animals; Brain Neoplasms; Carmustine; Glioma; Kinetics; Male; Neoplasms, Experimental; Rats | 1981 |
[High-dose chemotherapy with autologous bone marrow rescue for malignant brain tumors (author's transl)].
Topics: Antineoplastic Agents; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Child; Glioma; Huma | 1982 |
[High-dose chemotherapy with autologous bone marrow rescue for malignant brain tumors (author's transl)].
Topics: Antineoplastic Agents; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Child; Glioma; Huma | 1982 |
[High-dose chemotherapy with autologous bone marrow rescue for malignant brain tumors (author's transl)].
Topics: Antineoplastic Agents; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Child; Glioma; Huma | 1982 |
[Effect of perfluorochemicals on BCNU chemotherapy in a 9L rat brain tumor model].
Topics: Animals; Brain Neoplasms; Carmustine; Drug Therapy, Combination; Fluorocarbons; Glioma; Male; Neopla | 1982 |
[Effect of perfluorochemicals on BCNU chemotherapy in a 9L rat brain tumor model].
Topics: Animals; Brain Neoplasms; Carmustine; Drug Therapy, Combination; Fluorocarbons; Glioma; Male; Neopla | 1982 |
[Effect of perfluorochemicals on BCNU chemotherapy in a 9L rat brain tumor model].
Topics: Animals; Brain Neoplasms; Carmustine; Drug Therapy, Combination; Fluorocarbons; Glioma; Male; Neopla | 1982 |
[Chemotherapy of experimental meningeal gliomatosis].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain; Carmustine; Glioma; Male; | 1984 |
[Chemotherapy of experimental meningeal gliomatosis].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain; Carmustine; Glioma; Male; | 1984 |
[Chemotherapy of experimental meningeal gliomatosis].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain; Carmustine; Glioma; Male; | 1984 |
Interferon as adjuvant therapy with initial radiotherapy of patients with anaplastic gliomas.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Combined Modality Therapy; Glioma; Humans; Interferons; Mi | 1984 |
Interferon as adjuvant therapy with initial radiotherapy of patients with anaplastic gliomas.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Combined Modality Therapy; Glioma; Humans; Interferons; Mi | 1984 |
Interferon as adjuvant therapy with initial radiotherapy of patients with anaplastic gliomas.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Combined Modality Therapy; Glioma; Humans; Interferons; Mi | 1984 |
Treatment of five subcutaneous human glioma tumor lines in athymic mice with carmustine, procarbazine, and mithramycin.
Topics: Animals; Carmustine; Disease Models, Animal; Drug Therapy, Combination; Glioma; Humans; Mice; Mice, | 1983 |
Treatment of five subcutaneous human glioma tumor lines in athymic mice with carmustine, procarbazine, and mithramycin.
Topics: Animals; Carmustine; Disease Models, Animal; Drug Therapy, Combination; Glioma; Humans; Mice; Mice, | 1983 |
Treatment of five subcutaneous human glioma tumor lines in athymic mice with carmustine, procarbazine, and mithramycin.
Topics: Animals; Carmustine; Disease Models, Animal; Drug Therapy, Combination; Glioma; Humans; Mice; Mice, | 1983 |
Biology of gliomas: potential clinical implications of glioma cellular heterogeneity.
Topics: Adult; Aged; Animals; Brain Neoplasms; Carmustine; Cell Line; Female; Glioblastoma; Glioma; Humans; | 1981 |
Biology of gliomas: potential clinical implications of glioma cellular heterogeneity.
Topics: Adult; Aged; Animals; Brain Neoplasms; Carmustine; Cell Line; Female; Glioblastoma; Glioma; Humans; | 1981 |
Biology of gliomas: potential clinical implications of glioma cellular heterogeneity.
Topics: Adult; Aged; Animals; Brain Neoplasms; Carmustine; Cell Line; Female; Glioblastoma; Glioma; Humans; | 1981 |
Evaluation of the lipid-soluble diaminopyrimidines, metoprine and etoprine, in the avian sarcoma virus rat glioma model.
Topics: Animals; Antineoplastic Agents; Avian Sarcoma Viruses; Carmustine; Drug Therapy, Combination; Glioma | 1982 |
Evaluation of the lipid-soluble diaminopyrimidines, metoprine and etoprine, in the avian sarcoma virus rat glioma model.
Topics: Animals; Antineoplastic Agents; Avian Sarcoma Viruses; Carmustine; Drug Therapy, Combination; Glioma | 1982 |
Evaluation of the lipid-soluble diaminopyrimidines, metoprine and etoprine, in the avian sarcoma virus rat glioma model.
Topics: Animals; Antineoplastic Agents; Avian Sarcoma Viruses; Carmustine; Drug Therapy, Combination; Glioma | 1982 |
Clinical toxicity of combined modality treatment with nitrosourea derivatives for central nervous system tumors.
Topics: Bone Marrow Diseases; Brain Neoplasms; Carmustine; Gastrointestinal Diseases; Glioblastoma; Glioma; | 1982 |
Clinical toxicity of combined modality treatment with nitrosourea derivatives for central nervous system tumors.
Topics: Bone Marrow Diseases; Brain Neoplasms; Carmustine; Gastrointestinal Diseases; Glioblastoma; Glioma; | 1982 |
Clinical toxicity of combined modality treatment with nitrosourea derivatives for central nervous system tumors.
Topics: Bone Marrow Diseases; Brain Neoplasms; Carmustine; Gastrointestinal Diseases; Glioblastoma; Glioma; | 1982 |
[Kinetics of multicellular spheroids developed from a human glioblastoma, and effect of 1,3-bis (2-chloroethyl)-1-nitrosourea].
Topics: Brain Neoplasms; Carmustine; Cell Division; Cells, Cultured; Glioma; Humans; Kinetics | 1983 |
[Kinetics of multicellular spheroids developed from a human glioblastoma, and effect of 1,3-bis (2-chloroethyl)-1-nitrosourea].
Topics: Brain Neoplasms; Carmustine; Cell Division; Cells, Cultured; Glioma; Humans; Kinetics | 1983 |
[Kinetics of multicellular spheroids developed from a human glioblastoma, and effect of 1,3-bis (2-chloroethyl)-1-nitrosourea].
Topics: Brain Neoplasms; Carmustine; Cell Division; Cells, Cultured; Glioma; Humans; Kinetics | 1983 |
Intraarterial 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and systemic chemotherapy for malignant gliomas: a follow-up study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 1983 |
Intraarterial 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and systemic chemotherapy for malignant gliomas: a follow-up study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 1983 |
Intraarterial 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and systemic chemotherapy for malignant gliomas: a follow-up study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 1983 |
Megadose chemotherapy with bone marrow rescue.
Topics: Animals; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Combined Modality Therapy; Glioma | 1984 |
Megadose chemotherapy with bone marrow rescue.
Topics: Animals; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Combined Modality Therapy; Glioma | 1984 |
Megadose chemotherapy with bone marrow rescue.
Topics: Animals; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Combined Modality Therapy; Glioma | 1984 |
Feasibility study of combining metronidazole with chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Carcinoma, Sq | 1983 |
Feasibility study of combining metronidazole with chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Carcinoma, Sq | 1983 |
Feasibility study of combining metronidazole with chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Carcinoma, Sq | 1983 |
Combination radiofrequency hyperthermia and chemotherapy (BCNU) for brain malignancy. Animal experience and two case reports.
Topics: Animals; Brain Neoplasms; Carmustine; Chordoma; Combined Modality Therapy; Diathermy; Female; Fronta | 1984 |
Combination radiofrequency hyperthermia and chemotherapy (BCNU) for brain malignancy. Animal experience and two case reports.
Topics: Animals; Brain Neoplasms; Carmustine; Chordoma; Combined Modality Therapy; Diathermy; Female; Fronta | 1984 |
Combination radiofrequency hyperthermia and chemotherapy (BCNU) for brain malignancy. Animal experience and two case reports.
Topics: Animals; Brain Neoplasms; Carmustine; Chordoma; Combined Modality Therapy; Diathermy; Female; Fronta | 1984 |
Complications associated with intra-arterial BCNU administered in combination with vincristine and procarbazine for the treatment of malignant brain tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 1984 |
Complications associated with intra-arterial BCNU administered in combination with vincristine and procarbazine for the treatment of malignant brain tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 1984 |
Complications associated with intra-arterial BCNU administered in combination with vincristine and procarbazine for the treatment of malignant brain tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 1984 |
Heterogeneity of tumor cell DNA content.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Cycle; DNA, Neoplasm; Flow Cytometry; Glioma; Humans; Tum | 1984 |
Heterogeneity of tumor cell DNA content.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Cycle; DNA, Neoplasm; Flow Cytometry; Glioma; Humans; Tum | 1984 |
Heterogeneity of tumor cell DNA content.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Cycle; DNA, Neoplasm; Flow Cytometry; Glioma; Humans; Tum | 1984 |
Combination therapy with 1,3-bis(2-chloroethyl)-1-nitrosourea and low dose rate radiation in the 9L rat brain tumor and spheroid models: implications for brain tumor brachytherapy.
Topics: Animals; Brachytherapy; Brain Neoplasms; Carmustine; Combined Modality Therapy; Frontal Lobe; Glioma | 1984 |
Combination therapy with 1,3-bis(2-chloroethyl)-1-nitrosourea and low dose rate radiation in the 9L rat brain tumor and spheroid models: implications for brain tumor brachytherapy.
Topics: Animals; Brachytherapy; Brain Neoplasms; Carmustine; Combined Modality Therapy; Frontal Lobe; Glioma | 1984 |
Combination therapy with 1,3-bis(2-chloroethyl)-1-nitrosourea and low dose rate radiation in the 9L rat brain tumor and spheroid models: implications for brain tumor brachytherapy.
Topics: Animals; Brachytherapy; Brain Neoplasms; Carmustine; Combined Modality Therapy; Frontal Lobe; Glioma | 1984 |
[Meningeal gliomatosis models as a chemosensitivity assay system].
Topics: Animals; Antineoplastic Agents; Carmustine; Cell Division; Cell Survival; Disease Models, Animal; Dr | 1984 |
[Meningeal gliomatosis models as a chemosensitivity assay system].
Topics: Animals; Antineoplastic Agents; Carmustine; Cell Division; Cell Survival; Disease Models, Animal; Dr | 1984 |
[Meningeal gliomatosis models as a chemosensitivity assay system].
Topics: Animals; Antineoplastic Agents; Carmustine; Cell Division; Cell Survival; Disease Models, Animal; Dr | 1984 |
Malignant anorexia after nitrosourea therapy: case report.
Topics: Adult; Anorexia; Brain Neoplasms; Carmustine; Feeding and Eating Disorders; Glioma; Humans; Male | 1984 |
Malignant anorexia after nitrosourea therapy: case report.
Topics: Adult; Anorexia; Brain Neoplasms; Carmustine; Feeding and Eating Disorders; Glioma; Humans; Male | 1984 |
Malignant anorexia after nitrosourea therapy: case report.
Topics: Adult; Anorexia; Brain Neoplasms; Carmustine; Feeding and Eating Disorders; Glioma; Humans; Male | 1984 |
New therapeutic approaches to treatment of malignant gliomas: chemotherapy and immunotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Blood-Brain Barrier; Brain Neoplasms; C | 1983 |
New therapeutic approaches to treatment of malignant gliomas: chemotherapy and immunotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Blood-Brain Barrier; Brain Neoplasms; C | 1983 |
New therapeutic approaches to treatment of malignant gliomas: chemotherapy and immunotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Blood-Brain Barrier; Brain Neoplasms; C | 1983 |
Human brain tumor xenografts in nude mice as a chemotherapy model.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carmustine; Disease Models, Animal; Glioma; Humans; | 1983 |
Human brain tumor xenografts in nude mice as a chemotherapy model.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carmustine; Disease Models, Animal; Glioma; Humans; | 1983 |
Human brain tumor xenografts in nude mice as a chemotherapy model.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carmustine; Disease Models, Animal; Glioma; Humans; | 1983 |
Intracerebral growth of a human glioma tumor line in athymic mice and treatment with procarbazine, 1,3-bis(2-chloroethyl)-1-nitrosourea, aziridinylbenzoquinone, and cis-platinum.
Topics: Animals; Antineoplastic Agents; Aziridines; Azirines; Benzoquinones; Brain Neoplasms; Carmustine; Ce | 1983 |
Intracerebral growth of a human glioma tumor line in athymic mice and treatment with procarbazine, 1,3-bis(2-chloroethyl)-1-nitrosourea, aziridinylbenzoquinone, and cis-platinum.
Topics: Animals; Antineoplastic Agents; Aziridines; Azirines; Benzoquinones; Brain Neoplasms; Carmustine; Ce | 1983 |
Intracerebral growth of a human glioma tumor line in athymic mice and treatment with procarbazine, 1,3-bis(2-chloroethyl)-1-nitrosourea, aziridinylbenzoquinone, and cis-platinum.
Topics: Animals; Antineoplastic Agents; Aziridines; Azirines; Benzoquinones; Brain Neoplasms; Carmustine; Ce | 1983 |
Intra-arterial BCNU chemotherapy for treatment of malignant gliomas of the central nervous system.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Injections, Intra-Arterial; Male; | 1984 |
Intra-arterial BCNU chemotherapy for treatment of malignant gliomas of the central nervous system.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Injections, Intra-Arterial; Male; | 1984 |
Intra-arterial BCNU chemotherapy for treatment of malignant gliomas of the central nervous system.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Injections, Intra-Arterial; Male; | 1984 |
Sensitization of 9L rat brain gliosarcoma cells to 1,3-bis(2-chloroethyl)-1-nitrosourea by alpha-difluoromethylornithine, an ornithine decarboxylase inhibitor.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Cycle; Cell Line; Cell Survival; Dose-Response Relationsh | 1981 |
Sensitization of 9L rat brain gliosarcoma cells to 1,3-bis(2-chloroethyl)-1-nitrosourea by alpha-difluoromethylornithine, an ornithine decarboxylase inhibitor.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Cycle; Cell Line; Cell Survival; Dose-Response Relationsh | 1981 |
Sensitization of 9L rat brain gliosarcoma cells to 1,3-bis(2-chloroethyl)-1-nitrosourea by alpha-difluoromethylornithine, an ornithine decarboxylase inhibitor.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Cycle; Cell Line; Cell Survival; Dose-Response Relationsh | 1981 |
Improved treatment of a brain-tumor model. Part 2: Sequential therapy with BCNU and 5-fluorouracil.
Topics: Animals; Brain Neoplasms; Carmustine; Clone Cells; Disease Models, Animal; Drug Therapy, Combination | 1983 |
Improved treatment of a brain-tumor model. Part 2: Sequential therapy with BCNU and 5-fluorouracil.
Topics: Animals; Brain Neoplasms; Carmustine; Clone Cells; Disease Models, Animal; Drug Therapy, Combination | 1983 |
Improved treatment of a brain-tumor model. Part 2: Sequential therapy with BCNU and 5-fluorouracil.
Topics: Animals; Brain Neoplasms; Carmustine; Clone Cells; Disease Models, Animal; Drug Therapy, Combination | 1983 |
Stem cell studies of human malignant brain tumors. Part 1: Development of the stem cell assay and its potential.
Topics: Biological Assay; Brain Neoplasms; Carmustine; Clone Cells; Drug Resistance; Glioma; Humans | 1983 |
Stem cell studies of human malignant brain tumors. Part 1: Development of the stem cell assay and its potential.
Topics: Biological Assay; Brain Neoplasms; Carmustine; Clone Cells; Drug Resistance; Glioma; Humans | 1983 |
Stem cell studies of human malignant brain tumors. Part 1: Development of the stem cell assay and its potential.
Topics: Biological Assay; Brain Neoplasms; Carmustine; Clone Cells; Drug Resistance; Glioma; Humans | 1983 |
Solvent systems for intracarotid 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) infusion.
Topics: Brain Neoplasms; Carmustine; Glioma; Humans; Infusions, Intra-Arterial; Osmolar Concentration; Solub | 1983 |
Solvent systems for intracarotid 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) infusion.
Topics: Brain Neoplasms; Carmustine; Glioma; Humans; Infusions, Intra-Arterial; Osmolar Concentration; Solub | 1983 |
Solvent systems for intracarotid 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) infusion.
Topics: Brain Neoplasms; Carmustine; Glioma; Humans; Infusions, Intra-Arterial; Osmolar Concentration; Solub | 1983 |
Radiation and drug response of the rat glioma RG2.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Line; Cell Survival; Drug Resistance; Glioma; Male; Neopl | 1982 |
Radiation and drug response of the rat glioma RG2.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Line; Cell Survival; Drug Resistance; Glioma; Male; Neopl | 1982 |
Radiation and drug response of the rat glioma RG2.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Line; Cell Survival; Drug Resistance; Glioma; Male; Neopl | 1982 |
Rational planning of brain tumour therapy based on laboratory investigations: comparison of single- and multiple-dose BCNU schedules.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Survival; Drug Administration Schedule; Glioma; Humans; N | 1980 |
Rational planning of brain tumour therapy based on laboratory investigations: comparison of single- and multiple-dose BCNU schedules.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Survival; Drug Administration Schedule; Glioma; Humans; N | 1980 |
Rational planning of brain tumour therapy based on laboratory investigations: comparison of single- and multiple-dose BCNU schedules.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Survival; Drug Administration Schedule; Glioma; Humans; N | 1980 |
Proper analysis of clinical trials for malignant glioma.
Topics: Carmustine; Glioma; Humans; Lomustine; Methods; Statistics as Topic | 1982 |
Proper analysis of clinical trials for malignant glioma.
Topics: Carmustine; Glioma; Humans; Lomustine; Methods; Statistics as Topic | 1982 |
Proper analysis of clinical trials for malignant glioma.
Topics: Carmustine; Glioma; Humans; Lomustine; Methods; Statistics as Topic | 1982 |
Potentiation of carmustine-cranial irradiation-induced myelosuppression by cimetidine.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Cimetidine; Drug Synergism; Female; Glioma; Guanidines; He | 1982 |
Potentiation of carmustine-cranial irradiation-induced myelosuppression by cimetidine.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Cimetidine; Drug Synergism; Female; Glioma; Guanidines; He | 1982 |
Potentiation of carmustine-cranial irradiation-induced myelosuppression by cimetidine.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Cimetidine; Drug Synergism; Female; Glioma; Guanidines; He | 1982 |
Combined modality treatment using radiation and/or chemotherapy in an athymic nude mouse-human medulloblastoma and glioblastoma xenograft model.
Topics: Animals; Aziridines; Benzoquinones; Brain Neoplasms; Carmustine; Cell Line; Glioma; Humans; Medullob | 1982 |
Combined modality treatment using radiation and/or chemotherapy in an athymic nude mouse-human medulloblastoma and glioblastoma xenograft model.
Topics: Animals; Aziridines; Benzoquinones; Brain Neoplasms; Carmustine; Cell Line; Glioma; Humans; Medullob | 1982 |
Combined modality treatment using radiation and/or chemotherapy in an athymic nude mouse-human medulloblastoma and glioblastoma xenograft model.
Topics: Animals; Aziridines; Benzoquinones; Brain Neoplasms; Carmustine; Cell Line; Glioma; Humans; Medullob | 1982 |
Malignant glioma. Results of combined modality therapy.
Topics: Adult; Aged; Anaplasia; Brain; Brain Neoplasms; Carmustine; Glioma; Humans; Middle Aged; Postoperati | 1982 |
Malignant glioma. Results of combined modality therapy.
Topics: Adult; Aged; Anaplasia; Brain; Brain Neoplasms; Carmustine; Glioma; Humans; Middle Aged; Postoperati | 1982 |
Malignant glioma. Results of combined modality therapy.
Topics: Adult; Aged; Anaplasia; Brain; Brain Neoplasms; Carmustine; Glioma; Humans; Middle Aged; Postoperati | 1982 |
Combination carmustine (BCNU) and dianhydrogalactitol in the treatment of primary brain tumors recurring after irradiation.
Topics: Adult; Aged; Astrocytoma; Brain Neoplasms; Carmustine; Dianhydrogalactitol; Drug Therapy, Combinatio | 1982 |
Combination carmustine (BCNU) and dianhydrogalactitol in the treatment of primary brain tumors recurring after irradiation.
Topics: Adult; Aged; Astrocytoma; Brain Neoplasms; Carmustine; Dianhydrogalactitol; Drug Therapy, Combinatio | 1982 |
Combination carmustine (BCNU) and dianhydrogalactitol in the treatment of primary brain tumors recurring after irradiation.
Topics: Adult; Aged; Astrocytoma; Brain Neoplasms; Carmustine; Dianhydrogalactitol; Drug Therapy, Combinatio | 1982 |
Limitations of high dose intra-arterial 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) chemotherapy for malignant gliomas.
Topics: Brain Neoplasms; Carmustine; Carotid Arteries; Female; Glioma; Humans; Infusions, Intra-Arterial; Ma | 1982 |
Limitations of high dose intra-arterial 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) chemotherapy for malignant gliomas.
Topics: Brain Neoplasms; Carmustine; Carotid Arteries; Female; Glioma; Humans; Infusions, Intra-Arterial; Ma | 1982 |
Limitations of high dose intra-arterial 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) chemotherapy for malignant gliomas.
Topics: Brain Neoplasms; Carmustine; Carotid Arteries; Female; Glioma; Humans; Infusions, Intra-Arterial; Ma | 1982 |
[Effect of perfluorochemicals on BCNU chemotherapy in a rat brain-tumor model].
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carmustine; Drug Synergism; Fluorocarbons; Glioma; | 1982 |
[Effect of perfluorochemicals on BCNU chemotherapy in a rat brain-tumor model].
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carmustine; Drug Synergism; Fluorocarbons; Glioma; | 1982 |
[Effect of perfluorochemicals on BCNU chemotherapy in a rat brain-tumor model].
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carmustine; Drug Synergism; Fluorocarbons; Glioma; | 1982 |
Effect of perfluorochemicals on BCNU chemotherapy: preliminary study in a rat brain tumor model.
Topics: Animals; Brain; Brain Neoplasms; Carmustine; Drug Combinations; Drug Therapy, Combination; Fluorocar | 1982 |
Effect of perfluorochemicals on BCNU chemotherapy: preliminary study in a rat brain tumor model.
Topics: Animals; Brain; Brain Neoplasms; Carmustine; Drug Combinations; Drug Therapy, Combination; Fluorocar | 1982 |
Effect of perfluorochemicals on BCNU chemotherapy: preliminary study in a rat brain tumor model.
Topics: Animals; Brain; Brain Neoplasms; Carmustine; Drug Combinations; Drug Therapy, Combination; Fluorocar | 1982 |
Heterogeneous chemosensitivities of subpopulations of human glioma cells in culture.
Topics: Carmustine; Cell Division; Cell Line; Cell Survival; Cisplatin; Colony-Forming Units Assay; Dose-Res | 1982 |
Heterogeneous chemosensitivities of subpopulations of human glioma cells in culture.
Topics: Carmustine; Cell Division; Cell Line; Cell Survival; Cisplatin; Colony-Forming Units Assay; Dose-Res | 1982 |
Heterogeneous chemosensitivities of subpopulations of human glioma cells in culture.
Topics: Carmustine; Cell Division; Cell Line; Cell Survival; Cisplatin; Colony-Forming Units Assay; Dose-Res | 1982 |
The use of cisplatinum for treatment of malignant glioma.
Topics: Brain Neoplasms; Carmustine; Cisplatin; Glioma; Humans; Male; Middle Aged; Tomography, X-Ray Compute | 1982 |
The use of cisplatinum for treatment of malignant glioma.
Topics: Brain Neoplasms; Carmustine; Cisplatin; Glioma; Humans; Male; Middle Aged; Tomography, X-Ray Compute | 1982 |
The use of cisplatinum for treatment of malignant glioma.
Topics: Brain Neoplasms; Carmustine; Cisplatin; Glioma; Humans; Male; Middle Aged; Tomography, X-Ray Compute | 1982 |
Combined cyclotron fast-neutron and BCNU therapy in a rat brain-tumor model.
Topics: Animals; Brain Neoplasms; Carmustine; Disease Models, Animal; Dose-Response Relationship, Drug; Dose | 1981 |
Combined cyclotron fast-neutron and BCNU therapy in a rat brain-tumor model.
Topics: Animals; Brain Neoplasms; Carmustine; Disease Models, Animal; Dose-Response Relationship, Drug; Dose | 1981 |
Combined cyclotron fast-neutron and BCNU therapy in a rat brain-tumor model.
Topics: Animals; Brain Neoplasms; Carmustine; Disease Models, Animal; Dose-Response Relationship, Drug; Dose | 1981 |
1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU)-induced pulmonary fibrosis.
Topics: Adolescent; Adult; Aged; Biopsy; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Lung; Male; Mi | 1980 |
1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU)-induced pulmonary fibrosis.
Topics: Adolescent; Adult; Aged; Biopsy; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Lung; Male; Mi | 1980 |
1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU)-induced pulmonary fibrosis.
Topics: Adolescent; Adult; Aged; Biopsy; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Lung; Male; Mi | 1980 |
Chemosensitivity testing for human brain tumors.
Topics: Brain Neoplasms; Carmustine; Cell Separation; Cell Survival; Clone Cells; Glioma; Humans | 1980 |
Chemosensitivity testing for human brain tumors.
Topics: Brain Neoplasms; Carmustine; Cell Separation; Cell Survival; Clone Cells; Glioma; Humans | 1980 |
Chemosensitivity testing for human brain tumors.
Topics: Brain Neoplasms; Carmustine; Cell Separation; Cell Survival; Clone Cells; Glioma; Humans | 1980 |
Growth and chemotherapeutic response in athymic mice of tumors arising from human glioma-derived cell lines.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Line; Disease Models, Animal; Glioma; Mice; Mice, Nude; N | 1981 |
Growth and chemotherapeutic response in athymic mice of tumors arising from human glioma-derived cell lines.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Line; Disease Models, Animal; Glioma; Mice; Mice, Nude; N | 1981 |
Growth and chemotherapeutic response in athymic mice of tumors arising from human glioma-derived cell lines.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Line; Disease Models, Animal; Glioma; Mice; Mice, Nude; N | 1981 |
Heterogeneous response to chemotherapy of human gliomas grown in nude mice and as clones in vitro.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Line; Clone Cells; Glioma; Humans; Kinetics; Mice; Mice, | 1981 |
Heterogeneous response to chemotherapy of human gliomas grown in nude mice and as clones in vitro.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Line; Clone Cells; Glioma; Humans; Kinetics; Mice; Mice, | 1981 |
Heterogeneous response to chemotherapy of human gliomas grown in nude mice and as clones in vitro.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Line; Clone Cells; Glioma; Humans; Kinetics; Mice; Mice, | 1981 |
Potentials and limitations of a clonogenic cell assay for human brain tumors.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Cells, Cultured; Clone Cells; Dose-Response Relationship, | 1981 |
Potentials and limitations of a clonogenic cell assay for human brain tumors.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Cells, Cultured; Clone Cells; Dose-Response Relationship, | 1981 |
Potentials and limitations of a clonogenic cell assay for human brain tumors.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Cells, Cultured; Clone Cells; Dose-Response Relationship, | 1981 |
Prediction of BCNU pulmonary toxicity in patients with malignant gliomas: an assessment of risk factors.
Topics: Adult; Analysis of Variance; Bone Marrow; Carmustine; Child; Drug Therapy, Combination; Female; Glio | 1980 |
Prediction of BCNU pulmonary toxicity in patients with malignant gliomas: an assessment of risk factors.
Topics: Adult; Analysis of Variance; Bone Marrow; Carmustine; Child; Drug Therapy, Combination; Female; Glio | 1980 |
Prediction of BCNU pulmonary toxicity in patients with malignant gliomas: an assessment of risk factors.
Topics: Adult; Analysis of Variance; Bone Marrow; Carmustine; Child; Drug Therapy, Combination; Female; Glio | 1980 |
Treatment of autochthonous rat brain tumors with fractionated radiotherapy. The effects of graded radiation doses and of combined therapy with BCNU or steroids.
Topics: Animals; Brain Neoplasms; Carmustine; Disease Models, Animal; Glioma; Methylprednisolone; Neoplasms, | 1980 |
Treatment of autochthonous rat brain tumors with fractionated radiotherapy. The effects of graded radiation doses and of combined therapy with BCNU or steroids.
Topics: Animals; Brain Neoplasms; Carmustine; Disease Models, Animal; Glioma; Methylprednisolone; Neoplasms, | 1980 |
Treatment of autochthonous rat brain tumors with fractionated radiotherapy. The effects of graded radiation doses and of combined therapy with BCNU or steroids.
Topics: Animals; Brain Neoplasms; Carmustine; Disease Models, Animal; Glioma; Methylprednisolone; Neoplasms, | 1980 |
Response of cultured human brain tumors to nitrosoureas: correlation with clinical data.
Topics: Adult; Brain Neoplasms; Carmustine; Cells, Cultured; Drug Evaluation, Preclinical; Female; Glioma; H | 1981 |
Response of cultured human brain tumors to nitrosoureas: correlation with clinical data.
Topics: Adult; Brain Neoplasms; Carmustine; Cells, Cultured; Drug Evaluation, Preclinical; Female; Glioma; H | 1981 |
Response of cultured human brain tumors to nitrosoureas: correlation with clinical data.
Topics: Adult; Brain Neoplasms; Carmustine; Cells, Cultured; Drug Evaluation, Preclinical; Female; Glioma; H | 1981 |
Effect of pharmacologic doses of zinc on the therapeutic index of brain tumor chemotherapy with carmustine.
Topics: Animals; Bone Marrow; Brain Neoplasms; Carmustine; Cell Division; Dose-Response Relationship, Drug; | 1994 |
Effect of pharmacologic doses of zinc on the therapeutic index of brain tumor chemotherapy with carmustine.
Topics: Animals; Bone Marrow; Brain Neoplasms; Carmustine; Cell Division; Dose-Response Relationship, Drug; | 1994 |
Effect of pharmacologic doses of zinc on the therapeutic index of brain tumor chemotherapy with carmustine.
Topics: Animals; Bone Marrow; Brain Neoplasms; Carmustine; Cell Division; Dose-Response Relationship, Drug; | 1994 |
Contribution of O6-methylguanine-DNA methyltransferase to resistance to 1,3-(2-chloroethyl)-1-nitrosourea in human brain tumor-derived cell lines.
Topics: Brain Neoplasms; Carmustine; Cell Adhesion; Colonic Neoplasms; Culture Media; Drug Resistance; Drug | 1995 |
Contribution of O6-methylguanine-DNA methyltransferase to resistance to 1,3-(2-chloroethyl)-1-nitrosourea in human brain tumor-derived cell lines.
Topics: Brain Neoplasms; Carmustine; Cell Adhesion; Colonic Neoplasms; Culture Media; Drug Resistance; Drug | 1995 |
Contribution of O6-methylguanine-DNA methyltransferase to resistance to 1,3-(2-chloroethyl)-1-nitrosourea in human brain tumor-derived cell lines.
Topics: Brain Neoplasms; Carmustine; Cell Adhesion; Colonic Neoplasms; Culture Media; Drug Resistance; Drug | 1995 |
O6-methylguanine-DNA methyltransferase in tumors and cells of the oligodendrocyte lineage.
Topics: Adult; Animals; Astrocytes; Brain Neoplasms; Carmustine; Cell Differentiation; Cell Survival; Female | 1995 |
O6-methylguanine-DNA methyltransferase in tumors and cells of the oligodendrocyte lineage.
Topics: Adult; Animals; Astrocytes; Brain Neoplasms; Carmustine; Cell Differentiation; Cell Survival; Female | 1995 |
O6-methylguanine-DNA methyltransferase in tumors and cells of the oligodendrocyte lineage.
Topics: Adult; Animals; Astrocytes; Brain Neoplasms; Carmustine; Cell Differentiation; Cell Survival; Female | 1995 |
Formation and repair of 1,3-bis-(2-chloroethyl)-1-nitrosourea and cisplatin induced total genomic DNA interstrand crosslinks in human glioma cells.
Topics: Carmustine; Cisplatin; Cross-Linking Reagents; DNA; DNA Damage; DNA Repair; DNA, Neoplasm; Drug Resi | 1995 |
Formation and repair of 1,3-bis-(2-chloroethyl)-1-nitrosourea and cisplatin induced total genomic DNA interstrand crosslinks in human glioma cells.
Topics: Carmustine; Cisplatin; Cross-Linking Reagents; DNA; DNA Damage; DNA Repair; DNA, Neoplasm; Drug Resi | 1995 |
Formation and repair of 1,3-bis-(2-chloroethyl)-1-nitrosourea and cisplatin induced total genomic DNA interstrand crosslinks in human glioma cells.
Topics: Carmustine; Cisplatin; Cross-Linking Reagents; DNA; DNA Damage; DNA Repair; DNA, Neoplasm; Drug Resi | 1995 |
In vivo enhanced antitumor activity of carmustine [N,N'-bis(2-chloroethyl)-N-nitrosourea] by simvastatin.
Topics: Animals; Astrocytoma; Carmustine; Cell Cycle; Cell Division; Cell Line; DNA, Neoplasm; Drug Synergis | 1995 |
In vivo enhanced antitumor activity of carmustine [N,N'-bis(2-chloroethyl)-N-nitrosourea] by simvastatin.
Topics: Animals; Astrocytoma; Carmustine; Cell Cycle; Cell Division; Cell Line; DNA, Neoplasm; Drug Synergis | 1995 |
In vivo enhanced antitumor activity of carmustine [N,N'-bis(2-chloroethyl)-N-nitrosourea] by simvastatin.
Topics: Animals; Astrocytoma; Carmustine; Cell Cycle; Cell Division; Cell Line; DNA, Neoplasm; Drug Synergis | 1995 |
Effectiveness of controlled release of a cyclophosphamide derivative with polymers against rat gliomas.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carmustine; Cyclophosphamide; Decanoic Acids; Delay | 1995 |
Effectiveness of controlled release of a cyclophosphamide derivative with polymers against rat gliomas.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carmustine; Cyclophosphamide; Decanoic Acids; Delay | 1995 |
Effectiveness of controlled release of a cyclophosphamide derivative with polymers against rat gliomas.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carmustine; Cyclophosphamide; Decanoic Acids; Delay | 1995 |
Differentiation therapy is potentiated by chemotherapy and hyperthermia in human and canine brain tumor cells in vitro.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Bucladesine; Butyrates; Butyric Acid; Carmustine; C | 1994 |
Differentiation therapy is potentiated by chemotherapy and hyperthermia in human and canine brain tumor cells in vitro.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Bucladesine; Butyrates; Butyric Acid; Carmustine; C | 1994 |
Differentiation therapy is potentiated by chemotherapy and hyperthermia in human and canine brain tumor cells in vitro.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Bucladesine; Butyrates; Butyric Acid; Carmustine; C | 1994 |
Altered cytotoxicity of (2-chloroethyl)-3-sarcosinamide-1-nitrosourea in human glioma cell lines SK-MG-1 and SKI-1 correlates with differential transport kinetics.
Topics: Antineoplastic Agents; Biological Transport; Carmustine; Chromatography, Thin Layer; Glioma; Humans; | 1994 |
Altered cytotoxicity of (2-chloroethyl)-3-sarcosinamide-1-nitrosourea in human glioma cell lines SK-MG-1 and SKI-1 correlates with differential transport kinetics.
Topics: Antineoplastic Agents; Biological Transport; Carmustine; Chromatography, Thin Layer; Glioma; Humans; | 1994 |
Altered cytotoxicity of (2-chloroethyl)-3-sarcosinamide-1-nitrosourea in human glioma cell lines SK-MG-1 and SKI-1 correlates with differential transport kinetics.
Topics: Antineoplastic Agents; Biological Transport; Carmustine; Chromatography, Thin Layer; Glioma; Humans; | 1994 |
Cognitive functioning in long-term survivors of high-grade glioma.
Topics: Adult; Antineoplastic Agents; Aziridines; Benzoquinones; Brain Neoplasms; Carmustine; Cognition; Fem | 1994 |
Cognitive functioning in long-term survivors of high-grade glioma.
Topics: Adult; Antineoplastic Agents; Aziridines; Benzoquinones; Brain Neoplasms; Carmustine; Cognition; Fem | 1994 |
Cognitive functioning in long-term survivors of high-grade glioma.
Topics: Adult; Antineoplastic Agents; Aziridines; Benzoquinones; Brain Neoplasms; Carmustine; Cognition; Fem | 1994 |
Biodegradable polymers for controlled delivery of chemotherapy with and without radiation therapy in the monkey brain.
Topics: Animals; Brain Edema; Brain Neoplasms; Carmustine; Decanoic Acids; Dicarboxylic Acids; Drug Combinat | 1994 |
Biodegradable polymers for controlled delivery of chemotherapy with and without radiation therapy in the monkey brain.
Topics: Animals; Brain Edema; Brain Neoplasms; Carmustine; Decanoic Acids; Dicarboxylic Acids; Drug Combinat | 1994 |
Biodegradable polymers for controlled delivery of chemotherapy with and without radiation therapy in the monkey brain.
Topics: Animals; Brain Edema; Brain Neoplasms; Carmustine; Decanoic Acids; Dicarboxylic Acids; Drug Combinat | 1994 |
Prognostic factors in malignant gliomas with special reference to intra-arterial chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Ad | 1993 |
Prognostic factors in malignant gliomas with special reference to intra-arterial chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Ad | 1993 |
Prognostic factors in malignant gliomas with special reference to intra-arterial chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Ad | 1993 |
Carmustine toxicity presenting as a lobar infiltrate.
Topics: Adult; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Pulmonary Fibrosis; Vital Capacity | 1993 |
Carmustine toxicity presenting as a lobar infiltrate.
Topics: Adult; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Pulmonary Fibrosis; Vital Capacity | 1993 |
Carmustine toxicity presenting as a lobar infiltrate.
Topics: Adult; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Pulmonary Fibrosis; Vital Capacity | 1993 |
Transport of (2-chloroethyl)-3-sarcosinamide-1-nitrosourea in the human glioma cell line SK-MG-1 is mediated by an epinephrine-sensitive carrier system.
Topics: Antineoplastic Agents; Biological Transport; Carmustine; Epinephrine; Glioma; Humans; Sodium; Temper | 1993 |
Transport of (2-chloroethyl)-3-sarcosinamide-1-nitrosourea in the human glioma cell line SK-MG-1 is mediated by an epinephrine-sensitive carrier system.
Topics: Antineoplastic Agents; Biological Transport; Carmustine; Epinephrine; Glioma; Humans; Sodium; Temper | 1993 |
Transport of (2-chloroethyl)-3-sarcosinamide-1-nitrosourea in the human glioma cell line SK-MG-1 is mediated by an epinephrine-sensitive carrier system.
Topics: Antineoplastic Agents; Biological Transport; Carmustine; Epinephrine; Glioma; Humans; Sodium; Temper | 1993 |
Comparison between BCNU and procarbazine chemotherapy for treatment of gliomas.
Topics: Adult; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Male; Procarbazine | 1993 |
Comparison between BCNU and procarbazine chemotherapy for treatment of gliomas.
Topics: Adult; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Male; Procarbazine | 1993 |
Comparison between BCNU and procarbazine chemotherapy for treatment of gliomas.
Topics: Adult; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Male; Procarbazine | 1993 |
Interstitial chemotherapy of the 9L gliosarcoma: controlled release polymers for drug delivery in the brain.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carmustine; Delayed-Action Preparations; Glioma; Ma | 1993 |
Interstitial chemotherapy of the 9L gliosarcoma: controlled release polymers for drug delivery in the brain.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carmustine; Delayed-Action Preparations; Glioma; Ma | 1993 |
Interstitial chemotherapy of the 9L gliosarcoma: controlled release polymers for drug delivery in the brain.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carmustine; Delayed-Action Preparations; Glioma; Ma | 1993 |
Oxidative stress in a clonal cell line of neuronal origin: effects of antioxidant enzyme modulation.
Topics: Animals; Brain; Carmustine; Catalase; Cell Fractionation; Cell Survival; Clone Cells; Cytosol; Gliom | 1993 |
Oxidative stress in a clonal cell line of neuronal origin: effects of antioxidant enzyme modulation.
Topics: Animals; Brain; Carmustine; Catalase; Cell Fractionation; Cell Survival; Clone Cells; Cytosol; Gliom | 1993 |
Oxidative stress in a clonal cell line of neuronal origin: effects of antioxidant enzyme modulation.
Topics: Animals; Brain; Carmustine; Catalase; Cell Fractionation; Cell Survival; Clone Cells; Cytosol; Gliom | 1993 |
Identification of a 116 kDa protein able to bind 1,3-bis(2-chloroethyl)-1-nitrosourea-damaged DNA as poly(ADP-ribose) polymerase.
Topics: Antineoplastic Agents, Alkylating; Blotting, Southern; Blotting, Western; Carmustine; DNA Damage; DN | 1996 |
Identification of a 116 kDa protein able to bind 1,3-bis(2-chloroethyl)-1-nitrosourea-damaged DNA as poly(ADP-ribose) polymerase.
Topics: Antineoplastic Agents, Alkylating; Blotting, Southern; Blotting, Western; Carmustine; DNA Damage; DN | 1996 |
Identification of a 116 kDa protein able to bind 1,3-bis(2-chloroethyl)-1-nitrosourea-damaged DNA as poly(ADP-ribose) polymerase.
Topics: Antineoplastic Agents, Alkylating; Blotting, Southern; Blotting, Western; Carmustine; DNA Damage; DN | 1996 |
The sequential changes in DNA synthesis, glucose utilization, protein synthesis, and peripheral benzodiazepine receptor density in C6 brain tumors after chemotherapy to predict the response of tumors to chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Bromodeoxyuridine; Carmustine; DNA; Fem | 1996 |
The sequential changes in DNA synthesis, glucose utilization, protein synthesis, and peripheral benzodiazepine receptor density in C6 brain tumors after chemotherapy to predict the response of tumors to chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Bromodeoxyuridine; Carmustine; DNA; Fem | 1996 |
The sequential changes in DNA synthesis, glucose utilization, protein synthesis, and peripheral benzodiazepine receptor density in C6 brain tumors after chemotherapy to predict the response of tumors to chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Bromodeoxyuridine; Carmustine; DNA; Fem | 1996 |
Buthionine sulfoximine induction of gamma-L-glutamyl-L-cysteine synthetase gene expression, kinetics of glutathione depletion and resynthesis, and modulation of carmustine-induced DNA-DNA cross-linking and cytotoxicity in human glioma cells.
Topics: Antineoplastic Agents, Alkylating; Base Sequence; Buthionine Sulfoximine; Carmustine; Cell Survival; | 1996 |
Buthionine sulfoximine induction of gamma-L-glutamyl-L-cysteine synthetase gene expression, kinetics of glutathione depletion and resynthesis, and modulation of carmustine-induced DNA-DNA cross-linking and cytotoxicity in human glioma cells.
Topics: Antineoplastic Agents, Alkylating; Base Sequence; Buthionine Sulfoximine; Carmustine; Cell Survival; | 1996 |
Buthionine sulfoximine induction of gamma-L-glutamyl-L-cysteine synthetase gene expression, kinetics of glutathione depletion and resynthesis, and modulation of carmustine-induced DNA-DNA cross-linking and cytotoxicity in human glioma cells.
Topics: Antineoplastic Agents, Alkylating; Base Sequence; Buthionine Sulfoximine; Carmustine; Cell Survival; | 1996 |
Characterization of the catecholamine extraneuronal uptake2 carrier in human glioma cell lines SK-MG-1 and SKI-1 in relation to (2-chloroethyl)-3-sarcosinamide-1-nitrosourea (SarCNU) selective cytotoxicity.
Topics: Antineoplastic Agents; Carmustine; Catecholamines; Cell Line; Dose-Response Relationship, Drug; Epin | 1996 |
Characterization of the catecholamine extraneuronal uptake2 carrier in human glioma cell lines SK-MG-1 and SKI-1 in relation to (2-chloroethyl)-3-sarcosinamide-1-nitrosourea (SarCNU) selective cytotoxicity.
Topics: Antineoplastic Agents; Carmustine; Catecholamines; Cell Line; Dose-Response Relationship, Drug; Epin | 1996 |
Characterization of the catecholamine extraneuronal uptake2 carrier in human glioma cell lines SK-MG-1 and SKI-1 in relation to (2-chloroethyl)-3-sarcosinamide-1-nitrosourea (SarCNU) selective cytotoxicity.
Topics: Antineoplastic Agents; Carmustine; Catecholamines; Cell Line; Dose-Response Relationship, Drug; Epin | 1996 |
Daunorubicin and doxorubicin but not BCNU have deleterious effects on organotypic multicellular spheroids of gliomas.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Su | 1996 |
Daunorubicin and doxorubicin but not BCNU have deleterious effects on organotypic multicellular spheroids of gliomas.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Su | 1996 |
Daunorubicin and doxorubicin but not BCNU have deleterious effects on organotypic multicellular spheroids of gliomas.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Su | 1996 |
Computer-assisted microscope characterization of BCNU-induced modifications in the collective behavior of 12 human brain cancer cell lines.
Topics: Brain Neoplasms; Carcinogens; Carmustine; Cell Count; Cell Death; Cell Division; Cell Survival; Colo | 1996 |
Computer-assisted microscope characterization of BCNU-induced modifications in the collective behavior of 12 human brain cancer cell lines.
Topics: Brain Neoplasms; Carcinogens; Carmustine; Cell Count; Cell Death; Cell Division; Cell Survival; Colo | 1996 |
Computer-assisted microscope characterization of BCNU-induced modifications in the collective behavior of 12 human brain cancer cell lines.
Topics: Brain Neoplasms; Carcinogens; Carmustine; Cell Count; Cell Death; Cell Division; Cell Survival; Colo | 1996 |
Intrathecal chemotherapy with 1,3-bis(2-chloroethyl)-1-nitrosourea encapsulated into hybrid liposomes for meningeal gliomatosis: an experimental study.
Topics: Animals; Antineoplastic Agents, Alkylating; Carmustine; Cell Division; Dogs; Drug Carriers; Glioma; | 1996 |
Intrathecal chemotherapy with 1,3-bis(2-chloroethyl)-1-nitrosourea encapsulated into hybrid liposomes for meningeal gliomatosis: an experimental study.
Topics: Animals; Antineoplastic Agents, Alkylating; Carmustine; Cell Division; Dogs; Drug Carriers; Glioma; | 1996 |
Intrathecal chemotherapy with 1,3-bis(2-chloroethyl)-1-nitrosourea encapsulated into hybrid liposomes for meningeal gliomatosis: an experimental study.
Topics: Animals; Antineoplastic Agents, Alkylating; Carmustine; Cell Division; Dogs; Drug Carriers; Glioma; | 1996 |
Blocking of glioma proliferation in vitro and in vivo and potentiating the effects of BCNU and cisplatin: UCN-01, a selective protein kinase C inhibitor.
Topics: Alkaloids; Brain Neoplasms; Carmustine; Cisplatin; Dose-Response Relationship, Drug; Enzyme Inhibito | 1996 |
Blocking of glioma proliferation in vitro and in vivo and potentiating the effects of BCNU and cisplatin: UCN-01, a selective protein kinase C inhibitor.
Topics: Alkaloids; Brain Neoplasms; Carmustine; Cisplatin; Dose-Response Relationship, Drug; Enzyme Inhibito | 1996 |
Blocking of glioma proliferation in vitro and in vivo and potentiating the effects of BCNU and cisplatin: UCN-01, a selective protein kinase C inhibitor.
Topics: Alkaloids; Brain Neoplasms; Carmustine; Cisplatin; Dose-Response Relationship, Drug; Enzyme Inhibito | 1996 |
Quantitative DNA analysis of an intracerebrally transplanted brain tumour model after experimental chemotherapy with BCNU and CCNU.
Topics: Animals; Brain Neoplasms; Brain Tissue Transplantation; Carmustine; Cell Division; Cytophotometry; D | 1995 |
Quantitative DNA analysis of an intracerebrally transplanted brain tumour model after experimental chemotherapy with BCNU and CCNU.
Topics: Animals; Brain Neoplasms; Brain Tissue Transplantation; Carmustine; Cell Division; Cytophotometry; D | 1995 |
Quantitative DNA analysis of an intracerebrally transplanted brain tumour model after experimental chemotherapy with BCNU and CCNU.
Topics: Animals; Brain Neoplasms; Brain Tissue Transplantation; Carmustine; Cell Division; Cytophotometry; D | 1995 |
Effects of hypoxia on drug resistance phenotype and genotype in human glioma cell lines.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brain Neoplasms; Car | 1996 |
Effects of hypoxia on drug resistance phenotype and genotype in human glioma cell lines.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brain Neoplasms; Car | 1996 |
Effects of hypoxia on drug resistance phenotype and genotype in human glioma cell lines.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brain Neoplasms; Car | 1996 |
Inhibition of cell growth and sensitization to oxidative damage by overexpression of manganese superoxide dismutase in rat glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Buthionine Sulfoximine; Carmustine; Catalase; Cell Divis | 1996 |
Inhibition of cell growth and sensitization to oxidative damage by overexpression of manganese superoxide dismutase in rat glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Buthionine Sulfoximine; Carmustine; Catalase; Cell Divis | 1996 |
Inhibition of cell growth and sensitization to oxidative damage by overexpression of manganese superoxide dismutase in rat glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Buthionine Sulfoximine; Carmustine; Catalase; Cell Divis | 1996 |
Human brain tumor O(6)-methylguanine-DNA methyltransferase mRNA and its significance as an indicator of selective chloroethylnitrosourea chemotherapy.
Topics: Antineoplastic Agents, Alkylating; Biomarkers; Brain Neoplasms; Carmustine; DNA Repair; Glioma; Huma | 1996 |
Human brain tumor O(6)-methylguanine-DNA methyltransferase mRNA and its significance as an indicator of selective chloroethylnitrosourea chemotherapy.
Topics: Antineoplastic Agents, Alkylating; Biomarkers; Brain Neoplasms; Carmustine; DNA Repair; Glioma; Huma | 1996 |
Human brain tumor O(6)-methylguanine-DNA methyltransferase mRNA and its significance as an indicator of selective chloroethylnitrosourea chemotherapy.
Topics: Antineoplastic Agents, Alkylating; Biomarkers; Brain Neoplasms; Carmustine; DNA Repair; Glioma; Huma | 1996 |
DNA interstrand cross-linking and cytotoxicity induced by chloroethylnitrosoureas and cisplatin in human glioma cell lines which vary in cellular concentration of O6-alkylguanine-DNA alkyltransferase.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Cisplatin; DNA Adducts; DNA, Neoplasm; Drug Scre | 1997 |
DNA interstrand cross-linking and cytotoxicity induced by chloroethylnitrosoureas and cisplatin in human glioma cell lines which vary in cellular concentration of O6-alkylguanine-DNA alkyltransferase.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Cisplatin; DNA Adducts; DNA, Neoplasm; Drug Scre | 1997 |
DNA interstrand cross-linking and cytotoxicity induced by chloroethylnitrosoureas and cisplatin in human glioma cell lines which vary in cellular concentration of O6-alkylguanine-DNA alkyltransferase.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Cisplatin; DNA Adducts; DNA, Neoplasm; Drug Scre | 1997 |
Visual pathway glioma: an erratic tumour with therapeutic dilemmas.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy | 1997 |
Visual pathway glioma: an erratic tumour with therapeutic dilemmas.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy | 1997 |
Visual pathway glioma: an erratic tumour with therapeutic dilemmas.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy | 1997 |
Advantage of treating anaplastic gliomas with aggressive protocol combining chemotherapy and radiotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasm | 1997 |
Advantage of treating anaplastic gliomas with aggressive protocol combining chemotherapy and radiotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasm | 1997 |
Advantage of treating anaplastic gliomas with aggressive protocol combining chemotherapy and radiotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasm | 1997 |
Survival, prognostic factors, and therapeutic efficacy in low-grade glioma: a retrospective study in 379 patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Child; Chil | 1997 |
Survival, prognostic factors, and therapeutic efficacy in low-grade glioma: a retrospective study in 379 patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Child; Chil | 1997 |
Survival, prognostic factors, and therapeutic efficacy in low-grade glioma: a retrospective study in 379 patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Child; Chil | 1997 |
2-Chloroethyl-3-sarcosinamide-1-nitrosourea, a novel chloroethylnitrosourea analogue with enhanced antitumor activity against human glioma xenografts.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Alkylating; Carmustine; Drug Administration Sc | 1997 |
2-Chloroethyl-3-sarcosinamide-1-nitrosourea, a novel chloroethylnitrosourea analogue with enhanced antitumor activity against human glioma xenografts.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Alkylating; Carmustine; Drug Administration Sc | 1997 |
2-Chloroethyl-3-sarcosinamide-1-nitrosourea, a novel chloroethylnitrosourea analogue with enhanced antitumor activity against human glioma xenografts.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Alkylating; Carmustine; Drug Administration Sc | 1997 |
Radiation therapy and hydroxyurea followed by the combination of 6-thioguanine and BCNU for the treatment of primary malignant brain tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 1998 |
Radiation therapy and hydroxyurea followed by the combination of 6-thioguanine and BCNU for the treatment of primary malignant brain tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 1998 |
Radiation therapy and hydroxyurea followed by the combination of 6-thioguanine and BCNU for the treatment of primary malignant brain tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 1998 |
Preclinical evaluation of 9-chloro-2-methylellipticinium acetate alone and in combination with conventional anticancer drugs for the treatment of human brain tumor xenografts.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; | 1998 |
Preclinical evaluation of 9-chloro-2-methylellipticinium acetate alone and in combination with conventional anticancer drugs for the treatment of human brain tumor xenografts.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; | 1998 |
Preclinical evaluation of 9-chloro-2-methylellipticinium acetate alone and in combination with conventional anticancer drugs for the treatment of human brain tumor xenografts.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; | 1998 |
Activity of fotemustine in medulloblastoma and malignant glioma xenografts in relation to O6-alkylguanine-DNA alkyltransferase and alkylpurine-DNA N-glycosylase activity.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cere | 1998 |
Activity of fotemustine in medulloblastoma and malignant glioma xenografts in relation to O6-alkylguanine-DNA alkyltransferase and alkylpurine-DNA N-glycosylase activity.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cere | 1998 |
Activity of fotemustine in medulloblastoma and malignant glioma xenografts in relation to O6-alkylguanine-DNA alkyltransferase and alkylpurine-DNA N-glycosylase activity.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Cere | 1998 |
Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Busulfan; Camptothecin; Carmusti | 1998 |
Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Busulfan; Camptothecin; Carmusti | 1998 |
Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents.
Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Busulfan; Camptothecin; Carmusti | 1998 |
Excision repair cross-complementing rodent repair deficiency gene 2 expression and chloroethylnitrosourea resistance in human glioma cell lines.
Topics: Brain Neoplasms; Carmustine; Colorimetry; DNA Helicases; DNA Repair; DNA-Binding Proteins; DNA, Neop | 1998 |
Excision repair cross-complementing rodent repair deficiency gene 2 expression and chloroethylnitrosourea resistance in human glioma cell lines.
Topics: Brain Neoplasms; Carmustine; Colorimetry; DNA Helicases; DNA Repair; DNA-Binding Proteins; DNA, Neop | 1998 |
Excision repair cross-complementing rodent repair deficiency gene 2 expression and chloroethylnitrosourea resistance in human glioma cell lines.
Topics: Brain Neoplasms; Carmustine; Colorimetry; DNA Helicases; DNA Repair; DNA-Binding Proteins; DNA, Neop | 1998 |
Interferon-alpha enhances CD95L-induced apoptosis of human malignant glioma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Carmustine; Caspase 3; Caspases; Cell Membrane; Cystei | 1998 |
Interferon-alpha enhances CD95L-induced apoptosis of human malignant glioma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Carmustine; Caspase 3; Caspases; Cell Membrane; Cystei | 1998 |
Interferon-alpha enhances CD95L-induced apoptosis of human malignant glioma cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Carmustine; Caspase 3; Caspases; Cell Membrane; Cystei | 1998 |
Chemosensitivity of human malignant glioma: modulation by p53 gene transfer.
Topics: Amino Acid Substitution; Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Brai | 1998 |
Chemosensitivity of human malignant glioma: modulation by p53 gene transfer.
Topics: Amino Acid Substitution; Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Brai | 1998 |
Chemosensitivity of human malignant glioma: modulation by p53 gene transfer.
Topics: Amino Acid Substitution; Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Brai | 1998 |
Malignant glioma: who benefits from adjuvant chemotherapy?
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; | 1998 |
Malignant glioma: who benefits from adjuvant chemotherapy?
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; | 1998 |
Malignant glioma: who benefits from adjuvant chemotherapy?
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; | 1998 |
Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging.
Topics: Animals; Antineoplastic Agents, Alkylating; Body Water; Brain Neoplasms; Carmustine; Cell Count; Cel | 1997 |
Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging.
Topics: Animals; Antineoplastic Agents, Alkylating; Body Water; Brain Neoplasms; Carmustine; Cell Count; Cel | 1997 |
Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging.
Topics: Animals; Antineoplastic Agents, Alkylating; Body Water; Brain Neoplasms; Carmustine; Cell Count; Cel | 1997 |
Growth kinetics and treatment response of the intracerebral rat 9L brain tumor model: a quantitative in vivo study using magnetic resonance imaging.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Calibration; Carmustine; Cell Division; | 1995 |
Growth kinetics and treatment response of the intracerebral rat 9L brain tumor model: a quantitative in vivo study using magnetic resonance imaging.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Calibration; Carmustine; Cell Division; | 1995 |
Growth kinetics and treatment response of the intracerebral rat 9L brain tumor model: a quantitative in vivo study using magnetic resonance imaging.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Calibration; Carmustine; Cell Division; | 1995 |
Modulation of angiogenesis by human glioma xenograft models that differentially express vascular endothelial growth factor.
Topics: Animals; Antineoplastic Agents, Alkylating; Capillaries; Carmustine; Cell Hypoxia; Dacarbazine; DNA, | 1998 |
Modulation of angiogenesis by human glioma xenograft models that differentially express vascular endothelial growth factor.
Topics: Animals; Antineoplastic Agents, Alkylating; Capillaries; Carmustine; Cell Hypoxia; Dacarbazine; DNA, | 1998 |
Modulation of angiogenesis by human glioma xenograft models that differentially express vascular endothelial growth factor.
Topics: Animals; Antineoplastic Agents, Alkylating; Capillaries; Carmustine; Cell Hypoxia; Dacarbazine; DNA, | 1998 |
Protamine inhibits angiogenesis and growth of C6 rat glioma; a synergistic effect when combined with carmustine.
Topics: Animals; Antineoplastic Agents, Alkylating; Carmustine; Cell Division; Dose-Response Relationship, D | 1998 |
Protamine inhibits angiogenesis and growth of C6 rat glioma; a synergistic effect when combined with carmustine.
Topics: Animals; Antineoplastic Agents, Alkylating; Carmustine; Cell Division; Dose-Response Relationship, D | 1998 |
Protamine inhibits angiogenesis and growth of C6 rat glioma; a synergistic effect when combined with carmustine.
Topics: Animals; Antineoplastic Agents, Alkylating; Carmustine; Cell Division; Dose-Response Relationship, D | 1998 |
Beyond the barrier: devices inside the brain.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Drug Implants; Glioma; Humans; Neopl | 1995 |
Beyond the barrier: devices inside the brain.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Drug Implants; Glioma; Humans; Neopl | 1995 |
Beyond the barrier: devices inside the brain.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Drug Implants; Glioma; Humans; Neopl | 1995 |
Sensitization of 1,3-bis(2-chloroethyl)-1-nitrosourea and cisplatin cytotoxicity by 5-bromo-2'-deoxyuridine in human glioma.
Topics: Bromodeoxyuridine; Carmustine; Cell Survival; DNA Damage; DNA, Neoplasm; Drug Synergism; Glioma; Hum | 1999 |
Sensitization of 1,3-bis(2-chloroethyl)-1-nitrosourea and cisplatin cytotoxicity by 5-bromo-2'-deoxyuridine in human glioma.
Topics: Bromodeoxyuridine; Carmustine; Cell Survival; DNA Damage; DNA, Neoplasm; Drug Synergism; Glioma; Hum | 1999 |
Sensitization of 1,3-bis(2-chloroethyl)-1-nitrosourea and cisplatin cytotoxicity by 5-bromo-2'-deoxyuridine in human glioma.
Topics: Bromodeoxyuridine; Carmustine; Cell Survival; DNA Damage; DNA, Neoplasm; Drug Synergism; Glioma; Hum | 1999 |
Relationship between drug delivery and the intra-arterial infusion rate of SarCNU in C6 rat brain tumor model.
Topics: Animals; Antineoplastic Agents; Autoradiography; Brain; Brain Neoplasms; Carmustine; Cell Line; Fema | 1999 |
Relationship between drug delivery and the intra-arterial infusion rate of SarCNU in C6 rat brain tumor model.
Topics: Animals; Antineoplastic Agents; Autoradiography; Brain; Brain Neoplasms; Carmustine; Cell Line; Fema | 1999 |
Relationship between drug delivery and the intra-arterial infusion rate of SarCNU in C6 rat brain tumor model.
Topics: Animals; Antineoplastic Agents; Autoradiography; Brain; Brain Neoplasms; Carmustine; Cell Line; Fema | 1999 |
O(6)-methylguanine-DNA methyltransferase gene (MGMT) expression in human glioblastomas in relation to patient characteristics and p53 accumulation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Adj | 1999 |
O(6)-methylguanine-DNA methyltransferase gene (MGMT) expression in human glioblastomas in relation to patient characteristics and p53 accumulation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Adj | 1999 |
O(6)-methylguanine-DNA methyltransferase gene (MGMT) expression in human glioblastomas in relation to patient characteristics and p53 accumulation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Adj | 1999 |
Prolonged inhibition of O(6)-methylguanine DNA methyltransferase in human tumor cells by O(6)-benzylguanine in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Enzyme Inhibitors; Female; | 1999 |
Prolonged inhibition of O(6)-methylguanine DNA methyltransferase in human tumor cells by O(6)-benzylguanine in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Enzyme Inhibitors; Female; | 1999 |
Prolonged inhibition of O(6)-methylguanine DNA methyltransferase in human tumor cells by O(6)-benzylguanine in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Enzyme Inhibitors; Female; | 1999 |
Enhanced antitumor activity of sarCNU in comparison to BCNU in an extraneuronal monoamine transporter positive human glioma xenograft model.
Topics: Animals; Antineoplastic Agents; Carmustine; Carrier Proteins; Disease Models, Animal; Drug Screening | 1999 |
Enhanced antitumor activity of sarCNU in comparison to BCNU in an extraneuronal monoamine transporter positive human glioma xenograft model.
Topics: Animals; Antineoplastic Agents; Carmustine; Carrier Proteins; Disease Models, Animal; Drug Screening | 1999 |
Enhanced antitumor activity of sarCNU in comparison to BCNU in an extraneuronal monoamine transporter positive human glioma xenograft model.
Topics: Animals; Antineoplastic Agents; Carmustine; Carrier Proteins; Disease Models, Animal; Drug Screening | 1999 |
Accumulation of mutant p53(V143A) modulates the growth, clonogenicity, and radiochemosensitivity of malignant glioma cells independent of endogenous p53 status.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain N | 1999 |
Accumulation of mutant p53(V143A) modulates the growth, clonogenicity, and radiochemosensitivity of malignant glioma cells independent of endogenous p53 status.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain N | 1999 |
Accumulation of mutant p53(V143A) modulates the growth, clonogenicity, and radiochemosensitivity of malignant glioma cells independent of endogenous p53 status.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain N | 1999 |
Expression of superoxide dismutases, catalase, and glutathione peroxidase in glioma cells.
Topics: Animals; Blotting, Western; Buthionine Sulfoximine; Carmustine; Catalase; Fluorescent Antibody Techn | 1999 |
Expression of superoxide dismutases, catalase, and glutathione peroxidase in glioma cells.
Topics: Animals; Blotting, Western; Buthionine Sulfoximine; Carmustine; Catalase; Fluorescent Antibody Techn | 1999 |
Expression of superoxide dismutases, catalase, and glutathione peroxidase in glioma cells.
Topics: Animals; Blotting, Western; Buthionine Sulfoximine; Carmustine; Catalase; Fluorescent Antibody Techn | 1999 |
Serial CT and MR imaging of carmustine wafers.
Topics: Antineoplastic Agents, Alkylating; Biocompatible Materials; Brain Diseases; Carmustine; Drug Deliver | 2000 |
Serial CT and MR imaging of carmustine wafers.
Topics: Antineoplastic Agents, Alkylating; Biocompatible Materials; Brain Diseases; Carmustine; Drug Deliver | 2000 |
Serial CT and MR imaging of carmustine wafers.
Topics: Antineoplastic Agents, Alkylating; Biocompatible Materials; Brain Diseases; Carmustine; Drug Deliver | 2000 |
Intracerebral clysis in a rat glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Carmustine; Dextrans; Drug Deliv | 2000 |
Intracerebral clysis in a rat glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Carmustine; Dextrans; Drug Deliv | 2000 |
Intracerebral clysis in a rat glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Carmustine; Dextrans; Drug Deliv | 2000 |
Effects of radiation on a model of malignant glioma invasion.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Carmustine; Combined Modality Therapy; Dose-Response | 1999 |
Effects of radiation on a model of malignant glioma invasion.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Carmustine; Combined Modality Therapy; Dose-Response | 1999 |
Effects of radiation on a model of malignant glioma invasion.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Carmustine; Combined Modality Therapy; Dose-Response | 1999 |
Differential effect of cycloheximide on neuronal and glioma cells treated with chemotherapy and radiation.
Topics: Animals; Antineoplastic Agents, Alkylating; Carmustine; Cell Death; Cell Line, Transformed; Cyclohex | 1999 |
Differential effect of cycloheximide on neuronal and glioma cells treated with chemotherapy and radiation.
Topics: Animals; Antineoplastic Agents, Alkylating; Carmustine; Cell Death; Cell Line, Transformed; Cyclohex | 1999 |
Differential effect of cycloheximide on neuronal and glioma cells treated with chemotherapy and radiation.
Topics: Animals; Antineoplastic Agents, Alkylating; Carmustine; Cell Death; Cell Line, Transformed; Cyclohex | 1999 |
Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camp | 2000 |
Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camp | 2000 |
Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camp | 2000 |
An investigation of the cytotoxicity of the morpholino anthracycline MX2 against glioma cells in vitro.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine | 2000 |
An investigation of the cytotoxicity of the morpholino anthracycline MX2 against glioma cells in vitro.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine | 2000 |
An investigation of the cytotoxicity of the morpholino anthracycline MX2 against glioma cells in vitro.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine | 2000 |
Poly(ADP-ribose) polymerase-independent potentiation of nitrosourea cytotoxicity by 3-aminobenzamide in human malignant glioma cells.
Topics: Benzamides; Binding Sites; Carmustine; Cell Survival; Dose-Response Relationship, Drug; Drug Synergi | 2000 |
Poly(ADP-ribose) polymerase-independent potentiation of nitrosourea cytotoxicity by 3-aminobenzamide in human malignant glioma cells.
Topics: Benzamides; Binding Sites; Carmustine; Cell Survival; Dose-Response Relationship, Drug; Drug Synergi | 2000 |
Poly(ADP-ribose) polymerase-independent potentiation of nitrosourea cytotoxicity by 3-aminobenzamide in human malignant glioma cells.
Topics: Benzamides; Binding Sites; Carmustine; Cell Survival; Dose-Response Relationship, Drug; Drug Synergi | 2000 |
Estimating a treatment effect with the accelerated hazards models.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Glioma; Hu | 2000 |
Estimating a treatment effect with the accelerated hazards models.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Glioma; Hu | 2000 |
Estimating a treatment effect with the accelerated hazards models.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Glioma; Hu | 2000 |
Effects of carmustine and lomustine on arylamine N-acetyltransferase activity and 2-aminofluorene-DNA adducts in rat glial tumor cells.
Topics: Animals; Arylamine N-Acetyltransferase; Brain Neoplasms; Carmustine; DNA Adducts; Fluorenes; Glioma; | 2000 |
Effects of carmustine and lomustine on arylamine N-acetyltransferase activity and 2-aminofluorene-DNA adducts in rat glial tumor cells.
Topics: Animals; Arylamine N-Acetyltransferase; Brain Neoplasms; Carmustine; DNA Adducts; Fluorenes; Glioma; | 2000 |
Effects of carmustine and lomustine on arylamine N-acetyltransferase activity and 2-aminofluorene-DNA adducts in rat glial tumor cells.
Topics: Animals; Arylamine N-Acetyltransferase; Brain Neoplasms; Carmustine; DNA Adducts; Fluorenes; Glioma; | 2000 |
Identification of transforming growth factor-beta1-binding protein overexpression in carmustine-resistant glioma cells by MRNA differential display.
Topics: Aged; Antineoplastic Agents, Alkylating; Blotting, Northern; Blotting, Southern; Carmustine; Carrier | 2000 |
Identification of transforming growth factor-beta1-binding protein overexpression in carmustine-resistant glioma cells by MRNA differential display.
Topics: Aged; Antineoplastic Agents, Alkylating; Blotting, Northern; Blotting, Southern; Carmustine; Carrier | 2000 |
Identification of transforming growth factor-beta1-binding protein overexpression in carmustine-resistant glioma cells by MRNA differential display.
Topics: Aged; Antineoplastic Agents, Alkylating; Blotting, Northern; Blotting, Southern; Carmustine; Carrier | 2000 |
Bax expressed from a herpes viral vector enhances the efficacy of N,N'-bis(2-hydroxyethyl)-N-nitrosourea treatment in a rat glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; bcl-2-Associated X Protein; Brain Neoplasms; Carmustine; | 2000 |
Bax expressed from a herpes viral vector enhances the efficacy of N,N'-bis(2-hydroxyethyl)-N-nitrosourea treatment in a rat glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; bcl-2-Associated X Protein; Brain Neoplasms; Carmustine; | 2000 |
Bax expressed from a herpes viral vector enhances the efficacy of N,N'-bis(2-hydroxyethyl)-N-nitrosourea treatment in a rat glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; bcl-2-Associated X Protein; Brain Neoplasms; Carmustine; | 2000 |
Injectable chemotherapeutic microspheres and glioma I: enhanced survival following implantation into the cavity wall of debulked tumors.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carboplatin; Carmustine; Delayed-Action Preparation | 2000 |
Injectable chemotherapeutic microspheres and glioma I: enhanced survival following implantation into the cavity wall of debulked tumors.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carboplatin; Carmustine; Delayed-Action Preparation | 2000 |
Injectable chemotherapeutic microspheres and glioma I: enhanced survival following implantation into the cavity wall of debulked tumors.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carboplatin; Carmustine; Delayed-Action Preparation | 2000 |
Injectable chemotherapeutic microspheres and glioma II: enhanced survival following implantation into deep inoperable tumors.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carboplatin; Carmustine; Corpus Striatum; Delayed-A | 2000 |
Injectable chemotherapeutic microspheres and glioma II: enhanced survival following implantation into deep inoperable tumors.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carboplatin; Carmustine; Corpus Striatum; Delayed-A | 2000 |
Injectable chemotherapeutic microspheres and glioma II: enhanced survival following implantation into deep inoperable tumors.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carboplatin; Carmustine; Corpus Striatum; Delayed-A | 2000 |
Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.
Topics: Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Disease-Free S | 2000 |
Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.
Topics: Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Disease-Free S | 2000 |
Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.
Topics: Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Disease-Free S | 2000 |
Pharmacogenomics--teaching old drugs new tricks.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; DNA Methylation; DNA, Neoplasm; Gene | 2000 |
Pharmacogenomics--teaching old drugs new tricks.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; DNA Methylation; DNA, Neoplasm; Gene | 2000 |
Pharmacogenomics--teaching old drugs new tricks.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; DNA Methylation; DNA, Neoplasm; Gene | 2000 |
O6-benzylguanine potentiates the antitumor effect of locally delivered carmustine against an intracranial rat glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2000 |
O6-benzylguanine potentiates the antitumor effect of locally delivered carmustine against an intracranial rat glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2000 |
O6-benzylguanine potentiates the antitumor effect of locally delivered carmustine against an intracranial rat glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2000 |
Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors.
Topics: Adolescent; Adult; Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; C | 2000 |
Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors.
Topics: Adolescent; Adult; Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; C | 2000 |
Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors.
Topics: Adolescent; Adult; Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; C | 2000 |
Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors.
Topics: Adolescent; Adult; Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; C | 2000 |
Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors.
Topics: Adolescent; Adult; Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; C | 2000 |
Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors.
Topics: Adolescent; Adult; Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; C | 2000 |
Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors.
Topics: Adolescent; Adult; Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; C | 2000 |
Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors.
Topics: Adolescent; Adult; Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; C | 2000 |
Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors.
Topics: Adolescent; Adult; Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; C | 2000 |
Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors.
Topics: Adolescent; Adult; Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; C | 2000 |
Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors.
Topics: Adolescent; Adult; Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; C | 2000 |
Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors.
Topics: Adolescent; Adult; Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; C | 2000 |
Detecting treatment-by-centre interaction in multi-centre clinical trials.
Topics: Aged; Antineoplastic Agents, Alkylating; Aziridines; Benzoquinones; Brain Neoplasms; Carmustine; Com | 2001 |
Detecting treatment-by-centre interaction in multi-centre clinical trials.
Topics: Aged; Antineoplastic Agents, Alkylating; Aziridines; Benzoquinones; Brain Neoplasms; Carmustine; Com | 2001 |
Detecting treatment-by-centre interaction in multi-centre clinical trials.
Topics: Aged; Antineoplastic Agents, Alkylating; Aziridines; Benzoquinones; Brain Neoplasms; Carmustine; Com | 2001 |
Altered nuclear localization of bax protein in BCNU-resistant glioma cells.
Topics: Annexin A5; Antineoplastic Agents, Alkylating; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; | 2000 |
Altered nuclear localization of bax protein in BCNU-resistant glioma cells.
Topics: Annexin A5; Antineoplastic Agents, Alkylating; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; | 2000 |
Altered nuclear localization of bax protein in BCNU-resistant glioma cells.
Topics: Annexin A5; Antineoplastic Agents, Alkylating; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; | 2000 |
The DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.
Topics: Antineoplastic Agents, Alkylating; Carmustine; Combined Modality Therapy; DNA Methylation; DNA, Neop | 2001 |
The DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.
Topics: Antineoplastic Agents, Alkylating; Carmustine; Combined Modality Therapy; DNA Methylation; DNA, Neop | 2001 |
The DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.
Topics: Antineoplastic Agents, Alkylating; Carmustine; Combined Modality Therapy; DNA Methylation; DNA, Neop | 2001 |
The DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.
Topics: Age Distribution; Antineoplastic Agents, Alkylating; Carmustine; Combined Modality Therapy; DNA Meth | 2001 |
The DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.
Topics: Age Distribution; Antineoplastic Agents, Alkylating; Carmustine; Combined Modality Therapy; DNA Meth | 2001 |
The DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.
Topics: Age Distribution; Antineoplastic Agents, Alkylating; Carmustine; Combined Modality Therapy; DNA Meth | 2001 |
The DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.
Topics: Adult; Antineoplastic Agents, Alkylating; Carmustine; Combined Modality Therapy; DNA Methylation; DN | 2001 |
The DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.
Topics: Adult; Antineoplastic Agents, Alkylating; Carmustine; Combined Modality Therapy; DNA Methylation; DN | 2001 |
The DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.
Topics: Adult; Antineoplastic Agents, Alkylating; Carmustine; Combined Modality Therapy; DNA Methylation; DN | 2001 |
The DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.
Topics: Antineoplastic Agents, Alkylating; Carmustine; DNA Methylation; DNA, Neoplasm; Glioma; Humans; O(6)- | 2001 |
The DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.
Topics: Antineoplastic Agents, Alkylating; Carmustine; DNA Methylation; DNA, Neoplasm; Glioma; Humans; O(6)- | 2001 |
The DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.
Topics: Antineoplastic Agents, Alkylating; Carmustine; DNA Methylation; DNA, Neoplasm; Glioma; Humans; O(6)- | 2001 |
Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2001 |
Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2001 |
Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2001 |
Inducible nitric oxide synthase neutralizes carbamoylating potential of 1,3-bis(2-chloroethyl)-1-nitrosourea in c6 glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Antisense Elements (Genetics); Carmustine; Drug Resistan | 2001 |
Inducible nitric oxide synthase neutralizes carbamoylating potential of 1,3-bis(2-chloroethyl)-1-nitrosourea in c6 glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Antisense Elements (Genetics); Carmustine; Drug Resistan | 2001 |
Inducible nitric oxide synthase neutralizes carbamoylating potential of 1,3-bis(2-chloroethyl)-1-nitrosourea in c6 glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Antisense Elements (Genetics); Carmustine; Drug Resistan | 2001 |
Multimodality program involving stereotactic surgery in brain tumor management.
Topics: Adult; Antineoplastic Agents, Alkylating; Biopsy; Brachytherapy; Brain Neoplasms; Carmustine; Chemot | 2000 |
Multimodality program involving stereotactic surgery in brain tumor management.
Topics: Adult; Antineoplastic Agents, Alkylating; Biopsy; Brachytherapy; Brain Neoplasms; Carmustine; Chemot | 2000 |
Multimodality program involving stereotactic surgery in brain tumor management.
Topics: Adult; Antineoplastic Agents, Alkylating; Biopsy; Brachytherapy; Brain Neoplasms; Carmustine; Chemot | 2000 |
Effects of chemotherapy by 1,3-bis(2-chloroethyl)-1-nitrosourea on single-quantum- and triple-quantum-filtered 23Na and 31P nuclear magnetic resonance of the subcutaneously implanted 9L glioma.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Gli | 2001 |
Effects of chemotherapy by 1,3-bis(2-chloroethyl)-1-nitrosourea on single-quantum- and triple-quantum-filtered 23Na and 31P nuclear magnetic resonance of the subcutaneously implanted 9L glioma.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Gli | 2001 |
Effects of chemotherapy by 1,3-bis(2-chloroethyl)-1-nitrosourea on single-quantum- and triple-quantum-filtered 23Na and 31P nuclear magnetic resonance of the subcutaneously implanted 9L glioma.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Gli | 2001 |
Antitumor efficacy of SarCNU in a human glioma xenograft model expressing both MGMT and extraneuronal monoamine transporter.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Carr | 2001 |
Antitumor efficacy of SarCNU in a human glioma xenograft model expressing both MGMT and extraneuronal monoamine transporter.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Carr | 2001 |
Antitumor efficacy of SarCNU in a human glioma xenograft model expressing both MGMT and extraneuronal monoamine transporter.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Carr | 2001 |
Inactivation of p53 sensitizes U87MG glioma cells to 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Antineoplastic Agents, Alkylating; Carmustine; Cell Cycle; Cell Survival; Cyclin-Dependent Kinase In | 2001 |
Inactivation of p53 sensitizes U87MG glioma cells to 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Antineoplastic Agents, Alkylating; Carmustine; Cell Cycle; Cell Survival; Cyclin-Dependent Kinase In | 2001 |
Inactivation of p53 sensitizes U87MG glioma cells to 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Antineoplastic Agents, Alkylating; Carmustine; Cell Cycle; Cell Survival; Cyclin-Dependent Kinase In | 2001 |
Adenovirally-mediated transfer of E2F-1 potentiates chemosensitivity of human glioma cells to temozolomide and BCNU.
Topics: Adenoviridae; Antineoplastic Agents, Alkylating; Carmustine; Cell Cycle Proteins; Cell Survival; Cyc | 2001 |
Adenovirally-mediated transfer of E2F-1 potentiates chemosensitivity of human glioma cells to temozolomide and BCNU.
Topics: Adenoviridae; Antineoplastic Agents, Alkylating; Carmustine; Cell Cycle Proteins; Cell Survival; Cyc | 2001 |
Adenovirally-mediated transfer of E2F-1 potentiates chemosensitivity of human glioma cells to temozolomide and BCNU.
Topics: Adenoviridae; Antineoplastic Agents, Alkylating; Carmustine; Cell Cycle Proteins; Cell Survival; Cyc | 2001 |
Accelerated hazards regression model and its adequacy for censored survival data.
Topics: Antineoplastic Agents, Alkylating; Biometry; Brain Neoplasms; Carmustine; Glioma; Humans; Neoplasm R | 2001 |
Accelerated hazards regression model and its adequacy for censored survival data.
Topics: Antineoplastic Agents, Alkylating; Biometry; Brain Neoplasms; Carmustine; Glioma; Humans; Neoplasm R | 2001 |
Accelerated hazards regression model and its adequacy for censored survival data.
Topics: Antineoplastic Agents, Alkylating; Biometry; Brain Neoplasms; Carmustine; Glioma; Humans; Neoplasm R | 2001 |
Quinacrine enhances carmustine therapy of experimental rat glioma.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Survival; Dose-Response Relationship, Drug; Drug Synergis | 2001 |
Quinacrine enhances carmustine therapy of experimental rat glioma.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Survival; Dose-Response Relationship, Drug; Drug Synergis | 2001 |
Quinacrine enhances carmustine therapy of experimental rat glioma.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Survival; Dose-Response Relationship, Drug; Drug Synergis | 2001 |
Apoptosis induced by adenovirus-mediated p53 gene transfer in human glioma correlates with site-specific phosphorylation.
Topics: Adenoviridae; Antineoplastic Agents; Apoptosis; Carmustine; Cisplatin; DNA Damage; Gene Transfer Tec | 2002 |
Apoptosis induced by adenovirus-mediated p53 gene transfer in human glioma correlates with site-specific phosphorylation.
Topics: Adenoviridae; Antineoplastic Agents; Apoptosis; Carmustine; Cisplatin; DNA Damage; Gene Transfer Tec | 2002 |
Apoptosis induced by adenovirus-mediated p53 gene transfer in human glioma correlates with site-specific phosphorylation.
Topics: Adenoviridae; Antineoplastic Agents; Apoptosis; Carmustine; Cisplatin; DNA Damage; Gene Transfer Tec | 2002 |
Injection of chemotherapeutic microspheres and glioma. IV: Eradicating tumors in rats.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carboplatin; Car | 2002 |
Injection of chemotherapeutic microspheres and glioma. IV: Eradicating tumors in rats.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carboplatin; Car | 2002 |
Injection of chemotherapeutic microspheres and glioma. IV: Eradicating tumors in rats.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carboplatin; Car | 2002 |
Single-agent chemotherapy of brain tumors. A five-year review.
Topics: Astrocytoma; Bone Marrow Diseases; Brain Neoplasms; Carmustine; Glioma; Humans; Imidazoles; Lomustin | 1976 |
Single-agent chemotherapy of brain tumors. A five-year review.
Topics: Astrocytoma; Bone Marrow Diseases; Brain Neoplasms; Carmustine; Glioma; Humans; Imidazoles; Lomustin | 1976 |
Single-agent chemotherapy of brain tumors. A five-year review.
Topics: Astrocytoma; Bone Marrow Diseases; Brain Neoplasms; Carmustine; Glioma; Humans; Imidazoles; Lomustin | 1976 |
BCNU-5-fluorouracil combination therapy for recurrent malignant brain tumors.
Topics: Astrocytoma; Bone Marrow; Brain Neoplasms; Carmustine; Drug Therapy, Combination; Fluorouracil; Glio | 1978 |
BCNU-5-fluorouracil combination therapy for recurrent malignant brain tumors.
Topics: Astrocytoma; Bone Marrow; Brain Neoplasms; Carmustine; Drug Therapy, Combination; Fluorouracil; Glio | 1978 |
BCNU-5-fluorouracil combination therapy for recurrent malignant brain tumors.
Topics: Astrocytoma; Bone Marrow; Brain Neoplasms; Carmustine; Drug Therapy, Combination; Fluorouracil; Glio | 1978 |
[Value of chemotherapy associated with conventional treatment of malignant gliomas of the brain. Study of 95 cases with histological verification and follow-up of 1 to 6 years 9 months].
Topics: Administration, Oral; Adult; Brain Neoplasms; Carmustine; Drug Evaluation; Drug Therapy, Combination | 1979 |
[Value of chemotherapy associated with conventional treatment of malignant gliomas of the brain. Study of 95 cases with histological verification and follow-up of 1 to 6 years 9 months].
Topics: Administration, Oral; Adult; Brain Neoplasms; Carmustine; Drug Evaluation; Drug Therapy, Combination | 1979 |
[Value of chemotherapy associated with conventional treatment of malignant gliomas of the brain. Study of 95 cases with histological verification and follow-up of 1 to 6 years 9 months].
Topics: Administration, Oral; Adult; Brain Neoplasms; Carmustine; Drug Evaluation; Drug Therapy, Combination | 1979 |
Synergism between BCNU and irradiation in the treatment of anaplastic gliomas. An in vivo study using the avian sarcoma virus-induced glioma model.
Topics: Animals; Avian Sarcoma Viruses; Brain Neoplasms; Carmustine; Glioma; Neoplasms, Experimental; Rats | 1979 |
Synergism between BCNU and irradiation in the treatment of anaplastic gliomas. An in vivo study using the avian sarcoma virus-induced glioma model.
Topics: Animals; Avian Sarcoma Viruses; Brain Neoplasms; Carmustine; Glioma; Neoplasms, Experimental; Rats | 1979 |
Synergism between BCNU and irradiation in the treatment of anaplastic gliomas. An in vivo study using the avian sarcoma virus-induced glioma model.
Topics: Animals; Avian Sarcoma Viruses; Brain Neoplasms; Carmustine; Glioma; Neoplasms, Experimental; Rats | 1979 |
Neuropathology of tissues from patients treated by the Brain Tumor Study Group.
Topics: Adult; Anaplasia; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Male; Necrosis; Radiation Inj | 1977 |
Neuropathology of tissues from patients treated by the Brain Tumor Study Group.
Topics: Adult; Anaplasia; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Male; Necrosis; Radiation Inj | 1977 |
Neuropathology of tissues from patients treated by the Brain Tumor Study Group.
Topics: Adult; Anaplasia; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Male; Necrosis; Radiation Inj | 1977 |
Treatment of primitive malignant tumors of the central nervous system. Clinical evaluation of 91 cases.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Ependymoma; Glioma; Humans; Lomustine; Oligodendroglioma | 1979 |
Treatment of primitive malignant tumors of the central nervous system. Clinical evaluation of 91 cases.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Ependymoma; Glioma; Humans; Lomustine; Oligodendroglioma | 1979 |
Treatment of primitive malignant tumors of the central nervous system. Clinical evaluation of 91 cases.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Ependymoma; Glioma; Humans; Lomustine; Oligodendroglioma | 1979 |
BCNU and malignant glioma.
Topics: Brain Neoplasms; Carmustine; Drug Evaluation; Follow-Up Studies; Glioma; Humans | 1979 |
BCNU and malignant glioma.
Topics: Brain Neoplasms; Carmustine; Drug Evaluation; Follow-Up Studies; Glioma; Humans | 1979 |
BCNU and malignant glioma.
Topics: Brain Neoplasms; Carmustine; Drug Evaluation; Follow-Up Studies; Glioma; Humans | 1979 |
Desmosterol: a biochemical marker of glioma growth.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Cholesterol; Chromatography, Gas; Desmosterol; Diagnosis, | 1977 |
Desmosterol: a biochemical marker of glioma growth.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Cholesterol; Chromatography, Gas; Desmosterol; Diagnosis, | 1977 |
Desmosterol: a biochemical marker of glioma growth.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Cholesterol; Chromatography, Gas; Desmosterol; Diagnosis, | 1977 |
Variations in response of human brain tumors to BCNU in vitro.
Topics: Brain Neoplasms; Carmustine; Cells, Cultured; Glioma; Humans; Meningeal Neoplasms; Meningioma | 1978 |
Variations in response of human brain tumors to BCNU in vitro.
Topics: Brain Neoplasms; Carmustine; Cells, Cultured; Glioma; Humans; Meningeal Neoplasms; Meningioma | 1978 |
Variations in response of human brain tumors to BCNU in vitro.
Topics: Brain Neoplasms; Carmustine; Cells, Cultured; Glioma; Humans; Meningeal Neoplasms; Meningioma | 1978 |
Combined chemotherapy with VM 26 and BCNU for recurrent malignant gliomas after operation and irradiation.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Drug Therapy, Combination; Female; Glioma; Humans; Male; M | 1978 |
Combined chemotherapy with VM 26 and BCNU for recurrent malignant gliomas after operation and irradiation.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Drug Therapy, Combination; Female; Glioma; Humans; Male; M | 1978 |
Combined chemotherapy with VM 26 and BCNU for recurrent malignant gliomas after operation and irradiation.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Drug Therapy, Combination; Female; Glioma; Humans; Male; M | 1978 |
Where are we heading--heat and otherwise.
Topics: Animals; Body Temperature; Brain Neoplasms; Carmustine; Glioma; Hot Temperature; Humans; Radiotherap | 1978 |
Where are we heading--heat and otherwise.
Topics: Animals; Body Temperature; Brain Neoplasms; Carmustine; Glioma; Hot Temperature; Humans; Radiotherap | 1978 |
Where are we heading--heat and otherwise.
Topics: Animals; Body Temperature; Brain Neoplasms; Carmustine; Glioma; Hot Temperature; Humans; Radiotherap | 1978 |
Immunotherapy of brain tumors--is there a future?
Topics: Antibodies, Neoplasm; BCG Vaccine; Brain Neoplasms; Carmustine; Cytotoxicity, Immunologic; Glioma; H | 1978 |
Immunotherapy of brain tumors--is there a future?
Topics: Antibodies, Neoplasm; BCG Vaccine; Brain Neoplasms; Carmustine; Cytotoxicity, Immunologic; Glioma; H | 1978 |
Immunotherapy of brain tumors--is there a future?
Topics: Antibodies, Neoplasm; BCG Vaccine; Brain Neoplasms; Carmustine; Cytotoxicity, Immunologic; Glioma; H | 1978 |
The contemporary role of chemotherapy in the treatment of malignant brain tumor.
Topics: Adrenal Cortex Hormones; Animals; Brain Neoplasms; Carmustine; Dose-Response Relationship, Drug; Dru | 1978 |
The contemporary role of chemotherapy in the treatment of malignant brain tumor.
Topics: Adrenal Cortex Hormones; Animals; Brain Neoplasms; Carmustine; Dose-Response Relationship, Drug; Dru | 1978 |
The contemporary role of chemotherapy in the treatment of malignant brain tumor.
Topics: Adrenal Cortex Hormones; Animals; Brain Neoplasms; Carmustine; Dose-Response Relationship, Drug; Dru | 1978 |
Radiation therapy of malignant brain tumors.
Topics: Animals; Brain Neoplasms; Brain Stem; Carmustine; Ependymoma; Glioma; Humans; Medulloblastoma; Neopl | 1978 |
Radiation therapy of malignant brain tumors.
Topics: Animals; Brain Neoplasms; Brain Stem; Carmustine; Ependymoma; Glioma; Humans; Medulloblastoma; Neopl | 1978 |
Radiation therapy of malignant brain tumors.
Topics: Animals; Brain Neoplasms; Brain Stem; Carmustine; Ependymoma; Glioma; Humans; Medulloblastoma; Neopl | 1978 |
Surgical therapy of primary malignant brain tumors.
Topics: Adrenal Cortex Hormones; Adult; Aged; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Male; Mid | 1978 |
Surgical therapy of primary malignant brain tumors.
Topics: Adrenal Cortex Hormones; Adult; Aged; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Male; Mid | 1978 |
Surgical therapy of primary malignant brain tumors.
Topics: Adrenal Cortex Hormones; Adult; Aged; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Male; Mid | 1978 |
Correlations between experimental chemotherapy in the murine glioma and effectiveness of clinical therapy regimens.
Topics: Animals; Carmustine; Dianhydrogalactitol; Drug Therapy, Combination; Ellipticines; Glioma; Lomustine | 1978 |
Correlations between experimental chemotherapy in the murine glioma and effectiveness of clinical therapy regimens.
Topics: Animals; Carmustine; Dianhydrogalactitol; Drug Therapy, Combination; Ellipticines; Glioma; Lomustine | 1978 |
Correlations between experimental chemotherapy in the murine glioma and effectiveness of clinical therapy regimens.
Topics: Animals; Carmustine; Dianhydrogalactitol; Drug Therapy, Combination; Ellipticines; Glioma; Lomustine | 1978 |
Combined growth-inhibitory responses and ultrastructural alterations produced by 1,3-bis(2-chloroethyl)-1-nitrosourea and dexamethasone in rat glioma cell cultures.
Topics: Carmustine; Cell Division; Cells, Cultured; Dexamethasone; Dose-Response Relationship, Drug; Drug In | 1977 |
Combined growth-inhibitory responses and ultrastructural alterations produced by 1,3-bis(2-chloroethyl)-1-nitrosourea and dexamethasone in rat glioma cell cultures.
Topics: Carmustine; Cell Division; Cells, Cultured; Dexamethasone; Dose-Response Relationship, Drug; Drug In | 1977 |
Combined growth-inhibitory responses and ultrastructural alterations produced by 1,3-bis(2-chloroethyl)-1-nitrosourea and dexamethasone in rat glioma cell cultures.
Topics: Carmustine; Cell Division; Cells, Cultured; Dexamethasone; Dose-Response Relationship, Drug; Drug In | 1977 |
Brain-tumor therapy. Quantitative analysis using a model system.
Topics: Animals; Brain Neoplasms; Carmustine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug | 1977 |
Brain-tumor therapy. Quantitative analysis using a model system.
Topics: Animals; Brain Neoplasms; Carmustine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug | 1977 |
Brain-tumor therapy. Quantitative analysis using a model system.
Topics: Animals; Brain Neoplasms; Carmustine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug | 1977 |
Increased volumes of mitochondria and granular endoplasmic reticulum in rat glioma cells treated with anti-tumor agents.
Topics: Carmustine; Cell Division; Cells, Cultured; Dexamethasone; Endoplasmic Reticulum; Glioma; Mitochondr | 1977 |
Increased volumes of mitochondria and granular endoplasmic reticulum in rat glioma cells treated with anti-tumor agents.
Topics: Carmustine; Cell Division; Cells, Cultured; Dexamethasone; Endoplasmic Reticulum; Glioma; Mitochondr | 1977 |
Increased volumes of mitochondria and granular endoplasmic reticulum in rat glioma cells treated with anti-tumor agents.
Topics: Carmustine; Cell Division; Cells, Cultured; Dexamethasone; Endoplasmic Reticulum; Glioma; Mitochondr | 1977 |
Neurosurgical aspects of supratentorial malignant gliomas.
Topics: Biopsy; Brain Neoplasms; Carmustine; Craniotomy; Glioma; Methotrexate | 1976 |
Neurosurgical aspects of supratentorial malignant gliomas.
Topics: Biopsy; Brain Neoplasms; Carmustine; Craniotomy; Glioma; Methotrexate | 1976 |
Neurosurgical aspects of supratentorial malignant gliomas.
Topics: Biopsy; Brain Neoplasms; Carmustine; Craniotomy; Glioma; Methotrexate | 1976 |
Chemotherapy of brain tumors.
Topics: Brain Neoplasms; Carmustine; Drug Combinations; Glioma; Humans; Lomustine; Methotrexate; Podophyllot | 1976 |
Chemotherapy of brain tumors.
Topics: Brain Neoplasms; Carmustine; Drug Combinations; Glioma; Humans; Lomustine; Methotrexate; Podophyllot | 1976 |
Chemotherapy of brain tumors.
Topics: Brain Neoplasms; Carmustine; Drug Combinations; Glioma; Humans; Lomustine; Methotrexate; Podophyllot | 1976 |
Nitrosourea pharmacodynamics in relation to the central nervous system.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Glioma; Humans; Lomustine; Mice; Molecula | 1976 |
Nitrosourea pharmacodynamics in relation to the central nervous system.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Glioma; Humans; Lomustine; Mice; Molecula | 1976 |
Nitrosourea pharmacodynamics in relation to the central nervous system.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Glioma; Humans; Lomustine; Mice; Molecula | 1976 |
Nitrosourea chemotherapy for primary malignant gliomas.
Topics: Brain Neoplasms; Carmustine; Drug Therapy, Combination; Fluorouracil; Glioma; Humans; Lomustine; Neo | 1976 |
Nitrosourea chemotherapy for primary malignant gliomas.
Topics: Brain Neoplasms; Carmustine; Drug Therapy, Combination; Fluorouracil; Glioma; Humans; Lomustine; Neo | 1976 |
Nitrosourea chemotherapy for primary malignant gliomas.
Topics: Brain Neoplasms; Carmustine; Drug Therapy, Combination; Fluorouracil; Glioma; Humans; Lomustine; Neo | 1976 |
Sterols in cerebrospinal fluid during nitrosourea chemotherapy of human brain tumors.
Topics: Adult; Astrocytoma; Brain Neoplasms; Carmustine; Cholesterol; Desmosterol; Female; Glioma; Humans; I | 1976 |
Sterols in cerebrospinal fluid during nitrosourea chemotherapy of human brain tumors.
Topics: Adult; Astrocytoma; Brain Neoplasms; Carmustine; Cholesterol; Desmosterol; Female; Glioma; Humans; I | 1976 |
Sterols in cerebrospinal fluid during nitrosourea chemotherapy of human brain tumors.
Topics: Adult; Astrocytoma; Brain Neoplasms; Carmustine; Cholesterol; Desmosterol; Female; Glioma; Humans; I | 1976 |
Chemotherapy of primary malignant brain tumors in children.
Topics: Antineoplastic Agents; Brain Neoplasms; Brain Stem; Carmustine; Child; Ependymoma; Glioma; Humans; M | 1975 |
Chemotherapy of primary malignant brain tumors in children.
Topics: Antineoplastic Agents; Brain Neoplasms; Brain Stem; Carmustine; Child; Ependymoma; Glioma; Humans; M | 1975 |
Chemotherapy of primary malignant brain tumors in children.
Topics: Antineoplastic Agents; Brain Neoplasms; Brain Stem; Carmustine; Child; Ependymoma; Glioma; Humans; M | 1975 |
Long-term survival of patients treated with BCNU for brain tumors.
Topics: Adolescent; Adult; Astrocytoma; Bone Marrow; Brain; Brain Neoplasms; Carmustine; Dose-Response Relat | 1975 |
Long-term survival of patients treated with BCNU for brain tumors.
Topics: Adolescent; Adult; Astrocytoma; Bone Marrow; Brain; Brain Neoplasms; Carmustine; Dose-Response Relat | 1975 |
Long-term survival of patients treated with BCNU for brain tumors.
Topics: Adolescent; Adult; Astrocytoma; Bone Marrow; Brain; Brain Neoplasms; Carmustine; Dose-Response Relat | 1975 |
Editorial: Brain tumor. Current status of treatment and its complications.
Topics: Brain Neoplasms; Carcinoma; Carmustine; Glioma; Humans; Meninges; Methotrexate; Neoplasm Metastasis; | 1975 |
Editorial: Brain tumor. Current status of treatment and its complications.
Topics: Brain Neoplasms; Carcinoma; Carmustine; Glioma; Humans; Meninges; Methotrexate; Neoplasm Metastasis; | 1975 |
Editorial: Brain tumor. Current status of treatment and its complications.
Topics: Brain Neoplasms; Carcinoma; Carmustine; Glioma; Humans; Meninges; Methotrexate; Neoplasm Metastasis; | 1975 |
[Effect of pretreatment with N-methyl-N-nitrosourea or streptozotocin on the cytotoxicity and the induction of sister chromatid exchanges in human and rodent brain tumor cells treated with chloroethylnitrosourea].
Topics: Animals; Brain Neoplasms; Carmustine; Cell Survival; Drug Resistance; Drug Synergism; Ethylnitrosour | 1992 |
[Effect of pretreatment with N-methyl-N-nitrosourea or streptozotocin on the cytotoxicity and the induction of sister chromatid exchanges in human and rodent brain tumor cells treated with chloroethylnitrosourea].
Topics: Animals; Brain Neoplasms; Carmustine; Cell Survival; Drug Resistance; Drug Synergism; Ethylnitrosour | 1992 |
[Effect of pretreatment with N-methyl-N-nitrosourea or streptozotocin on the cytotoxicity and the induction of sister chromatid exchanges in human and rodent brain tumor cells treated with chloroethylnitrosourea].
Topics: Animals; Brain Neoplasms; Carmustine; Cell Survival; Drug Resistance; Drug Synergism; Ethylnitrosour | 1992 |
In vitro analysis of the cellular resistance to chemotherapeutic BCNU.
Topics: Carmustine; Cell Differentiation; Cell Division; Clone Cells; DNA Repair; Dose-Response Relationship | 1992 |
In vitro analysis of the cellular resistance to chemotherapeutic BCNU.
Topics: Carmustine; Cell Differentiation; Cell Division; Clone Cells; DNA Repair; Dose-Response Relationship | 1992 |
In vitro analysis of the cellular resistance to chemotherapeutic BCNU.
Topics: Carmustine; Cell Differentiation; Cell Division; Clone Cells; DNA Repair; Dose-Response Relationship | 1992 |
Effect of intra-arterial cisplatin and 1,3-bis(2chloroethyl)-1-nitrosourea (BCNU) dosage on radiographic response and regional toxicity in malignant glioma patients: proposal of a new method of intra-arterial dosage calculation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Cis | 1992 |
Effect of intra-arterial cisplatin and 1,3-bis(2chloroethyl)-1-nitrosourea (BCNU) dosage on radiographic response and regional toxicity in malignant glioma patients: proposal of a new method of intra-arterial dosage calculation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Cis | 1992 |
Effect of intra-arterial cisplatin and 1,3-bis(2chloroethyl)-1-nitrosourea (BCNU) dosage on radiographic response and regional toxicity in malignant glioma patients: proposal of a new method of intra-arterial dosage calculation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Cis | 1992 |
Metoclopramide as a sensitizer of 1,3-bis(2-chloroethyl)-1-nitrosourea treatment of brain tumors in the rat.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Brain Neoplasms; Carmustine; F | 1992 |
Metoclopramide as a sensitizer of 1,3-bis(2-chloroethyl)-1-nitrosourea treatment of brain tumors in the rat.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Brain Neoplasms; Carmustine; F | 1992 |
Metoclopramide as a sensitizer of 1,3-bis(2-chloroethyl)-1-nitrosourea treatment of brain tumors in the rat.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Brain Neoplasms; Carmustine; F | 1992 |
Maculopathy caused by intra-arterially administered cisplatin and intravenously administered carmustine.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Cisplatin; Electrophysiology; Fluorescein Angiography; Fun | 1992 |
Maculopathy caused by intra-arterially administered cisplatin and intravenously administered carmustine.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Cisplatin; Electrophysiology; Fluorescein Angiography; Fun | 1992 |
Maculopathy caused by intra-arterially administered cisplatin and intravenously administered carmustine.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Cisplatin; Electrophysiology; Fluorescein Angiography; Fun | 1992 |
Adjuvant chemotherapy with carmustine and cisplatin for patients with malignant gliomas.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Cisplatin; Female; Glioma; Humans; | 1992 |
Adjuvant chemotherapy with carmustine and cisplatin for patients with malignant gliomas.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Cisplatin; Female; Glioma; Humans; | 1992 |
Adjuvant chemotherapy with carmustine and cisplatin for patients with malignant gliomas.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Cisplatin; Female; Glioma; Humans; | 1992 |
The MTT assay for chemosensitivity testing of human tumors of the central nervous system. Part II: Evaluation of patient- and drug-specific variables.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Cell Survival; Colony-Forming Units Assay; Color | 1992 |
The MTT assay for chemosensitivity testing of human tumors of the central nervous system. Part II: Evaluation of patient- and drug-specific variables.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Cell Survival; Colony-Forming Units Assay; Color | 1992 |
The MTT assay for chemosensitivity testing of human tumors of the central nervous system. Part II: Evaluation of patient- and drug-specific variables.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Cell Survival; Colony-Forming Units Assay; Color | 1992 |
Simvastatin, an inhibitor of cholesterol biosynthesis, shows a synergistic effect with N,N'-bis(2-chloroethyl)-N-nitrosourea and beta-interferon on human glioma cells.
Topics: Anticholesteremic Agents; Carmustine; Cell Count; Cell Division; Culture Media; Dose-Response Relati | 1992 |
Simvastatin, an inhibitor of cholesterol biosynthesis, shows a synergistic effect with N,N'-bis(2-chloroethyl)-N-nitrosourea and beta-interferon on human glioma cells.
Topics: Anticholesteremic Agents; Carmustine; Cell Count; Cell Division; Culture Media; Dose-Response Relati | 1992 |
Simvastatin, an inhibitor of cholesterol biosynthesis, shows a synergistic effect with N,N'-bis(2-chloroethyl)-N-nitrosourea and beta-interferon on human glioma cells.
Topics: Anticholesteremic Agents; Carmustine; Cell Count; Cell Division; Culture Media; Dose-Response Relati | 1992 |
Transport of amino acid amide sarcosinamide and sarcosinamide chloroethylnitrosourea in human glioma SK-MG-1 cells.
Topics: Biological Transport, Active; Carmustine; Glioma; Glycine; Humans; Hydrogen-Ion Concentration; In Vi | 1990 |
Transport of amino acid amide sarcosinamide and sarcosinamide chloroethylnitrosourea in human glioma SK-MG-1 cells.
Topics: Biological Transport, Active; Carmustine; Glioma; Glycine; Humans; Hydrogen-Ion Concentration; In Vi | 1990 |
Transport of amino acid amide sarcosinamide and sarcosinamide chloroethylnitrosourea in human glioma SK-MG-1 cells.
Topics: Biological Transport, Active; Carmustine; Glioma; Glycine; Humans; Hydrogen-Ion Concentration; In Vi | 1990 |
Glutathione levels and chemosensitizing effects of buthionine sulfoximine in human malignant glioma cells.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Brain Neoplasms; Buthionine Sulfoximine; C | 1991 |
Glutathione levels and chemosensitizing effects of buthionine sulfoximine in human malignant glioma cells.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Brain Neoplasms; Buthionine Sulfoximine; C | 1991 |
Glutathione levels and chemosensitizing effects of buthionine sulfoximine in human malignant glioma cells.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Brain Neoplasms; Buthionine Sulfoximine; C | 1991 |
Alkalosis monitored by 31P NMR in a human glioma cell line exposed to the anti-tumor drug 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Carmustine; Drug Screening Assays, Antitumor; Glioma; Glucose-6-Phosphate; Glucosephosphates; Humans | 1991 |
Alkalosis monitored by 31P NMR in a human glioma cell line exposed to the anti-tumor drug 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Carmustine; Drug Screening Assays, Antitumor; Glioma; Glucose-6-Phosphate; Glucosephosphates; Humans | 1991 |
Alkalosis monitored by 31P NMR in a human glioma cell line exposed to the anti-tumor drug 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Carmustine; Drug Screening Assays, Antitumor; Glioma; Glucose-6-Phosphate; Glucosephosphates; Humans | 1991 |
Brain necroses after intraarterial chemotherapy and irradiation of malignant gliomas--a complication of both ACNU and BCNU?
Topics: Brain; Brain Diseases; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Combined Modality Therap | 1991 |
Brain necroses after intraarterial chemotherapy and irradiation of malignant gliomas--a complication of both ACNU and BCNU?
Topics: Brain; Brain Diseases; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Combined Modality Therap | 1991 |
Brain necroses after intraarterial chemotherapy and irradiation of malignant gliomas--a complication of both ACNU and BCNU?
Topics: Brain; Brain Diseases; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; Combined Modality Therap | 1991 |
Thermal enhancement of ACNU and potentiation of thermochemotherapy with ACNU by hypertonic glucose in the BT4An rat glioma.
Topics: Animals; Brain Neoplasms; Carmustine; Combined Modality Therapy; Drug Screening Assays, Antitumor; D | 1991 |
Thermal enhancement of ACNU and potentiation of thermochemotherapy with ACNU by hypertonic glucose in the BT4An rat glioma.
Topics: Animals; Brain Neoplasms; Carmustine; Combined Modality Therapy; Drug Screening Assays, Antitumor; D | 1991 |
Thermal enhancement of ACNU and potentiation of thermochemotherapy with ACNU by hypertonic glucose in the BT4An rat glioma.
Topics: Animals; Brain Neoplasms; Carmustine; Combined Modality Therapy; Drug Screening Assays, Antitumor; D | 1991 |
Pharmacokinetics of 11C-labelled BCNU and SarCNU in gliomas studied by PET.
Topics: Antineoplastic Agents; Brain Neoplasms; Carbon Radioisotopes; Carmustine; Edetic Acid; Gallium Radio | 1991 |
Pharmacokinetics of 11C-labelled BCNU and SarCNU in gliomas studied by PET.
Topics: Antineoplastic Agents; Brain Neoplasms; Carbon Radioisotopes; Carmustine; Edetic Acid; Gallium Radio | 1991 |
Pharmacokinetics of 11C-labelled BCNU and SarCNU in gliomas studied by PET.
Topics: Antineoplastic Agents; Brain Neoplasms; Carbon Radioisotopes; Carmustine; Edetic Acid; Gallium Radio | 1991 |
31P magnetic resonance spectroscopy is sensitive to tumor hypoxia: perfusion and oxygenation of rat 9L gliosarcoma after treatment with BCNU.
Topics: Animals; Carmustine; Cell Hypoxia; Female; Glioma; Magnetic Resonance Spectroscopy; Oxygen; Perfusio | 1991 |
31P magnetic resonance spectroscopy is sensitive to tumor hypoxia: perfusion and oxygenation of rat 9L gliosarcoma after treatment with BCNU.
Topics: Animals; Carmustine; Cell Hypoxia; Female; Glioma; Magnetic Resonance Spectroscopy; Oxygen; Perfusio | 1991 |
31P magnetic resonance spectroscopy is sensitive to tumor hypoxia: perfusion and oxygenation of rat 9L gliosarcoma after treatment with BCNU.
Topics: Animals; Carmustine; Cell Hypoxia; Female; Glioma; Magnetic Resonance Spectroscopy; Oxygen; Perfusio | 1991 |
Hyperthermic potentiation of BCNU toxicity in BCNU-resistant human glioma cells.
Topics: Carmustine; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance; Glioma; Hot Temperatur | 1991 |
Hyperthermic potentiation of BCNU toxicity in BCNU-resistant human glioma cells.
Topics: Carmustine; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance; Glioma; Hot Temperatur | 1991 |
Hyperthermic potentiation of BCNU toxicity in BCNU-resistant human glioma cells.
Topics: Carmustine; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance; Glioma; Hot Temperatur | 1991 |
A three-dimensional micro-organ culture system optimized for in vitro growth of human malignant brain tumors.
Topics: Animals; Brain Neoplasms; Bromodeoxyuridine; Carmustine; Cell Survival; Glioma; Humans; Immunohistoc | 1991 |
A three-dimensional micro-organ culture system optimized for in vitro growth of human malignant brain tumors.
Topics: Animals; Brain Neoplasms; Bromodeoxyuridine; Carmustine; Cell Survival; Glioma; Humans; Immunohistoc | 1991 |
A three-dimensional micro-organ culture system optimized for in vitro growth of human malignant brain tumors.
Topics: Animals; Brain Neoplasms; Bromodeoxyuridine; Carmustine; Cell Survival; Glioma; Humans; Immunohistoc | 1991 |
Thyroid function after treatment of brain tumors in children.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine | 1991 |
Thyroid function after treatment of brain tumors in children.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine | 1991 |
Thyroid function after treatment of brain tumors in children.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine | 1991 |
In vitro response of human glioblastoma and canine glioma cells to hyperthermia, radiation, and chemotherapy.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Survival; Cisplatin; Combined Modality Therapy; Dogs; Gli | 1991 |
In vitro response of human glioblastoma and canine glioma cells to hyperthermia, radiation, and chemotherapy.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Survival; Cisplatin; Combined Modality Therapy; Dogs; Gli | 1991 |
In vitro response of human glioblastoma and canine glioma cells to hyperthermia, radiation, and chemotherapy.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Survival; Cisplatin; Combined Modality Therapy; Dogs; Gli | 1991 |
Positive therapeutic interaction between thiopurines and alkylating drugs in human glioma xenografts.
Topics: Alkylating Agents; Animals; Antineoplastic Combined Chemotherapy Protocols; Carmustine; DNA; Glioma; | 1991 |
Positive therapeutic interaction between thiopurines and alkylating drugs in human glioma xenografts.
Topics: Alkylating Agents; Animals; Antineoplastic Combined Chemotherapy Protocols; Carmustine; DNA; Glioma; | 1991 |
Positive therapeutic interaction between thiopurines and alkylating drugs in human glioma xenografts.
Topics: Alkylating Agents; Animals; Antineoplastic Combined Chemotherapy Protocols; Carmustine; DNA; Glioma; | 1991 |
Laboratory studies of berberine used alone and in combination with 1,3-bis(2-chloroethyl)-1-nitrosourea to treat malignant brain tumors.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Berberine; Brain Neo | 1990 |
Laboratory studies of berberine used alone and in combination with 1,3-bis(2-chloroethyl)-1-nitrosourea to treat malignant brain tumors.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Berberine; Brain Neo | 1990 |
Laboratory studies of berberine used alone and in combination with 1,3-bis(2-chloroethyl)-1-nitrosourea to treat malignant brain tumors.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Berberine; Brain Neo | 1990 |
Statin expression in the untreated and SarCNU-exposed human glioma cell line, SK-MG-1.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Brain Neoplasms; Carmustine; Cell Cycle; Cell Cycle P | 1990 |
Statin expression in the untreated and SarCNU-exposed human glioma cell line, SK-MG-1.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Brain Neoplasms; Carmustine; Cell Cycle; Cell Cycle P | 1990 |
Statin expression in the untreated and SarCNU-exposed human glioma cell line, SK-MG-1.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Brain Neoplasms; Carmustine; Cell Cycle; Cell Cycle P | 1990 |
The VM model of glioma: preparation of multicellular tumour spheroids (MTS) and their response to chemotherapy.
Topics: Animals; Carmustine; Cell Division; Disease Models, Animal; Drug Screening Assays, Antitumor; Glioma | 1990 |
The VM model of glioma: preparation of multicellular tumour spheroids (MTS) and their response to chemotherapy.
Topics: Animals; Carmustine; Cell Division; Disease Models, Animal; Drug Screening Assays, Antitumor; Glioma | 1990 |
The VM model of glioma: preparation of multicellular tumour spheroids (MTS) and their response to chemotherapy.
Topics: Animals; Carmustine; Cell Division; Disease Models, Animal; Drug Screening Assays, Antitumor; Glioma | 1990 |
[Chemotherapy in malignant gliomas].
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Combined Modality Therapy; Cytarabine; Follow-Up | 1990 |
[Chemotherapy in malignant gliomas].
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Combined Modality Therapy; Cytarabine; Follow-Up | 1990 |
[Chemotherapy in malignant gliomas].
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Combined Modality Therapy; Cytarabine; Follow-Up | 1990 |
Sensitivity of human malignant intracranial tumors against MCNU in vitro in comparison to ACNU and BCNU.
Topics: Aged; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Drug Screening Assays, Antitu | 1990 |
Sensitivity of human malignant intracranial tumors against MCNU in vitro in comparison to ACNU and BCNU.
Topics: Aged; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Drug Screening Assays, Antitu | 1990 |
Sensitivity of human malignant intracranial tumors against MCNU in vitro in comparison to ACNU and BCNU.
Topics: Aged; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Drug Screening Assays, Antitu | 1990 |
Chemosensitivity testing of human gliomas using a fluorescent microcarrier technique.
Topics: Antineoplastic Agents; Benzimidazoles; Carmustine; Cell Division; Drug Screening Assays, Antitumor; | 1990 |
Chemosensitivity testing of human gliomas using a fluorescent microcarrier technique.
Topics: Antineoplastic Agents; Benzimidazoles; Carmustine; Cell Division; Drug Screening Assays, Antitumor; | 1990 |
Chemosensitivity testing of human gliomas using a fluorescent microcarrier technique.
Topics: Antineoplastic Agents; Benzimidazoles; Carmustine; Cell Division; Drug Screening Assays, Antitumor; | 1990 |
Chemotherapy for malignant gliomas of the brain: a review of ten-years experience.
Topics: Antineoplastic Agents; Aziridines; Benzoquinones; Brain Neoplasms; Carmustine; Cyclohexenes; Glioma; | 1990 |
Chemotherapy for malignant gliomas of the brain: a review of ten-years experience.
Topics: Antineoplastic Agents; Aziridines; Benzoquinones; Brain Neoplasms; Carmustine; Cyclohexenes; Glioma; | 1990 |
Chemotherapy for malignant gliomas of the brain: a review of ten-years experience.
Topics: Antineoplastic Agents; Aziridines; Benzoquinones; Brain Neoplasms; Carmustine; Cyclohexenes; Glioma; | 1990 |
Use of verapamil to enhance the antiproliferative activity of BCNU in human glioma cells: an in vitro and in vivo study.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Division; Drug Screening Assays, Antitumor; Fluorescent D | 1990 |
Use of verapamil to enhance the antiproliferative activity of BCNU in human glioma cells: an in vitro and in vivo study.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Division; Drug Screening Assays, Antitumor; Fluorescent D | 1990 |
Use of verapamil to enhance the antiproliferative activity of BCNU in human glioma cells: an in vitro and in vivo study.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Division; Drug Screening Assays, Antitumor; Fluorescent D | 1990 |
Mechanisms of resistance to (2-chloroethyl)-3-sarcosinamide-1-nitrosourea (SarCNU) in sensitive and resistant human glioma cells.
Topics: Acetyltransferases; Antineoplastic Agents; Biological Transport; Carmustine; DNA; DNA Glycosylases; | 1990 |
Mechanisms of resistance to (2-chloroethyl)-3-sarcosinamide-1-nitrosourea (SarCNU) in sensitive and resistant human glioma cells.
Topics: Acetyltransferases; Antineoplastic Agents; Biological Transport; Carmustine; DNA; DNA Glycosylases; | 1990 |
Mechanisms of resistance to (2-chloroethyl)-3-sarcosinamide-1-nitrosourea (SarCNU) in sensitive and resistant human glioma cells.
Topics: Acetyltransferases; Antineoplastic Agents; Biological Transport; Carmustine; DNA; DNA Glycosylases; | 1990 |
[Application of renal subcapsular assay to human malignant glioma--a new screening method in vivo for antitumoral drugs].
Topics: Animals; Antineoplastic Agents; Bleomycin; Brain Neoplasms; Carmustine; Cell Division; Cisplatin; Dr | 1985 |
[Application of renal subcapsular assay to human malignant glioma--a new screening method in vivo for antitumoral drugs].
Topics: Animals; Antineoplastic Agents; Bleomycin; Brain Neoplasms; Carmustine; Cell Division; Cisplatin; Dr | 1985 |
[Application of renal subcapsular assay to human malignant glioma--a new screening method in vivo for antitumoral drugs].
Topics: Animals; Antineoplastic Agents; Bleomycin; Brain Neoplasms; Carmustine; Cell Division; Cisplatin; Dr | 1985 |
Combined intraarterial and systemic chemotherapy for intracerebral tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neoplasms; | 1987 |
Combined intraarterial and systemic chemotherapy for intracerebral tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neoplasms; | 1987 |
Combined intraarterial and systemic chemotherapy for intracerebral tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neoplasms; | 1987 |
An isotope agarose assay for rapid testing of the sensitivity of glioma biopsies to chemotherapeutic drugs and biological response modifiers. Effects of BCNU, vincristine, lymphokines and the recombinant agents interferon alpha 2c, interferon gamma and tu
Topics: Adult; Aged; Antineoplastic Agents; Astrocytoma; Biopsy; Carmustine; Cells, Cultured; Child, Prescho | 1988 |
An isotope agarose assay for rapid testing of the sensitivity of glioma biopsies to chemotherapeutic drugs and biological response modifiers. Effects of BCNU, vincristine, lymphokines and the recombinant agents interferon alpha 2c, interferon gamma and tu
Topics: Adult; Aged; Antineoplastic Agents; Astrocytoma; Biopsy; Carmustine; Cells, Cultured; Child, Prescho | 1988 |
An isotope agarose assay for rapid testing of the sensitivity of glioma biopsies to chemotherapeutic drugs and biological response modifiers. Effects of BCNU, vincristine, lymphokines and the recombinant agents interferon alpha 2c, interferon gamma and tu
Topics: Adult; Aged; Antineoplastic Agents; Astrocytoma; Biopsy; Carmustine; Cells, Cultured; Child, Prescho | 1988 |
The cytotoxicity of a 2-chloroethylnitrosourea analog of sarcosinamide in the SK-MG-1 human glioma cell line as a possible indicator for transport.
Topics: Antineoplastic Agents; Biological Transport; Brain Neoplasms; Carmustine; Cell Line; Dose-Response R | 1989 |
The cytotoxicity of a 2-chloroethylnitrosourea analog of sarcosinamide in the SK-MG-1 human glioma cell line as a possible indicator for transport.
Topics: Antineoplastic Agents; Biological Transport; Brain Neoplasms; Carmustine; Cell Line; Dose-Response R | 1989 |
The cytotoxicity of a 2-chloroethylnitrosourea analog of sarcosinamide in the SK-MG-1 human glioma cell line as a possible indicator for transport.
Topics: Antineoplastic Agents; Biological Transport; Brain Neoplasms; Carmustine; Cell Line; Dose-Response R | 1989 |
Treatment of high grade glioma xenografts with nitrosoureas in nude mice.
Topics: Animals; Carmustine; Glioblastoma; Glioma; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Nimus | 1989 |
Treatment of high grade glioma xenografts with nitrosoureas in nude mice.
Topics: Animals; Carmustine; Glioblastoma; Glioma; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Nimus | 1989 |
Treatment of high grade glioma xenografts with nitrosoureas in nude mice.
Topics: Animals; Carmustine; Glioblastoma; Glioma; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Nimus | 1989 |
Ocular complications after intracarotid BCNU for intracranial tumors.
Topics: Adolescent; Adult; Brain Neoplasms; Carmustine; Eye Diseases; Female; Fluorescein Angiography; Gliob | 1989 |
Ocular complications after intracarotid BCNU for intracranial tumors.
Topics: Adolescent; Adult; Brain Neoplasms; Carmustine; Eye Diseases; Female; Fluorescein Angiography; Gliob | 1989 |
Ocular complications after intracarotid BCNU for intracranial tumors.
Topics: Adolescent; Adult; Brain Neoplasms; Carmustine; Eye Diseases; Female; Fluorescein Angiography; Gliob | 1989 |
Tumour recurrence vs radionecrosis: an indication for multitrajectory serial stereotactic biopsies.
Topics: Astrocytoma; Biopsy, Needle; Brain; Brain Neoplasms; Carmustine; Combined Modality Therapy; Female; | 1989 |
Tumour recurrence vs radionecrosis: an indication for multitrajectory serial stereotactic biopsies.
Topics: Astrocytoma; Biopsy, Needle; Brain; Brain Neoplasms; Carmustine; Combined Modality Therapy; Female; | 1989 |
Tumour recurrence vs radionecrosis: an indication for multitrajectory serial stereotactic biopsies.
Topics: Astrocytoma; Biopsy, Needle; Brain; Brain Neoplasms; Carmustine; Combined Modality Therapy; Female; | 1989 |
[Internal carotid arterial BCNU perfusion in the treatment of cerebral glioma].
Topics: Adult; Brain Neoplasms; Carmustine; Carotid Artery, Internal; Female; Glioma; Humans; Infusions, Int | 1989 |
[Internal carotid arterial BCNU perfusion in the treatment of cerebral glioma].
Topics: Adult; Brain Neoplasms; Carmustine; Carotid Artery, Internal; Female; Glioma; Humans; Infusions, Int | 1989 |
[Internal carotid arterial BCNU perfusion in the treatment of cerebral glioma].
Topics: Adult; Brain Neoplasms; Carmustine; Carotid Artery, Internal; Female; Glioma; Humans; Infusions, Int | 1989 |
Early metabolic changes following chemotherapy of human gliomas in vivo demonstrated by phosphorus magnetic resonance spectroscopy.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Glioma; Humans; Hydrogen-Ion Concentration; Infusions, Int | 1989 |
Early metabolic changes following chemotherapy of human gliomas in vivo demonstrated by phosphorus magnetic resonance spectroscopy.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Glioma; Humans; Hydrogen-Ion Concentration; Infusions, Int | 1989 |
Early metabolic changes following chemotherapy of human gliomas in vivo demonstrated by phosphorus magnetic resonance spectroscopy.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Glioma; Humans; Hydrogen-Ion Concentration; Infusions, Int | 1989 |
Establishment and characterization of human glioblastoma cell lines in vitro and their xenografts in nude mice.
Topics: Animals; Brain Neoplasms; Carmustine; DNA, Neoplasm; Flow Cytometry; Glioma; Humans; Karyotyping; Ma | 1989 |
Establishment and characterization of human glioblastoma cell lines in vitro and their xenografts in nude mice.
Topics: Animals; Brain Neoplasms; Carmustine; DNA, Neoplasm; Flow Cytometry; Glioma; Humans; Karyotyping; Ma | 1989 |
Establishment and characterization of human glioblastoma cell lines in vitro and their xenografts in nude mice.
Topics: Animals; Brain Neoplasms; Carmustine; DNA, Neoplasm; Flow Cytometry; Glioma; Humans; Karyotyping; Ma | 1989 |
In vivo 31P nuclear magnetic resonance spectroscopy of rat 9L gliosarcoma treated with BCNU: dose response of spectral changes.
Topics: Animals; Carmustine; Dose-Response Relationship, Drug; Glioma; Magnetic Resonance Spectroscopy; Neop | 1989 |
In vivo 31P nuclear magnetic resonance spectroscopy of rat 9L gliosarcoma treated with BCNU: dose response of spectral changes.
Topics: Animals; Carmustine; Dose-Response Relationship, Drug; Glioma; Magnetic Resonance Spectroscopy; Neop | 1989 |
In vivo 31P nuclear magnetic resonance spectroscopy of rat 9L gliosarcoma treated with BCNU: dose response of spectral changes.
Topics: Animals; Carmustine; Dose-Response Relationship, Drug; Glioma; Magnetic Resonance Spectroscopy; Neop | 1989 |
Intravenous BCNU and AZQ in patients with recurrent malignant gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aziridines; Benzoquinones; | 1989 |
Intravenous BCNU and AZQ in patients with recurrent malignant gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aziridines; Benzoquinones; | 1989 |
Intravenous BCNU and AZQ in patients with recurrent malignant gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aziridines; Benzoquinones; | 1989 |
Fatal necrotizing encephalopathy complicating treatment of malignant gliomas with intra-arterial BCNU and irradiation: a pathological study.
Topics: Brain Diseases; Brain Neoplasms; Carmustine; Combined Modality Therapy; Glioma; Humans; Infusions, I | 1989 |
Fatal necrotizing encephalopathy complicating treatment of malignant gliomas with intra-arterial BCNU and irradiation: a pathological study.
Topics: Brain Diseases; Brain Neoplasms; Carmustine; Combined Modality Therapy; Glioma; Humans; Infusions, I | 1989 |
Fatal necrotizing encephalopathy complicating treatment of malignant gliomas with intra-arterial BCNU and irradiation: a pathological study.
Topics: Brain Diseases; Brain Neoplasms; Carmustine; Combined Modality Therapy; Glioma; Humans; Infusions, I | 1989 |
New xenograft model for assessing experimental therapy of central nervous system tumors: human glioblastoma in the intrathecal compartment of the nude mouse.
Topics: Animals; Carmustine; Cell Line; Disease Models, Animal; Drug Screening Assays, Antitumor; Glioma; Hu | 1988 |
New xenograft model for assessing experimental therapy of central nervous system tumors: human glioblastoma in the intrathecal compartment of the nude mouse.
Topics: Animals; Carmustine; Cell Line; Disease Models, Animal; Drug Screening Assays, Antitumor; Glioma; Hu | 1988 |
New xenograft model for assessing experimental therapy of central nervous system tumors: human glioblastoma in the intrathecal compartment of the nude mouse.
Topics: Animals; Carmustine; Cell Line; Disease Models, Animal; Drug Screening Assays, Antitumor; Glioma; Hu | 1988 |
Glutathione and related enzymes in rat brain tumor cell resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea and nitrogen mustard.
Topics: Animals; Brain Neoplasms; Buthionine Sulfoximine; Carmustine; Cell Line; Cell Survival; Chromatograp | 1987 |
Glutathione and related enzymes in rat brain tumor cell resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea and nitrogen mustard.
Topics: Animals; Brain Neoplasms; Buthionine Sulfoximine; Carmustine; Cell Line; Cell Survival; Chromatograp | 1987 |
Glutathione and related enzymes in rat brain tumor cell resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea and nitrogen mustard.
Topics: Animals; Brain Neoplasms; Buthionine Sulfoximine; Carmustine; Cell Line; Cell Survival; Chromatograp | 1987 |
Application of in vivo and in vitro pharmacokinetics for physiologically relevant drug exposure in a human tumor clonogenic cell assay.
Topics: Antineoplastic Agents; Aziridines; Benzoquinones; Biological Assay; Brain Neoplasms; Carmustine; Cel | 1987 |
Application of in vivo and in vitro pharmacokinetics for physiologically relevant drug exposure in a human tumor clonogenic cell assay.
Topics: Antineoplastic Agents; Aziridines; Benzoquinones; Biological Assay; Brain Neoplasms; Carmustine; Cel | 1987 |
Application of in vivo and in vitro pharmacokinetics for physiologically relevant drug exposure in a human tumor clonogenic cell assay.
Topics: Antineoplastic Agents; Aziridines; Benzoquinones; Biological Assay; Brain Neoplasms; Carmustine; Cel | 1987 |
Ischemic optic neuropathy secondary to intracarotid infusion of BCNU.
Topics: Adult; Brain Neoplasms; Carmustine; Carotid Artery, Internal; Fluorescein Angiography; Glioma; Human | 1987 |
Ischemic optic neuropathy secondary to intracarotid infusion of BCNU.
Topics: Adult; Brain Neoplasms; Carmustine; Carotid Artery, Internal; Fluorescein Angiography; Glioma; Human | 1987 |
Ischemic optic neuropathy secondary to intracarotid infusion of BCNU.
Topics: Adult; Brain Neoplasms; Carmustine; Carotid Artery, Internal; Fluorescein Angiography; Glioma; Human | 1987 |
Superselective cerebral arterial infusion of BCNU in high-grade glioma: the radiologist's point of view.
Topics: Brain Neoplasms; Carmustine; Catheterization; Cerebral Angiography; Cerebral Arteries; Female; Gliom | 1988 |
Superselective cerebral arterial infusion of BCNU in high-grade glioma: the radiologist's point of view.
Topics: Brain Neoplasms; Carmustine; Catheterization; Cerebral Angiography; Cerebral Arteries; Female; Gliom | 1988 |
Superselective cerebral arterial infusion of BCNU in high-grade glioma: the radiologist's point of view.
Topics: Brain Neoplasms; Carmustine; Catheterization; Cerebral Angiography; Cerebral Arteries; Female; Gliom | 1988 |
Ocular and orbital toxicity following intracarotid injection of BCNU (carmustine) and cisplatinum for malignant gliomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Carotid Arteries | 1985 |
Ocular and orbital toxicity following intracarotid injection of BCNU (carmustine) and cisplatinum for malignant gliomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Carotid Arteries | 1985 |
Ocular and orbital toxicity following intracarotid injection of BCNU (carmustine) and cisplatinum for malignant gliomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Carotid Arteries | 1985 |
Radiotherapy and combination chemotherapy with carmustine, vincristine, and procarbazine (BVP) in primary brain tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Combined M | 1985 |
Radiotherapy and combination chemotherapy with carmustine, vincristine, and procarbazine (BVP) in primary brain tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Combined M | 1985 |
Radiotherapy and combination chemotherapy with carmustine, vincristine, and procarbazine (BVP) in primary brain tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Combined M | 1985 |
Supraophthalmic carotid infusion for recurrent glioma: rationale, technique, and preliminary results for cisplatin and BCNU.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Car | 1985 |
Supraophthalmic carotid infusion for recurrent glioma: rationale, technique, and preliminary results for cisplatin and BCNU.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Car | 1985 |
Supraophthalmic carotid infusion for recurrent glioma: rationale, technique, and preliminary results for cisplatin and BCNU.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Car | 1985 |
Intensive 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) monochemotherapy and autologous marrow transplantation for malignant glioma.
Topics: Adolescent; Adult; Aged; Astrocytoma; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Chil | 1986 |
Intensive 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) monochemotherapy and autologous marrow transplantation for malignant glioma.
Topics: Adolescent; Adult; Aged; Astrocytoma; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Chil | 1986 |
Intensive 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) monochemotherapy and autologous marrow transplantation for malignant glioma.
Topics: Adolescent; Adult; Aged; Astrocytoma; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Chil | 1986 |
Phase II study of combined carmustine, 5-fluorouracil, hydroxyurea, and 6-mercaptopurine (BFHM) for the treatment of malignant gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 1986 |
Phase II study of combined carmustine, 5-fluorouracil, hydroxyurea, and 6-mercaptopurine (BFHM) for the treatment of malignant gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 1986 |
Phase II study of combined carmustine, 5-fluorouracil, hydroxyurea, and 6-mercaptopurine (BFHM) for the treatment of malignant gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 1986 |
Intracarotid infusion of ACNU and BCNU as adjuvant therapy of malignant gliomas. Clinical aspects and critical considerations.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Carotid Arteries; Combined Modality Therapy; Follow-Up Stu | 1987 |
Intracarotid infusion of ACNU and BCNU as adjuvant therapy of malignant gliomas. Clinical aspects and critical considerations.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Carotid Arteries; Combined Modality Therapy; Follow-Up Stu | 1987 |
Intracarotid infusion of ACNU and BCNU as adjuvant therapy of malignant gliomas. Clinical aspects and critical considerations.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Carotid Arteries; Combined Modality Therapy; Follow-Up Stu | 1987 |
Effect of difluoromethylornithine on the antiglioma therapeutic efficacy of intra-arterial BCNU.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Eflornithine; | 1986 |
Effect of difluoromethylornithine on the antiglioma therapeutic efficacy of intra-arterial BCNU.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Eflornithine; | 1986 |
Effect of difluoromethylornithine on the antiglioma therapeutic efficacy of intra-arterial BCNU.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Eflornithine; | 1986 |
Sensitivity of human glioma cells to cytotoxic heteroconjugates.
Topics: Animals; Antigens, Neoplasm; Carmustine; Cell Survival; Glioma; HLA-DR Antigens; Humans; Immunotoxin | 1988 |
Sensitivity of human glioma cells to cytotoxic heteroconjugates.
Topics: Animals; Antigens, Neoplasm; Carmustine; Cell Survival; Glioma; HLA-DR Antigens; Humans; Immunotoxin | 1988 |
Sensitivity of human glioma cells to cytotoxic heteroconjugates.
Topics: Animals; Antigens, Neoplasm; Carmustine; Cell Survival; Glioma; HLA-DR Antigens; Humans; Immunotoxin | 1988 |
Effect of Fluosol-DA on the response of intracranial 9L tumors to X rays and BCNU.
Topics: Administration, Inhalation; Animals; Brain Neoplasms; Carbon Dioxide; Carmustine; Combined Modality | 1988 |
Effect of Fluosol-DA on the response of intracranial 9L tumors to X rays and BCNU.
Topics: Administration, Inhalation; Animals; Brain Neoplasms; Carbon Dioxide; Carmustine; Combined Modality | 1988 |
Effect of Fluosol-DA on the response of intracranial 9L tumors to X rays and BCNU.
Topics: Administration, Inhalation; Animals; Brain Neoplasms; Carbon Dioxide; Carmustine; Combined Modality | 1988 |
[Mechanisms of cellular resistance to chloroethylnitrosourea in cell lines derived from human brain tumors].
Topics: Brain Neoplasms; Carmustine; Cell Line; DNA Damage; Drug Resistance; Glioma; Humans; Nimustine; Nitr | 1988 |
[Mechanisms of cellular resistance to chloroethylnitrosourea in cell lines derived from human brain tumors].
Topics: Brain Neoplasms; Carmustine; Cell Line; DNA Damage; Drug Resistance; Glioma; Humans; Nimustine; Nitr | 1988 |
[Mechanisms of cellular resistance to chloroethylnitrosourea in cell lines derived from human brain tumors].
Topics: Brain Neoplasms; Carmustine; Cell Line; DNA Damage; Drug Resistance; Glioma; Humans; Nimustine; Nitr | 1988 |
Establishment, characterization and chemosensitivity of two human glioma derived cell lines.
Topics: Animals; Carmustine; Cell Cycle; Cell Division; Cell Line; Cell Survival; Cisplatin; Culture Techniq | 1988 |
Establishment, characterization and chemosensitivity of two human glioma derived cell lines.
Topics: Animals; Carmustine; Cell Cycle; Cell Division; Cell Line; Cell Survival; Cisplatin; Culture Techniq | 1988 |
Establishment, characterization and chemosensitivity of two human glioma derived cell lines.
Topics: Animals; Carmustine; Cell Cycle; Cell Division; Cell Line; Cell Survival; Cisplatin; Culture Techniq | 1988 |
Comparison of in vitro cloning assays for drug sensitivity testing of human brain tumours.
Topics: Antineoplastic Agents; Aziridines; Benzoquinones; Brain Neoplasms; Carmustine; Colony-Forming Units | 1988 |
Comparison of in vitro cloning assays for drug sensitivity testing of human brain tumours.
Topics: Antineoplastic Agents; Aziridines; Benzoquinones; Brain Neoplasms; Carmustine; Colony-Forming Units | 1988 |
Comparison of in vitro cloning assays for drug sensitivity testing of human brain tumours.
Topics: Antineoplastic Agents; Aziridines; Benzoquinones; Brain Neoplasms; Carmustine; Colony-Forming Units | 1988 |
More on the question of chemotherapy for CNS glioma.
Topics: Brain Neoplasms; Carmustine; Combined Modality Therapy; Glioma; Humans | 1987 |
More on the question of chemotherapy for CNS glioma.
Topics: Brain Neoplasms; Carmustine; Combined Modality Therapy; Glioma; Humans | 1987 |
More on the question of chemotherapy for CNS glioma.
Topics: Brain Neoplasms; Carmustine; Combined Modality Therapy; Glioma; Humans | 1987 |
In vivo 31P nuclear magnetic resonance spectroscopy of subcutaneous 9L gliosarcoma: effects of tumor growth and treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea on tumor bioenergetics and histology.
Topics: Animals; Carmustine; Energy Metabolism; Extracellular Space; Glioma; Magnetic Resonance Spectroscopy | 1988 |
In vivo 31P nuclear magnetic resonance spectroscopy of subcutaneous 9L gliosarcoma: effects of tumor growth and treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea on tumor bioenergetics and histology.
Topics: Animals; Carmustine; Energy Metabolism; Extracellular Space; Glioma; Magnetic Resonance Spectroscopy | 1988 |
In vivo 31P nuclear magnetic resonance spectroscopy of subcutaneous 9L gliosarcoma: effects of tumor growth and treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea on tumor bioenergetics and histology.
Topics: Animals; Carmustine; Energy Metabolism; Extracellular Space; Glioma; Magnetic Resonance Spectroscopy | 1988 |
Selective delivery of chemotherapeutic agents with a new catheter system.
Topics: Brain Neoplasms; Carmustine; Carotid Artery, Internal; Catheters, Indwelling; Cerebral Arteries; Gli | 1988 |
Selective delivery of chemotherapeutic agents with a new catheter system.
Topics: Brain Neoplasms; Carmustine; Carotid Artery, Internal; Catheters, Indwelling; Cerebral Arteries; Gli | 1988 |
Selective delivery of chemotherapeutic agents with a new catheter system.
Topics: Brain Neoplasms; Carmustine; Carotid Artery, Internal; Catheters, Indwelling; Cerebral Arteries; Gli | 1988 |
Visual system toxicity following intra-arterial chemotherapy.
Topics: Brain Neoplasms; Carmustine; Cisplatin; Glioma; Humans; Infusions, Intra-Arterial; Retinal Diseases; | 1988 |
Visual system toxicity following intra-arterial chemotherapy.
Topics: Brain Neoplasms; Carmustine; Cisplatin; Glioma; Humans; Infusions, Intra-Arterial; Retinal Diseases; | 1988 |
Visual system toxicity following intra-arterial chemotherapy.
Topics: Brain Neoplasms; Carmustine; Cisplatin; Glioma; Humans; Infusions, Intra-Arterial; Retinal Diseases; | 1988 |
Patterns of recurrence in glioma patients after interstitial irradiation and chemotherapy: report of three cases.
Topics: Adult; Brachytherapy; Brain Neoplasms; Carmustine; Combined Modality Therapy; Female; Glioma; Humans | 1988 |
Patterns of recurrence in glioma patients after interstitial irradiation and chemotherapy: report of three cases.
Topics: Adult; Brachytherapy; Brain Neoplasms; Carmustine; Combined Modality Therapy; Female; Glioma; Humans | 1988 |
Patterns of recurrence in glioma patients after interstitial irradiation and chemotherapy: report of three cases.
Topics: Adult; Brachytherapy; Brain Neoplasms; Carmustine; Combined Modality Therapy; Female; Glioma; Humans | 1988 |
Pilot studies of microwave-induced brain hyperthermia and systemic BCNU in a rat glioblastoma model.
Topics: Animals; Carmustine; Combined Modality Therapy; Female; Glioma; Hyperthermia, Induced; Male; Microwa | 1988 |
Pilot studies of microwave-induced brain hyperthermia and systemic BCNU in a rat glioblastoma model.
Topics: Animals; Carmustine; Combined Modality Therapy; Female; Glioma; Hyperthermia, Induced; Male; Microwa | 1988 |
Pilot studies of microwave-induced brain hyperthermia and systemic BCNU in a rat glioblastoma model.
Topics: Animals; Carmustine; Combined Modality Therapy; Female; Glioma; Hyperthermia, Induced; Male; Microwa | 1988 |
The cytotoxicity of sarcosinamide chloroethylnitrosourea (SarCNU) and BCNU in primary gliomas and glioma cell lines: analysis of data in reference to theoretical peak plasma concentrations in man.
Topics: Carmustine; Cell Line; Cell Survival; Glioma; Humans; Lethal Dose 50; Tumor Stem Cell Assay | 1988 |
The cytotoxicity of sarcosinamide chloroethylnitrosourea (SarCNU) and BCNU in primary gliomas and glioma cell lines: analysis of data in reference to theoretical peak plasma concentrations in man.
Topics: Carmustine; Cell Line; Cell Survival; Glioma; Humans; Lethal Dose 50; Tumor Stem Cell Assay | 1988 |
The cytotoxicity of sarcosinamide chloroethylnitrosourea (SarCNU) and BCNU in primary gliomas and glioma cell lines: analysis of data in reference to theoretical peak plasma concentrations in man.
Topics: Carmustine; Cell Line; Cell Survival; Glioma; Humans; Lethal Dose 50; Tumor Stem Cell Assay | 1988 |
In vivo 31P nuclear magnetic resonance spectroscopy of subcutaneous 9L gliosarcoma: effects of tumor growth and treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea on tumor bioenergetics and histology.
Topics: Animals; Brain Neoplasms; Carmustine; Glioma; Humans; Magnetic Resonance Spectroscopy; Necrosis; Rat | 1988 |
In vivo 31P nuclear magnetic resonance spectroscopy of subcutaneous 9L gliosarcoma: effects of tumor growth and treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea on tumor bioenergetics and histology.
Topics: Animals; Brain Neoplasms; Carmustine; Glioma; Humans; Magnetic Resonance Spectroscopy; Necrosis; Rat | 1988 |
In vivo 31P nuclear magnetic resonance spectroscopy of subcutaneous 9L gliosarcoma: effects of tumor growth and treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea on tumor bioenergetics and histology.
Topics: Animals; Brain Neoplasms; Carmustine; Glioma; Humans; Magnetic Resonance Spectroscopy; Necrosis; Rat | 1988 |
31P and 1H NMR spectroscopy of tumors in vivo: untreated growth and response to chemotherapy.
Topics: Animals; Carmustine; Cyclophosphamide; Fibrosarcoma; Glioma; Hydrogen; Magnetic Resonance Spectrosco | 1987 |
31P and 1H NMR spectroscopy of tumors in vivo: untreated growth and response to chemotherapy.
Topics: Animals; Carmustine; Cyclophosphamide; Fibrosarcoma; Glioma; Hydrogen; Magnetic Resonance Spectrosco | 1987 |
31P and 1H NMR spectroscopy of tumors in vivo: untreated growth and response to chemotherapy.
Topics: Animals; Carmustine; Cyclophosphamide; Fibrosarcoma; Glioma; Hydrogen; Magnetic Resonance Spectrosco | 1987 |
Cellular resistance to chloroethylnitrosoureas, nitrogen mustard, and cis-diamminedichloroplatinum(II) in human glial-derived cell lines.
Topics: Carmustine; Cell Line; Cell Survival; Cisplatin; DNA; Dose-Response Relationship, Drug; Drug Resista | 1987 |
Cellular resistance to chloroethylnitrosoureas, nitrogen mustard, and cis-diamminedichloroplatinum(II) in human glial-derived cell lines.
Topics: Carmustine; Cell Line; Cell Survival; Cisplatin; DNA; Dose-Response Relationship, Drug; Drug Resista | 1987 |
Cellular resistance to chloroethylnitrosoureas, nitrogen mustard, and cis-diamminedichloroplatinum(II) in human glial-derived cell lines.
Topics: Carmustine; Cell Line; Cell Survival; Cisplatin; DNA; Dose-Response Relationship, Drug; Drug Resista | 1987 |
[Anticancer drug induced sister chromatid exchange and correlation to cell survival in human brain tumor cells].
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Cell Line; Cell Survival; Cisplatin; Glioma; Hum | 1987 |
[Anticancer drug induced sister chromatid exchange and correlation to cell survival in human brain tumor cells].
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Cell Line; Cell Survival; Cisplatin; Glioma; Hum | 1987 |
[Anticancer drug induced sister chromatid exchange and correlation to cell survival in human brain tumor cells].
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Cell Line; Cell Survival; Cisplatin; Glioma; Hum | 1987 |
Pharmacokinetics of superselective intra-arterial and intravenous [11C]BCNU evaluated by PET.
Topics: Adult; Aged; Brain Neoplasms; Carbon Radioisotopes; Carmustine; Drug Evaluation; Female; Glioma; Hal | 1986 |
Pharmacokinetics of superselective intra-arterial and intravenous [11C]BCNU evaluated by PET.
Topics: Adult; Aged; Brain Neoplasms; Carbon Radioisotopes; Carmustine; Drug Evaluation; Female; Glioma; Hal | 1986 |
Pharmacokinetics of superselective intra-arterial and intravenous [11C]BCNU evaluated by PET.
Topics: Adult; Aged; Brain Neoplasms; Carbon Radioisotopes; Carmustine; Drug Evaluation; Female; Glioma; Hal | 1986 |
Prolongation of survival for high-grade malignant gliomas with adjuvant high-dose BCNU and autologous bone marrow transplantation.
Topics: Adult; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Combined Modality Therapy; Female; | 1987 |
Prolongation of survival for high-grade malignant gliomas with adjuvant high-dose BCNU and autologous bone marrow transplantation.
Topics: Adult; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Combined Modality Therapy; Female; | 1987 |
Prolongation of survival for high-grade malignant gliomas with adjuvant high-dose BCNU and autologous bone marrow transplantation.
Topics: Adult; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Combined Modality Therapy; Female; | 1987 |
Intracarotid chemotherapy with 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) in 5% dextrose in water in the treatment of malignant glioma.
Topics: Adult; Aged; Astrocytoma; Brain Neoplasms; Carmustine; Carotid Arteries; Combined Modality Therapy; | 1987 |
Intracarotid chemotherapy with 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) in 5% dextrose in water in the treatment of malignant glioma.
Topics: Adult; Aged; Astrocytoma; Brain Neoplasms; Carmustine; Carotid Arteries; Combined Modality Therapy; | 1987 |
Intracarotid chemotherapy with 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) in 5% dextrose in water in the treatment of malignant glioma.
Topics: Adult; Aged; Astrocytoma; Brain Neoplasms; Carmustine; Carotid Arteries; Combined Modality Therapy; | 1987 |
Cytosine arabinoside plus cisplatin and other drugs as chemotherapy for gliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Caffeine; Carmustine; Cisplatin; Cy | 1987 |
Cytosine arabinoside plus cisplatin and other drugs as chemotherapy for gliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Caffeine; Carmustine; Cisplatin; Cy | 1987 |
Cytosine arabinoside plus cisplatin and other drugs as chemotherapy for gliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Caffeine; Carmustine; Cisplatin; Cy | 1987 |
Intracranial BCNU.
Topics: Brain Neoplasms; Carmustine; Glioma; Humans; Infusions, Intra-Arterial | 1987 |
Intracranial BCNU.
Topics: Brain Neoplasms; Carmustine; Glioma; Humans; Infusions, Intra-Arterial | 1987 |
Intracranial BCNU.
Topics: Brain Neoplasms; Carmustine; Glioma; Humans; Infusions, Intra-Arterial | 1987 |
Inhibition of O6-alkylguanine-DNA-alkyltransferase activity potentiates cytotoxicity and induction of SCEs in human glioma cells resistant to 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Carmustine; Cell Line; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance; Glioma; Hum | 1987 |
Inhibition of O6-alkylguanine-DNA-alkyltransferase activity potentiates cytotoxicity and induction of SCEs in human glioma cells resistant to 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Carmustine; Cell Line; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance; Glioma; Hum | 1987 |
Inhibition of O6-alkylguanine-DNA-alkyltransferase activity potentiates cytotoxicity and induction of SCEs in human glioma cells resistant to 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Carmustine; Cell Line; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance; Glioma; Hum | 1987 |
Intracarotid BCNU for glioma.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Carotid Arteries; Female; Glioma; Humans; Injections, Intr | 1987 |
Intracarotid BCNU for glioma.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Carotid Arteries; Female; Glioma; Humans; Injections, Intr | 1987 |
Intracarotid BCNU for glioma.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Carotid Arteries; Female; Glioma; Humans; Injections, Intr | 1987 |
Hyperprolactinemia and hypothyroidism following cytotoxic therapy for central nervous system malignancies.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Carmustine; Cerebellar Neoplasms; Child; Child, Preschool; | 1987 |
Hyperprolactinemia and hypothyroidism following cytotoxic therapy for central nervous system malignancies.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Carmustine; Cerebellar Neoplasms; Child; Child, Preschool; | 1987 |
Hyperprolactinemia and hypothyroidism following cytotoxic therapy for central nervous system malignancies.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Carmustine; Cerebellar Neoplasms; Child; Child, Preschool; | 1987 |
Drug cytotoxicity at elevated temperature. In vitro study on the U-87MG glioma cell line.
Topics: Antineoplastic Agents; Aziridines; Benzoquinones; Brain Neoplasms; Carmustine; Cell Line; Cisplatin; | 1987 |
Drug cytotoxicity at elevated temperature. In vitro study on the U-87MG glioma cell line.
Topics: Antineoplastic Agents; Aziridines; Benzoquinones; Brain Neoplasms; Carmustine; Cell Line; Cisplatin; | 1987 |
Drug cytotoxicity at elevated temperature. In vitro study on the U-87MG glioma cell line.
Topics: Antineoplastic Agents; Aziridines; Benzoquinones; Brain Neoplasms; Carmustine; Cell Line; Cisplatin; | 1987 |
Superselective intracerebral chemotherapy of malignant tumours with BCNU. Neuroradiological considerations.
Topics: Blood-Brain Barrier; Brain; Brain Neoplasms; Carmustine; Carotid Artery, Internal; Catheterization; | 1986 |
Superselective intracerebral chemotherapy of malignant tumours with BCNU. Neuroradiological considerations.
Topics: Blood-Brain Barrier; Brain; Brain Neoplasms; Carmustine; Carotid Artery, Internal; Catheterization; | 1986 |
Superselective intracerebral chemotherapy of malignant tumours with BCNU. Neuroradiological considerations.
Topics: Blood-Brain Barrier; Brain; Brain Neoplasms; Carmustine; Carotid Artery, Internal; Catheterization; | 1986 |
Increased repair of O6-alkylguanine DNA adducts in glioma-derived human cells resistant to the cytotoxic and cytogenetic effects of 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Alkylation; Carmustine; Cell Line; Cell Survival; DNA; DNA Repair; Dose-Response Relationship, Drug; | 1986 |
Increased repair of O6-alkylguanine DNA adducts in glioma-derived human cells resistant to the cytotoxic and cytogenetic effects of 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Alkylation; Carmustine; Cell Line; Cell Survival; DNA; DNA Repair; Dose-Response Relationship, Drug; | 1986 |
Increased repair of O6-alkylguanine DNA adducts in glioma-derived human cells resistant to the cytotoxic and cytogenetic effects of 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Alkylation; Carmustine; Cell Line; Cell Survival; DNA; DNA Repair; Dose-Response Relationship, Drug; | 1986 |
Supraophthalmic intracarotid infusion of BCNU for malignant glioma.
Topics: Adult; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Infusions, Intravenous; Male; Middle Age | 1986 |
Supraophthalmic intracarotid infusion of BCNU for malignant glioma.
Topics: Adult; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Infusions, Intravenous; Male; Middle Age | 1986 |
Supraophthalmic intracarotid infusion of BCNU for malignant glioma.
Topics: Adult; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Infusions, Intravenous; Male; Middle Age | 1986 |
Experiences with sodium thiosulfate after intracarotid infusion of cisplatin and BCNU for malignant gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cisplatin; | 1986 |
Experiences with sodium thiosulfate after intracarotid infusion of cisplatin and BCNU for malignant gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cisplatin; | 1986 |
Experiences with sodium thiosulfate after intracarotid infusion of cisplatin and BCNU for malignant gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cisplatin; | 1986 |
Neurological deficit after carotid infusion of cisplatin and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) for malignant glioma: an analysis of risk factors.
Topics: Brain Diseases; Brain Neoplasms; Carmustine; Carotid Artery, Internal; Cisplatin; Glioma; Humans; In | 1986 |
Neurological deficit after carotid infusion of cisplatin and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) for malignant glioma: an analysis of risk factors.
Topics: Brain Diseases; Brain Neoplasms; Carmustine; Carotid Artery, Internal; Cisplatin; Glioma; Humans; In | 1986 |
Neurological deficit after carotid infusion of cisplatin and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) for malignant glioma: an analysis of risk factors.
Topics: Brain Diseases; Brain Neoplasms; Carmustine; Carotid Artery, Internal; Cisplatin; Glioma; Humans; In | 1986 |
Prediction of human tumor cell chemosensitivity using the sister chromatid exchange assay.
Topics: Brain Neoplasms; Carmustine; Cell Line; Cell Survival; Colony-Forming Units Assay; Dose-Response Rel | 1986 |
Prediction of human tumor cell chemosensitivity using the sister chromatid exchange assay.
Topics: Brain Neoplasms; Carmustine; Cell Line; Cell Survival; Colony-Forming Units Assay; Dose-Response Rel | 1986 |
Prediction of human tumor cell chemosensitivity using the sister chromatid exchange assay.
Topics: Brain Neoplasms; Carmustine; Cell Line; Cell Survival; Colony-Forming Units Assay; Dose-Response Rel | 1986 |
Supraophthalmic carotid infusion with low dose cisplatin and BCNU for malignant glioma.
Topics: Brain Neoplasms; Carmustine; Carotid Arteries; Cisplatin; Dose-Response Relationship, Drug; Glioma; | 1986 |
Supraophthalmic carotid infusion with low dose cisplatin and BCNU for malignant glioma.
Topics: Brain Neoplasms; Carmustine; Carotid Arteries; Cisplatin; Dose-Response Relationship, Drug; Glioma; | 1986 |
Supraophthalmic carotid infusion with low dose cisplatin and BCNU for malignant glioma.
Topics: Brain Neoplasms; Carmustine; Carotid Arteries; Cisplatin; Dose-Response Relationship, Drug; Glioma; | 1986 |
Central neurotoxicity following intracarotid BCNU chemotherapy for malignant gliomas.
Topics: Brain Neoplasms; Carmustine; Glioma; Hemiplegia; Humans; Injections, Intra-Arterial; Time Factors; T | 1986 |
Central neurotoxicity following intracarotid BCNU chemotherapy for malignant gliomas.
Topics: Brain Neoplasms; Carmustine; Glioma; Hemiplegia; Humans; Injections, Intra-Arterial; Time Factors; T | 1986 |
Central neurotoxicity following intracarotid BCNU chemotherapy for malignant gliomas.
Topics: Brain Neoplasms; Carmustine; Glioma; Hemiplegia; Humans; Injections, Intra-Arterial; Time Factors; T | 1986 |
Nalbuphine and droperidol in combination for sedation and prevention of nausea and vomiting during intra-carotid BCNU infusion.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Carotid Arteries; Diazepam; Droperidol; Drug Therapy, Comb | 1986 |
Nalbuphine and droperidol in combination for sedation and prevention of nausea and vomiting during intra-carotid BCNU infusion.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Carotid Arteries; Diazepam; Droperidol; Drug Therapy, Comb | 1986 |
Nalbuphine and droperidol in combination for sedation and prevention of nausea and vomiting during intra-carotid BCNU infusion.
Topics: Adult; Aged; Brain Neoplasms; Carmustine; Carotid Arteries; Diazepam; Droperidol; Drug Therapy, Comb | 1986 |
Utilization of the HTSCA and CFU-C assay to identify two new 2-chloroethylnitrosourea congeners of amino acid amides with increased in vitro activity against human glioma compared with BCNU.
Topics: Antineoplastic Agents; Bone Marrow; Carmustine; Colony-Forming Units Assay; Glioma; Humans; In Vitro | 1985 |
Utilization of the HTSCA and CFU-C assay to identify two new 2-chloroethylnitrosourea congeners of amino acid amides with increased in vitro activity against human glioma compared with BCNU.
Topics: Antineoplastic Agents; Bone Marrow; Carmustine; Colony-Forming Units Assay; Glioma; Humans; In Vitro | 1985 |
Utilization of the HTSCA and CFU-C assay to identify two new 2-chloroethylnitrosourea congeners of amino acid amides with increased in vitro activity against human glioma compared with BCNU.
Topics: Antineoplastic Agents; Bone Marrow; Carmustine; Colony-Forming Units Assay; Glioma; Humans; In Vitro | 1985 |
Intra-arterial BCNU chemotherapy for malignant gliomas.
Topics: Brain Neoplasms; Carmustine; Diffuse Cerebral Sclerosis of Schilder; Glioma; Humans; Injections, Int | 1985 |
Intra-arterial BCNU chemotherapy for malignant gliomas.
Topics: Brain Neoplasms; Carmustine; Diffuse Cerebral Sclerosis of Schilder; Glioma; Humans; Injections, Int | 1985 |
Intra-arterial BCNU chemotherapy for malignant gliomas.
Topics: Brain Neoplasms; Carmustine; Diffuse Cerebral Sclerosis of Schilder; Glioma; Humans; Injections, Int | 1985 |
Thymidine kinase in brain-tumor cysts.
Topics: Brain Neoplasms; Carmustine; Cysts; Glioma; Humans; Thymidine Kinase | 1985 |
Thymidine kinase in brain-tumor cysts.
Topics: Brain Neoplasms; Carmustine; Cysts; Glioma; Humans; Thymidine Kinase | 1985 |
Thymidine kinase in brain-tumor cysts.
Topics: Brain Neoplasms; Carmustine; Cysts; Glioma; Humans; Thymidine Kinase | 1985 |
Intraarterial 1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy for the treatment of malignant gliomas of the brain: a preliminary report.
Topics: Aged; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Injections, Intra-Arterial; Male; Middle | 1985 |
Intraarterial 1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy for the treatment of malignant gliomas of the brain: a preliminary report.
Topics: Aged; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Injections, Intra-Arterial; Male; Middle | 1985 |
Intraarterial 1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy for the treatment of malignant gliomas of the brain: a preliminary report.
Topics: Aged; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Injections, Intra-Arterial; Male; Middle | 1985 |
Intra-arterial and intravenous chemotherapy for the treatment of malignant glioma. Preliminary results.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Aziridines; Benzoquinones; Brain Neoplasms; C | 1985 |
Intra-arterial and intravenous chemotherapy for the treatment of malignant glioma. Preliminary results.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Aziridines; Benzoquinones; Brain Neoplasms; C | 1985 |
Intra-arterial and intravenous chemotherapy for the treatment of malignant glioma. Preliminary results.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Aziridines; Benzoquinones; Brain Neoplasms; C | 1985 |
Reduced systemic drug exposure by combining intra-arterial chemotherapy with hemoperfusion of regional venous drainage.
Topics: Adolescent; Adult; Brain Neoplasms; Carmustine; Extracorporeal Circulation; Female; Glioma; Hemoperf | 1985 |
Reduced systemic drug exposure by combining intra-arterial chemotherapy with hemoperfusion of regional venous drainage.
Topics: Adolescent; Adult; Brain Neoplasms; Carmustine; Extracorporeal Circulation; Female; Glioma; Hemoperf | 1985 |
Reduced systemic drug exposure by combining intra-arterial chemotherapy with hemoperfusion of regional venous drainage.
Topics: Adolescent; Adult; Brain Neoplasms; Carmustine; Extracorporeal Circulation; Female; Glioma; Hemoperf | 1985 |
Rationale for preirradiation chemotherapy in treatment of malignant gliomas.
Topics: Brain Neoplasms; Carmustine; Glioma; Humans; Premedication | 1985 |
Rationale for preirradiation chemotherapy in treatment of malignant gliomas.
Topics: Brain Neoplasms; Carmustine; Glioma; Humans; Premedication | 1985 |
Rationale for preirradiation chemotherapy in treatment of malignant gliomas.
Topics: Brain Neoplasms; Carmustine; Glioma; Humans; Premedication | 1985 |
Topographic electroencephalographic study with power ratio index mapping in patients with malignant brain tumors.
Topics: Adult; Aged; Brain Edema; Brain Neoplasms; Carmustine; Cerebral Cortex; Electroencephalography; Fema | 1985 |
Topographic electroencephalographic study with power ratio index mapping in patients with malignant brain tumors.
Topics: Adult; Aged; Brain Edema; Brain Neoplasms; Carmustine; Cerebral Cortex; Electroencephalography; Fema | 1985 |
Topographic electroencephalographic study with power ratio index mapping in patients with malignant brain tumors.
Topics: Adult; Aged; Brain Edema; Brain Neoplasms; Carmustine; Cerebral Cortex; Electroencephalography; Fema | 1985 |
[Clonogenicity and BCNU response of subpopulations of human glioma cells sorted according to DNA content].
Topics: Adult; Carmustine; Cell Separation; Cells, Cultured; Child; Colony-Forming Units Assay; DNA, Neoplas | 1985 |
[Clonogenicity and BCNU response of subpopulations of human glioma cells sorted according to DNA content].
Topics: Adult; Carmustine; Cell Separation; Cells, Cultured; Child; Colony-Forming Units Assay; DNA, Neoplas | 1985 |
[Clonogenicity and BCNU response of subpopulations of human glioma cells sorted according to DNA content].
Topics: Adult; Carmustine; Cell Separation; Cells, Cultured; Child; Colony-Forming Units Assay; DNA, Neoplas | 1985 |
Necrotizing encephalopathy following intraventricular instillation of methotrexate.
Topics: Adolescent; Brain; Brain Diseases; Brain Neoplasms; Carmustine; Cerebellar Neoplasms; Cerebral Ventr | 1973 |
Necrotizing encephalopathy following intraventricular instillation of methotrexate.
Topics: Adolescent; Brain; Brain Diseases; Brain Neoplasms; Carmustine; Cerebellar Neoplasms; Cerebral Ventr | 1973 |
Necrotizing encephalopathy following intraventricular instillation of methotrexate.
Topics: Adolescent; Brain; Brain Diseases; Brain Neoplasms; Carmustine; Cerebellar Neoplasms; Cerebral Ventr | 1973 |
The effect of chemotherapeutic agents on the incorporation of DNA precursors by experimental brain tumors.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Bone Marrow; Brain; Brain Neoplasms; Carbon Iso | 1972 |
The effect of chemotherapeutic agents on the incorporation of DNA precursors by experimental brain tumors.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Bone Marrow; Brain; Brain Neoplasms; Carbon Iso | 1972 |
The effect of chemotherapeutic agents on the incorporation of DNA precursors by experimental brain tumors.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Bone Marrow; Brain; Brain Neoplasms; Carbon Iso | 1972 |